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Abstract 
 
Introduction 
Lower Respiratory Tract Infection (LRTI) and pneumonia are leading causes of death in the UK 
and costly health problems to the NHS. The aetiological pathogen is rarely found making 
targeted therapy difficult, hospital bed pressures are growing year on year and our current 
vaccinations are sub-optimal. 
Key questions 
Current UK priorities include 1) Better diagnostics - without knowing the causal pathogen we 
cannot treat our patients effectively nor determine what pathogen to develop better vaccines 
against. Could nasal samples from hospitalised patients with LRTI/pneumonia be useful in 
aetiological diagnosis? 2) Better therapeutics – acute hospital bed pressures and hospital 
acquired infections rates are increasing. Could hospitalised patients with LRTI/pneumonia be 
discharged home sooner by support and treatment in the community from an early supported 
discharge scheme (ESDS)? 3) Better prevention – current pneumonia vaccines are inadequate. 
Could a new experimental model in humans using live pneumococcal bacteria help us to 
select from candidate pneumococcal vaccines? 
Main findings 
We found that prior antibiotic treatment meant that nasal sampling in hospitalised patients 
was not useful. ESDS is safe and reduces the total hospital bed days with high rates of patient 
and carer/next of kin satisfaction. A large recruitment effort is needed. Using our 
Experimental Human Pneumococcal Carriage (EHPC) model confirmed that the current 
pneumococcal vaccine reduces rates of pneumococcal acquisition and carriage density.  
 
 
xxix 
 
Implications 
A community based study of nasal sampling techniques in patients with LRTI/pneumonia prior 
to antibiotic therapy may be useful. An ESDS is worthwhile but needs better integration within 
well-established CCG-funded chronic obstructive pulmonary disease (COPD) schemes to form 
a ‘Respiratory ESDS’ and a national multi-site RCT trial. Our robust EHPC model can now be 
used to test novel candidate vaccines using a smaller sample size and shorter timescales than 
clinical community studies in order to reduce cost and time to market
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CHAPTER 1: Introduction 
 
 
 
 
 
 
 
1.1 Burden of Pneumonia and Lower Respiratory Tract Infection (LRTI) 
 
In the developed world pneumonia and lower respiratory tract infection (LRTI) remain a 
common cause of GP consultation, hospital admission and death (1). Acute respiratory illness 
is the most common reason for consulting a GP in the UK. In the adult population, the annual 
incidence is 5–11/1000 population with 22–42% admitted to hospital and 5–10% requiring 
intensive care management. CAP and LRTI are major causes of hospital admission worldwide 
and admission rates continue to rise (2). In the UK, they are important health problems that 
are very costly to the NHS. In England from 2009-10 there were ≥ 260,000 admissions with 
pneumonia, influenza and LRTI combined; more admissions than ischaemic heart disease and 
with 2.3 million bed days annually; more bed days than cerebrovascular disease (3). Mortality 
rates are high with over 66 000 people dying from pneumonia and influenza in the UK in 1999 
(4). 
In Europe, pneumonia costs over €10 billion annually with inpatient care accounting for €5.7 
billion, outpatient care €0.5 billion and drugs €0.2 billion (5). In the USA, 90% of CAP 
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expenditure relates to the cost of in-patient care (6). In the UK, direct CAP health care costs 
in 1992-3 were £441 million annually (7). 
Major risk groups include children, the elderly, the immunocompromised (HIV) and those 
with co-morbidities. This thesis concentrates on the general adult population including those 
≥65 yrs olds and with co-morbidities. 
In the UK, CAP mostly affects the older population (5) with the median age being 76yrs old 
and two-thirds over 65yrs old (7). The annual incidence is up to 22.4/1000 in those over 85 
years old (8). The elderly may present later to medical services or have delayed diagnosis due 
to altered clinical and physical signs (9); their clinical disease course may also differ from 
younger adults. Elderly patients presenting with severe pneumonia, poor pre-morbid 
functional status and with recent antibiotic exposure have increased risk of multi-resistant 
organisms (10). It has been reported that 2-year mortality was independently related to 
severe co-morbidity but not to age (11). The number of elderly admissions in particular is an 
increasing burden on health resources (12) and in such patients hospital admission may in 
fact be more detrimental than care in their own residence (13). Over the next decade, the 
incidence of CAP will increase further as the population ages; as will the associated co-
morbidities (14).  
Between 25-70% of cases of pneumonia are caused by Streptococcus pneumoniae also known 
as pneumococcus (15) (16); reported rates vary dependent on diagnostic tests and 
geographical region (17). In the USA, there were approximately 570 000 confirmed 
pneumococcal pneumonia cases accounting for over 175 000 hospitalisations (18). Mortality 
rates from pneumococcal pneumonia can exceed 20% (19). The high clinical and econoburden 
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(5) and increasing incidence of antibiotic resistance make the need for pneumonia prevention 
even more urgent (20). 
1.2 Current Priorities in Pneumonia and LRTI 
 
There has been no significant reduction in age standardised mortality rates for pneumonia in 
the last 25 years (21). Reducing respiratory mortality is a key target of the UK DoH. Since 50% 
of antibiotics used in the community are for respiratory tract infections (22, 23), the threat of 
antimicrobial resistance is clear (24). To improve clinical outcomes current priorities in 
pneumonia and LRTI care in the UK are: 1. Better diagnostics - in order to aid a reduction in 
antibiotic use or duration of use to reduce the threat of antimicrobial resistance; 2. Reducing 
morbidity and mortality - early diagnosis and tailored treatment, ‘where for care’ (reducing 
hospital length of stay, hospital acquired infection and costs) and care bundles; 3. Pneumonia 
prevention - through improved pneumococcal vaccinations to protect against pneumonia and 
LRTI. 
This thesis concentrates on: 
• Diagnostics - can nasal pneumococcal carriage/ colonisation be used as a means to 
increase diagnostic precision in patients with LRTI and therefore potentially reduce 
antibiotic usage? Personalised diagnosis and therapy for the individual. 
• Therapeutics - ‘where for care’. Can an early supported discharge scheme for patients 
with LRTI reduce hospital length of stay and costs? Personalised care for the individual. 
• Prevention - a new model for testing novel pneumococcal vaccinations. Can an 
experimental pneumococcal carriage model be used to select from novel candidate 
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vaccines in order to reduce development costs and time to market? Personalised 
vaccination for the individual. 
1.2.1 Diagnostics for Pneumonia and LRTI 
1.2.1.1 Definitions - What are Pneumonia and LRTI? 
 
The definitions of both pneumonia and lower respiratory tract infection (LRTI) vary 
significantly in current literature and clinical practice. 
1.2.1.1.1 Pneumonia 
 
Pneumonia is inflammation of lung tissue which is due usually to infection with bacteria, 
viruses or fungi. Pneumonia presents as an acute illness and can range from a mild illness to 
a severe life-threatening disease. Although the disease can occur in young and healthy 
people, it is more common and serious in children, the elderly, the immunocompromised and 
those with co-morbidities. Pneumonia is pathologically characterised primarily by alveolar 
inflammation or by alveoli that are filled with fluid. 
The classical definition of pneumonia is: symptoms/syndrome of respiratory infection (cough, 
fever, sweats, sputum, breathlessness, chest pain) with clinical signs / radiological 
consolidation [either on chest radiograph (CXR) or thoracic computerised tomography (20) 
(25)]. The definition of CAP may differ depending on whether the setting is primary or 
secondary care. In primary care, UK GPs do not have the benefit of immediate investigations 
or radiology, and therefore the diagnosis is often based on clinical features only (7). In 
community studies the clinical definition of CAP varies widely (7). In the BTS guidelines, (7) 
CAP in primary care is defined as: 
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• Symptoms of an acute lower respiratory tract illness (cough and ≥1 other lower 
respiratory tract symptom) 
• New focal chest signs on examination 
• At least one systemic feature (either a symptom complex of sweating, fevers, shivers, 
aches and pains +/- temperature of ≥38°C) 
• No other explanation for the illness. 
 
In secondary care CAP is defined in BTS guidelines as (7): 
• Symptoms and signs consistent with an acute lower respiratory tract infection (LRTI) 
associated with new radiographic shadowing for which there is no other explanation (e.g. 
not pulmonary oedema or infarction) 
• The illness is the primary reason for hospital admission. 
 
NICE guidelines use the terms CAP and clinical diagnosis of CAP (26). These are defined as: 
• Clinical diagnosis of CAP - Diagnosis based on symptoms and signs of LRTI in a patient who, 
in the opinion of the GP and in the absence of a CXR, is likely to have CAP. This might be 
because of the presence of focal chest signs, illness severity or other features. They 
suggest that this approach in the community has been shown to be both pragmatic and 
sensible as focal signs correlate strongly with radiological changes. 
• CAP - Pneumonia that is acquired outside hospital. When managed in hospital the 
diagnosis is usually confirmed by CXR. Pneumonia that develops in a nursing home 
resident is included in this definition.  
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Hospital-acquired pneumonia (HAP) is defined as pneumonia that develops ≥48 hours or 
more after hospital admission and that was not incubating at hospital admission.  
Only 5-12% of patients in primary care have radiographic pneumonia and 50% of those 
patients with CXR changes recover without antibiotic therapy (27). In primary care, sputum 
production, dyspnoea, fever >38oC, HR >100bpm, decreased breath sounds, coarse crackles 
and progression of symptoms after 5 days significantly increased the likelihood of the 
diagnosis being CAP rather than acute bronchitis (termed LRTI in this thesis) (28). The 
reported duration of acute bronchitis is around 7 days (29, 30). If a patient does in fact have 
CAP they are likely deteriorate after several days in the absence of antibiotic treatment. 
Whilst delaying antibiotic therapy in CAP in primary care may alter recovery speed or duration 
and potentially increase the risk of bronchiectasis, it does reduce the risk of unnecessary 
antibiotic prescription for those with simple LRTI. CXR is therefore mostly used in primary care 
to identify complications (e.g. pleural effusion) or find underlying pathology (e.g. cancer) 
rather than to diagnose. 
1.2.1.1.2 LRTI 
 
LRTI may be used as an ‘umbrella term’ encompassing infective alveolitis, infective 
pneumonitis, acute bronchitis, bronchiolitis, tracheitis, tracheobronchitis (all often self-
limiting and not requiring antibiotics) and pneumonia. LRTI may be defined as symptoms of 
respiratory infection with clinical signs (crackles on auscultation) with and without 
radiological consolidation (31). The 2014 NICE pneumonia guidelines (26) define LRTI as an 
acute illness (present for 21 days or less), usually with cough as the main symptom, and with 
at least 1 other lower respiratory tract symptom (such as fever, sputum production, 
breathlessness, wheeze or chest discomfort or pain) and no alternative explanation (such as 
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sinusitis or asthma). Pneumonia, acute bronchitis and exacerbation of chronic obstructive 
airways disease are included in this definition. Upper respiratory tract infection (URTI) is more 
clearly defined and encompasses the common cold, epiglottitis and laryngitis. 
1.2.1.2 Diagnostic Difficulties 
 
There are significant difficulties in diagnosing pneumonia due to varied nomenclature and 
definitions; particularly when the diagnosis requires a radiological interpretation. This varied 
nomenclature may hinder research into new diagnostics as well as treatment, management 
and prognostication. Where the definition requires radiological consolidation, CXR has a high 
specificity but low sensitivity for CAP, since CXR changes may lag behind the onset of clinical 
symptoms and can worsen despite an improving clinical picture. In a large case series of 
hospitalised patients with clinical features of CAP, one third (n=911) had no consolidation on 
CXR, and no significant mortality difference was noted between groups with or without CXR 
consolidation (9). Arguably the relevance of the diagnostic term may be less important than 
assessing severity of the respiratory infection and therefore prognostic risk stratification, 
treatment options and who will deteriorate and require hospital admission or develop 
complications. 
In this thesis the term ‘LRTI’ encompasses patients with symptoms of an acute lower 
respiratory tract infection both with or without pneumonic radiological consolidation and 
infiltration, as well as those with CAP [BTS definition in secondary care (7)] and HAP (defined 
as presenting within 14 days of hospital discharge or ≥ 48 hrs after hospital admission). 
Since the most common aetiological pathogen causing pneumonia is the pneumococcus, (5, 
9) effective prevention and treatment is a top international priority.  
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1.2.1.3 Pneumococcal Pneumonia 
 
Streptococcus pneumoniae is an encapsulated Gram positive diplococcus. There are over 90 
structurally and serologically distinct pneumococcal strains or serotypes. The serotype is 
determined by the capsule; this is the outermost layer of the cell and is made of repeating 
units of simple sugars. The pneumococcus can cause a spectrum of diseases including invasive 
(organism isolated from a normally sterile site such as CSF [meningitis], blood [bacteraemic 
pneumonia]) and mucosal [otitis media, sinusitis, pneumonia] disease. Figure 1 demonstrates 
the inverse relationship between the frequency and severity of pneumococcal 
disease/carriage (colonisation). 
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Figure 1: The Burden of Pneumococcal Disease and Carriage/Colonisation 
(32, 33). 
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1.2.1.4 Microbiological Diagnosis of Pneumococcal Pneumonia 
1.2.1.4.1 Overview 
Effective management and treatment of pneumococcal pneumonia is hampered by the 
difficulty in accurately diagnosing (34). Microbiological diagnosis to confirm the pathogen in 
patients with pneumonia and LRTI remains poor; with no causal micro-organism found in the 
majority of patients (35, 36). In a US study of >2000 patients with radiographic evidence of 
pneumonia, a pathogen (viral or bacterial) was detected in only 38%. Indeed, the most 
common pathogen found was human rhinovirus - 9% and influenza virus - 6% with 
Streptococcus pneumoniae found in only 5%. This is much lower than the commonly quoted 
‘50%’ of pneumonia that is thought to be pneumococcal in aetiology (37). In a local 
pneumonia study in Liverpool only 8 of 155 (5%) patients were pneumococcal positive (by 
blood culture or sputum) (38). Most epidemiological studies instead report the incidence of 
bacteraemic or invasive pneumococcal disease (IPD); grossly underestimating the true 
pneumococcal pneumonia burden in adults (39). For every case of bacteraemic 
pneumococcal pneumonia, it has been estimated that there are at least 3 additional cases of 
non-bacteraemic pneumococcal pneumonia (39).  
Traditional aetiological tests require a clinical sample (pleural fluid, blood, nasal swab, 
sputum) to be cultured, a result is usually obtained after 2-3 days. Guidance suggests that 
clinicians should administer empirical broad-spectrum antibiotics as soon as possible to 
patients with suspected pneumonia. Unfortunately, this approach affects the yield of these 
diagnostic tests and leads to complications related to broad-spectrum antibiotic use (40). 
Antigen detection tests are available for Streptococcus pneumoniae. UK guidelines 
recommend their use for all severe CAP cases. Multiplex quantitative polymerase chain 
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reaction (qPCR) tests could potentially greatly improve the speed and precision of 
microbiological diagnosis in pneumonia and LRTI (41). 
1.2.1.4.2 Quantitative Polymerase Chain Reaction (qPCR) 
 
Rapid pre-antibiotic aetiological tests could mean more appropriate and targeted antibiotic 
therapy resulting in decreased antibiotic use and resistance, reduced antibiotic-related 
complications and a reduction in repeat appointments in primary care and hospital length of 
stay (26). Unlike classical microbiological culture, real time (rt)-qPCR can deliver results within 
a few hours (2-6hrs usually), thereby meaning there is potential for this test to have an impact 
on the critical phase of early clinical care (42). 
Rt-qPCR may also have prognostic utility. High pneumococcal load in blood has been 
associated with septic shock (OR 8.00) and mortality (OR 5.43) in patients with CAP (42, 43) 
[Figure 2]. 
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Figure 2: Pneumococcal Pneumonia Mortality Rate and rt-qPCR Pneumococcal Load 
(42) 
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CAP severity (as defined by PSI, CURB-65, ICU admission, in-hospital death and admission 
duration) has been shown to correlate with pneumococcal presence and load/density in 
serum but not in urine or sputum, using qPCR. In sputum, qPCR shows increased sensitivity 
compared to classical culture (34). qPCR positive sputum was less common in patients that 
had received antibiotics prior to hospitalisation (OR 0.52), there was no effect in serum or 
urine. This study showed no association between bacterial density/load and prior antibiotic 
therapy whilst another noted lower bacterial density (plasma/pleural fluid) with prior 
antibiotic therapy (44).  
In a South African study of predominantly HIV infected patients with CAP (27% pneumococcal 
positive on composite diagnostic testing - blood and sputum culture, Gram stain and urine 
Binax), those with CAP were more frequently nasally colonised than controls (44.9 v 11.7% 
using classical culture and 62.8 v 19.8% using lytA rt-qPCR). HIV-infected patients with CAP 
with positive composite diagnostic tests for pneumococcus had higher density on 
nasopharyngeal swabs than those without pneumococcus identified on composite testing. 
The higher the density the more likely the HIV-infected patient with CAP was to be 
pneumococcal positive on composite testing (45). The authors suggest that adding nasal qPCR 
bacterial load to pneumonia scoring systems may improve risk stratification to allow a more 
accurate determination of an individual’s clinical outcome (42).  
The sensitivity of qPCR is difficult to define since there is no ‘gold standard’ available. The LytA 
gene is thought to be present in most, if not all pneumococcal serotypes (46). While false 
positives may still occur however due to non-pneumococcal strains that contain the LytA gene 
(47), LytA is more sensitive than Ply qPCR (46). It is important to note that if pneumococcus is 
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found using qPCR it may be difficult to identify if it is indeed a pathogen or simply a coloniser 
(46, 48), since this technique detects both viable (live) and non-viable (dead) bacteria. 
The main challenge in primary care is which of the many patients who currently receive 
antibiotics do not need them. Antibiotic use in the community for respiratory tract infections 
is very high. Fifty percent of antibiotics used in the community are for respiratory tract 
infections and some 70% of patients presenting with acute LRTI symptoms are given 
antibiotics (22, 23). In most cases antibiotic use is neither warranted nor associated with any 
known significant benefit (49) (50). There are no adequately powered studies to develop 
prediction rules for adverse health outcomes in patients in the community with non-
pneumonic LRTI which could help to restrict antibiotic treatment to high risk patients only 
(51). If a clinical diagnosis of CAP is likely, antibiotics should be commenced as soon as possible 
as this is associated with improved 30-day mortality (52). A ‘point-of-care’ test (rtPCR) using 
nasal samples could potentially help make a more accurate diagnosis (of pneumococcal 
pneumonia) and therefore lead to implementation of a more focused and efficient 
management strategy allowing more targeted antibiotic therapy (53) both in the community 
and in hospital practice. 
1.2.1.4 Pneumococcal Carriage 
1.2.1.4.1 Carriage in Health 
 
Pneumococcal disease is preceded by colonisation of the nasopharynx of uninfected adults 
and children (54). Nasopharyngeal carriage is thought to be both the source of horizontal 
spread (transmission) within the community and the source of disease. Children are believed 
to be the main source of transmission due to their higher frequency (and density) colonisation 
and higher ‘crowding’ index (55). 
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Smoking and crowding are known to effect the nasopharyngeal niche and both increase the 
rate of carriage (56). The risk of horizontal spread is increased by overcrowding (nursery, 
prison, hospital) (57-60). Factors including being at the extremes of age, having lower immune 
status, greater household density, biomass and smoke exposure, lower nutritional status and 
socio-economic conditions or contact with young children increase carriage rates therefore 
disease rate (57, 60-66). 
Pneumococcal carriage rates vary greatly. Rates ranging from 11-70% (16, 67, 68) are seen in 
healthy children. Carriage rates are ~10% in the first few months of life to a maximum of ~50% 
at 3-4 years old declining again to adult rates by the age of 10 years old (69). In adults in 
developed countries rates range from 1-10% (70, 71). Rates of carriage in those adults without 
pre-school children in the family are 2-9% and in those with pre-school children are 18% and 
in the pre-schoolers themselves are 35-54% (70, 71). Carriage episodes occur earlier in low 
income countries (Figure 3) but in developed countries <50% of children experience their first 
carriage episode in their first year of life (71). 
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Figure 3: Population and Carriage Rates in an Israeli Study of Pneumococcal Carriage 
(71) 
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Carriage rates of 4.6% (n=195) were noted in the elderly (age >65yrs old) in Israel (71) but 
<1% (n=315) in hospitalised elderly in Australia (72) (10 had respiratory infection at the time 
of nasal swab). 
The duration of carriage varies with age and pneumococcal serotype (73, 74). It has been 
suggested that the low carriage rates seen in adults may in fact be due to shorter duration of 
carriage meaning that point estimates are lower, rather than a lack of carriage entirely (75). 
Studies have shown the younger the infant was at the time of acquisition, the longer a strain 
is carried for (76, 77).  
1.2.1.4.2 Pneumococcal Carriage and Respiratory Infection 
 
Pneumococcal colonisation rates tend to be higher during respiratory tract infection and otitis 
media. In Chinese children, more frequent pneumococcal colonisation was detected in those 
with pneumonia than without (78). Vietnamese children with pneumonia had higher density 
colonisation than those with bronchitis or healthy children (79). An increased nasal 
pneumococcal PCR load was associated with radiologically confirmed pneumonia, viral co-
infection, and presence of pneumococcal capsule in Vietnamese children aged <5yrs old 
(patients with pneumonia n=274 v with LRTI n=276) (80). This may support the theory of 
greater adherence during (viral) infections (62) or higher pneumococcal density during 
infection meaning greater detection. With rising burden of organisms in the nasopharynx at 
a critical colonisation density, it is believed that the risk of micro-aspiration and therefore 
pneumonia increases (81, 82). 
There is no data on pneumococcal carriage in hospitalised patients with respiratory infection 
in the UK. It is possible that the UK population could show either the high carriage seen in 
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South Africa and Vietnam or more likely the low carriage rates seen in Australia. Knowledge 
of pneumococcal carriage in a population of hospitalised patients with respiratory infection 
could improve the care of patients with LRTI by increasing understanding about potential new 
microbiological diagnostic tests (nasal wash, NPS) for these patients and result in more 
targeted and accurate antibiotic therapy reducing the prescription of unnecessary antibiotics 
(45). Earlier accurate treatment may reduce the risk of developing more severe disease that 
could result in hospital admission +/- more prolonged hospital LOS. 
1.2.1.4.3 Pneumococcal Carriage and Host Immunity 
 
Children have increased carriage rates and increased disease however it is not clear why the 
elderly have increased disease but low carriage rates. It is possible that in the elderly a failure 
to establish occasional pneumococcal carriage (due to defective mucosal T cell function) leads 
to a loss of the immunising function of carriage and hence increased susceptibility to disease.  
It is hypothesised that persistent and recurrent colonisation (and therefore potentially 
infection) may be due to a poor mucosal immune response, where as a brisk local mucosal 
immune response may eliminate colonisation (clearance) and protect against re-colonisation 
and therefore disease (61, 83). Most episodes of carriage result in improved immunity to 
future infection without the development of disease. Our group has shown for the first time 
that pneumococcal carriage in adults is an immunising event and induces protective immunity 
against pneumococcal re-challenge (84-86) (87, 88). 
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1.2.2 Therapeutics 
 
1.2.2.1 Risk Stratification 
 
Arguably assessing disease severity and therefore appropriately risk stratifying (ideally 
informing prognosis, morbidity and mortality), using optimal treatment strategies and 
providing best patient care is more important than making a diagnosis. Scoring systems are 
used to prognosticate by defining mortality risk and consequently the need for hospital 
admission. Such prognostic models offer an objective complementary assessment of disease 
severity and are not recommended for exclusive use, hence the caveat of always 
incorporating clinical judgement (89). 
Hospital LOS for CAP has reduced over recent years mainly due to increased use of pneumonia 
severity scores (e.g. CURB-65, CRB-65 and PSI [Pneumonia Severity Index]) (90). The 
pneumonia severity scoring systems use initial admission data to predict mortality; they are 
used to aid clinical decision-making about ‘best place of care’ for the individual. For 
community LRTI patients there are no adequately powered studies allowing prediction of 
adverse health outcomes. Such studies could help to restrict antibiotic treatment to high risk 
patients only (51). Below the different scoring systems are described in more detail. 
CURB-65: The patient gains one point for confusion, urea >7mmol/l, respiratory rate ≥30 SBP 
<90mmHg, DBP ≤60mmHg and age ≥65. 
The 30 day mortality rates are CURB-65 0 - 0.6%, 1 - 2.7%, 2 - 6.8%, 3 - 14.0%, 4 or 5 - 27.8%. 
CURB-65 is used to aid clinical decision making with regards to place of care: 
• 0-1: Treat as an outpatient, do not normally require hospitalisation for clinical reasons 
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• 2: Consider a short stay in hospital or watch closely as an outpatient 
• 3-5: Requires hospitalisation and consider need for intensive care unit. 
CRB-65: In this score, the patient gains one point for confusion (recent), respiratory rate ≥30 
SBP <90mmHg, DBP ≤60mmHg and age ≥65. Essentially CRB-65 is the same as CURB-65 but 
without the urea. It is used to aid clinical decision making with regards to place of care: 
• 0: Treat as an outpatient, do not normally require hospitalisation for clinical reasons 
• 1-2: Consider hospital referral and assessment 
• 3-5: Require urgent hospitalisation. 
SOAR: This is used for patients in a nursing home with pneumonia to assess best place of care. 
It modified the CURB-65 by removing confusion and urea and adding in PaO2. One point for 
Partial arterial oxygen pressure to FIO2 ratio (PaO2/FIO2 ratio) <250, Respiratory rate ≥30, 
SBP <90mmHg, DBP ≤60mmHg and age≥65. SOAR is used to aid clinical decision making with 
regards to place of care: 
• 0-1: Outpatient management (30-day mortality <8%) 
• 2 or more: Inpatient management (30-day mortality 33%) 
 
 
 
PSI (Pneumonia Severity Index) 
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The PSI is the most complicated of all the severity scores: It uses the following parameters: 
Age  
Gender  -10 for female, 0 for male 
Nursing home resident +10 for yes, 0 for no 
Neoplastic disease  0 for no, +30 for yes 
Liver disease history 0 for no, +10 for yes 
CHF history  0 for no, +10 for yes 
Cerebrovascular disease history  0 for no, +10 for yes 
Renal disease history  0 for no, +10 for yes 
Altered mental status  0 for no, +20 for yes 
Respiratory rate > 29  0 for no, +20 for yes 
Systolic blood pressure < 90 mmHg 0 for no, +20 for yes 
Temperature < 35C or > 39.9C  0 for no, +15 for yes 
Pulse > 124  0 for no, +10 for yes 
pH < 7.35  0 for no, +30 for yes 
Urea > 29 0 for no, +20 for yes 
Sodium < 130  0 for no, +20 for yes 
Glucose > 13.8  0 for no, +10 for yes 
Haematocrit < 30%  0 for no, +10 for yes 
Partial pressure of oxygen < 60 mmHg  0 for no, +10 for yes 
Pleural effusion on x-ray  0 for no, +10 for yes 
 
Step 1: 
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• If the patient is >50 years of age, assign to risk class II - V and proceed to step 2. 
• If the patient is <50 years of age, but has a history of neoplastic disease, congestive 
heart failure, cerebrovascular disease, renal disease or liver disease, assign to risk class 
II - V and proceed to step 2. 
• If the patient has an altered mental status, pulse ≥ 125/minute, respiratory rate ≥ 
30/minute, systolic blood pressure ≤ 90 mm Hg, or temperature < 35° C or ≥ 40° C, 
assign to risk class II - V and proceed to step 2 
• If none of the above apply, assign to risk class I = low risk. 
Step 2: 
• Assign points based on age, gender, nursing home residence, co-morbid illness, 
physical examination findings, and laboratory and radiographic findings as listed 
above. 
• Place of care: ≤70 points = low risk therefore outpatient care. 71-90 points = low risk 
therefore outpatient or admit for observation. 91-130 points = moderate risk 
therefore inpatient admission. >130 points = high risk therefore inpatient admission. 
All the scoring systems have limitations. In community settings CRB-65 may over-predict 30-
day mortality, potentially leading to more hospital admissions (91). PSI was developed and 
validated to identify patients with a low mortality risk who could be safely managed out of 
hospital but it may potentially underestimate illness severity, especially in young patients 
without co-morbidities who have abnormal vital signs; whilst overestimating the mortality 
risk in older patients (as it is heavily age-weighted) with minimal acute disease process but a 
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high frequency of stable co-morbidities (92). CURB-65 on the other hand may be ideal for 
identifying patients with a high mortality risk because of acute vital sign derangement who 
may otherwise be overlooked but can underestimate disease severity in younger patients 
with subtle vital sign abnormalities and decompensated co-morbid illness. CURB-65 appears 
to have a higher sensitivity for predicting mortality (93). Another approach in the elderly is 
SOAR (94) which omits urea and confusion; common in the elderly. PSI and CURB-65 both 
show a progressive decline in the predictive power for 30-day mortality with increasing 
patient age (93). Age, in fact, has little impact on mortality after correcting for disease severity 
variables using PSI, indeed removing age from PSI and CURB-65 does not alter the tools’ 
predictive value; one solution may be much higher age cut-off values. Given that all severity 
scores have advantages and disadvantages we decided to use CURB-65 for studies in this 
thesis since it is the most commonly used score in UK hospitals and is easy and simple to use. 
The optimum time for a patient to be discharged from hospital is difficult to determine. 
Pneumonia severity scores are useful to guide the ‘best place of care’ thereby reducing 
hospital admissions, but do not assist the clinician is determining ‘best time for hospital 
discharge’ – it is instead vital to assess clinical improvement/ stability and response to 
treatment. BTS guidelines for the discharge of patients with CAP state that patients suitable 
for discharge should demonstrate clinical stability and ‘usually not more than one of the 
following – temperature >37.8oC, HR >100bpm, RR >24bpm, Systolic BP (SBP) <90mmHg, 
oxygen (O2) saturations (sats) <90%, inability for oral (po) intake, altered mental state’ (95). 
In 2014, after the projects in this thesis were completed, the 2014 NICE pneumonia guidelines 
were published recommending that patients with CAP should not ‘routinely’ be discharged if 
in the past 24 hours they have had 2 or more of the above findings, temperature > 37.5°C 
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rather than >37.8 oC in the BTS recommendations (26). O2 sats ≤90% have good specificity but 
low sensitivity for adverse outcomes in CAP. O2 sats are more useful in patients with asthma 
and those aged <50 years old at predicting adverse outcomes but less reliable in nursing home 
residents and patients with COPD.  
1.2.2.2 Therapeutics 
1.2.2.2.1 Hospital at Home in General 
 
With increasing bed pressures on acute hospital trusts, Hospital at Home (HAH) schemes and 
innovations that reduce the demand for beds have become increasingly popular (96). 
Inappropriate hospitals admissions and prolonged hospital stay contribute to the increased 
risk of hospital-acquired infections (HAI) such as MRSA, Clostridium difficile diarrhoea and 
hospital-acquired pneumonia (HAP). 
HAH is defined as a service where active treatment is provided by healthcare professionals in 
the patient's residence for a condition that otherwise would require acute hospital in-patient 
care, for a limited time period (97). HAH schemes are commonly divided into admission 
avoidance [AA] (avoiding hospital admission entirely) and early supported discharge [ESDS], 
i.e. discharging patients from hospital earlier than standard care thereby reducing hospital 
LOS. The development of HAH services allows more patients to be managed outside of acute 
hospitals (98). 
The concept of HAH originated with ‘Hospitalisation a Domicile’ in France in 1961 (99), an idea 
that many other countries have now adopted.  HAH schemes vary in their conformation, 
disease focus and level of care. In the UK, HAH schemes tend to focus on providing a personal, 
nurse-led care rather than technical services. HAH schemes exist for COPD, stroke, heart 
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failure and post-operative patients. However in other countries, such as USA, home 
intravenous drug administration and blood transfusion is common place (100). Interpreting 
the function of services in different healthcare systems is not always straightforward. Patient-
related outcomes as well as economic outcomes are critical in the efficacy assessment of HAH 
services.  
The concept of HAH is clearly consistent with current strategic NHS policies and the stated 
objectives and strategies of national research organisations (NIHR/MRC strategy for public 
health infection research). QIPP (Quality, Innovation, Prevention(s) and Productivity) is a 
strategy that seeks to improve clinical outcomes and experience for patients and to maximise 
resource use. QIPP aims to reduce unscheduled hospital admissions by 20%, reduce hospital 
LOS by 25% and maximise the number of patients controlling their own disease through 
systematic knowledge transfer and care planning (101). The NHS Outcomes Framework 
(2011/12) states that it is of paramount importance that we provide safe and effective 
treatment and care (measured by clinical and patient-reported outcomes) (102). HAH 
schemes have good fit with the reforms in the current White Paper that state we should ‘aim 
to provide the NHS with greater incentives to increase efficiency and quality’ and state that 
‘patient choice will reward the most efficient, high quality services; reducing expenditure on 
less efficient care’ (103). 
The success of HAH schemes for acute exacerbations of chronic obstructive pulmonary 
disease (COPD) in many countries suggests both potential economic and patient and carer 
benefits (97, 104). It would seem appropriate therefore that such schemes could encompass 
patients with respiratory infection (with or without underlying chronic respiratory disease). 
Some patients with bronchiectasis are already discharged from hospital to home intravenous 
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(IV) antibiotic teams who are often supported by district nurses/community matrons. Patients 
with acute pneumonia/LRTI could potentially be managed at home safely. 
1.2.2.2.2 Hospital at Home for LRTI/ Pneumonia 
 
Pneumonia and LRTI are common and costly health problems to the NHS: They are 
responsible for more admissions than ischaemic heart disease and more bed days than 
cerebrovascular disease (3). Despite the fact that ~75% of community acquired pneumonia 
(CAP) is managed in the community. In Europe and the USA, 57% and 90% of pneumonia/CAP 
expenditure relates to the cost of in-patient care (5) (6). Reduction of this resource burden is 
an international priority. Choudhury et al suggested that more patients (18-20%) could be 
managed at home by family practitioners with application of current guidelines. With the 
provision of medical support at home many more patients could be managed as outpatients 
(98, 105, 106). 
Strategies to enable increased outpatient care must be safe, acceptable to patients & 
potentially reduce costs & improve patient outcomes. In a recent meta-analysis, no significant 
differences in patient satisfaction, mortality or hospital re-admission rates were noted with 
out-patient care and admission avoidance schemes were considered potentially useful (107). 
Earlier discharge and admission avoidance for patients with respiratory infection has become 
increasingly common but the evidence base in pneumonia and LRTI is very limited (108). A 
recent meta-analysis suggested that emergency departments should be encouraged to 
develop strategies to manage more even patients within the community (107). 
Despite the widespread adoption of clinical decision tools, a significant proportion of patients 
admitted with CAP are low-risk (7) but account for a significant proportion of bed days and 
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costs (106). In community settings, CRB-65 scoring may over-predict the probability of 30-day 
mortality, potentially leading to more hospital admissions (91). Current guidelines suggest 
that only patients with CURB-65 >2 generally require hospitalisation, but up to 70% of 
pneumonia admissions are CURB-65 ≤2 (7). 
The median LOS for CAP varies widely from 6 - 12.9 days (98). Physicians tend to over-estimate 
the likelihood of death from pneumonia (109) and there is large variability in rates and lengths 
of hospitalisation for patients with pneumonia across nearby geographical regions suggesting 
that criteria for hospital admission may be not only be uncertain and physician dependent 
but also dependent on socio-economic status and social support (106, 110, 111). Notably the 
risk of adverse outcomes (death, readmission rates, delayed return to work/usual activity) 
does not increase in hospitals with shorter LOS (106).  
Despite the fact that most low-risk patients (according to severity score) could be managed 
as out-patients, factors other than disease severity often prompt or prolong hospital 
admission such to inability to take oral antibiotics, co-morbid illnesses, low socioeconomic 
status, homelessness, substance abuse or inability to cope at home alone 
(105),(112),(106),(90). One study showed that of 253 patients admitted to hospital, over 50% 
were potentially suitable for out-patient treatment based on ‘appropriateness evaluation 
protocol criteria’ for hospital admission. However, factors such as substance abuse and 
homelessness meant that only 20 patients (8% of all low-risk CAPs) were suitable for 
unsupervised out-patient treatment; the percentage that would have been suitable with 
supervision is not known (106). It is probable that with ‘HAH style support’ available more 
patients could be managed in the community by supporting them with the factors, other than 
disease severity, that often prompt or prolong the hospital admission (98). More evidence 
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regarding early supported discharge schemes (ESDS) to facilitate the discharge of patients 
with more complex needs is required (107). 
Hospital discharge guidance for CAP patients exists (N.B – a patient is usually not discharged 
if more than one of the following) temperature>37.8oC, HR>100 bpm, RR>24 bpm, 
SBP<90mmHg, saturations <90% on air, inability to intake orally and altered mental state (95, 
113). Patients with respiratory infection often have co-morbidities which mean they do not 
have normal baseline observations i.e. they have increased RR and low saturations (88-92%). 
Hence using these parameters for discharge may not always be useful and a more pragmatic 
approach may be needed by the clinician to avoid an extended hospital length of stay (LOS). 
The elderly in particular may benefit from HAH, since hospital admission (13) can lead to 
increased confusion and HAI (96),(114),(115). It has been reported that frail elderly patients 
with dementia cared for with HAH were less likely to be institutionalised at longer term 
follow-up. Hospital admission rates for CAP in this group are as high as 25-40%, with an 
inpatient mortality rate at 10% with even more dying within 1 - 6mths of discharge (116). 
Expert review suggests the need to investigate which elderly patients with CAP truly benefit 
from hospitalisation and states that supported home care for patients with CAP ‘show 
enormous potential for improving the care of elderly and disabled patients, and should be 
further evaluated in terms of efficacy and cost-effectiveness’ (117). 
Patient satisfaction with HAH is high. An RCT from New Zealand, where both ESD and AA 
models were used, showed patient satisfaction improved by 40% (p<0.001) in those allocated 
to supported home care (118).  A HAH scheme containing a mixed cohort of patients including 
those with respiratory illness (32% CAP, COPD 28%) reported increased patient satisfaction 
with HAH (96, 104). Evidence suggests that patient satisfaction is innately related to the 
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quality of communication and personal care received (119).Findings indicating increased 
satisfaction for patients allocated to HAH must be balanced against carers satisfaction. Carer 
satisfaction has been noted to be higher in the HAH group (119).  
Evidence suggests that HAH is safe. A non-randomised Spanish study (specifically for CAP 
patients n=327) showed that whilst the majority (88%) of patients had low risk scores (CURB-
65 0-1), patients with higher severity scores could also be safely cared for at home (120). 
There is no obvious increase in mortality or symptom severity or decline in functional status 
(118, 121). A meta-analysis on admission avoidance schemes showed that those allocated to 
HAH had significantly reduced risk of death at 6 months (104). Admission avoidance HAH 
services reduce hospital admission rates (96) but this may be at the cost of higher re-
admission rates (104). 
The potential economic benefits to a healthcare system are clear (97). HAH appears to be less 
expensive than SHC in the specific setting of the individual studies (118, 121) with this service 
configuration, although evidence for cost effectiveness internationally is clearly limited as is 
often difficult to compare costs between different healthcare systems and countries. 
Differences in the way that a service is structured, organised and delivered clearly affect cost 
(e.g. 24hr care v. once daily visits v. telephone support). A USA study estimated that a ½ day 
reduction in hospital LOS for CAP patients would generate a potential cost saving of $8500-
8900 million annually or $457-846 per episode (based on median LOS 5.3 days and $13000 
cost per hospitalisation and a CAP incidence of 1.9%/yr and 20% hospitalisation rate). This 
suggests that a relatively small decrease in hospital LOS may have a substantial economic 
impact (6). 
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1.2.3 Prevention 
1.2.3.1 Current Pneumococcal Vaccines 
 
The pneumococcal capsule is the current vaccine target because it is the focus of the mature 
human immune response and it influences pathogen transmission (122), the epidemiology of 
infection (123) and disease virulence (124). Current pneumococcal vaccines have had great 
success in decreasing invasive pneumococcal disease (IPD) e.g. bacteraemia and meningitis, 
but do not confer optimal protection against mucosal disease e.g. non-bacteraemic 
pneumonia, sinusitis and otitis media, which account for the largest burden of disease. The 
limitations of the 23 valent polysaccharide vaccine (PPV-23) prompted the development of 
the conjugate vaccines (PCV). 
 
1.2.3.2 Polysaccharide Pneumococcal Vaccine  
 
The 23-valent polysaccharide pneumococcal vaccination (23vPS/PPV-23 - Pneumovax II, 
Sanofi Pasteur MSD) was first introduced in 1983 (39). The 23 serotypes included in the 
vaccine account for over 90% of the prevalent disease serotypes in Western countries (125). 
Its use is currently recommended in most developed countries in those aged ≥65yrs old and 
in certain high-risk groups in both children aged ≥2yrs old and adults. In the UK, it is 
recommended as a one-off dose for ≥ 65yrs old. In the Netherlands, it is only recommended 
in certain high-risk individuals. PPV-23 provides protection against IPD but is less protective 
against pneumonia in adults (126) and is ineffective in young children. Pneumococcal 
polysaccharides are unable to bind with class II major histocompatibility complex and are 
therefore T cell independent antigens. Since long-term protective immune response in 
children require T cell help and the generation of immunological memory (which is achieved 
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by conjugating polysaccharide to a protein); the vaccine therefore offers little protection in 
children (Table 1).  
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Table 1: The Properties of the Polysaccharide and Conjugate Vaccines with Regards to 
Immunity 
 
Property Polysaccharide Conjugate 
Immunogenicity age <2 yrs N Y 
B-cell dependent immune response Y Y 
T-cell dependent immune response N Y 
    Immune memory N Y 
    Booster effect N Y 
    Long term protection N Y 
    Reduction of carriage N Y 
    Herd protection N Y 
IPD prevention Y Y 
Pneumonia prevention N N 
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Evidence for the effectiveness of PPV-23 in the prevention of IPD in adults (including elderly) 
is mainly limited to non-randomised observational studies, unfortunately the RCT were not 
adequately powered. There is growing evidence that PPV-23 has no effect on rates of 
pneumonia in the elderly, with the only adequately powered study having wide confidence 
intervals (127). Meta-analyses did not answer the question either. Two studies showed that 
PPV-23 increased the RR of hospitalisation from pneumonia (RR 1.21 and HR 1.14; 95% CI 
1.02-1.28 respectively) despite a reduction in the rate of pneumococcal bacteraemia (RR 0.58 
and HR 0.56; 95% CI 0.33-0.93 respectively) (128, 129). Another study again showed little 
evidence of pneumonia protection in high-risk groups or elderly [HR 1.04; 95% CI 0.78-1.38] 
(130). Influenza vaccination but not pneumococcal vaccination is associated with a reduced 
risk of all-cause mortality in COPD (131). A recent meta-analysis concluded that there was no 
evidence to support routine use of PPV-23 to prevent all-cause pneumonia or mortality (132). 
There is also concern that repeated doses of PPV-23 (boosters) may lead to hypo 
responsiveness due to apoptosis of memory B cells (133); and that in the elderly the 
antibodies induced may be less effective due to reduced opsonophagocytic activity [OPA] 
(134).  
PPV-23 coverage in Europe amongst elderly adults remains low. It has a broad spectrum of 
coverage (80-90% of serotypes responsible for IPD in Europe) and prevents 50-80% of IPD 
cases requiring hospitalisation, and therefore is very cost effective, regardless of its impact or 
lack of on pneumonia (135).  
1.2.3.3 Pneumococcal Conjugate Vaccine 
 
PCV vaccines couple purified capsular S. pneumoniae polysaccharides with a nontoxic carrier 
protein. PCVs with increasing serotype coverage continue to be produced including PCV-7 
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(Prevnar, Wyeth – containing serotypes 4, 6B, 9V, 14, 18C, 19F and 23F), 10 (Synflorix, GSK - 
1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F), 13 (Prevenar 13, Pfizer 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 
18C, 19A, 19F and 23F), 15 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F 
conjugated to CRM197). The span of protection afforded against disease-causing serotypes 
depends on geographical region i.e. for PCV-7 >85% in the USA, 60-70% in Europe and 55% in 
Asia (136) and for PCV-13 is approximately 80% in high income countries (137).  
PCV-13 is currently licensed for use in the UK in the childhood immunisation strategy for 
children aged 6 weeks to 6 years to protect against IPD, pneumonia and acute otitis media. 
Since 2011, the European Medicine Agency (EMA) and Food and Drug Administration (FDA) 
extended the licence to adults aged > 50yrs old as a single dose for the prevention of 
pneumonia and IPD caused by PCV-13 serotypes (138, 139). The UK Joint Committee on 
Vaccines and Immunisations (JCVI) does not currently recommend its routine use in high risk 
groups. There is accumulating evidence of indirect population protection against PCV-13 
serotypes across the UK population due to the use of PCV-13 in the routine childhood 
immunisation programme. The JCVI concluded that the direct benefit from administering 
PCV-13 in clinical risk groups would lead to a declining benefit in the UK over the coming years 
and that the effectiveness and cost effectiveness were uncertain. Furthermore, given the 
evidence of accumulating indirect protection against PCV-13 serotypes across the UK 
population and the current absence of data on the effectiveness of PCV-13 in older adults, 
JCVI also advised against the introduction of a routine immunisation programme to offer PCV-
13 to older adults in the UK. The JCVI concluded that some clinical risk groups with a 
particularly high risk of IPD and high rates of mortality may benefit from immunisation with 
PCV-13 in the short-term (while PCV-13 serotypes continue to circulate) e.g. bone marrow 
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transplant patients, those with acute and chronic leukaemia, multiple myeloma, or genetic 
disorders severely affecting the immune system (140). Further JCVI and CDC guidance was 
expected after the results of a large placebo-controlled PCV-13 study (CAPITA) were available. 
Pneumococcal conjugate vaccine (PCV) show good serotype-specific immunity against IPD in 
children (83-94%) and has herd protection effects in adults (by reducing carriage) (141). The 
success of PCVs can largely be attributed to herd protection. The reduction in carriage of 
vaccine serotypes in children has resulted in a reduction in the number of circulating vaccine 
serotypes (and hence population exposure) (142). The reduction in disease has been seen in 
young infants too young to have been vaccinated (143), in unvaccinated children and in older 
children and adults too old to have received the vaccine (144). The herd protection effect in 
African countries has been variable, this may be due to the vaccination schedule and a 
children catch-up campaign is likely to be needed to generate good herd effect (personal 
communication Dr Neil French, University of Liverpool). 
PCV induces T-cell, as well as B cell, responses and therefore affords a protective immune 
response in children and the elderly as well as HIV infected patients (145-147). Induced 
antibody responses in the elderly to PCV-7, were noted to be similar or greater for all vaccine 
serotypes than those induced by PPV-23, and similar to those in young children. In children 
<5yrs old PCV-7 is highly effective at reducing vaccine-type (VT) IPD, VT acute otitis media 
(AOM) episodes and total pneumococcal pneumonia hospitalisations (148-152) (Figure 4). 
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Figure 4: Change in Hospitalisation Rates in USA for Pneumococcal Pneumonia (A) and All 
Causes (A) According to Age Group Post PCV-7 Introduction 
(151) 
(*statistically significant reduction) 
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Prior to the introduction of the pneumococcal conjugate vaccine (PCV), the incidence of IPD 
in children < 2 years old was 44.4/100,000/yr in Europe, 167/100,000/yr in USA and 
797/100,000/yr in Mozambique (16). In the post PCV era the incidence in USA has dropped 
to 23.6/100000/yr in children <5yrs old (153). 
Protein-conjugated pneumococcal polysaccharide (PCV) vaccines represent a landmark 
achievement showing good serotype-specific immunity against IPD (83-94%) in children and 
an important herd protection effect in adults, but they are not a final solution (141). 
PCV is less effective against mucosal disease (AOM, sinusitis and pneumonia) than IPD (154); 
this may in part be due to differences in mucosal and systemic defence. Defence against 
systemic infection is dependent on capsule-specific immunoglobulin, complement and 
phagocytes whilst in mucosal disease (murine models) cellular responses [especially Th17 
(155)] are critical (156). Figure 4 shows reduced rates of hospitalisation for all cause 
pneumonia in the <2’s and 18 - 39yr old age groups and reduction for pneumococcal 
pneumonia in 2 - 4yr old age group. No change was noted in the elderly group (151). Notably 
estimates of vaccine efficacy against pneumococcal pneumonia are hindered by the 
diagnostic difficulty of pneumonia. PCVs impact on pneumonia has been shown in children in 
Gambia and adults ≥65yrs old in the USA with a 33-36% (post PCV-13) (157) and 54% 
reduction respectively (158). The latter is attributed to herd protection. Studies assessing 
vaccine effect cannot be compared unless vaccine schedule, valency, epidemiological area, 
definition of pneumonia and coding are all controlled. 
PCV is difficult to manufacture, is expensive, has limited serotype coverage, is associated with 
serotype replacement and has an unclear effect on pneumonia, so clearly alternative 
vaccination strategies are needed. PCV is clearly not the full solution. PCV is known to induce 
anti-capsular antibodies but it is not known whether Th17 responses are also induced. In the 
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UK due to serotype replacement IPD incidence in children is now similar to that before the 
introduction of PCV (152). PCV-7 and -9 have shown reduction in VT carriage of up to 14% 
(159-162). The rate of this replacement also varies geographically. In patients with HIV the 
rate of IPD caused by pneumococcal serotypes that are not covered by the PCV vaccine 
(termed non-vaccine types or NVTs) has risen dramatically, a 44% increase from 1999 to 2003 
(163). Continuing surveillance is required to determine whether PCVs continue to reduce the 
rates of disease in the long term. 
Epidemiological data have also suggested a reduction in nasopharyngeal carriage by vaccine 
types after PCV in both children and adults (164, 165), both by direct protection of vaccinated 
individuals and by the reduction in exposure of unvaccinated individuals to vaccine types 
through herd protection. The current PCV has greatly decreased the incidence of IPD, through 
herd protection more than through a direct effect on immunized individuals. 
It has been noted that the immunogenicity of PCV is severely restricted if a previous dose of 
PPV-23 has been received (166). This has been a barrier to design of a large-scale PCV efficacy 
study in the elderly population (167). 
There are at least three major challenges facing the current use and future development of 
PCVs. Firstly, serotype replacement and resultant replacement disease. Could the solution be 
to develop vaccines that interfere with invasion and not colonisation? Secondly, optimisation 
of protection for vulnerable groups.  Perhaps a vaccine tailored to that specific group? And 
thirdly, an issue on a global scale, how to make efficient vaccines available to all in need? This 
is being addressed by a GAVI Alliance funded project - Pneumococcal vaccines Accelerated 
Development and Introduction Plan (PneumoADIP) – which aims to accelerate the 
introduction of pneumococcal vaccinations into low-income countries through partnership 
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networks between countries, donors, academia, international organizations and industry; in 
order to prevent 5.4 million deaths in children by 2030. 
1.2.3.4 The CAPITA Study 
 
CAPITA (Community Acquired Pneumonia Immunisation Trial in Adults) was a Phase 4 
randomised placebo-controlled clinical trial of PCV-13 efficacy in the prevention of vaccine-
type (VT) pneumococcal community acquired pneumonia (CAP) and IPD (167-169). The study 
which began in began in September 2008 took 5 years to complete. This study was conducted 
in the Netherlands since the elderly population (≥ 65 yrs) there do not routinely receive 
Pneumovax or PCV, and are therefore a pneumococcal vaccine naive population. 
The primary outcome measure was to compare the number of first episodes of VT 
pneumococcal CAP in each arm. The secondary outcomes were to compare: 1) the number of 
first episodes of VT IPD and 2) the number of first episodes of non-bacteraemic/non-invasive 
VT pneumococcal CAP in each study arm. The study also evaluated carriage rates in a subset 
of 2000 subjects – data awaited. 
Exclusion criteria included: 1) care residents; 2) vaccine hypersensitivity; 3) 
immunocompromise and 4) receipt of any licensed or experimental pneumococcal vaccine. 
Almost 85,000 subjects were recruited with a 1:1 random allocation to PCV-13 or placebo-
vaccine. 
The primary outcome required a clinical definition of CAP, independent interpretation of CXR 
consistent with pneumonia and determination of pneumococcus serotype (all 3 criteria had 
to be met for a definition of VT or non-VT pneumococcal pneumonia). Blood culture and 
positive urinary antigen were used to identify S. pneumoniae as the definite causative agent 
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for CAP. IPD was defined as the presence of pneumococcus in a normally sterile site (including 
CSF, blood, pleural fluid). 
Less than 0.2% of subjects recruited were diagnosed with VT CAP. VT CAP occurred in only 49 
subjects in the PCV13 group and 90 persons in the placebo group (vaccine efficacy, 45.6%; 
95% CI, 21.8 to 62.5). This was 46% reduction in rates of VT CAP. VT IPD occurred in 7 subjects 
in the PCV13 and 28 in the placebo group (vaccine efficacy, 75.0%; 95% CI, 41.4 to 90.8). CAP 
occurred in 747 subjects in the PCV13 and 787 in placebo group (vaccine efficacy, 5.1%; 95% 
CI, −5.1 to 14.2). This study disappointingly but perhaps not unsurprisingly showed that PCV13 
was effective in preventing VT CAP and VT IPD but did not prevent CAP from any cause. The 
vaccine was not shown to have significant efficacy on mortality. A post-hoc analysis showed 
that PCV-13 efficacy against VT CAP and VT IPD declined from 65% in 65 year old subjects to 
40% in 75 year olds (170). 
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1.2.3.5 Novel Pneumococcal Vaccines and Vaccine Testing Platforms 
 
Pneumococcal disease remains a major global health threat for which new affordable 
vaccines that confer broad protection against pneumococcal disease are urgently needed, 
particularly those that protect vulnerable children and adults against pneumonia. This 
urgency is further increased by a global increase in antibiotic resistance among pneumococci 
and in the number of susceptible people. New vaccines such as a protein vaccine could 
potentially overcome the problems faced by PCVs. An Experimental Human Pneumococcal 
Carriage (EHPC) model could provide a vaccine testing platform to help select from the 
multiple novel pneumococcal vaccines in development using prevention of carriage as a 
surrogate of vaccine induced immunity, rather than disease, as an endpoint. 
In order to prevent pneumococcal disease should we aim for vaccination to eradicate 
pneumococcal nasopharyngeal colonisation, or to prevent of bacterial invasion whilst leaving 
colonisation relatively unaffected? One approach may be to reduce the carriage density 
rather than carriage rate; this may reduce the rate of horizontal spread and the risk of disease. 
One major concern about the eradication of pneumococcal carriage is that nasopharyngeal 
niche may then be prime for other pathogens such as S. aureus (171) and N. meningitidis 
instead. 
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New vaccine development is hindered by the fact that placebo-controlled trials are no longer 
ethical in children and large sample size and study duration are needed when the primary 
outcome measure is disease; this increases development costs thereby later negating their 
use in the poorer countries most in need of such a vaccine. New vaccination routes, such as 
intranasal are also being examined. This less invasive route may be preferable and particularly 
useful in children. Since mucosal responses are mostly considered intact in HIV infected 
subjects, protection may also be afforded in this important immunocompromised group. 
New strategies focus mainly on protein antigens. Protein vaccines offer the advantage of 
serotype independence (and therefore no concerns regarding serotype replacement), 
reduced cost, protection for all ages and potentially improved protection against mucosal 
disease. 
An ideal protein antigen should be found on the cell surface and be highly expressed and 
conserved between serotypes. It is likely that multiple proteins are required to have a 
protective effect (172, 173). Live vaccinations may offer both mucosal and systemic immunity, 
whilst a whole cell vaccine (inactivated/attenuated) would have low manufacture costs and 
would offer serotype-independent protection. In mice the killed whole cell vaccine has shown 
protection against nasopharyngeal carriage and sepsis (174). Pneumococcal protein-based 
vaccines, live attenuated vaccines and whole cell vaccines are currently in development (Table 
2). 
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Table 2: Novel Pneumococcal Vaccinations at the Clinical Trial Stage 
 (156) 
Strategy Antigens Advantages Limitations Institute Phase 
Common 
pneumococcal 
protein-based 
vaccines 
PspA 
(pneumococcal 
surface protein A) 
Human antibodies to 
PspA protect mice 
from sepsis 
Antigen variability; 
cross-reactive 
antibodies to 
human myoglobulin 
Sanofi–
Pasteur 
Phase I 
complete 
PspA & PsaA 
(pneumococcal 
surface protein A 
and the metal-
binding proteins 
pneumococcal 
surface antigen 
A) 
Protective antibodies 
against carriage and 
IPD 
Uncertain about 
exposure of PsaA 
on pneumococcal 
surface 
Sanofi–
Pasteur/ CDC 
Phase I 
complete 
PiuA & PiaA 
(pneumococcal 
iron uptake A and 
pneumococcal 
iron acquisition 
A)  
Antigenically cross-
reactive 
Immunity to single 
antigen is not as 
protective as 
combination 
N/A Phase I 
complete 
BVH3/11V fusion 
protein [or PhpA 
and PhtB] 
(pneumococcal 
histidine triad B) 
Conserved antigen; 
surface exposed; 
interact with human 
complement. In mice 
confers protection 
against sepsis and 
pneumonia 
N/A ID BioMedical 
(acquired by 
GSK) 
Phase II 
complete 
Based on PsaA, 
PcsB & StkP 
(the metal-
binding proteins 
pneumococcal 
surface antigen A, 
protein required 
for cell wall 
separation and 
serine/ threonine 
protein kinase) 
Three conserved 
antigens, in mice 
confer protection to 
carriage, sepsis and 
pneumonia 
N/A InterCell 
AG/Novartis/
PATH 
Phase I 
complete 
PhtD 
(pneumococcal 
histidine triad D) 
Protective against 
sepsis; interaction 
with human 
complement 
Higher animal 
survival rates after 
lethal intranasal 
challenge 
GSK/ 
Biologicals SA 
Phase II 
complete 
PlyD1 
(pneumolysin D1) 
Present virtually in all 
strains 
Non-toxic 
pneumolysoids are 
best active as 
protein adjuvant 
rather than 
protective antigens 
Netherlands 
Vaccine 
Institute/ 
Sanofi–
Pasteur 
Phase I 
Live attenuated 
vaccines 
Live recombinant 
attenuated 
Salmonella Typhi 
expressing PspA 
Vaccine is well 
characterized in 
mice, induces 
mucosal response 
and protection 
against carriage and 
sepsis; oral single-
dose administration 
Expresses PspA that 
induces reactive 
antibodies to 
human myoglobulin 
Arizona State 
University/ 
Biodesign 
Institute 
Phase I 
complete 
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Strategy Antigens Advantages Limitations Institute Phase 
Whole cell 
vaccines 
Unencapsulated 
killed 
(inactivated) 
whole cell (Rx1 
LytA–/–, a rough 
derivative of 
serotype 2, D39) 
Administered as a 
nasal vaccine and is 
protective against 
carriage and sepsis 
Mechanism of 
protection 
described Th17 in 
mice, is not 
elucidate in humans 
Children's 
Hospital 
Boston/ 
Butantan 
Institute/ 
PATH 
Phase II 
complete 
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However, there is a bottleneck in pneumonia vaccine development as clinical trials with tens 
of thousands of participants are required to compare the new vaccine with the current gold 
standard vaccine using an outcome of disease reduction. (175). If a new vaccine could protect 
against colonisation, it could be possible to reduce transmission and achieve herd protection. 
At least initially studies using a reduction in carriage as an endpoint rather than disease could 
provide proof of concept for a new vaccine and be a stepping stone to pursuing large and 
expensive clinical trials with disease endpoints. A model that assesses a reduction or 
elimination in pneumococcal carriage can therefore be used as a vaccine testing platform. 
Such a design may be an efficient and cost-effective method to select between vaccine 
candidates and lend support to Phase 3 trial choice (175).  
1.2.3.6 Experimental Human Pneumococcal Carriage/Colonisation (EHPC) Studies 
 
Human challenge models have been used to study disease pathogenesis, investigate new 
antimicrobials and vaccine efficacy. McCool et al published the first EHPC study in 2002 (176). 
They inoculated healthy adults with serotypes 23F and 6B and examined the antibody 
response to carriage. Pre-existing high levels of pneumococcal surface protein A (PspA) [a 
potential protein vaccine candidate] antibody correlated with protection against 
experimental carriage. 
The EHPC technique is valuable as a vaccine testing platform but is complex and involves a 
measure of clinical risk from introducing a live pathogen into a human volunteer. The EHPC 
model can also be used to investigate the immunological correlates of protection. Different 
serotypes can be used either alone or combined, and different cohorts of subjects inoculated; 
healthy volunteers; those with respiratory disease; immunocompromised or the elderly.  
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1.2.3.6.1 The Usefulness of the EHPC Model in Novel Vaccine Testing 
 
Animal models play a key role in screening candidate vaccines, evaluating vaccine 
formulations, and providing initial safety and efficacy data. However, since the human is the 
only natural host of the pneumococcus, no animal data can predict vaccine efficacy in 
humans. The EHPC vaccine testing model could be used to determine the protective effect 
against carriage of novel vaccines in a small population compared to a placebo group and/or 
PCV group.  
Prior to the study in chapter 7, we developed a safe and reproducible EHPC model. In this 
model, carefully screened healthy adult participants are inoculated with doses of 
pneumococci – with a 50% colonisation rate at a density typical of natural colonisation and 
duration of 1 - 3 weeks (177, 178).  
1.2.3.6.2 The Ethics of the EHPC Model  
 
Safety is a major factor in the development of the EHPC model and is achieved through 
intensive subject screening and monitoring. The current EHPC model in use in England has 
been validated in over 150 healthy adult subjects in Liverpool. Stringent screening using strict 
inclusion and exclusion criteria occurs (178). Further information is contained within Chapter 
7. 
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1.3 Summary and Study Plans 
 
To summarise, Lower Respiratory Tract Infection (LRTI) and pneumonia are a leading cause of 
death in the UK and a costly health problem to the NHS. The various definitions of LRTI and 
pneumonia make both comparing current studies and designing future studies challenging. 
Pneumococcus is thought to be the main cause of LRTI/pneumonia and this thesis therefore 
focusses on this pathogen predominately. 
Current UK priorities include: 
1) Better diagnostics - Pneumococcal carriage or colonisation is very common in children, 
common in adults but rare in the elderly. It can be detected by nasal sampling techniques 
(swabs or washes) using classical microbiological culture or qPCR. Given that the aetiological 
pathogen is rarely found, better diagnostics are important and in an era of increasing 
antibiotic resistance, targeted antibiotic theory is vital. Nasal sampling has been shown to be 
useful in patients with pneumonia in South Africa. Could nasal samples from hospitalised 
patients with LRTI/pneumonia be useful in aetiological diagnosis? CHAPTER 3. 
2) Better therapeutics - Acute hospital bed pressures and hospital acquired infections rates 
are increasing. Investigating the possible causes for the increased length of hospital stay 
(LOHS) in these patients and assessing what an early supported discharge scheme (ESDS) 
would need to consist of and its potential effect on LOHS is key. CHAPTER 4, 5 AND 6. 
3) Better prevention - Current pneumonia vaccines are inadequate. New vaccine 
development is hindered by the fact that placebo-controlled trials are no longer ethical in 
children and large sample size and study duration are needed when the primary outcome 
measure is disease; this increases development costs thereby later negating their use in the 
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poorer countries most in need of such a vaccine. An Experimental Human Pneumococcal 
Carriage (EHPC) model using live pneumococcal bacteria could provide a vaccine testing 
platform to help select from the multiple pneumococcal vaccines in development using 
prevention of carriage as a surrogate of vaccine-induced immunity, rather than disease, as an 
endpoint. CHAPTER 7. 
The next chapter focuses on the complexities of modern clinical research studies and 
discusses and describes the details of the necessary regulatory processes, our personal 
experience of the challenges posed and how they were overcome. 
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CHAPTER 2: Methods 
 
 
 
 
 
 
2.1 Overview 
 
Modern clinical studies in NHS premises are subject to well-regulated processes that can be 
complex; these are summarised in Figure 5. The flowchart describes the process for the 
studies in this thesis from design to recruitment, highlighting the various approvals required. 
Particular points relevant to the studies in this thesis are described in further detail under the 
following headings: 
• Research Development and Innovation department (RD&I) 
• Ethics (Integrated Research Application System [IRAS] and Research Ethics Committee 
[REC]) 
• Medicines and Healthcare Products Regulatory Authority (MHRA) 
• Other approvals 
• Sponsorship 
• Patient and Public Involvement (PPI) 
• Recruitment and advertising 
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This chapter describes the broad methods relevant to all/most of the studies in this thesis. 
Specific methods relevant to a chapter are considered separately in each chapter to aid ease 
of reading of this thesis.  
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Develop all documentation for ethics: including patient 
information leaflet (PIL), consent form, protocol, GP 
letter, hospital advert. Set up Data Safety and Monitoring 
Committee (DMSC) if required. Engage with finance and 
pharmacy 
Research Development and Innovation department 
(RD&I) - Study number and title 
Review at local RD&I meeting (with 2 peer reviews 
required) – provisional intent to sponsor letter granted 
Develop study design and initial version of protocol +/- 
patient and public involvement (PPI) 
Complete Governance Registration Information 
Document (GRID) and Declaration of Interest (DoI) form 
from RD&I 
Complete Integrated Research Application System (IRAS) 
form – complete REC, R&D and Local Comprehensive 
Research Network (LCRN)/portfolio sections and submit 
JRO (Joint Research Office) application (CTIMP only) 
 
Arrange a date for Research Ethics Committee (REC) 
Medicines and Healthcare Products Regulatory Authority 
(MHRA) and Clinical Trials Application (CTA) in parallel or 
series with IRAS and EudraCT no. (CTIMP only) 
ISRCTN (International Standard Randomised Controlled 
Trials No.) or Clinical Trials.gov registered 
Attend REC 
Address all REC amendments and submit 
REC approval 
Trust agree to sponsor 
HOME FIRST 
Pilot 
specific REC 
required 
PCV 
EHPC 
ALL 
ALL 
ALL 
PCV 
EHPC 
only 
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Figure 5: Complex Process Study Flowchart 
ALL - includes all research studies, since chapter 4 contains audit work only this did not require the same rigorous approval process as the 
research studies in chapter 3, 5, 6 and 7. 
 
Finance and insurance 
Material Transfer Agreements (MTAs) 
Other approvals – Directorate manager, pharmacy 
(CTIMP), Clinical Research Unit (CRU) - if study 
conducted there 
Final trust approval 
Advertising and recruitment 
Site Specific Information Form (SSIF) submission on IRAS 
– only to be submitted right at end after green light and 
ready to start (30 day target) 
National Institute of Health Research (NIHR) Co-
ordinated System for obtaining NHS Permission (CSP) no. 
ALL 
ALL, 
not HF 
ALL 
ALL 
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2.2 Research Development and Innovation Department (RD&I) 
 
The Royal Liverpool and Broadgreen University Hospitals NHS Trust (RLBUHT) has a legal 
obligation as a research host site to ensure that it is aware of and records all research 
undertaken on its premises or by its staff [as per Research Governance Policy (RPOL001)]. 
In our research, each study protocol was sent to RD&I by a member of the study team along 
with a Governance Registration Information Document (GRID) [this form outlines what type 
of study (i.e. CTIMP, non-CTIMP), PI details, which departments within the trust will be used, 
type of study participants, finance details and LCRN involvement] and a Declaration of Interest 
(DoI) form.  Two peer reviews were arranged via RD&I (one internal and one external to our 
study group). At the monthly RD&I study meeting [or Joint Research Office (JRO) meeting for 
all Clinical Trials of Investigation Medicinal Products (CTIMPs) studies], each study was 
discussed and if there were no concerns or protocol amendments required a provisional 
intention of sponsor letter was granted. We then completed and submitted an Integrated 
Research Application System (IRAS) form for each study. 
We developed a strong relationship with RD&I offices at RLBUHT and LSTM. Certain RD&I staff 
members were very knowledgeable about processes and this speeded up the time from study 
registration to the start of recruitment significantly in the studies in Chapters 3, 5. 6 and 7. 
We found communication in person or by telephone particularly helpful rather than email. 
2.3 Ethics: Integrated Research Application System (IRAS) and Research 
and Ethics Committee (REC) 
 
In all 4 research studies (Chapters 3/5/6 and 7) in this thesis, full NHS Research and Ethics 
Committee (REC) approval was required since human volunteers (healthy adults or clinical 
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patients) were to be recruited. The IRAS form and other documents including (at a minimum) 
– a patient information leaflet (PIL), protocol, any questionnaires, provisional intention to 
sponsor letter, advert(s), GP letter and a checklist were uploaded. A REC date was obtained 
by telephoning the Central Booking Service (CBS) which has replaced the Central Allocation 
System (CAS). During the call the study team member confirmed they were ready to submit 
(that same day or within 3 working days), provide the IRAS project ID and contact details of 
the CI and sponsor and answered a series of questions about the study. 
Ethical approval for the studies was granted as follows (Table 3). 
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Table 3: Ethics Committee (and other necessary) Study Approvals for Research Studies 
within this Thesis 
 
Study REC REC approval 
number 
Other 
approvals/ 
registrations/ 
funding 
Sponsor 
Nasal Wash and Lower 
Respiratory Tract 
Infection 
 
Chapter 3 
 
Liverpool 
(East)  
12/NW/0713 NCT 01861184 
 
Pump priming, 
NIHR and BRC 
in microbial 
disease 
 
RLBUHT 
LSTM 
HOME FIRST Feasibility 
 
Chapter 5 
 
Liverpool 
(Central)  
11/NW/0670 ISRCTN 
25542492 
 
Pump priming, 
NIHR and BRC 
in microbial 
disease 
 
RLBUHT 
LSTM 
UHA 
HOME FIRST Pilot 
 
Chapter 6 
 
Manchester 
(South)  
12/NW/0731 NCT 02454114 
 
LHP 
RLBUHT 
LSTM 
Pneumococcal 
Conjugate Vaccine and 
Experimental Human 
Pneumococcal Carriage  
 
Chapter 7 
 
Liverpool 
(East)  
12/NW/0873 ISRCTN 
45340436  
EudraCT 2012-
005141-20 
 
BMG GCE II 
RLBUHT 
LSTM 
[REC (Research Ethics Committee , NCT (National Clinical Trials), ISRCTN (International Standard Randomised Controlled Trials No.), EudraCT 
(European Clinical Trials Database), RLBUHT (Royal Liverpool and Broadgreen University Hospital), UHA (University Hospital Aintree), LSTM 
(Liverpool School of Tropical Medicine), NIHR (National Institute and Health Research), BRC (Biomedical Research Centre), LHP (Liverpool 
Health Partners), BMG GCE II (Bill and Melinda Gates Grand Challenge II Programme)]. 
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In the HOME FIRST pilot study we recruited patients who lacked mental capacity, we therefore 
required approval by a ‘flagged REC’ (a REC able to approve studies involving adults unable to 
consent for themselves). 
The Mental Capacity Act (MCA) 2005 (179) establishes a framework for the protection of the 
rights of people who lack capacity to make a decision for themselves and includes safeguards 
for the conduct of research involving these people. The MCA is designed to ensure that the 
interests and safety of people who lack capacity are protected when they participate in 
research and to ensure that their current and previously expressed wishes and feelings are 
respected. In order for research to be lawful all researchers carrying out studies to which the 
requirements of the MCA apply, must act in accordance with the act. Medical research 
involving adults who lack mental capacity to consent, such as HOMEFIRST pilot, can lead to 
innovations in healthcare that can substantially improve their health and quality of life. Adults 
lacking capacity should be given the opportunity to participate in research, as excluding them 
would be discriminatory and would reduce their ability to participate as much as possible in 
society and would prevent researchers making progress in the understanding of many 
disorders that can affect the brain, and in the care and treatment of those who have such 
disorders (180). 
 
In all research, including those involving adults who lack mental capacity, we should comply 
with accepted principles of good practice, including the Declaration of Helsinki (181) and 
relevant European and UK legislation. Under UK legislation relating to research involving 
adults who lack the capacity to consent, REC approval is a legal requirement.  
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In the HOMEFIRST pilot study since we included patients who lacked mental capacity, their 
participation needed to be agreed by someone who was independent of the study and who 
could assess the potential participant’s interests in accordance with current guidance. This 
person was a relative, a carer or an independent representative. The flagged REC pre-meeting 
process of completing the IRAS form is understandably more complex than a form for a study 
that only includes participants with capacity. The REC meeting itself was relatively 
straightforward however since the REC felt that it was important that patients with a lack of 
capacity were included in our study. 
In line with guidance, where possible, we discussed or communicated with the potential 
participant themselves in a way appropriate to their understanding.  If a person who lacked 
capacity to consent did not seem in agreement with any intervention or part of the study, 
even if agreement has been given by another person, that person was excluded. If this 
happened we were expected to inform the individual’s independent representative that they 
will not be taking part despite the representative’s agreement, and tell them the reasons for 
our decision. This did not occur during in the HOMEFIRST pilot. 
The key principles we considered with regards to the participation of adults who lack capacity 
in our research (180) were: 
• The interests of the individual must always outweigh those of science and society 
• Our research must relate to a condition that affects the individual or the treatment of this 
condition 
• Equally effective research with adults who have the capacity to consent must not be possible 
• The potential benefits of the project should outweigh the risks: the level of acceptable risk 
depends partially on the possible benefit to that individual 
• To seek, where possible, the views of those close to the participant 
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• Only to include a participant where there were no indications that he/she objected to their 
participation. 
In order to decide whether an individual lacked the mental capacity to consent to HOME FIRST 
pilot study participation (180) we assumed capacity to be present unless it is shown to be 
absent. 
 
Capacity was absent if, at the time of decision making if: 
• The patient in question had impaired functioning of their mind or brain 
• This impairment made the person unable to decide whether to participate 
 
The patient was deemed unable to decide whether to take part in research if they could not: 
• Understand the information relevant to the decision (information was given in a way that is 
appropriate to the particular patient) 
• Retain that information for long enough to make the decision (this may be for a relatively 
short time, but still long enough to enable decision making to occur) 
• Use or weigh up that information as part of the process of making the decision (they needed 
to understand the consequences of each option and of not making the decision) 
• Communicate their decision through speech. 
 
With regards to consulting carers (or others) the MCA stipulates that before any decision is 
taken to involve a particular person in REC-approved research, researchers must identify a 
‘consultee’ who is willing to be consulted about the person’s participation (180).  With regards 
to the HOME FIRST pilot, we took reasonable steps to identify and consult a ‘personal 
consultee’. This is someone who cares for or is interested in the potential participant’s welfare 
Methods 
 
60 
 
6
0
 
other than in a professional or paid capacity. If a personal consultee was not available we 
consulted an independent mental capacity advocate (IMCA). It is good practice to involve any 
paid carers who are close to the participant in the decision-making process – even if the 
decision has to be taken by an independent nominee (180).  
 
We gave the consultee the following information in the form of a consultee patient 
information leaflet (PIL) - why they were being approached, their role as a consultee, an 
explanation that their role was completely voluntary and details of the study (as would be 
given to a potential participant with capacity). The consultee then provided ‘advice’ on 
whether the potential participant should take part in the study and what, in their opinion, the 
participant’s views and feelings would have been on taking part in the project had they 
retained capacity. The advice they provide should be recorded on a Consultee Declaration 
Form – this is rather like a consent form for a patient with capacity but importantly the 
consultee is giving their advice only and not their consent. If the consultee advised that the 
person in question would not have wanted to take part in the project, that person was not 
recruited. Similarly, the participant was withdrawn from the project if at any time the 
consultee believed that the participant would not have wished to continue. A consultee 
declaration form was signed by the consultee. Retrospective consent was required for any 
patients in whom a consultee declaration was initially used but who had re-gained capacity 
and were able to give their consent.  
2.4 Medicines and Healthcare Products Regulatory Authority (MHRA) 
 
All CTIMP studies require MHRA approval called Clinical Trial Authorisation (CTA). Either the 
study sponsor or someone authorised by them must apply. They must obtain a European 
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Clinical Trials Database (EudraCT) number. The REC submission and approval can occur 
before, in parallel or after the MHRA submission. Ours occurred before, this may have slowed 
down the process by 1-2mths overall, but leads to less document changes depending on the 
amount of alterations made by the REC. We downloaded and completed a CTA application 
form on the EudraCT website (the IRAS website is an alternative). The study in Chapter 7 (PCV 
EHPC) was a Phase IV CTIMP study and therefore required MHRA approval. A covering letter, 
a CTA form, a study protocol, a simplified IMP dossier (sIMPD), a Summary of Product 
Characteristics (SmPC), a Manufacturer’s Authorisation (MA) and a content of the labelling of 
the IMP were sent with our MHRA application. 
The initial assessment of a submission is completed within 30 days. The outcome of a 
submission can be 1) acceptance of the request for a CTA 2) acceptance of the request for a 
CTA subject to conditions or 3) grounds for non-acceptance of the request for a CTA – you are 
informed as to why and will usually have to amend your application and resubmit. We 
received an outcome 1. 
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2.4.1 Specific Issues Related to a CTIMP study 
 
2.4.1.1 Women of Child-Bearing Potential (WOCBP) 
 
For all CTIMP studies issues related to recruiting women of child-bearing potential (WOCBP) 
contraception and lactation must be addressed. In chapter 7, since the effects of the 
Prevenar-13 and Avaxim on the unborn child are not known, women who were pregnant or 
breast-feeding were not allowed to participate. We confirmed that sexually active women 
were using an effective form of birth control approved by the study team for 1 month prior 
to and after the final vaccination. Contraception methods could include – hormonal 
contraceptives (oral, injection, trans-dermal patch, implants, cervical ring), barrier methods 
(diaphragm with spermicide or a condom), an intra-uterine device, male sterilisation (for 
monogamous individuals only) and true abstinence. Women had to have a negative 
pregnancy test at enrolment and on the day of vaccination and confirmed that they did not 
intend to become pregnant during the study. During this study, any woman who believed they 
may be pregnant was urged to notify the study doctor immediately. Recruiting women of 
child-bearing age is therefore perhaps more challenging in any CTIMP study in terms of work 
load for the team and documentation. We also had to confirm their contraception with their 
GP, this was sometimes challenging as not all women get their contraception from their GP. 
2.4.1.2 Over-volunteering 
 
In CTIMP studies in order to prevent of ‘over-volunteering’, The Over-volunteering Protection 
System (TOPS) database should be used. For the study in chapter 7, we therefore entered the 
participant’s National Insurance (if a UK citizen) or passport number and country of origin (if 
not a UK citizen) and the date of the last dose of study medicine. We called other research 
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units to check the participant’s details as needed. Participant details may be kept for up to 3 
years on this database. A General Practitioner Questionnaire (GPQ) was completed for all 
participants, this is compulsory in all CTIMP studies. Only 1 patient was picked up by this 
system as a potential over-volunteer. We continue to use this system to date and find it 
especially useful to track patients that have previously been used in a pneumococcal carriage 
study that cannot therefore (usually) be re-inoculated. 
2.5 Other Approvals 
 
Given the numerous approvals necessary in RLBUHT especially for CTIMP studies, we 
developed a checklist and used this to ensure all approvals occurred in a timely fashion to 
improve efficiency when setting up our studies (Table 4). This improved our efficiency and 
was pasted to the clinical research unit to be used by other research teams in the future. 
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Table 4: Study Approvals Checklist 
Checklist Tick  
Research Development and Innovation (RD&I) number  
Study title  
Review at local RD&I meeting (with 2 peer reviews required)  
JRO (Joint Research Office) application - CTIMP only  
GRID Form (Governance Registration Information Document) to 
RD&I 
 
Declaration of Interest (DoI) form to RD&I  
Directorate Manager approval  
Intent to Sponsor approval letter (provisional)   
Clinical Research Unit (CRU) application  
Local Comprehensive Research Network (LCRN) portfolio submission  
Research and Ethics Committee (REC) submission [IRAS – REC, R&D 
and portfolio] 
 
RD&I submission  
REC meeting date  
REC post-meeting amendments submitted  
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REC approval  
EudraCT no.  
Medicine and Health Products Regulatory Authority (MHRA) 
Application and Clinical Trials Authorisation (CTA) Application - 
CTIMP only 
 
Finance  
Contracts (commercial)  
Material Transfer Agreements (MTAs)  
Pharmacy application  
Pharmacy green light  
Insurance (co – clinical trials)  
CRU approval  
Site Specific Information Form (SSIF) submission on IRAS – right at 
end post green light after ready to start (30 day target) 
 
RD&I final approval  
ISRCTN (International Standard Randomised Controlled Trials No.) or 
Clinical Trials.gov registered 
 
NIHR Co-ordinated System for obtaining NHS Permission (CSP) No.  
Methods 
 
66 
 
6
6
 
30 Day target achieved (date of PI signature on IRAS form)  
[CTIMP (Clinical Trials of investigational Medicinal Products), EudraCT (European Clinical Trials Database), IRAS (Integrated Research 
Application System), NIHR (National Institute of Health Research), PI (Primary Investigator)]. 
Methods 
 
67 
 
6
7
 
2.6 Sponsorship 
 
2.6.1 Overview 
 
The Trust must ensure that research conducted by its staff or on its premises safeguard’s 
participants and staff and produces accurate and appropriate data which is published. 
The Trust must recognise the role that research governance has to play as the key driver 
in the management, design, conduct and delivery of world class clinical research.  
All research undertaken in the NHS requires a sponsor according to the Research 
Governance Framework Edition 2 2005. For the purposes of drug research, sponsorship 
is defined by the Medicines for Human Use (Clinical Trials) Act regulation 3(1) as the 
institution who takes responsibility for the initiation, management and financing (or the 
arranging of financing) of that trial. For the purposes of research being submitted to REC 
this definition applies to all research. 
The Sponsor ensures that the research safeguards the rights, safety, dignity and wellbeing of 
participants. The sponsor can be any organisation that is a legal entity that funds, initiates, 
hosts or employs staff involved in research.  
Co-sponsorship (in the case of all 4 studies within this thesis between LSTM and RLBUHT +/- 
UHA) involved formal division of the sponsor responsibilities between the parties. In the case 
of a CTIMP like the study in Chapter 7 (PCV EHPC) this was by sponsorship agreement. 
Sponsorship may be withdrawn at the discretion of the Research Governance Committee 
Chair. A Trial Master File (site file) is a legal requirement for CTIMP studies and was kept in 
the locked respiratory research office. The sponsors monitored study conduct in proportion 
to the study risk. Therefore, monitoring for PCV EHPC and HOMEFIRST was relatively tight. 
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2.6.2 Trial Steering Committees (TSCs) and Data Management (and Safety) 
Committees (DM[S]Cs) 
 
All interventional studies should have a TSC. If a study is blinded in the case of the PCV EHPC 
study there is also a legal requirement for a DMC. All DMC’s should conform to the Damocles 
Charter 2005. A DMC or DMSC is a group of people that reviews accumulating data during a 
clinical trial and advises the sponsor on the future management of the trial. They mainly 
review safety and efficacy data but may also review quality and compliance data.  
Not all trials will require a DMC since there is no statutory requirement under the Medicines 
for Human Use (Clinical Trials) Regulations 2004 for the sponsor to appoint a DMC, and where 
a DMC is appointed it has no statutory role.  
The REC receives interim data about clinical trials in progress reports, annual safety reports 
or reports of serious adverse events (SAEs), including any suspected unexpected serious 
adverse reactions (SUSARs) occurring in CTIMPs at UK sites. The REC is not responsible for 
assessing these data however and relies on assurances from the sponsor that it has adequate 
monitoring arrangements in place for monitoring the safety and ethical conduct of a clinical 
trial. 
DMC members are usually themselves experienced trialists. A DMC usually consists of at least 
3 members consisting of clinicians and at least one statistician. The specific role and function 
of the DMC is described in a Charter. The Charter describes the DMC’s membership, roles, 
meeting frequency, how decisions are reached and the reporting structure (Table 5). The 
DAMOCLES group provide a template charter which we then adjusted for the HOMEFIRST 
pilot (chapter 6) and PCV EHPC (chapter 7) studies (182). The sponsor(s) were responsible for 
ensuring that a Charter was in place for the DMC. The REC was aware of the proposed role 
and function of the DMC at the time of the ethical review but did not require a copy of the 
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Charter. The sponsors maintained oversight of both the HOMEFIRST pilot and PCV EHPC 
studies by reviewing the open minutes of TSC’s and DMC’s at the Research Governance 
Committee meetings. 
 
In the study in chapter 7, the DMSC received weekly updates on all recruitment (by email) 
and met formally biannually and also in the event of any serious unexpected serious adverse 
reactions (SUSARs). The DMSC received a weekly safety report from the research team (Table 
6). When the DMSC formally met they reviewed the SmPCs (on medicines.org.uk) for both 
Avaxim and Prevenar-13 vaccinations for updates, any SAEs from the study so far, and 
updated the protocol as necessary.  
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Table 5: Headings from the DAMOCLES Template DMC Charter 
1. INTRODUCTION  
• Name of trial (and Sponsor’s trial no.) 
• Objectives of trial 
• Outline of scope of Charter  
2. ROLES AND RESPONSIBILITIES  
• A broad statement of the aims of the committee  
• Terms of reference (ToR) 
• Specific roles of the DMC  
3. BEFORE OR EARLY IN THE TRIAL  
• Whether the DMC will have input into the study protocol  
• Whether the DMC will meet before the start of the trial  
• Any specific regulatory issues  
• Any other issues specific to the treatment under study  
4. COMPOSITION  
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• Membership and size of the DMC including a chair 
• The Chairs responsibilities and role 
• The responsibilities of the trial statistician  
• The responsibilities of the DMC statistician  
5. RELATIONSHIPS 
• Clarification of whether the DMC is advisory (make recommendations) or executive 
(make decisions)  
• Payments to DMC members  
• The need for DMC members to disclose information about any competing interests 
6. ORGANISATION OF MEETINGS  
• Expected frequency of DMC meetings  
• Whether meetings will be face-to-face or by teleconference  
• How DMC meetings will be organised, especially regarding open and closed 
sessions, including who will be present in each session  
7. TRIAL DOCUMENTATION AND PROCEDURES TO ENSURE CONFIDENTIALITY AND 
PROPER COMMUNICATION  
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• Intended content of material to be available in open sessions  
• Intended content of material to be available in closed sessions  
• Whether or not the DMC will be blinded or unblinded to the treatment allocation  
• To whom the DMC will communicate the decisions/ recommendations that they 
reach and in what form 
8. DECISION MAKING 
• How decisions or recommendations will be reached within the DMC 
• When the DMC is quorate for decision-making  
• What happens to members who do not attend meetings 
10. AFTER THE TRIAL  
• Whether the DMC will have the opportunity to approve publications particularly in 
respect to reporting of any DMC recommendation regarding termination of a trial.  
(Adapted from Data Monitoring Committees in Clinical Trials/ Guidance for Research Ethics Committees – National Patient Safety Agency 
and National Research Ethics Service. May 2010) 
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Table 6: Data Collated on Weekly DMSC Safety Report for the PCV EHPC Study 
Patient ID 
Gender   
Age 
Natural Carrier 
Date of Vaccination  
Vaccination Number 
Vaccine Received 
Adverse Reaction to Vaccine 
Post Vaccine Carriage Status 
Date of Inoculation 
Bacterial Inoculation Dose (CFU/ul) 
Carriage Status at Day 2, 7, 14 and 21 
Post Inoculation Adverse Reaction Symptoms 
Bronchoscopy 
Additional Comments 
[CFU/ul (colony forming units), carriage/carrier = colonised/colonisation status]. 
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2.6.2.1 Adverse Events and Reporting  
 
The following definitions were used throughout this thesis: 
• Adverse drug reaction (ADR): any untoward and unintended response in a subject to an 
investigational medicinal product (IMP) which was related to any dose administered to 
that subject. 
• Unexpected adverse reaction: an adverse reaction the nature and severity of which was 
not consistent with the information about the IMP in the SmPC. 
• Serious adverse event (SAE) or serious unexpected serious adverse reaction (SUSAR): an 
adverse event, adverse reaction or unexpected adverse reaction, respectively, that: (a) 
resulted in death (b) was life-threatening (c) required hospitalisation or prolongation of 
existing hospitalisation (d) resulted in persistent or significant disability or incapacity (e) 
consisted of a congenital anomaly or birth defect. 
 
In the study in chapter 7, any SAEs were recorded and reported to the DMSC and sponsor 
(within 24hrs). It is important to note that hypersensitivity reactions to Prevenar-13 including 
facial oedema, dyspnoea and bronchospasm are rare SAEs. A reaction may result in brief 
hospitalisation (<48 hours), since only one vaccination occurred in this study, the participant 
was still able to remain in the study if this occurred. In the event of any SUSAR the trial was 
to be stopped temporarily for investigation and any further work then referred back to the 
REC and MHRA for further consideration, through the sponsor (within 7 days) [Figure 6]. 
Data on adverse events were collected and categorised as follows: headache, sore throat, 
nasal congestion/ running/ sneezing, myalgia, lethargy, earache/ muffling/ popping, pyrexia, 
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neck stiffness, hospital admission and other (including shivering, wheezy, cough, abdominal 
cramps, photophobia, sinus pain and generally unwell).  
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Figure 6: Trust Adverse Event (AE) and Serious Adverse Event (SAE) Flowchart 
Adapted from RLBUHT RD&I adverse and serious adverse event flowchart. 
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2.6.3 Roles and Responsibilities 
 
The RLBUHT Research Governance Committee maintained responsibility for oversight of 
sponsored research studies and ensured all research undertaken with RLBUHT as 
sponsor/co-sponsor complied with the Research Governance Framework. Our CI 
completed the REC, ensured the Trial Master File (site file) was maintained, archived 
appropriately to have study oversight, ensured the studies were run to relevant legal and 
national standard requirements and undertook any duties delegated by the sponsor via 
contract or sponsorship approval letter. 
The RD&I staff facilitated the Research Governance Committee, ensured all our research had 
a confirmed sponsor and undertook oversight activities on behalf of the Research Governance 
Committee. 
2.7 Patient and Public Involvement (PPI) 
 
PPI was only used in the HOME FIRST studies (chapters 5 and 6) as these were clinical and 
very patient relevant. A broad semi-quantitative analysis of the acceptability of HOME FIRST 
to patients was vital. PPI was very important; we recruited active members of the public to 
our group. LRTI is an acute disease, and is therefore different to chronic disease PPI groups. 
We decided upon a ‘rolling’ cohort of patients for our PPI group. Patients who had 
participated in other pneumonia studies within the Liverpool area were approached and 
asked if they would like to be involved in the design of this study. The group was 
demographically and ethnically representative of the population that presents with LRTI. The 
British Lung Foundation’s ‘Breathe-easy’ patient support groups were also consulted. The 
feasibility study was developed with input from nurses and doctors involved with ‘COPD early 
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facilitated discharge schemes’; as well as respiratory physicians from various hospitals, in the 
UK and New Zealand.  
2.8 Recruitment and Advertising 
 
Participant recruitment is a major challenge in many research studies involving human 
subjects and strategies must be carefully considered prior to the start of the 
study.  Recruitment often both takes longer and is more difficult than expected. If a study is 
unable to fully recruit, this reduction in the sample size leads to reductions in the statistical 
power of the study. Recruitment involves a number of activities, including identifying eligible 
participants, adequately explaining the study to the potential participants and retaining 
participants until study completion. Full details of how participant recruitment will be 
achieved in a study must be completed on the IRAS form. The protocol and IRAS form must 
describe exactly how many participants will be identified, approached and recruited. 
A REC form must state precisely where the advertising will occur – e.g. a particular University, 
GP practices or dental surgeries. We learned to be through in our descriptions of where 
advertising could occur. During studies prior to those in this thesis had learned that we would 
need to go back to the REC to alter our advertising plan i.e. also advertise in Liverpool John 
Moore’s University campus as well as the University of Liverpool campus. A recruitment 
strategy that included the University fresher’s fair and sports fair proved particularly helpful 
for the study in Chapter 7, but the strategy of data collection at these events was also vital to 
maximise the recruitment.  
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2.9 Overview 
 
A clear understanding of the complex processes described in this chapter was fundamental 
to the smooth and efficient running of the studies themselves ensuring timely and effective 
recruitment in safe and ethical studies. The processes are frequently over complicated due to 
ever changing regulations, the acronyms are vast and as a team that was new to many of the 
processes involved in setting up a CTIMP study, advice and help was difficult to obtain within 
an NHS institution, unlike within pharmaceutical companies were departments exist for this 
very purpose. This chapter was partially written as an aide memoire for future trainees at the 
start of this process to better inform them after our experiences, and explaining how we 
overcame the challenges. 
In the following five chapters each of the studies will be discussed in turn working through 
from potential new diagnostics (Chapter 3 Pneumococcal Carriage as a Diagnostic in Adults - 
Lower Respiratory Tract Infection and Nasal Wash Study) , to improving therapeutics through 
early supported discharge schemes including scoping exercises and audits (Chapter 4 
Pneumonia audits), HOME FIRST feasibility (Chapter 5) and pilot (Chapter 6) and finally better 
prevention through developing a new model to test vaccines (Chapter 7 - the Pneumococcal 
Conjugate vaccine and Experimental Human Pneumococcal Carriage Study).  
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CHAPTER 3: Pneumococcal Carriage as a Diagnostic in Adults – Lower 
Respiratory Tract Infection and Nasal Wash (LRTI NW) Study. 
 
 
 
 
 
 
3.1 INTRODUCTION 
 
Recent studies have shown that detection and quantification of nasal pneumococcus 
(Streptococcus pneumoniae) by quantitative real time lytA Polymerase Chain Reaction (qPCR) 
could be used to identify pneumococci as the aetiological pathogen in adults with pneumonia 
(45) and could be useful as a disease severity marker (183). In that study from South Africa 
patients with community acquired pneumonia (CAP) were more frequently colonised than 
controls using classical culture (44.9 v. 11.7%) and qPCR (62.8 v. 19.8%) and, in addition, 
patients with pneumococcal CAP were also noted to have higher colonisation density than 
asymptomatic controls (45). 
 
The association of pneumonia and pneumococcal colonisation has been previously noted in 
children in whom those with radiological pneumonia were more frequently colonised with 
pneumococci than those without (78) and had a higher density of colonisation than those 
with bronchitis or without disease (79). In contrast, in the elderly very low colonisation rates 
have been shown; 0.3% in pneumococcal vaccine naive hospitalised Australians (by classical 
culture) (72) (of which 10 had respiratory infection) and 2.3% in a Portuguese community 
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cohort (184). Numerous studies have examined natural pneumococcal carriage and it is well 
known that rates vary by age and geographic area (71). In developed countries, pneumococcal 
colonisation rates in healthy adults are between 1 - 18%, and are affected by age, immune 
status, antibiotic use, household composition and contact with children (70, 71). There are no 
published data on pneumococcal colonisation in hospitalised patients with respiratory 
infection in the UK. 
 
We therefore aimed to determine the rate and density of pneumococcal colonisation by a) 
classical culture and b) qPCR in hospitalised adult patients with LRTI when compared with age 
and gender-matched controls in a developed country setting.  
3.2 METHODS 
3.2.1 Screening and Recruitment 
 
For full details see the study protocol in Appendix A. We recruited hospitalised adults with 
LRTI at the Royal Liverpool and Broadgreen University Hospital from January - July 2013 within 
72 hours (hrs) of admission. The syndrome of LRTI was defined as; symptoms of respiratory 
infection with clinical signs +/- radiological consolidation; therefore meeting the BTS 
definition of pneumonia as used in community (GP) practice. Clinical signs of LRTI included ≥2 
of: cough, breathlessness, pleuritic chest pain, fever, increased or new sputum production. 
Inclusion and exclusion criteria were used (Table 7 and 8). 
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Table 7: Inclusion and Exclusion Criteria for LRTI Patients 
Inclusion criteria  Exclusion criteria  
Community-acquired pneumonia (CAP) 
[radiological consolidation] or LRTI [no 
radiological consolidation] 
Infective exacerbation of COPD 
(IECOPD) or bronchiectasis [without 
radiological consolidation] 
Able to give fully informed consent 
(mental capacity assessed using trust 
guidelines) 
Aspiration pneumonia 
Age>18yrs old Oxygen saturations <86% on air 
Fluent English speaker Tuberculosis suspected 
Neutropenia 
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Table 8: Inclusion and Exclusion Criteria for Control Patients 
Inclusion criteria  Exclusion criteria  
Able to give fully informed consent (mental 
capacity assessed using trust guidelines) 
Signs/symptoms of respiratory 
infection 
Age>18yrs old Oxygen saturations <86% on air 
+/- 10 years of recruited LRTI patient Neutropenia 
Fluent English speaker  
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Patients with an infective exacerbation of chronic obstructive pulmonary disease (IECOPD) 
were excluded as these exacerbations are known to commonly be due to viruses (up to 60%) 
(185, 186), Haemophilus influenzae (up to 33%) (187) and Moraxella catarralis (around 10%) 
(188) rather than pneumococcus. Patients who had been a hospital inpatient for ≥72 hrs or 
had recently been discharged from hospital ≤14 days before were excluded since it is likely 
their nasal flora would have altered due to hospital exposures. Patients with oxygen 
saturations <86% on air were excluded since it was felt unsafe to remove their oxygen in order 
to perform a nasal wash (NW). 
A carefully selected control group of hospitalised patients with no signs of respiratory 
infection were recruited within 7 days (where possible or as soon after as possible) of the LRTI 
patient. The control group were matched for age (within 10 years of the LRTI patient) and 
gender. Exclusion criteria were: oxygen saturations <86% on air, neutropenia, ≥ 7 days after 
admission and recent hospital discharge ≤14 days.  
A list of potential participants was generated on a daily basis (Monday to Thursday) in 
combination the hospital capacity team, ward based case managers and medical co-
ordinators in accident and emergency (A&E), acute medical admissions unit (AMAU) and 
respiratory wards. To recruit for control participants we targeted surgical wards. Patient 
eligibility was confirmed by review of the medical records. If consent was given baseline 
clinical data of age, gender, history of presenting complaint, past medical history, vaccination 
history, antibiotic prescription, and contact with children (defined as at least alternate day 
contact with children aged ≤ 10yrs) on recruited patients was recorded. NW and urine 
samples were collected within 12 hours of recruitment. The study was approved by Liverpool 
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East, North-west NHS Research Ethics Committee (12/NW/0713) and registered with 
ClinicalTrials.gov (NCT01861184).  
3.2.2 Sampling 
 
NW was collected on the day of recruitment with a maximum of 20 mls of normal saline 
instilled into the nasopharynx as previously described (178, 189). A minimum of 5 mls of 
normal saline was recovered and processed in all cases. Nasal wash processing was as per 
SOP (Appendix A). In a subset of samples that exceeded 7 mls a proportion of the sample (3 
– 5 mls) was removed and centrifuged at 836 x g to obtain cellular material after which the 
supernatant was re-added to the rest of the sample for the high speed spin. 
3.2.3 DNA Extraction and qPCR 
 
For DNA extraction/qPCR methods see Appendix B. 
A sample was considered positive if both duplicates had a mean cycle threshold (CT) value of 
<35 (this value was chosen to maximise positive reactions indicative of moderate amounts of 
the target nucleic acid but to minimise positive reactions due to environmental 
contamination). Values of >8,000 copies/ml were considered clinically relevant according to 
Albrich and colleagues (45).  
3.2.4 Binax 
 
An immunochromatographic membrane test (ICT) (BinaxNOW Streptococcus pneumoniae; 
Binax) was performed on all patient’s unconcentrated urine specimens, according to the 
manufacturer’s recommendations. 
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3.2.5 Statistical Analysis Plan 
 
Using published data showing a carriage rate of 10% in developed countries in healthy adults, 
11.7% in healthy South African adults (including HIV positive), 1% in hospitalised elderly 
Australian patients and 45% in South African patients with CAP; to detect a difference 
between 1 and 11.7% with an 80% power we required n=107 in each group. To detect a 
difference between controls of 11% and patients of 45% we required n=55 in each group 
(power 97.8%) or n=40 (power 91.3%). We aimed to recruit 100 patients with LRTI and 100 
controls to the study. 90% power means the ability to demonstrate an association between 
pneumococcal colonisation rates and disease status (i.e. LRTI) if an association exists I.e. this 
study has a 90% chance of ending up with a p value of less than 5% if there really was an 
important difference between the variables. By convention, 80% is an acceptable level of 
power. 
3.3 RESULTS 
3.3.1 Screening and Recruitment 
 
We screened 826 patients and recruited 19 LRTI and 19 control (age, gender and season 
matched) patients. 217 were ‘potential’ LRTI patients, of which 198 were not eligible (Figure 
7). We planned to recruit 100 patients to each arm of the study, but stopped recruiting early 
on the grounds of futility due to high overall screen failure rate (778/816, 95.4%); data were 
analysed after this decision. For those patients with LRTI the recruitment rate was 8.8%, and 
for controls 3.1%. Recruiting age matched controls was difficult, especially for the younger 
LRTI patients (aged 36 - 46 yrs old). In 9 cases, the time between the recruitment of the LRTI 
patient and control was >7 days (range 9 - 43).  
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Figure 7: Screening and Recruitment Flowchart 
Reasons for non-recruitment for lower respiratory tract infection (LRTI) patients are detailed. Total no. screened n = 826. Note multiple 
reasons for non-recruitment per patient were possible.  
 
Assessed for eligibility 
for control group 
(n=609) 
Excluded (n=198) 
• Not meeting inclusion criteria (n=90) 
o No LRTI (n=58) 
o >72 hours after admission (n=48) 
• Meeting exclusion criteria (n=86) 
o Aspiration pneumonia (n=12)  
o No capacity (n=36) 
o Recent hospital discharge ≤14 days 
(n=17) 
o Oxygen saturations on air <86% (n=10) 
o Other reasons (n=14, including 
nasogastric tube insitu n=2, nasal 
abnormality n=1, neutropenia n=1, 
possible tuberculosis n=1, too unwell 
n=10, missed [discharged/not on ward] 
4) 
• Declined to participate (patient n=20, next of kin 
n=2) 
Recruited 
n=38 
Controls recruited 
n=19 
LRTI recruited 
n=19 
Assessed for eligibility 
for LRTI group    
(n=217) 
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58 patients did not have a syndrome of LRTI (acute exacerbation [AE] COPD n=22, AE 
bronchiectasis n = 5, AE asthma n=3, AE pulmonary fibrosis n= 1 and alternative diagnoses 
including pulmonary embolus (PE), congestive cardiac failure (CCF), sepsis of unknown cause 
and adult acute respiratory distress syndrome (ARDS) n = 30), 36 patients did not have 
capacity to consent (predominately due to dementia or acute delirium), 48 patients were 
identified >72 hours after admission and 17 after a recent hospital discharge ≤14 days before, 
20 patients declined to participate and 2 ‘next of kin’ refused permission for their relative to 
participate, 10 oxygen saturations <86% on air, 12 aspiration pneumonia, 14 were excluded 
for other reasons.  
3.3.2 Sampling: Rate of Colonisation  
 
All recruited patients were successful at providing a nasal sample. One patient was unable to 
replicate the NW technique (as per protocol) and had a nasopharyngeal swab instead. NW 
volumes were not significantly different between LRTI patients and controls (Table 9). 
Pneumococcal colonisation was detected using classical microbiology in 1 LRTI patient and 3 
controls (p=0.6). Using qPCR 10 LRTI patients and 8 controls were positive (p=0.516) [Table 
10]. One of the controls was positive for colonisation by culture but considered negative by 
qPCR as the CT value was >35.  
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Table 9: Baseline Demographics, Antibiotic Status, Nasal Wash Volume Returned and 
Evidence of Pneumococcal Disease Investigation Results of Patients with Lower 
Respiratory Tract Infection (LRTI) and Age and Gender Matched Hospitalised Controls. 
 
 LRTI (n=19) Control (n=19) p value 
Gender: Male n (%) 
 
9 (47.4) 9 (47.4) 1.000 * 
Age Years ± SD 
 
64.47 ± 15.78 64.58 ±14.50 0.954 β 
Smoker/ ex-smoker n (%) 
 
15 (78.9) 10 (52.6) 0.170 α 
23 PPV Pneumovax n (%) 
 
7 (36.8) 8 (42.1) 0.740 * 
Contact with children n (%) 
 
10 (52.6) 12 (63.2) 0.511 * 
Antibiotics at time of recruitment n (%) 
 
19 (100) 3 (15.8) 0.0001 α 
Nasal wash volume returned (ml) ± SD 
 
10.14 ± 3.14 10.36 ± 4.83 0.855 β 
Evidence of pneumococcal disease: 
Binax urine test positive n (%) 
2 (10.5) 0 (0) 0.486 α 
Evidence of pneumococcal disease: 
Blood or sputum culture positive n % 
0 (0) N/A N/A 
*Chi Square, β Mann Whitney U test, α Fisher’s Exact, SD standard deviation, PPV polysaccharide vaccine 
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Table 10: Pneumococcus Identification (by culture, qPCR) and Density (by qPCR) in 
Patients with Lower Respiratory Tract Infection (LRTI) and Age and Gender Matched 
Hospitalised Controls. 
 
 LRTI (n=19) Control (n=19) p value 
Culture positive n (%) 1 (5) 3 (15.8) 0.604 α 
qPCR positive n (%) at detection 
limit 
10 (52.6) 8 (42.1) 0.516 * 
Density (by qPCR) copies/ml 
geometric mean [95%CI] 
3066 [1225 – 7675] 2208 [244 – 19972] 0.408 β 
Clinically relevant density n (%) 
[by qPCR] >8000 copies/ml 
3 (16) 4 (21) 0.999 α 
α Fisher’s Exact, *Chi squared, β Mann Whitney U test, qPCR quantitative polymerase chain reaction 
Note low rates of culture positivity and high rates of qPCR positivity in both LRTI and control groups. 
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3.3.3 Sampling: Density of Colonisation by qPCR 
 
For qPCR a cut off value of >8000 copies/ml was used to define clinical relevance (45). In our 
study, 3 LRTI patients and 4 controls had values >8000 copies/ml. Of the 3 LRTI patients, only 
1 was culture positive; of the 4 controls, 2 were culture positive (Table 10). Of the 4 patients 
overall who were culture positive, 3 had >8000 copies/ml, 1 in the LRTI and 2 in the control 
group. 
3.3.4 Clinical Data 
 
Antibiotic usage prior to sampling was significantly higher in LRTI patients than controls 19 v. 
3 (p<0.001). Radiological consolidation was present in 7 out of 19 LRTI patients; only 2 out of 
38 urine samples were positive using BinaxNOW. None of the LRTI patients recruited were 
pneumococcal sputum or blood culture positive. There were no statistical differences 
between the groups with regards to smoking, contact with children age <10yrs old or 23 PPV 
pneumovax vaccination (Table 9).  
3.4 DISCUSSION 
 
We found low rates of pneumococcal colonisation by culture  in the LRTI group. Antibiotic use 
prior to hospital admission was high. All LRTI patients had received at least 2 doses (pre-
admission/pre-recruitment) prior to NW sampling; this is likely to have resulted in culture 
negativity. Previous antibiotic therapy has been noted to decrease culture and qPCR positivity 
by up to 50% (45). We also found no significant differences between the LRTI and colonisation 
groups in either colonisation rates using qPCR or colonisation density. 
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In our study classical pneumococcal pneumonia was rare. Accurately diagnosing pneumonia 
is challenging; inter-doctor variability in reporting of radiologically confirmed pneumonia is 
common (190). The Royal Liverpool hospital has ~1,400 admissions per year that are coded 
as “pneumonia”; approximately 20% of these cases are not in fact community acquired or the 
patients have no radiological features of pneumonia. Having ‘pneumonia diagnosed 
radiologically’ as an inclusion criterion in a study may in fact make the results less applicable 
to everyday hospital medicine. LRTI may be a more useful term for this clinical syndrome, 
particularly in instances where the guidelines suggest clinical rather than radiological 
diagnosis (7). A large number of our patients were referred with potential LRTI but alternative 
diagnoses such as PE, CCF, non-infective exacerbation of pulmonary fibrosis, sepsis of 
unknown cause, and aspiration pneumonia were common. This diagnostic imprecision has 
important implications for the use of NW sampling as a diagnostic technique since it would 
lead to many inappropriate samples being collected. Liverpool is in northwest England and 
has the second highest LRTI rate (age standardised episodes/1,000 person years) and the third 
highest CAP rate nationally (191). It is therefore an ideal area for recruitment for respiratory 
infection studies, although community antibiotic prescription rates are high.  
The main strength of this study is the large number of screened patients; the LRTI patients 
were well phenotyped, and the controls were matched in age, gender, and time of 
recruitment and had similar smoking habits, 23PPV (Pneumovax) vaccination rates, and child 
contact. Our cohort did not have CAP by the strict definition of radiological consolidation; 
rather a broad study group of LRTI patients was chosen due to its clinical relevance in United 
Kingdom hospital practice and admissions, making these results very generalisable. 
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Nationally, the antibiotic prescribing rate by GPs for LRTIs is very high but is lower for clinically 
diagnosed CAP (due to the usual immediate hospitalisation) (191). 
The limitations of the study are that this is a single centre study, which may reduce the 
generalisability of the results, specifically in areas where community antibiotic prescription 
rates are lower, that we were unable to fully recruit for the study despite the high numbers 
of individuals screened, and that the NW sampling technique, rather than nasopharyngeal 
swab may not have been ideal in this population. 
In this elderly population research nurses noted poor performance and lower yields after 
nasal wash than in the cohort of healthy volunteers in which we more commonly use this 
technique (data not shown). Nevertheless, patient comfort is higher (192), and the sensitivity 
for colonisation density is very high (193). We know from our Experimental Human 
Pneumococcal Colonisation (EHPC) studies that antibiotic usage terminates pneumococcal 
colonisation; after an interim analysis noted 100% antibiotic usage in the LRTI group prior to 
recruitment and low rates of colonisation (on culture), the study was stopped on the grounds 
of futility as continued recruitment in this population was considered unethical. Controls in 
particular were hard to recruit, patients frequently declined to participate. This may have 
been because they were feeling too unwell and therefore not keen to be involved in a 
research study, or because they were less motivated to be involved in research of a condition 
that they felt did not directly affect or benefit them. Recruitment also occurred whilst I was 
on maternity leave in early 2013. Screening was carried out by two senior nurses (1 an 
experienced researcher) and a junior doctor. I believe that the lack of clear daily leadership 
and therefore search strategy meant that the numbers screened were higher than necessary 
and the whole process less efficient. This process was not aided by difficult old hospital 
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computer systems (these have more recently been updated at RLBUHT). It would have helped 
recruitment if there was a small reimbursement for the controls, the REC had informed us 
that this should be removed from our initial draft protocol unfortunately.  
We found very low colonisation rates in LRTI patients. Previous studies have shown 
colonisation rates of 44.9% and 62.8% in patients with radiologically confirmed CAP compared 
to 11.7% and 19.8% in controls by culture and qPCR, respectively (45); in comparison, we 
detected colonisation rates of 5% and 15.8% (>8,000 copies/ml) in patients with LRTI and 
15.8% and 21.0% (>8,000 copies/ml) in controls. The differences between the two studies 
may be due to the fact that our patient cohort was considerably older (64.5 versus 38.4 years 
old) (45), had low rates of radiologically confirmed pneumonia (36.8%), had high rates of prior 
antibiotic treatment, had high rates of contact with children, and were presumed to be HIV 
uninfected (the overall incidence of HIV infection is low in Liverpool: 15 cases per 100,000/yr 
in 2011 [D. Sloan, unpublished local data]). Previously in Liverpool, we found natural 
colonisation rates of 10% in healthy non-smoking volunteers by classical culture (25/249, aged 
23 years old [SD±5.7]) (unpublished data). The higher rate (15.8%) in this cohort may be 
related to the high rates of contact with children and smoking history or our patients. There 
were also no significant differences in the colonisation rates in polysaccharide-vaccinated 
(23PPV, Pneumovax) and unvaccinated patients, consistent with previous literature stating 
that the vaccine does not protect against colonisation (162, 194). 
qPCR can deliver results within a few hours (usually 3 to 6 hrs), which might impact the critical 
phase of early clinical care (42); however, it does not distinguish between viable (live) and 
nonviable (dead) bacteria or determine whether the bacteria are pathogens or colonisers (46, 
48). Specificity can also be an issue with qPCR, and there have been concerns that lytA may 
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not discriminate between Streptococcus pneumoniae and Streptococcus viridans; however, 
lytA is currently the most widely used target gene for pneumococci, and we have previously 
shown that our assay specificity (193) is in line with that reported by others (195). 
Within this cohort, all LRTI patients had taken antibiotics prior to sampling, which probably 
accounts for the higher positivity rate of qPCR over culture. Although qPCR techniques detect 
both viable (live) and non-viable (dead) bacteria, prior antibiotic treatment has been shown 
to lower plasma and pleural fluid PCR load (28) as well as sputum and blood culture positivity. 
It is not known how rapidly pneumococci will be undetectable by qPCR in the NW samples of 
those with previous pneumococcal colonisation after antibiotic therapy. It may be that 
antibiotics reduce the pneumococcal load within the nasopharynx level within days. However, 
a lower cycle threshold value cannot be used in an attempt to compensate for the effect of 
the antibiotics, due to cross-reactivity from other pathogens (and therefore false positives) 
and contamination being a limitation with the qPCR technique. 
Albrich and colleagues suggested that a density of 103 to 104 may be the critical value at which 
colonisation leads to infection (45); however, we have found densities as high as or higher 
than these in our cohort of healthy volunteers after experimental colonisation without 
infection (177, 193). Colonisation densities were not different in the LRTI and control groups; 
we also found high mean densities of ≥103 in those without infection (n = 4 controls). It is 
possible, therefore, that if colonisation is dense and in the setting of the correct clinical 
syndrome, then the pneumococcus is a likely pathogen. Again, an important difference 
between the two study groups may be HIV infection status. Only 10.5% (2/19) of our LRTI 
group were BinaxNOW positive compared to 72.7% in patients with non-bacteraemic CAP in 
another study (45). The BinaxNOW results remain positive for at least 7 days after the 
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initiation of antibiotic treatment (196); notably, our urine samples were taken up to 72 h after 
admission but often several days after antibiotics had been started.  
In conclusion, we have shown that pneumococcal colonisation (assessed by culture and qPCR) 
cannot be used as a method of diagnosis for pneumococcal blood culture-negative 
hospitalised adults with LRTI in the United Kingdom, since such patients have already received 
antibiotic therapy in the community setting and the laboratory test is non-discriminatory. 
Further, the number of adults tested for potential LRTI on screening would be impracticable 
in terms of staff resources. Potentially a community-based study recruiting patients prior to 
antibiotic therapy may, however be a useful future step. In such a study, nasal washes could 
be performed by GPs or nurses in all patients with symptoms of respiratory infection prior to 
antibiotic therapy with the aim of eventually guiding treatment. 
Chapter 4, describes the beginnings of work relating to an early supported discharge scheme 
for patients with LRTI. 
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CHAPTER 4: Audits to Assess the Causes of Increased Hospital Length 
of Stay and the Feasibility of Early Supported Discharge in Adults with 
Pneumonia. 
 
 
 
 
 
 
 
4.1 INTRODUCTION 
 
Hospitals are working at full capacity and are struggling to meet the demands placed upon 
them (197). Not only are admissions rising yearly, patients are ever more likely to have 
multiple co-morbidities (198), and an increasing number and complexity of tests and 
treatments can be provided. Despite these pressures, acute hospital bed capacity has fallen 
over the past 25 years (199) thus there is a pressing need to reduce both the number of 
patients admitted and their length of stay (LOS); this is of particular relevance at the Royal 
Liverpool and Broadgreen University Hospital Trust (RLBUHT) since the new hospital opening 
in 2017 will have a 15% fewer beds, with the bed capacity reduced from 750 to 646 in total. 
Achieving reductions in numbers of patients admitted and LOS will require improvements in 
the efficiency of existing processes and action to address the significant number of in-patients 
who could be equally well treated elsewhere (199). In addition to the cost-savings, reducing 
unnecessary bed days also reduces the risk of potentially serious adverse events (SAEs) such 
as hospital-acquired infections (HAI). 
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Hospital at Home (HAH) schemes and other innovations that reduce the demand for beds 
have become increasingly popular (96). They offer the potential to reduce admission rates, 
LOS and costs (97). They have been successfully implemented for some diseases (e.g. chronic 
obstructive pulmonary disease [COPD] and heart failure) (104), however little evidence for 
HAH schemes exists for patients with lower respiratory tract infections (LRTI) and pneumonia. 
Influenza and LRTI (including pneumonia in this definition) are the most common infection-
related causes of hospital admission in the UK (200) but a patient’s prolonged LOS is often 
unrelated to the severity of the acute illness (90). Physicians also tend to over-estimate the 
likelihood of death from pneumonia (201) and there is large variability in rates of 
hospitalisation across nearby geographical regions. The risk of adverse outcomes (death, 
readmission rates, delayed return to work/usual activity) does not vary between hospitals 
when comparing LOS (106). Dr Foster data benchmarks LOS outliers by diagnostic group for 
all hospitals in England (202). In 2010, these data indicated that investigating the prolonged 
LOS amongst patients with pneumonia at RLBUHT should be a Trust priority, due to our 
hospital being an outlier in terms of increased LOS. 
This chapter describes the scoping exercise and feasibility testing by a retrospective coding 
audit. In part 1 we investigated the possible causes for the increased LOS in patients at 
RLBUHT (methods and results are presented sequentially), and in part 2 we investigated the 
proportion of patients in whom the LOS could have potentially been reduced if they were 
discharged with a hypothetical early supported discharge scheme [ESDS] (again methods and 
then results discussed sequentially), in order to assess the feasibility of an ESDS for patients 
with LRTI.  
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4.2 METHODS AND RESULTS 
1.2.1 Part 1 - Methods 
 
We set out to define the possible causes of increased length of hospital stay (LOHS) for cases 
of pneumonia. Factors considered included: severity of illness often defined by CURB-65 
(actually a mortality risk not severity score), co-morbidities, low oxygen saturations, lack of 
social support, excess alcohol consumption, illicit drug use and the development of 
pulmonary or medical complications. During this retrospective case-note audit data were 
collected to address the clinical coding accuracy for pneumonia, LOS and clinical course during 
the hospital stay. We assessed all admissions coded as ‘pneumonia’ over a 2mth period in 
2011 (this included hospital-acquired, community-acquired and aspiration pneumonias) and 
located their case notes. We considered patients to have been correctly coded as pneumonia 
if they demonstrated ALL 3 of the following 1) symptoms of pneumonia 2) clinical signs of 
pneumonia and 3) radiological evidence of consolidation.  
1.2.2 Part 1 – Results 
 
130 patients were admitted and coded as pneumonia during this 6 week period, their case 
notes were located and assessed.  
Demographics 
The median LOS 7 days in males versus 6.5 (1-43) days in females was similar (p=0.626). In age 
groups 51-60 yrs old and 81-90 yrs old almost 50% patients died and for those ≥ 90 yrs old 
mortality was 100% (Figure 8). 
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Figure 8: Patient Age and Outcome - Hospital Discharge or Death for Patients Coded as 
Pneumonia 
The number of patients grouped by age (in 10 year blocks) discharged from hospital compared with mortality. 
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Diagnostic accuracy 
Of the 130 cases reviewed, 47 cases (36%) fulfilled the 3 diagnostic criteria of pneumonia. 
Median LOS in correctly coded pneumonia cases was 11 days vs 10.5 days for miscoded 
pneumonia cases (p=0.4). 
Outcome 
Median LOS for patients with vs without associated co-morbidities was 11.4 vs 8.4 days. 
Median LOS for patients with a complication or another medical condition during their stay 
(n=26) was 14 vs 7 days for patients who had an uneventful recovery (n=21). 
1.2.3 Part 2 - Methods 
 
We then performed a further retrospective case-note audit from all admissions coded as ICD-
10 ‘J-code 10-18’ (Table 11) over a representative 2-mth period in 2011. We selected every 
10th case note for review. Two reviewers reviewed the selected case notes using pre-defined 
inclusion and exclusion criteria to assess the patients’ potential eligibility and suitability to an 
early supported discharge home care scheme (Table 12 and 13). Eligibility is defined in this 
thesis study as a patient with an appropriate respiratory infection that means they are eligible 
for a home-based respiratory infection ESDS. J-codes 10-18 were chosen as they include all 
patients coded by the hospital coding team on hospital discharge as either having a diagnosis 
of influenza, viral pneumonia, bacterial pneumonia and pneumonia of unknown aetiology. 
The International Statistical Classification of Diseases and Related Health Problems 10th 
Revision (ICD-10) 2015 is a medical classification list from the World Health Organisation 
(WHO). It contains codes for diseases, signs and symptoms, abnormal findings, complaints, 
social circumstances, and external causes of injury or diseases. J-codes code for diseases of 
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the respiratory system, whilst G-codes code for diseases of the nervous system and K-codes 
for the digestive system. 
A patient was considered eligible if they had a diagnosis of respiratory infection as defined in 
Table 12. Patients with or without mental capacity were considered eligible. A patient was 
considered suitable if they not only had the appropriate diagnosis (i.e. were eligible) but also 
a number of other criteria (inclusion) were met including ‘able to manage activities of daily 
living with current support’ and stable pre-defined observations, whilst other criteria 
(exclusion) were not met such as, no fixed abode or neutropenia (Table 13). Many of these 
suitability criteria amount to ensuring the safety of a patient for discharge from hospital. 
 
Pneumonia Audits 
 
105 
 
1
0
5
 
Table 11: International Statistical Classification of Diseases and Related Health Problems 
10th Revision (ICD-10) 2015. Diseases of the Respiratory System – J10-18 
J10 Influenza due to other identified influenza virus 
J10.0 Influenza with pneumonia, other influenza virus identified 
J10.1 Influenza with other respiratory manifestations, other influenza virus 
identified 
J10.8 Influenza with other manifestations, other influenza virus identified 
J11 Influenza, virus not identified 
J11.0 Influenza with pneumonia, virus not identified 
J11.1 Influenza with other respiratory manifestations, virus not identified 
J11.8 Influenza with other manifestations, virus not identified 
J12 Viral pneumonia, not elsewhere classified 
J12.0 Adenoviral pneumonia 
J12.1 Respiratory syncytial virus pneumonia 
J12.2 Parainfluenza virus pneumonia 
J12.3 Human metapneumovirus pneumonia 
J12.8 Other viral pneumonia 
J12.9 Viral pneumonia, unspecified 
J13 Pneumonia due to Streptococcus pneumoniae 
J14 Pneumonia due to Haemophilus influenzae 
J15 Bacterial pneumonia, not elsewhere classified 
J15.0 Pneumonia due to Klebsiella pneumoniae 
J15.1 Pneumonia due to Pseudomonas 
J15.2 Pneumonia due to staphylococcus 
J15.3 Pneumonia due to streptococcus, group B 
J15.4 Pneumonia due to other streptococci 
J15.5 Pneumonia due to Escherichia coli 
J15.6 Pneumonia due to other Gram-negative bacteria 
J15.7 Pneumonia due to Mycoplasma pneumoniae 
J15.8 Other bacterial pneumonia 
J15.9 Bacterial pneumonia, unspecified 
J16 Pneumonia due to other infectious organisms, not elsewhere classified 
J16.0 Chlamydial pneumonia 
J16.8 Pneumonia due to other specified infectious organisms 
J17 Pneumonia in diseases classified elsewhere 
J17.0 Pneumonia in bacterial diseases classified elsewhere 
J17.1 Pneumonia in viral diseases classified elsewhere 
J17.2 Pneumonia in mycoses 
J17.3 Pneumonia in parasitic diseases 
J17.8 Pneumonia in other diseases classified elsewhere 
J18Pneumonia, organism unspecified 
J18.0 Bronchopneumonia, unspecified 
J18.1 Lobar pneumonia, unspecified 
J18.2 Hypostatic pneumonia, unspecified 
J18.8 Other pneumonia, organism unspecified 
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J18.9 Pneumonia, unspecified 
Pneumonia Audits 
 
107 
 
1
0
7
 
Table 12: Pre-defined Inclusion and Exclusion Criteria to Assess Eligibility to the Early 
Supported Discharge Scheme (ESDS) 
INCLUSION CRITERIA EXCLUSION CRITERIA 
The below criteria were used to assess eligibility for ESDS: 
• Pneumonia - community acquired (CAP) 
or hospital acquired (HAP) 
• Acute tracheo-bronchitis & acute 
bronchitis 
• Non-pneumonic LRTI 
• Infective exacerbation of asthma 
• Infective exacerbation of bronchiectasis 
• Lung abscess 
• Pneumonia with concomitant COPD (if 
this service was not already provided 
elsewhere) 
Acute exacerbations of COPD – 
infective & non-infective (other 
services already provided) 
 
[HAP (hospital acquired pneumonia), CAP (community acquired pneumonia), LRTI (lower respiratory tract infection), COPD (chronic 
obstructive pulmonary disease)]. 
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Table 13A: Pre-defined Inclusion and Exclusion Criteria to Assess Suitability to Early 
Supported Discharge Scheme (ESDS) 
INCLUSION CRITERIA EXCLUSION CRITERIA 
The below criteria were used to assess suitability for ESDS: 
Simple pleural effusions only (ideally a 
diagnostic pleural tap is performed in 
all cases) 
Patients with CURB-65 >3 (MUST be 
discussed with the study doctor prior to 
discharge to define treatment ceilings 
and future plans) 
Can manage ADLs with current support 
– immediate OT/ physiotherapist/ 
social assessment/ care can be 
arranged prior to discharge (if needed) 
and continued at home 
Patients unable to manage at home even 
with maximal support from ESDS (this 
may include some patients IV drug users, 
with ETOH excess or mental health 
problems) 
Has a phone Serious co-morbidities requiring hospital 
treatment (e.g: CKD, CCF) or deemed 
unstable (significant AKD) 
Age>18yrs old Neutropenia 
Improving inflammatory markers 
(WCC/CRP) 
Empyema or complicated 
parapneumonic effusion 
Stable or improving U&Es Sats <92% on air (unless patient has 
underlying respiratory disease [except 
asthma] when sats <88% - all these cases 
MUST be discussed with study doctor) 
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Patients requiring oral or IV antibiotics SBP <90mmHg 
EWS ≤2 (see Table 13B) AND SBP >90 
AND mild confusion only. All 
observations must be stable for 12-
24hrs  
Suspected MI/NSTEMI OR acute ECG 
changes (within 5 days of discharge date) 
Well enough for discharge without ESDS 
scheme support 
Tuberculosis suspected 
No fixed abode 
[ADLs (activities of daily Living), OT (occupational therapist), ESDS (early supported discharge scheme), CKD (chronic kidney disease), CCF 
(congestive cardiac failure), AKD (acute kidney disease), IV (intravenous), WCC (white cell count), CRP (C-reactive protein), sats (oxygen 
saturations), U&Es (urea and electrolytes), po (per oral), MI (myocardial infarction), TnI (troponin I), SBP (systolic blood pressure), EWS (early 
warning score – see Table 13B), NSTEMI (non-ST-elevation myocardial infarction, ECG (electrocardiogram), NOK (next of kin)]. NB: If 
escalation of care not appropriate & palliative care appropriate if no improvement within 48hrs: then ONLY criteria -  stable SBP>90 AND 
sats>90% air AND phone AND >18yrs old apply 
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Table 14B: RLBUHT Early Warning Score Scale 
Score 3 2 1 0 1 2 3 
Respiratory rate 
(breaths/min) 
>35 31-35 21-30 9-20 
  
<9 
SpO2 (%) <85 85-89 90-92 >92 
   
Temperature (C) 
 
>38.9 38-38.9 36-37.9 35-35.9 34-34.9 <34 
Systolic BP 
(mmHg) 
 
>199 
 
100-
199 
80-99 70-79 <70 
Heart rate 
(bpm) 
>129 110-129 100-
109 
50-99 40-49 30-39 <30 
AVPU 
   
Alert Voice Pain Unconscious 
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1.2.4 Part 2 - Results 
 
54 case notes were randomly selected from 549 admissions. Of the 54 case notes reviewed, 
59% (n=31) of patients coded as CAP had a CURB65 <3. The mean age was 70 (18-96) yrs old 
and mean CURB-65 = 1.93 (range 0-4). Of n=38 CAP patients, CURB-65 scores were as follows: 
0-1=32%, 2 = 26%, 3-5 = 34%. 46 patients were eligible for ESDS and of these 22 (48%) were 
suitable. 85% (n=39) of eligible patients had co-morbidities, but these did not necessarily 
make patients unsuitable for ESDS. Co-morbidities were common and are described in detail 
in Table 14. Where discharge was deemed to be delayed reasons are described in Table 15. 
We calculated the total reduction in LOS with ESDS using our inclusion/exclusion criteria as 
2.75 (1-7) days.  
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Table 15: Percentage of All Patients Coded as Community-Acquired Pneumonia with the 
Top Four Associated Co-morbidities 
CO-MORBIDITY n (%) 
Chronic Obstructive Pulmonary Disease (COPD)  16 (30%) 
Cancer  13 (24%) 
Ischaemic heart disease (IHD) 10 (19%) 
Dementia 8 (15%) 
NB – multiple reasons may apply 
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Table 16: Reasons for Delayed Hospital Discharge for Patients Coded as Community-
Acquired Pneumonia 
REASON FOR DELAYED DISCHARGE n (%) 
Unstable non-pneumonia acute/ chronic co-morbidities 9 (17%) 
Delayed medical review or senior medical review 6 (11%) 
Lack of social support 5 (9%) 
Awaiting medical investigations 
(Urgent out-patient investigations were deemed suitable) 
2 (4%) 
NB – multiple reasons may apply 
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4.3 DISCUSSION 
 
Our Findings 
 
Data from the first audit (part 1) showed that although coding at RLBUHT was poor, the 
specific diagnosis (i.e. LRTI – no radiological consolidation, pneumonia – definite radiological 
consolidation) had little effect on LOS. The data showed that mortality from pneumonia 
increases with age and that co-morbidities, complications and co-presenting medical issues 
were common in these patients and significantly affected LOS. We had hypothesised that 
women may have a longer LOS as they are more likely to be widowed and therefore living 
alone with a lack of social support; however, gender had no effect on LOS. 
The second audit (part 2) suggested that a proactive ESDS scheme could enable almost 50% 
of patients to be provided with high-quality safe, effective, efficient patient-centred care, 
tailored to their needs, in their own home and that this ‘hypothetical’ intervention was both 
amenable to and worthy of randomised control trial (RCT) testing. To maximise effectiveness 
since data from the first audit suggested LOS was the same for both LRTI (no radiological 
consolidation/ infiltration) and pneumonia (radiological consolidation/ infiltration) we 
decided that conditions beyond CAP should indeed be included in such a trial. Most patients 
had co-morbidities but these did not necessarily make patients unsuitable for ESDS. To 
provide an early discharge we needed to affect the reasons for delayed hospital discharge 
that we had found in this audit. If a senior experienced clinician was available for daily medical 
reviews for potentially suitable patients, if there was access to urgent outpatient clinic 
appointments (the wait at the time of this audit for a respiratory clinic appointment was over 
16 weeks) and if we were able to also provide immediate light ‘social support’ by a team 
member attending the patient’s home up to twice per day (and could assist with some care 
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needs/bring or arrange food etc) then we may be able to assist with supporting a patient at 
home to enable an earlier hospital discharge.  
We hypothesised that a more heterogeneous group of patients, including those with lower 
respiratory tract infections (LRTI) and even with hospital-acquired pneumonia (HAP) could 
also safely benefit from such a scheme. Miscoding is commonplace meaning that these data 
are in fact from patients with ‘LRTI’ (with and without radiological consolidation/ infiltration) 
rather than patients with definite pneumonia (i.e. radiological consolidation/ infiltration).  
Hospital Episode Statistics (HES) data from England for pneumonia, influenza with respiratory 
manifestation and acute LRTI (2009-10), showed annual admissions of over 250,000 per year, 
using this in combination with an ESDS utilising these broader inclusion criteria resulting in a 
total reduction in median LOS of 2.75 days we calculated a potential saving of 687,500 bed 
days annually in England. With a conservative estimate of 2400 pneumonia admissions 
annually & a 10-day mean LOS (=24,000 bed days/yr), an ESDS could result in 6600 bed 
days/yr saved in the RLBUHT alone. 
Strengths and Weaknesses  
 
These two audits/ studies are simple and brief with clear aims and objectives. Since the coding 
was poor what we had initially thought would be pneumonia data were in fact a ‘mixed bag’ 
of CAP, HAP and LRTI (with no radiological consolidation/ infiltration). The studies were used 
as a scoping exercise and feasibility test respectively hence their retrospective nature. 
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Similarities and Differences 
 
ESDS for people with acute exacerbations of COPD exist; care is usually provided by a hospital 
outreach team which included specialist respiratory nurses and access to usual primary care. 
A Cochrane review of COPD HAH showed a trend towards lower mortality in the HAH group 
(P = 0.07); however no firm conclusions could be made with regards to health-related quality 
of life, and direct costs. The reviewers concluded that selected patients with acute 
exacerbations of COPD can be safely and successfully treated at home with support from 
respiratory nurses (203).  
Coding difficulties are well known. In the US by assigning sepsis and respiratory failure codes 
more liberally, hospitals might improve their reported performance for pneumonia. This may 
bias efforts to compare hospital performance regarding pneumonia outcomes (204).  
In the UK between 1997 and 2005 there was a marked increase in hospitalisation rates for 
patients with a primary diagnosis of pneumonia; the increase was more marked in older 
adults. As in our data, median LOS, mortality rate and the presence of comorbidities were 
highest in the older age groups. The median duration of stay in hospital increased with age. 
The LOS for patients <65 years was 3 days vs  9 days >85 years (p<0.001), both notably shorter 
than our LOS at RLBUHT (8). 
Implications 
These studies imply that an ESDS may indeed be feasible for patients with LRTI and may 
significantly reduce hospital LOS. Chapter 5 describes how we set-up and ran a feasibility 
study of an ESDS called HOME FIRST - Home Followed-up with Infection Respiratory Support 
Team. 
Pneumonia Audits 
 
117 
 
1
1
7
 
4.4 ACKNOWLEDGMENTS 
 
In this chapter, I would like to acknowledge my predecessor, Dr Sherouk el-Batrawy for her 
initiation of the audit process in part 1, Dr Adam Hill, Dr Wei Shen Lim, Dr Mark Woodhead, 
Prof Stephen Gordon and Dr Dan Wootton who attended a IDRN meeting in Lancashire in 
2010 with myself, to discuss and prioritise research ideas related to pneumonia in adults in 
the UK – the idea of home-based care for patients was initially conceptualised and discussed 
at this meeting, and Dr John Williams, Dr Lisa Davies and Dr Justine Hadcroft for helping with 
the ESDS inclusion/exclusion criteria. Dr Sarah Wilks assisted with data collection for part 2 of 
the audit. 
HOME FIRST Feasibility 
 
118 
 
1
1
8
 
CHAPTER 5: Home-based Care - HOME FIRST Feasibility Study for 
Early Supported Discharge in Adults with Respiratory Infection. 
 
 
 
 
 
 
5.1 INTRODUCTION 
 
Seventy percent of UK pneumonia admissions are for patients with low-risk pneumonia 
(CURB-65 score 0-2) (90); guidelines suggest that these patients do not require admission 
however they account for a significant proportion of bed days and costs (106). Often, factors 
other than disease severity prompt or prolong hospital admission such as the inability to cope 
at home alone or to tolerate oral antibiotics, co-morbid illnesses, homelessness and 
substance abuse (112, 205). Reduction of the resource burden of inpatient care for patients 
with pneumonia and LRTI is an international priority (5) (6). With the provision of medical 
support at home (hospital at home – HAH) many more patients with pneumonia and LRTI 
could be managed as outpatients (98). The evidence base for HAH schemes in pneumonia and 
LRTI is very limited. A recent expert review suggested that supported home care for patients 
with CAP ‘shows enormous potential for improving the care of elderly and disabled patients, 
and should be further evaluated in terms of efficacy and cost-effectiveness’ (117). 
This chapter describes the Home Followed-up with Infection Respiratory Support Team 
(HOME FIRST) prospective randomised controlled feasibility study. The concept of HOME 
HOME FIRST Feasibility 
 
119 
 
1
1
9
 
FIRST - an early supported discharge scheme (ESDS) for patients with LRTI (including 
pneumonia in this definition) was developed and we set out to recruit sequential patients 
admitted to the Royal Liverpool and Broadgreen (RLBUHT) and Aintree University (UHA) 
Teaching Hospitals with symptoms of LRTI. With this proactive, innovative and creative ESDS 
we aimed to enable patients with LRTI to be provided with high-quality safe, effective, 
efficient patient-centred care, tailored to their needs in their own home; therefore, improving 
the overall experience of the service-user and patient outcomes whilst reducing hospital LOS. 
The HOME FIRST strategy was to improve health policy, healthcare delivery and services and 
to simultaneously reduce hospital length of stay (LOS), an area of major strategic importance 
to the NHS. A DoH/NHS document stated that ‘The NHS will support creative approaches to 
service provision, which will improve choice, personalisation, efficiency and effectiveness e.g. 
identify new service solutions to avoid …. hospital admissions and deliver new and innovative 
services in community settings/homes’ (206). There are potential aspirational benefits of such 
a scheme these may include patient-related benefits such as: 
• Reducing risk of HAI (HAP, MRSA and C. difficile) (115) 
• Able to be cared for in their own home 
• Improved sleep (118) 
• Faster recovery 
• Increased satisfaction (patients and carers) (97, 118) 
• Reduced risk of delirium 
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• Reduced chance of later post hospital discharge institutionalisation. 
And health service benefits such as: 
• Reduced hospital LOS (economic benefit) 
• Reduced risk of HAI (economic benefit)  
• Improved self-management of condition (through improved education given by 
HOME FIRST team as they have more time per patient than clinical staff on the 
wards). 
This was a feasibility study and patients were randomised to either standard hospital care 
(SHC) or ESDS in order to assess patient’s acceptability to the randomisation process.  
5.2 METHODS 
5.2.1 Overview 
 
For full details see the study protocol in Appendix A. We carried out a feasibility study of a 
randomised trial of early supported discharge scheme (ESDS) versus standard hospital care 
(SHC) for patients admitted to hospital with pneumonia or lower respiratory tract infection 
(LRTI). We recruited from January – April 2012, aiming to recruit 10 patients to each arm of 
the study.  
Standard hospital care in our city-centre teaching hospital consists of patients being admitted 
through the emergency department (self-presenting) or directly to the acute medical 
admissions unit (AMAU) via a GP. All patients that are to remain inpatients then stay on AMAU 
for at least 12 hours in general prior to ward transfer. On the AMAU, the patient was clerked 
by a junior doctor, and then reviewed by an acute medical consultant within 12 hours on the 
post-take ward round prior to transfer to a medical (general, elderly, respiratory or infectious 
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disease) ward, depending on bed capacity. After this the number and seniority of reviews 
differs per ward but in general consultant wards rounds occur 2 – 3 times weekly and registrar 
ward rounds once to twice weekly, the patient was reviewed on a daily basis on week days by 
a FY1, 2 or CMT trainee when there was no senior doctor ward round. Patients are referred 
to respiratory medicine for specialist opinion as deemed necessary by their team. 
In order to participate, patients were required to meet study eligibility criteria (designed to 
identify patients suitable for early supported discharge from hospital) and provide written 
informed consent. With regards to patients with CAP, all CURB-65 scores were considered. 
We decided to include patients with CAP, HAP, aspiration pneumonia and LRTI. We made this 
decision as we wanted the scheme to be inclusive of all patients with respiratory infection 
rather than prescriptive like many of the current COPD schemes that only accept patients 
without consolidation and with a formal diagnosis of COPD, but without other existing 
respiratory disease such as chronic asthma or interstitial lung disease. 
The main developments / alterations from the pneumonia audits in Chapter 4 were:  
1. Patient’s still requiring IV antibiotics were excluded from the feasibility study (deemed not 
yet clinically stable for hospital discharge and therefore not suitable for ESD). This therefore 
excluded many patients with significant infective exacerbations of bronchiectasis and lung 
abscesses. 
2. Only patients with full mental capacity able to give informed consent were included in the 
feasibility study. 
3. Patients in whom further escalation of care was felt to be inappropriate if continued clinical 
deterioration were to occur were excluded from the feasibility study. 
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These criteria alterations were made by the study team and the patient and public 
involvement (PPI) group (see Chapter 2 - Methods) in order to minimise the risk to patients 
discharged from hospital with HOME FIRST and to enable feasibility testing of the 
acceptability of randomisation. 
5.2.2 Safety 
5.2.2.1 Patient Safety 
 
An experienced specialist respiratory doctor (a senior respiratory registrar with more than 10 
years of clinical experience) and respiratory nurses (band 6) with ward and community 
experience used strict patient selection criteria (Table 16, 17 and 18) to ensure patient safety. 
Patients in the HOME FIRST arm received thorough education and personalised verbal and 
written self-management plan for their specific condition, a digital thermometer and a 
detailed patient information leaflet (PIL) with ‘red-flag’ symptoms that should prompt contact 
with the study team (Appendix C): fever >38oC, increasing drowsiness, worsening cough/ 
sputum or increasingly unwell. The study team provided daily patient monitoring, regular 
home visit and a 24hr telephone on-call service. A portable observation machine was used by 
the HOME FIRST team to monitor blood pressure (BP), heart rate (HR), oxygen saturations 
(sats) and temperature during home visits. Pendant ‘lifeline chains’ were supplied if 
necessary. Fast tracked re-admission was arranged if required. A coordinated multi-
disciplinary team (MDT) was important to optimise care for patients in the HOME FIRST arm; 
all patients were discussed at a weekly case-notes meeting. Fast-track readmission was 
arranged if deemed necessary. We collected data regarding pneumonia recovery (CAP-SYM) 
and functional health status (SF-12) [see section 5.2.4.5] during the study to allow us to assess 
any significant lack of return to baseline in order to ensure that early discharge was not 
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detrimental to a patient’s health. CAP-SYM (CAP Symptom questionnaire) is a practical 
patient-based outcome questionnaire that evaluates symptoms in CAP.  It is an 18-item, 
interviewer-administered questionnaire that measures the severity of 18 symptoms during 
the past 24 hours using a 6-point Likert scale. It is more responsive than the generic SF-36 as 
a measure of outcome in CAP (207). 
We planned to stop the study if there was any mortality in the HOME FIRST arm whilst 
patients were at home. In the event of a serious AE (SAE) the REC and sponsor(s) were 
informed immediately. 
5.2.2.2 Staff Safety  
Specific important staff safety issues were carefully considered and addressed since staff 
were attending a patient’s own residence. Staff carried personal GPS tracking alarm devices 
at all times. 
5.2.2.3 Sites 
The study was conducted at 2 sites, RLBUHT (750 beds in city-centre) and UHA (743 beds in 
suburban area). They were chosen as they are large tertiary hospitals with high rates of 
pneumonia and LRTI admission. Liverpool is an area of poor lung health for many reasons 
including due to tobacco smoking habits, industrial exposures, poverty and malnutrition. The 
catchment area for the RLBUHT (and UHA) is relatively small (the maximum distance that 
most patients live from RLBUHT is 6 miles) making home visits relatively practical without long 
journey times. 
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5.2.4 Screening, Recruitment, Randomisation and Intervention 
5.2.4.1 Screening 
 
Patients from AMAU, ED and other wards within RLBUHT and UHA were screened. Potentially 
eligible patients were identified using a standard protocol. Only patients who would have 
required at least one more night of hospitalisation before discharge were considered. We 
hypothesised that various reasons for this continued hospitalisation may exist, since there is 
no specific guidance as to when a patient recovering from LRTI is suitable for discharge and 
therefore inter-physician variability exists. Where the study doctor considered a patient well 
enough for discharge without support, the usual medical team were notified. Age, gender and 
reason(s) for a lack of eligibility/suitability were noted for all screened patients. Patients 
already on home oxygen (O2) therapy with chronic respiratory disease were included in the 
study if their saturations were >87% on their usual Fi02. Screened patients were entered into 
a screening log in order to track their admission. 
The study team were in regular communication with bed managers, nursing and medical co-
ordinators in A&E, the medical admissions unit and the respiratory wards at RLBUHT and UHA. 
A list of potential patients was generated on a daily basis in combination with these 
personnel, and discussed twice per day at pre-defined times (by phone or bleep) to alert the 
study team to a potential recruit.  
5.2.4.2 Inclusion and Exclusion Criteria 
 
All CURB scores were accepted. Tables 16, 17 and 18 describe patient eligibility, inclusion and 
exclusion criteria in detail.  
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Table 17: Eligibility Criteria for the HOME FIRST Feasibility Study 
Patients with any 
of the following 
conditions: 
 
• Pneumonia – CAP or HAP [radiological consolidation and 
symptoms/signs of respiratory infection] N.B. if CURB-65 ≥3 
MUST have had at least 24hrs of in-patient observation 
before recruitment.  
 
• Non-pneumonic lower respiratory tract infection [No 
radiological consolidation but symptoms/ signs of 
respiratory infection] 
 
• Pneumonia with concomitant COPD (if this service is not 
provided elsewhere) 
[(CAP (community acquired pneumonia), HAP (hospital acquired pneumonia), COPD (chronic obstructive pulmonary disease)]. 
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Table 18:  Inclusion Criteria for the HOME FIRST Feasibility Study – to assess suitability 
INCLUSION CRITERIA 
Features on history 
 
• Patient able to give fully informed consent 
• Has a phone 
• Age>18yrs old 
Features on examination 
(stability indicator) 
• ≤2 (EWS – see Table 13B) AND SBP>90 AND AMTS ≥7. 
All observations must be stable for 12-24hrs 
Features of social 
situation 
• Can manage ADLs with current support (immediate 
OT/physiotherapy/social care can be arranged) 
[EWS (Early warning score), SBP (systolic blood pressure), AMTS (Abbreviated mini-mental test score), WCC (white cell count), CRP (C-
reactive protein), U&Es (urea and electrolytes, (ADLs (activities of daily living), OT (occupational therapist)]. 
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The justification for the inclusion criteria were as follows; 
• The study was focused on adults with LRTI, therefore it was inappropriate to include 
patients younger than 18. 
• Stable and improving observations indicated a patient was likely to be beginning to 
recover and therefore with HOME FIRST monitoring, and should therefore be safe to 
recover at home. 
• An early supported discharge scheme (ESDS) should have been of benefit to the patient; 
therefore it was essential that they were able to manage with activities of daily living 
(ADLs); otherwise this would have caused more burden to the patient. 
• A telephone was required for emergency use and to keep patients updated. 
• Fluent English was required in order for the patient to understand the aims of the study, 
to communicate over the telephone with the study team and if complications arose to be 
able to take action without a translator. 
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Table 19: Exclusion Criteria for the HOME FIRST Feasibility Study – to assess suitability 
EXCLUSION CRITERIA  
Features on history 
 
• Well enough for discharge without home care support  
• No fixed abode  
Features on 
examination 
(instability indicator) 
• SBP <90mmHg 
• Increasing inflammatory markers (WCC/CRP) 
• Increasing U&Es (If known CKD an increase in baseline of 
<25% was acceptable, as long as eGFR not <15) 
• For patients with chronic respiratory illness: sats <88% on 
air [except asthma] 
• For patients without chronic respiratory illness: sats <92% 
on air 
Features of diagnosis 
(indicating cause for 
concern) 
 
• Suspected MI/ raised TnI/ T consistent with NSTEMI within 
5 days of discharge  
• Empyema or complicated parapneumonic effusion  
• Tuberculosis suspected 
• Neutropenia 
• Acute exacerbations of COPD – infective & non-infective 
(other services are already provided)  
• Serious co-morbidities requiring hospital treatment (e.g: 
CKD, CCF) or deemed unstable (significant AKD)  
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Features of social 
situation 
• Patients unable to manage at home even with maximal 
support (e.g. IV drug users, alcohol excess or mental health 
problems) 
[COPD (chronic obstructive pulmonary disease), CKD (chronic kidney disease), CCF (congestive cardiac failure), AKD (acute kidney disease), 
IV (intravenous), sats (oxygen saturations), MI (myocardial infarction), TnI/T (troponin I/T), SBP (systolic blood pressure), NSTEMI (non-ST-
elevation myocardial infarction]. 
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The justification for the exclusion criteria were as follows: 
• Acute COPD exacerbations were excluded as these patients were more suited to the 
ACTRITE (Acute Chest Triage Rapid Intervention Team) discharge team which is an already 
established service at RLBUHT and UHA. 
• Patients observations were required to be within the ranges stated; if not they were 
excluded as they may have required continued hospital admission or have been at higher 
risk of deteriorating at home. 
• Patients with lower oxygen saturations were carefully considered as their condition may 
not have improved sufficiently for ESDS – clinical judgement was required for patient 
safety purposes. 
• Serious co-morbidities and other respiratory diseases were considered carefully and 
patients were excluded if other conditions may have hindered their progress at home and 
warranted hospital readmission. 
• Similarly, to the inclusion criteria, ESDS should aim to benefit the patient, therefore 
patients were excluded if they did not have a fixed abode or study staff believed they 
would have struggled even with HOME FIRST support. 
• Patients well enough for discharge were discharged as normal as continued support would 
not necessarily have been of benefit. 
• Rather than prescriptive numbers or percentage increase/decrease for CRP/WCC and 
U&Es, we used a more pragmatic approach of excluding patients only with bloods that 
were obviously deteriorating. Patients with acute kidney injury could only be considered 
when their renal function was at or <125% of baseline. If the patient had known CKD an 
increase in baseline of <25% was acceptable as long as eGFR was not <15. 
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5.2.4.3 Repeat Reviews 
 
Patients admitted to hospital are generally acutely ill; therefore repeated reviews were often 
needed in order to track patients’ progress to the point where they may have been suitable 
for recruitment.  
• At their screening visit potential patients may not have been well enough for discharge. 
These patients required repeat review at a defined later date to give time for the condition 
to settle. Some of these patients ended up being discharged / self-discharge before this 
first repeat review, whilst others remained unwell for longer requiring continued 
hospitalisation. 
• Some patients were well enough to go home but were awaiting blood or scan results – in 
some instances these were followed up by HOME FIRST team and did not need to prevent 
recruitment. 
5.2.4.4 Randomisation 
 
If a patient was selected for inclusion and consented to participation, they were then 
randomly assigned using computer generated random numbers to receive either ESDS or SHC. 
Allocation was obtained by telephoning an independent co-ordinator (closed envelope 
system).  
5.2.4.5 Recruitment 
 
A clinical examination and mental state (an Abbreviated Mental Test Score [AMTS]) 
assessment were conducted. A repeat AMTS was then performed if a staff member was 
concerned about increased confusion in that patient. 
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Recruited patients provided a clinical history, were examined by the study doctor and 
completed an SF-12 (Short Form-12) questionnaire (208) (functional and quality of life 
assessment tool) at day 0 [Appendix D] and two CAP-SYM (Community-Acquired Pneumonia 
Symptom) questionnaires (207) (symptom score) for day 0 and day ‘minus 30’ (the patient 
was asked to recall their symptoms from 30 days prior to study recruitment) [Appendix D]. 
Baseline clinical data including age, gender, history of presenting complaint, past medical 
history, a complete social history, drug history and allergies, was recorded by the study 
doctor. SF-12 and CAP-SYM questionnaires (+/- clinical bloods as needed) were completed on 
day 0, 2 and 7; for patients who had been discharged, these investigations were performed 
in their home. 
5.2.4.6 Study Intervention – HOME FIRST 
 
The patient was followed by the same study doctor until stable for discharge from the ESDS, 
after this, care was provided by their general practitioner as usual. Fast-access to discharge 
medications, a disease-specific patient information leaflet and ‘meals-on-wheels’ (ready-
made food delivery service) were provided as required. Oxygen [O2] (if not already receiving 
domiciliary O2), intravenous (IV) fluids and IV antibiotics were not provided. 
Patients in the ESDS arm were transferred home the same day with appropriate medications, 
an emergency 24hr contact telephone number, a list of symptoms to prompt healthcare 
contact (fever> 38oC, increasing drowsiness, worsening cough or sputum and/or increasingly 
unwell) and an observations machine capable of recording temperature, blood pressure (BP), 
heart rate (HR) and O2 saturations. If discharge was before 3pm the patient was reviewed at 
home later that evening by the team; if after 3pm the review was the next morning. 
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For all readmissions a ‘treatment failure or complication development’ proforma on the CRF 
was completed. Home visits occurred from 08.00 - 17.00 up to 5-days-per-week. Telephone 
visits were available 7 days per week with 24hr cover via telephone to the HOME FIRST study 
team. In the event of an emergency an ambulance was called by either the 
patient/relative/carer or on-call study member. If the patient needed non-emergency medical 
attention at home between 17.00 - 08.00 week days or at weekends, a district nurse or out-
of-hours GP was contacted by the study team.  
5.2.4.6.1 Initial and Subsequent Follow-up with HOMEFIRST 
 
Patients randomised to HOME FIRST care initially received up to twice daily respiratory 
specialist nurse visits for the first 48 hours. After this time period, the frequency and duration 
of visits depended on clinical need. Telephone calls were used instead of home visits where 
the study team felt this suitable. Each visit lasted between 10-30mins.  
There was no maximum duration of follow-up. The study nurse established the need for the 
involvement of other MDT team members. Laboratory tests were performed as clinically 
indicated at the discretion of the study team. Frequency of venepuncture depended on 
clinical assessment of need by their regular medical team. If a patient became unwell they 
called the emergency numbers on the emergency PIL (Appendix C). 
Patients discharged from hospital remained the responsibility of the PI during the time that 
they were supported by HOME FIRST. The patient's GP and hospital consultant (as of 
discharge day) were informed of any specific interventions and outcomes by dictated 
discharge summary. Patients recruited to the study that were randomised to SHC remained 
under the care of their current consultant.  
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5.2.4.6.2 Discharge from HOME FIRST 
 
In order for discharge from HOMEFIRST, patients had to fulfil all 7 criteria:  
(1) Resolution of the reason for prolonged hospitalisation  
(2) Temperature<37.5oC 
(3) SBP>90mmHg 
(4) O2 saturations > 86% on oxygen or 90% on air  
(5) 50% reduction in highest CRP (unless non-infective reason for high CRP)  
(6) Stable non-pneumonic co-morbidities (patient handed over to community team if 
further follow-up needed)  
(7) Able to manage with current care level  
5.2.4.6.3 Readmission to Hospital from HOME FIRST   
 
Patients could be readmitted to the hospital as determined by the study team via the bed 
managers at any time. The PI was notified of all readmissions. Observations in many of our 
cohort were not expected to be within normal physiological limits due to their many other 
co-morbidities predominately respiratory and cardiac.  
If the team were at all concerned, the study doctor was contacted. They then either arranged 
for direct readmission via AMAU, arranged to visit the patient, arranged to see the patient in 
the CRU or gave advice to the patient over the phone. The CRF provided the study team with 
a guide for recognising patients needing consideration for readmission to hospital, using a 
simple set of clinical and functional questions. Reasons for readmission were:  social concern 
(by patient or staff), reduced eating & drinking, a fall, increasing CRP/WCC, the inability to 
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take antibiotics, oxygen saturations drop >2%, RR rise ≥10bpm, Temp ≥38oC, persistent 
symptoms of fever, GCS drop≥2, No PU>12hrs and any other cause of clinical concern.  
5.2.4.7 Standard Hospital Care (SHC) Arm 
 
All management and discharge decisions in SHC arm were made by the patient's usual hospital 
team. Clinical tests were performed at the discretion of the medical team. If any significant or 
concerning clinical issues were noted during study team's visits, the usual medical team was 
alerted. Patients recruited to the study who were randomised to SHC remained under the 
care of their current consultant. SHC comprises of both systematic and as required medical 
review in our hospitals.  
5.2.4.8 Follow-up  
 
Two weeks after recruitment all patients and their next of kin (NOK)/carer received a 
telephone call from an independent assessor to complete a care satisfaction questionnaire 
(Appendix D). All patients were asked to attend an outpatient appointment (OPA) at 1 and 6 
months post recruitment; a clinical assessment, CAP-SYM, SF-12 and bloods (including serum) 
+/- chest X-ray were performed. 
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5.2.5 Outcome Measures 
 
Our study question(s) were: (i) Is a study in which patients are randomised to ESDS or SHC 
acceptable to patients? (ii) Can selected patients with respiratory infection benefit from care 
at home?  
5.2.5.1 Primary 
 
Our primary outcome was patient acceptability to randomisation. We aimed to assess the 
patient uptake of participation in a study in which participants are randomised to early 
supported discharge with HOME FIRST or SHC. Uptake/acceptability in this study was defined 
as - the proportion of patients that are both eligible and suitable (fit all inclusion/exclusion 
criteria) who are prepared to ‘ACCEPT’, and give their consent to, be involved in a research 
study in which they are randomised to either SHC or HOME FIRST compared to the proportion 
that are eligible and suitable and do not give their consent. 
5.2.5.2 Secondary  
 
A. Safety (mortality and readmission rates)  
We assessed the safety i.e. to ensure there was no delayed recovery (using CAPSYM and SF-
12 at 6 weeks), no increase in pneumonia (or non-pneumonia) complications (readmission 
rates) or increase in mortality in the HOME FIRST arm. HAI/delirium was noted. We aimed for 
equivalence. 
B. Patient and carer satisfaction  
HOME FIRST should have at least equivalence with SHC. A validated questionnaire was 
conducted via telephone to both patient and NOK/main carer).  
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C. LOS in hospital and total LOS (including hospital and home care)  
E. Functional status (physical and mental) and quality of life (QOL)  
Validated (CAP-Sym and SF-12) questionnaires were completed to assess recovery. We aimed 
for equivalence. 
F. Operational and logistical questions - 
e.g. what frequency of home visits is required and for what duration? What is the maximum 
number of patients that can be safely looked after at home with HOME FIRST at one time? 
5.2.6 Sample Size and Statistical Methods 
 
To identify >50% decline in consent (at 80% power) required a sample size of 22 patients (to 
be recruited). We estimated that we would need to screen a minimum of 100 patients in a 
single winter season. 
5.3 RESULTS 
 
Patient screening and recruitment are summarised in the consort diagram (Figure 9). Briefly 
during the 4-month study period 200 patients with symptoms suggestive of respiratory 
infection were screened. Of these 158 were ineligible (reasons summarised in Table 19), 
unsuitable or their physician declined. The most common reason for exclusion or non-
recruitment was the inability to give informed consent. Broadly these can be categorised into 
medical reasons (66%), social reasons (19%) and other reasons [‘missed’ or declined] (15%).  
Of the 42 eligible patients, 18 declined consent (either patient themselves or NOK or carer), 
10 were missed at repeat review and 14 were recruited and randomised to either standard 
hospital care [SHC] (n=6) or early supported discharge scheme [ESDS] (n=8).  
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Figure 9: Screening and Final Recruitment Numbers 
Note no patients withdrew consent or were lost to follow-up. ‘Missed’ means missed due to logistical reasons e.g. by the time of repeat 
patient review by the study team the patient was well enough for discharge without ESDS support or the patient was discharged outside of 
the hours/days of study recruitment.  
 
 
Non-recruited (missed 
at repeat review) n=10 
Ineligible/unsuitable/ 
physician declined 
n=158 
Recruited n=14 
Patient/NOK/carer 
declined n=18 
Eligible n=42 
ESDS n=8 SHC n=6 
Screened (symptoms 
suggestive of respiratory 
tract infection) 
n=200 
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Table 20: Reasons for Non-recruitment 
Reasons for non-recruitment N % 
Confusion (Abbreviated Mini-mental Test Score <7) 37 20 
Require more complex multi-disciplinary team input 
(physiotherapy, occupational therapy, social services) 
35 19 
Infective exacerbation of COPD [other services available] 20 11 
Other co-morbidities requiring in patient stay 18 9.5 
Clinical deterioration or mental health issues 17 9 
Patient declined 13 7 
Awaiting investigations to exclude pulmonary emboli 11 6 
‘Missed’ 10 5 
Too well (suitable for discharge without support) 10 5 
Carer/next of kin declined 5 2.5 
Too hypoxic 4 2 
No respiratory infection  3 2 
INR issues 3 2 
Total 186 100 
INR – international normalised ratio, COPD – Chronic Obstructive Pulmonary Disease. 
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The demographics and clinical characteristics of those recruited and those who declined are 
shown in Table 20. Reasons given by patients for not wishing to consent included extra blood 
tests [n=1], extra outpatient appointment [n=1], ‘feel too unwell for home yet’ [n=5] and 
other (‘not keen on research’, ‘steep stairs’, ‘daughter on holiday’) [n=5]. The mean age of 
recruited patients was 64.6 (29-90) yrs old; this was lower than in those whose NOK declined 
consent. Subjects were allocated a CURB-65 score whether or not consolidation was seen on 
their chest radiograph. New radiological consolidation was defined as definite, possible or 
none; this was decided by discussion between 2 respiratory clinicians. The median CURB-65 
of all recruited patients was 1 (range 0-3), the majority of patients lived with spouse or family 
(72%) compared to all of those whose NOK declined who lived alone. The average time from 
admission to recruitment was 8 (1-9) days. Two recruited patients had positive microbiology 
– one Haemophilus influenza in sputum, the other Streptococcus pneumoniae in blood 
cultures.  
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Table 21: Demographics and Characteristics of Patients who Declined or were Recruited 
 Declined Recruited 
Patient 
(n=13) 
NOK (n=5) SHC (n=6) ESDS (n=8) 
Age (mean [range]) 66 [25 – 84] 79 [68 – 87] 70 [52 – 90] 61 [29 – 82] 
Gender (M:F) 6 : 7 3 : 2 2 : 4 5 : 3 
Smoking status Not recorded 
 
Ex - 3 
Current - 2 
Never - 1 
Ex - 3 
Current - 2 
Never - 3 
Social history Live alone - 4 
With spouse - 
6 
With family - 
3 
Live alone – 
5 
Live alone - 3 
With spouse - 
2 
With family - 1 
Live alone - 1 
With spouse - 
5 
With family - 2 
CURB-65 (median 
[range]) 
Not recorded 
 
2 [1 – 3] 1 [0 – 2] 
Total hospital LOS (mean 
days [range]) 
Not recorded 
 
8.33 [1 – 31] 3.4 [1 – 7] 
New radiological 
consolidation/infiltration 
Not recorded 
 
Definite - 5 
Possible - 0 
None - 1 
Definite - 4 
Possible - 2 
None - 2 
Age, gender, smoking status and social history were recorded from screening data.  
HOME FIRST Feasibility 
 
142 
 
1
4
2
 
Safety and efficacy of intervention 
Two subjects from SHC, and none from ESDS were readmitted (within 30 days) of discharge. 
There was 1 death in ESDS arm (known palliative lung cancer) and 1 death in SHC arm 
(aspiration pneumonia on readmission – possible underlying lung malignancy). The total LOS 
was 8.33 (1-31) days in SHC and 3.4 (1-7) days in the ESDS arm respectively. One subject from 
the SHC arm developed a presumed HAI. The maximum number of home visits needed was 4 
(generally 1-3). The total LOS in the ESDS was between 2- 6 days. Subject and carer/NOK 
satisfaction was generally good.  
Twelve subjects completed all SF-12 questionnaires [day 0, 2, 7 and 28]. Overall mean 
increase of 0.4 points (±S.D. 0.2)/subject was seen in SHC, and 1 point/subject in ESDS 
between day 0 and day 28; therefore, no statistical difference was seen. NB: using the SF-36 
(a similar questionnaire with 36 questions) a 20-point change in the scale is believed to 
represent a clinically meaningful change; using SF-12 at least a 6-point change is deemed 
necessary for clinical significance). 
With regards to symptom improvement, using CAP-SYM questionnaires, % recovery at day 28 
(from baseline) could only be calculated in 3 SHC and 6 ESDS patients; with 88% and 90% 
recovery seen respectively at 28 days; therefore, no statistical difference was seen between 
the 2 groups.  
During the study, we collated a table of the common obstacles to recruitment (Table 21) 
that mainly refer to staff practice within the hospitals. 
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Table 22: Common Obstacles to Recruitment 
Medical 
 
 
• Pneumonia may be a vague diagnosis in hospital practice 
therefore large numbers of patients with respiratory 
infection need to be screened to find eligible patients 
• Lack of capacity to give consent 
Staff • Lack of physician ‘buy-in’ and resistance to change 
Social • Hospital stay may be seen as a respite opportunity for 
some carers 
Patient belief • Some patients believe that they must be 100% better 
before hospital discharge; some were suspicious of a 
new or research-based service. 
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5.4 DISCUSSION 
 
In this feasibility study we have shown that using defined criteria for recruitment and a 
defined interventional package, it is feasible for some patients with LRTI and pneumonia, who 
would otherwise have been treated in hospital, to be treated at home. 
The ESDS package was successfully implemented in 7 patients with no adverse events. 
Randomisation was acceptable to patients and only deters those who do not wish to go home. 
The main strengths of this study are its novelty.  We have been able to recognise common 
recruitment obstacles and find solutions to aid future project development. It has been noted 
previously in similar schemes that patient/carer refusal tends to reduce if a scheme becomes 
an adopted hospital service rather than a research project.  
The weaknesses of this study are that it is a small feasibility study in a single city therefore no 
powered outcome data are available. The criterion of requiring at least one more night of 
hospitalisation is a subjective one. The overall aim of the study is to reduce hospital bed days 
within a ‘real-life’ hospital setting in the UK. One more night of hospitalisation may be due to 
a variety of reasons and cannot simply be defined according to pre-defined signs or 
symptoms, as appropriate time for discharge for a patient with LRTI is physician-specific and 
no specific guidelines exist.  We considered reasons that a patient would have ‘taken up’ a 
bed in hospital for at least one more night if ESDS were not available, these included: the need 
for further daily INR checks and low molecular weight heparin administration (with no 
facilities to have this performed immediately daily in the community), physician suggesting a 
further period of inpatient review for at least 24 hours after having changed from intravenous 
to oral antibiotics to ensure no pyrexia develops, no ability to get food supplies in at the 
patient’s home until the next day and insufficient ward staff to organise oxygen delivery and 
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transport the same day, all leading to delayed discharge. All patients recruited received more 
intensive medical care than standard hospital care due to clinician sampling visits; this may 
affect the results of satisfaction questionnaires. Questionnaire data may be subject to recall 
bias. Also day 0 was defined as the day that the patient was deemed fit to be discharged home 
with support and not the first day of illness or day of admission; therefore this may not have 
captured the peak impact of the illness on their symptoms. 
Using our current model however large numbers of patients needed to be screened (n=200) 
in order to recruit low numbers (n=14). The main obstacle to eligibility was lack of capacity to 
give informed consent. The number of eligible patients could be doubled if chronically 
confused or demented patients were included. Having noticed this as a recruitment obstacle 
we also considered whether it was indeed appropriate to include such patients in this 
research. LRTI and pneumonia is very common in elderly patients who may often have 
dementia/memory loss, of varying severity, and the respiratory infection itself can cause 
worsening of this condition or even new acute confusion. It is important that such patients 
are not excluded from future research to which they would potentially benefit from. We also 
noticed anecdotally virtual visits (via telephone), rather than home visits may be adequate 
after the first 48hrs after discharge.  
Our study, like previous studies of AA and ESDS for CAP and LRTI have shown recruitment may 
be difficult. In one study, 985 patients needed to be screened to find 214 eligible and 84 
recruits, of which 53 had a diagnosis of CAP (209), in another 540 were screened to recruit 25 
in each arm of study (118). In patients with COPD exacerbations only 14- 35% of people were 
both suitable and agreed to be recruited into the HAH trials, which may limit the potential for 
a hospital at home approach to be used widely in managing COPD exacerbations (210). 
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Low programme acceptance has been noted due to decline by physician (11%), patient (38%) 
or next of kin (36%) (211). A study recruiting 55 patients with CAP in New Zealand in 2005 
showed improved patient satisfaction by 40% (p<0.001) and improved sleep but increased 
total days of care and no improvement in symptom score or function at 2 & 6 weeks (118). 
Other studies have shown reduced bed days and hospitalisation (12% reduction) and overall 
cost reductions of $1489 and $(CAN) 1016 (121, 209). 
We interpret our feasibility study data to indicate that to improve recruitment future study 
directions should include: (1) Hospital logistics - working with hospital management to 
improve hospital systems to reduce time spent screening ineligible patients, increasing 
recruitment hours up to 12 hours-per-day, 7-days-per-week and improved ESDS ‘marketing’ 
(2) Medical conditions - the use of consultee declarations and retrospective consent allowing 
recruitment of suitable patients who lack capacity [Refer to 2.3] (3) Staff - improving physician 
education with regards to pneumonia and LRTI diagnosis and PE risk in order to reduce over-
investigation/defensive practice, better study and clinical team integration (knowledge that 
the study team can reduce the team’s workload by facilitating discharge and conducting out-
patient appointments) thereby decreasing physician refusal and earlier patient contact with 
the study team, enabling closer relationships to be formed thereby reducing the likelihood of 
‘mixed messages’. We estimate that by implementing the various methods described to 
overcome barriers to recruitment (in particular recruitment of patients without capacity and 
improving relationships in order to reduce the patient and carer/NOK participatory decline 
rate Table 19) that we could improve recruitment by >25%.  
This is an opportunity to improve health policy, healthcare delivery/services & reduce 
admission rates and HAI rates; an area of major strategic importance to the NHS. We have 
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considered what the components of an effective supported home care scheme for CAP would 
include. A complete service should incorporate fast-access to occupational therapy, 
physiotherapy and social services as well as to outpatient investigations and clinics.  
Future developments to our model may include accepting patients in whom clear decisions 
have been made that no escalation in care is appropriate if after 48hrs no improvement is 
seen as terminal care may be more appropriately delivered at home (212) and also 
encouraging clear management decisions to be made.  Accepting patients on IV antibiotics 
and developing closer links with ‘early response teams’ in order to facilitate fast and effective 
discharge of more complex patients may be useful, as the numbers of hospital beds reduce in 
the UK (97). Constraints during the feasibility study are discussed in detail in Table 22. 
Having therefore established that an early supported discharge scheme (ESDS) for patients 
with lower respiratory tract infection (LRTI) is indeed feasible; Chapter 6 describes the follow 
on ESDS pilot study. 
 
 
HOME FIRST Feasibility 
 
148 
 
1
4
8
 
Table 23: Constraints During the Feasibility Study 
Constraint/issue Reason Solution likely for 
the pilot 
1. Max no. of 2 patients at 
home any one time due to 
safety 
Due to team size for 
patient safety 
No, funding and 
therefore staff is 
limited 
2. No weekend/ evening 
screening/ recruitment/ 
home visits 
Due to team size No, due to limited 
staff resource 
3. Lack of engagement by 
CCG and existing 
community COPD services 
Staff shortages and the 
need for prioritisation of 
service provision 
No, issues likely to 
remain unresolved 
4. No provision for IV abx in 
community 
Safety Yes, for patients with 
bronchiectasis by 
links with the home 
IV team 
5. Did not recruit patients 
without capacity 
Unaware that this would 
limit recruitment 
significantly 
Yes, ethics to recruit 
patients without 
capacity 
6. Extensive discussions with 
regards to ceiling of care 
needed in some 
Many patients judged to 
have poor QoL, need 
advanced care planned 
and decisions to 
withdraw care if no 
improvement within a 
set time period 
Partially, difficult as 
needs significant 
integration between 
senior doctors in the 
usual team and 
research team 
7. Better social care liaison/ 
integration 
Current NHS systems are 
poorly integrated 
No 
8. More effective hospital 
systems to reduce 
screening times 
No current investment in 
IT systems 
No, unlikely to be 
resolved 
9. Patients not well known to 
junior and nursing staff 
therefore no active 
referring of patients 
Due to lack of continuity 
of care due to EWTD and 
shift patterns 
Partial, better 
integration/ 
knowledge of the 
study team 
10. Some patients declined 
consent as they did not 
wish for NW to be 
performed 
Did not want extra tests Yes, remove any 
extra laboratory 
samples 
11. A NOK may decline 
consent (or tell their 
relative not to be involved) 
May need/ want a 
temporary break from 
carer role 
No 
12. Patients (especially 
elderly) finding it difficult 
to come to terms with an 
alteration in their 
Concern as to why it has 
changed/ don’t like 
change 
Yes, earlier 
integration with the 
study team 
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estimated date of 
discharge (EDD) 
13. Different physician 
management – physician 
decline 
No clear guidance Partially yes, better 
integration and 
knowledge of the 
study and therefore 
confidence in the 
safety of the study  
14. Randomisation post-
recruitment  
Only those patients 
happy to go home 
consented 
No, randomisation 
pre-consent is 
difficult and not 
common practice. 
 
HOME FIRST Feasibility 
 
150 
 
1
5
0
 
5.5 ACKNOWLEDGEMENTS 
 
In this chapter I would like to acknowledge ward and clinical research staff at UHA and 
RLBUHT for assisting with screening and recruitment. The study was funded by an LSTM 
Respiratory Infection Group departmental grant. The concept of studying admission 
avoidance or early supported discharge for patients with pneumonia was initially discussed 
at a ‘The Pneumonia Consortium’ in the Northwest of England in 2011, I would like to give 
thanks to Dr Adam Hill, Dr Wei Shen Lim and Dr Dan Wootton for their initial input with 
regards to this concept. 
HOME FIRST Pilot 
 
151 
 
1
5
1
 
CHAPTER 6: Home-based Care - Home First Pilot: A Study of Early 
Supported Discharge in Patients with Lower Respiratory Tract 
Infections. 
 
 
 
 
 
 
 
6.1 INTRODUCTION 
 
Studies in Chapter 5 established that HOME FIRST – an early supported discharge scheme 
(ESDS) for patients with lower respiratory tract infection (LRTI) - was indeed feasible but 
protocol alterations were necessary for a pilot study. Despite the large numbers of potentially 
eligible patients that needed to be screened in order to recruit patients to the feasibility study, 
satisfaction was generally good, outcomes at least as good as standard hospital care (SHC) 
and length of hospital stay (LOS) reduced. Earlier discharge clearly reduces hospital LOS, and 
therefore significantly reduces cost but may also reduce the risk of deconditioning and 
hospital acquired infections (HAIs) (213).  Our new city-centre hospital building, due for 
completion in 2017, will have 15% fewer beds, therefore it is of primary importance to our 
trust that we find other ways to care for patients other than continued acute hospital stay. 
From feasibility study data, we decided to address various issues within this pilot in order to 
improve recruitment; the main alteration was to include patients with a lack of capacity. We 
also decided to include these patients since they may be the most likely to benefit from such 
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an intervention. We set out to address (1) Hospital engagement and study-clinical team 
integration – improving the ‘marketing’ strategy in order to improve staff awareness and 
knowledge particularly targeting AMAU, ED, respiratory, infectious disease, general medical 
wards and the complex case management/discharge nurses in order to decrease physician 
refusal. We planned to make staff aware that the study team could facilitate patient discharge 
and book and conduct outpatient appointments thereby reducing the workload of the usual 
care hospital team, (2) Inclusion criteria – we decided to use consultee declarations and 
retrospective consent to allow recruitment of suitable patients who lacked capacity [Refer to 
2.3],  (3) Early patient-study team contact – we planned to approach patients and provide 
them with a study PIL (Appendix C) ideally on AMAU and prior to clinical stability, to enable 
closer relationships to be formed thereby reducing the likelihood of ‘mixed messages’ with 
regards to estimated discharge dates and likely course of disease and hospital stay, in order 
to reduce patient and NOK refusal. 
We were unable to impact on current hospital systems in order to reduce screening time nor 
were we able to increase staff resource to allow screening and recruitment to 7 days per 
week, available staff resource only allowed for 4 days per week, home visits 5 day per week 
and telephone calls 7 days per week. 
This chapter describes the HOME FIRST pilot study. 
6.2 METHODS 
6.2.1 Overview 
 
For full details see the study protocol (Appendix A). We carried out a randomised 
interventional clinical pathway pilot study of an early supported discharge scheme (ESDS) – 
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termed HOME FIRST PILOT, in which we compared ESDS against standard hospital care (SHC) 
for patients admitted to hospital with LRTI. For improved clarity the main differences between 
the feasibility and pilot studies are highlighted in bold in Table 23. We developed a manual of 
procedures (MOP) and made extensive protocol changes from the feasibility study these 
were: more flowcharts for operational ease, better integration within the hospital, more 
telephone consultations, a daily clinical review sheet, a maximum duration of visits of 5 
working days, 1 recruitment site only, alterations in inclusion and exclusion criteria 
(predominately including patients without full capacity to consent), a health economic 
assessment and clearer staff tasks and responsibilities.  
6.2.2 Manual of Procedures (MOP) 
 
In complex interventional studies an MOP is commonly used; it is a handbook that details the 
study’s conduct and operations as well as facilitating consistency in protocol implementation 
and data collection across study staff, participants and site(s). It translates the study protocol 
into a guideline that describes each step of the study and how it is to be executed. Our MOP 
contained enough detail that the HOME FIRST pilot study could be run by an individual(s) at 
another site(s) consistently with only the information contained in the MOP and its 
appendices. 
6.2.3 Ethical Principles 
 
This is unaltered from the feasibility study (Chapter 5) with the exception of the ethical issues 
related to participants that lack capacity and consultee declarations which is covered in 
Chapter 2. 
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6.2.4 Safety and Adverse Event Reporting 
 
This was unaltered from the feasibility study (Chapter 5). 
6.2.5 Organisation and Governance 
6.2.5.1 Timescale 
 
We planned to screen patients for 2 winter seasons; the first from October 2013 - April 2014 
and October 2014 – April 2015 (4 days per week). 
6.2.5.2 Population 
 
All patients ≥18yrs old admitted to hospital with LRTI were considered for recruitment. There 
was no upper age limit. For those patients with radiological consolidation/ infiltration 
suggestive of pneumonia all CURB-65 scores were considered. 
6.2.5.3 Study Site 
 
We recruited at one site only; the Royal Liverpool and Broadgreen Hospital Trust [RLBUHT], 
Liverpool, UK with 750 beds. This hospital is being rebuilt and the new hospital will have ~ 
15% fewer beds.  
6.2.5.4 Sponsor 
 
The study was also co-sponsored by RLBUHT Research Development and Innovation (RD&I) 
office and LSTM (R&D Study Number: 4417). 
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6.2.5.5 Funding 
 
Funding was provided by a £40K grant in 2013 from the Liverpool Health Partnership (LHP). 
The Bill and Melinda Gates Foundation Grand Challenges II grant and pneumonia pump 
priming grants were also used. 
6.2.5.6 REC 
 
The local NHS Research and Ethics Committee (REC) North-West Liverpool Central 
(12/NW/0731) approved the study. 
6.2.6 Screening, Recruitment and Randomisation 
 
This was broadly the same as the feasibility study. Briefly, a list of potential patients was 
generated on a daily basis (4 days per week). Suitable patients were then approached by the 
study team who considered the patient’s capacity, clinical condition and appropriateness of 
their current environment for initial study discussion and a PIL was provided. A full clinical 
examination was performed by the study doctor before recruitment. Consent, consultee 
declaration and later retrospective consent (as needed) were taken by a fully trained study 
team member (Refer to 2.3). Baseline clinical data were recorded, these included age, gender, 
history of presenting complaint, past medical history, a complete social history, 
drug/vaccination history and allergies. The patient also completed a clinical history, a SF-12 
(functional and quality of life assessment tool) and CAP-Sym questionnaires (pneumonia 
symptom score) (Appendix D). Only patients who were considered to require at least one 
more night of hospitalisation before discharge by the last senior doctor (registrar or 
consultant) by whom they were seen that day were considered for inclusion. 
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At screening some patients were eligible but not currently suitable and therefore were 
reviewed at a later date for reassessment, multiple repeat reviews were often performed. 
Patients were not recruited at repeat review if they were: 1) completely ineligible according 
to eligibility criteria, 2) declined consent, 3)  ‘missed’ due to logistical reasons e.g. by the time 
of the repeat review the patient was believed well enough for discharge without ESDS support 
or the patient was discharged outside of the study recruitment times, self-discharged or died, 
4) the study was currently  full to recruitment (a maximum of 2 patients could be cared for by 
the ESDS at home at one time). The timeline for repeat review was based on the study team’s 
assessment of when a patient may be eligible by anticipating when IV antibiotic treatment 
would finish, when O2 saturations would improve, when other clinicians / therapists would 
have assessed the patient, when inpatient investigations would have occurred and also by 
study team staffing levels.  
Where the study doctor considered a patient well enough for discharge without ESDS support, 
the usual medical team were informed of this specialist respiratory opinion. Age, gender and 
reason(s) for a lack of eligibility/suitability were recorded for all screened patients.  
6.2.6.1 Screening 
 
A potential patient was approached as soon as possible after admission. The first encounter 
with a patient by the study team was for screening. At this screening visit patients were 
potentially eligible or ineligible. Patients considered completely ineligible at screening (or at 
a later repeat review) were not reviewed again.  
The main difference from the feasibility study was that the study team considered the 
patient’s capacity and depending on this assessment either provided the patient with a PIL 
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(Appendix C) or arranged to meet with their consultee (carer/NOK) to discuss the study 
further. Screened patients were entered into a screening log in order to track their admission.  
6.2.6.2 Inclusion and Exclusion Criteria 
 
Patients were required to meet study selection and inclusion/exclusion to determine 
eligibility and suitability criteria respectively in order to participate (Table 16, 17, 18 and 23). 
As mentioned patients who were unable to give fully informed written consent due to a lack 
of capacity were also recruited. A consultee declaration was gained and retrospective consent 
at a later date if appropriate.  
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Table 24: Selection Criteria for the HOME FIRST Pilot Study 
 
• EWS ≤2 AND SBP>90 (all observations must be stable for 12-24hrs) 
AMTS removed 
• We have removed ‘able to give fully informed consent’ 
Consultee declaration added 
• Acute exacerbations of bronchiectasis without consolidation not requiring 
prolonged IV antibiotic therapy (max B.D#) 
 
Added  
 
 
Amendments (protocol alterations after January 2014) 
• 02 sats ≥ 94% on air in patients without chronic respiratory failure - included 
• 02 sats ≥ 88% on air or LTOT in patients with chronic respiratory failure – 
excluding asthma - included 
• Suspected/proven pulmonary infarct – excluded 
NB - patients with co-existing pulmonary embolus who are prescribed warfarin receive a minimum of 5 days of LMWH (low molecular weight 
heparin); LMWH is discontinued when INR is therapeutic and stable. LTOT (long term oxygen therapy), EWS (early warning score), SBP 
(systolic blood pressure), AMTS (abbreviated mini-mental test score), WCC (white cell count), IV (intravenous), B.D (twice daily). # NB B.D 
max antibiotic therapy was the most frequent administration that the HOMEFIRST team were able to provide as we could not get any regular 
commitment from the home IV team to enable us to provide T.D.S IV antibiotic therapy. 
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The justification for the changes to the selection criteria were as follows; 
• The feasibility study showed that 20% of screened patients were not able to be recruited 
as they did not have full mental capacity. We believed that these vulnerable patients may 
in fact be one of the groups that would benefit most from study involvement, therefore 
patients unable to give consent were included. 
• After the SAE in January 2014 we altered the 02 saturations to be in line with the BTS 
oxygen guidelines. 
• Patients with acute exacerbations of bronchiectasis (without consolidation) not requiring 
IV antibiotics are cared for by ACTRITE (the COPD supported discharge scheme) already. 
6.2.6.3 Making Decisions with Physicians in Charge of Patients’ Care 
 
This was an important area of development in the pilot study. Doctors involved with usual 
patient care may not be familiar with the HOME FIRST study so building relationships in order 
to recruit their (suitable) patients was important. Making joint decisions was important in 
order to give the best outcome for the patients and to optimise recruitment and follow-up. 
We believed that facilitating discharges would help form strong relationships with clinicians, 
pharmacists and ward nursing staff.  
6.2.6.4 Repeat Reviews and Consent/ Consultee Declaration 
 
Repeat reviews and the consent procedure were unaltered from the feasibility study. For 
patients with either transient or permanent lack of capacity, a consultee declaration was 
obtained. Consent/consultee declaration stickers were put into patients’ case notes.  
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6.2.7 Study Intervention – HOME FIRST 
 
If the patient was discharged before 16:00hrs they were reviewed at home later that evening 
by the team; if after 16:00hrs the review was the next morning before 11:00hrs. The 
frequency and duration of home visits was determined by communication between the study 
team, patient and carer/ NOK. Telephone calls were used instead of home visits where 
appropriate.  
6.2.8 Aftercare by HOME FIRST 
 
This is mostly unaltered from the feasibility study. At each home visit the daily clinical review 
sheet in the CRF was completed. Telephone consultations were recorded in the CRF and daily 
clinical review sheet as per a standard home visit but were recorded as ‘telephone 
consultation’ at the bottom of the page.  
6.2.8.1 Initial and Subsequent Follow-up with HOMEFIRST 
 
This was unaltered from the feasibility study. Telephone visits were developed further in the 
pilot.  
6.2.8.2 Discharge from Hospital with HOME FIRST 
 
If a patient became unwell they consulted the emergency PIL (Appendix C).  
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6.2.8.3 Readmission to Hospital from HOME FIRST 
 
The escalation and readmission flowchart was used to determine whether readmission or 
escalation were warranted (Figure 10). 
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Figure 10: Escalation and Readmission Flowchart 
 [AED (accident and emergency department), AMAU (acute medical admissions unit), CRU (clinical research unit), PI (primary investigator), 
SAE (serious adverse event), CRP (C-reactive protein), WCC (white cell count), RR (respiratory rate), GCS (Glasgow coma score), PU (pass 
urine)] 
HOME FIRST Escalation & Readmission Flowchart 
Nurse 
concerned 
about patient 
condition (see 
escalation 
criteria) 
Discuss with 
study doctor 
Admit – direct 
to AED or 
contact the bed 
manager on 
AMAU (via 
switchboard) 
No 
admission 
necessary 
Doctor 
review 
needed 
Doctor 
review not 
needed, 
advice 
given 
CRU Home 
visit 
If admission 
required 
Notify study 
doctor (if 
not already 
aware) and 
PI 
If SAE 
follow 
study and 
trust 
protocols 
Criteria for escalation 
• Social concern 
• Reduced eating & drinking 
• Fall 
• Increasing CRP/WCC 
• Unable to take antibiotics 
• O2 saturations drop >2% 
• RR rise ≥10bpm 
• Temp ≥380C 
• GCS drop≥2 
• No PU>12hrs 
• Any other cause of clinical 
concern 
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6.2.8.4 Discharge from HOME FIRST 
 
In order for discharge from HOMEFIRST the following 7 criteria must have all been answered 
YES (Figure 11), although the criteria were unaltered from the feasibility study, a flowchart 
format was developed. Even if patients fulfilled all these criteria they may still have remained 
under HOMEFIRST care for up to 5 working days if deemed necessary by the study team. After 
the maximum duration of 5 working days of home visits if further follow-up was needed the 
patient was either readmitted to hospital or handed over to the community care team. 
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Figure 11: Discharge Flowchart 
 [CRP (C-reactive protein), SBP (systolic blood pressure)] 
 
HOME FIRST Review Criteria and Flowchart for Discharge for HOME 
FIRST 
Criteria for discharge include: 
• Resolution of the reason for continued hospitalisation 
• Temperature <37.50C 
• SBP > 90mmHg 
• O2 saturations -  if chronic respiratory disease (not asthma) ≥88% on air or LTOT) or if no chronic respiratory 
disease ≥94% on air 
• 50% reduction in highest CRP (unless non-infective reason for high CRP) 
• Stable non-pneumonic co-morbidities (patient handed over to community team if further follow-up needed) 
• Able to manage with current care level 
 
Fulfil all criteria 
Consider discharge or 
remain under HOME FIRST 
care if deemed necessary 
by study team 
Remain under HOME FIRST care 
for up to 5 working days  
Readmit or discharge 
to community care if 
appropriate 
Discharge Readmit or 
discharge to 
community care 
After 5 working days of 
HOME FIRST patient still 
does NOT fulfil all criteria 
YES 
NO 
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6.2.9 Standard Hospital Care (SHC) Arm 
 
Unaltered from the feasibility study (Chapter 5, 1.2). 
6.2.10 Follow-up  
 
As in the feasibility study an independent assessor telephoned the patient or carer/ NOK/ 
consultee in order to complete a validated care satisfaction questionnaire (Appendix D). 
All recruited participants were asked to attend an outpatient appointment 6 weeks after 
recruitment; a clinical assessment (and investigations as needed), RECRI (functional RECovery 
from Respiratory tract Infection) and CAP-Sym [Community Acquired Pneumonia SYMptom 
score], SF-12 (Short Form 12 – physical and mental functionality) questionnaires were 
performed (Appendix D). Further out-patient appointments (outside of the study) were 
arranged as required.  
6.2.11 Study Flowchart 
 
A study flowchart was developed (Figure 12). 
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Figure 12: HOME FIRST PILOT Study Flowchart 
Patient approached. Eligibility and capacity assessed. 
 
Initial assessment 
STANDARD HOSPITAL CARE 
Day 0 
Clinical examination & questionnaires 
completed 
Discharged with HOME VISIT – daily 
visits for at least 48hrs (clinical bloods 
and MDT involvement as needed) 
Consent gained. 
Recruited and randomised 
& usual medical team 
informed 
Out-patient visit at 6 weeks 
 Questionnaires and clinical 
examination 
Remain in hospital until fit for discharge 
clinical bloods and MDT involvement as 
needed 
2 wk telephone satisfaction questionnaire 
by independent assessor 
(Including carer/consultee) 
Not eligible 
Not suitable 
Up to 24hrs 
HOME FIRST 
Day 0 
Clinical examination & questionnaires 
completed 
Patient declines 
Have capacity, Patient information 
leaflet given 
 
Lack capacity, consultee approached, 
patient information leaflet given 
 
Consultee accepts Patient accepts Consultee declines 
declines 
Flowchart for HOME FIRST study 
Review later to 
reassess 
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6.2.12 Hospital Staff Engagement 
 
We concentrated heavily on this area for the pilot study building on aspects form the 
feasibility study. Initial engagement involved: 
• Adverts in hospital (put up in wards - near to computers where discharges are done and 
spoke to the nurses and medical teams at the same time) 
• Meetings/talks – Ward based, ward rounds, ad hoc visits. Spoke to different people each 
time. Speciality based, regional speciality meetings, respiratory MDTs, Grand Round, 
Foundation Doctors’ teaching, ward educational sessions on AMAU and respiratory 
wards. 
• Physician involvement – gained physician’s ‘buy in’ to the study idea. Busy clinicians may 
not always be able to be proactive about referring potentially suitable patients due to 
service demands. 
Continuing engagement involved: 
• Repeat meetings were arranged 
• Giving positive verbal feedback to staff on their patients that had been part of the study. 
6.2.13 Sample Size, Statistical Methods, Outcome Measures and Randomisation 
 
Using data on mean hospital LOS from our feasibility study, we estimated that 23 patients per 
arm were required to allow an 80% power. Any participants withdrawn from the study 
remained in the data analysis as intention to treat. Statistical analysis was performed using 
Microsoft Excel 2007, GraphPad Prism 4 and SAS9.4. Unpaired T test and Mann-Whitney U 
tests were used, p-values >0.05 were considered not significant. For satisfaction scores a 
linear regression analysis was applied, controlling gender.  
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Randomisation was as per the feasibility study but the allocation was obtained using a closed 
envelope system in a locked filing cabinet. 
The overall aim was to reduce length of hospital stay (LOHS). Professor Brian Faragher (LSTM 
research statistician) was involved in statistical discussions.  
Primary Outcome 
 
Our primary endpoint was ‘time to recovery’. At recruitment we recorded participant’s best 
exercise capacity in the last 3 months e.g chair to bed with 1, unlimited exercise tolerance at 
recruitment. At the 6 week OPA the patient was asked 4 simple questions: (marked on a 
Likert-type scale in days and weeks):  
1. When (if at all) did your sleep return to normal?  
2. When (if at all) did your diet/appetite return to normal?  
3. When (if at all) did your (pre-defined) exercise capacity return to normal?  
4. When (if at all) did your capacity to work or socialise (delete as appropriate) return 
to normal? 
 [‘RECRI’ (functional RECovery from Respiratory tract Infection) questionnaire (non-
validated)] (Appendix D). 
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Secondary Outcome - Clinical  
 
1. Safety 
The safety of the scheme (i.e. no increase in morbidity (delayed recovery or complications) 
or mortality in the HOME FIRST arm) was assessed by 6-week mortality and readmission 
rates, functional status/quality of life (SF-12) and symptom improvement (CAP-SYM)  
We expected HOME FIRST to have at least equivalence with SHC. A SF-12 (physical and 
mental function) form was completed at day 0 and 6 weeks. A CAP-SYM (disease recovery 
rate) questionnaire was completed at day 0 (for both day 0 and day minus 30) and 6 
weeks.  
 
2. Patient and carer/consultee satisfaction 
We expected HOME FIRST to have at least equivalence with SHC.  
 
3. LOS in hospital and total LOS (including hospital +/- HF home care combined). 
 
Secondary Outcome - Health Economics 
 
The research outcome as the number of hospitalisation days saved was applied, comparing 
the ‘costs saved’ due to HOME FIRST intervention with its ‘intervention costs’. For estimating 
the ‘costs saved’ we used number of days of hospitalisation saved due to HOME FIRST and 
national tariff prices for hospital admissions with pneumonia (NICE, 2014). Category DZ11B 
was applied (Lobar, atypical or viral pneumonia with complications and comorbidities), there 
is a non-elective long stay trim point of 20 days, after this any additional days would receive 
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a tariff of £192/day. The cost of stay in hospital of one episode (20 days on an average) was 
2,401 GBP. It implied that each hospitalisation day saved due to intervention meant a cost 
saved of 2,401/20 or 120 GBP.  
On the other hand, to calculate the costs of intervention, we recorded interventional time 
only. This meant time spent by staff screening patients and attending home visits (visit and 
travel time). This did not therefore include time spent completing research paperwork and 
forms for recruited patients or out-patient appointments at 6 weeks (as these are both study 
specific and would not be an actual cost if this was a full clinical service), nor does it include 
time spent on study administration, requesting notes, collecting and collating data, time 
writing discharge medication prescriptions and discharge summaries, liaising with family or 
arranging transport or meals on wheels. Staff self-reported time data were independently 
validated; data were collected only during the second winter season of the study therefore 
the first winter season’s time data was extrapolated. 
Fuel/mileage and vehicle costs were not added to the calculations - home visits occurred 
within a 6-mile radius therefore costs were minimal but should be incorporated into future 
studies. 
6.2.14 General Research Staff Tasks and Responsibilities 
 
A table was developed to allow clarity of roles and responsibilities (Appendix E). 
6.2.15 Quality Control and Safety Monitoring 
6.2.15.1 Adverse Event Reporting, Patient and Staff Safety and Training 
 
This was unaltered from the feasibility study. 
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6.2.15.2 Trial Monitoring 
 
This area was significantly developed in the pilot study.  A Data Monitoring and Safety 
Committee (DMSC) was formed in January 2014 in the HOME FIRST pilot following an SAE. 
The DMSC consisted of Dr Rebecca Bancroft, Consultant Physician RLBUHT, Mr Arthur Ricky 
Kang’ombe, Lecturer/Biostatistician, Liverpool School of Tropical Medicine (LSTM), Dr John 
Blakey, Clinical Senior Lecturer LSTM and Professor Sasha Shepperd, Professor of Health 
Services Research, Oxford University. A terms of reference (Appendix E) document was 
developed. The DMSC provided an independent review of safety data by (1) reviewing 
emerging safety data throughout the study, these data was presented by spreadsheet weekly 
with responses copied to all by email. This system proved effective in our other research 
projects [Chapter 7], (2) reviewing, evaluating and making recommendations to the 
investigators and sponsor as to whether to modify, suspend, terminate or extend the study 
and, (3) being notified of any SUSAR without delay. The DMSC also reviewed SAEs/AEs on a 
regular basis and reviewed and assessed the causality of all AEs with regards to the patient 
selection criteria. Meetings were held by email circulation. There was one meeting prior to 
recruitment of 30 patients and one when a decision was made that sufficient patient numbers 
had been screened. At least weekly handovers occurred to the on-call team. 
6.2.16 Database Completion 
 
As per the feasibility study but developed further. Collated data for screened patients were 
initially recorded on paper and then uploaded daily onto an excel spreadsheet. Recruited 
patient data (SHC and HF) were recorded on an excel spreadsheet and updated with 
readmission, mortality and HAI data at the 6 week OPA. The main role of the DMSC was safety 
but they were involved in data management if required. 
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Time spent screening and attending home visits (including travel time) was recorded in season 
2 of the pilot to enable a health economic assessment. 
6.2.17 Communication 
 
GP letter, study advert and useful contacts list were not significantly altered from the 
feasibility study. 
6.2.18 Amendments 
 
During the pilot study a major amendment was submitted to and accepted by REC. The 
following documents were updated and developed - Clinical daily review form, criteria for 
discharge, DMSC ToR and charter and blank excel, escalation and readmission flowchart, 
protocol (the most up to date versions only are contained in this thesis). 
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6.3 RESULTS 
 
We screened 351 hospitalised patients with symptoms suggestive of respiratory infection and 
a total of 725 screens or reviews were performed between 15th October 2013 and 11th 
December 2014 (21 weeks of study recruitment – winter season 1 = 15/10/2013 – 1/2/2014 
and winter season 2 = 6/10/2014 – 8/12/2014) [Figure 13]. At initial screening of 217 patients 
were initially ineligible as they required further inpatient treatment (n = 116 required 
intravenous antibiotics or fluids, n = 43 had low oxygen saturation levels, n=58 various other 
reasons), repeat review was arranged. 15 patients were recruited at initial screening visit, 10 
at first repeat review and 1 at second repeat review. 16 patients were randomised to the HF 
arm, 10 to the SHC arm. No patients were ever recruited at third or later review. 99 patients 
were reviewed twice after screening, 35 patients x3 times and 23 ≥ x4 times. The first repeat 
review ranged from 0 and 14 days after initial screening visit. In total 17 patients declined 
participation (n=11 patients, n=1 spouse [acting as the consultee], n=5 physician or therapist 
declined). Of those who declined there was no difference in age noted but those who declined 
were more likely to live alone without social/family support (Table 25). 26 patients were 
recruited (26/351) = 7% screening:recruitment rate. No patients withdrew consent or were 
lost to follow-up after recruitment. No patients required retrospective consent since all 
patients recruited without capacity had chronic confusion (secondary to dementia) rather 
than acute delirium. 
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Figure 13: Consort Flow Diagram 
Initial screening, repeat review and final recruitment numbers are shown. 
Total no. of patients screened for 
eligibility (symptoms suggestive of 
LRTI) 
n=351 
Completely ineligible at 
screening = excluded 
n=130 
Repeat review as 
potentially eligible 
n=217 
‘Missed’ 
n=57 
Physician/ 
patient/NOK/carer declined  
n=13 
Total recruited and randomised 
n=26 
SHC n=10 ESDS n=16 
Study at full capacity 
 n=18 
 
 
 
 
 
 
 
Total no. 
of 
screens 
and 
repeat 
reviews 
n=725 
Ineligible at repeat review 
n=103 
Physician/ 
patient/NOK/carer declined  
n=4 
Recruited at 
screening 
n=15 
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The most common reason for non-recruitment was the need for continuing inpatient 
treatment such as IV medications/fluid, O2 or further investigations (43%). The full range of 
reasons for non-recruitment are shown in Table 24. Broadly these can be categorised into 
medical reasons (66%), social reasons (14%) and other reasons (20%). 
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Table 25: Reasons for Non-recruitment at Initial Screening or Repeat Review(s) 
Multiple reasons may apply for each patient at each visit and at subsequent reviews 
Category Reasons for non – recruitment at initial screening or 
repeat review 
n % 
 
 
Medical 
 
Requiring inpatient treatment inc. intravenous / oxygen 
therapy and / or further investigations including 
radiology 
307 42.3 
Too well (fit for discharge without Home First support) 39 5.4 
Too unwell/ died during repeat reviews 36 5.0 
No lower respiratory tract infection 35 4.8 
Other co-morbidities requiring inpatient stay 33 4.6 
 
Social 
 
Require more complex multi-disciplinary team input 
(physiotherapy, OT, social services) 
79 10.9 
Social issues / no fixed abode / non fluent English 
speaking 
20 2.8 
Requiring intermediate care bed 5 <1 
Mental health issues 3 <1 
 
Other 
 
Refused (Patient / clinician / carer / spouse / NOK) 17 2.3 
Missed discharge / patient self -discharged  55 7.6 
Infective exacerbation of COPD (other services available) 52 7.2 
Full to recruitment / study on hold 18 2.5 
NB: details of the number of refusals in which the patient did or not not have capacity were not recorded. 
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Table 26: Demographics and Characteristics of Patients who Declined or were Recruited 
 Declined Recruited 
Patient (n=11) NOK/ carer/ 
consultee (n=1) 
SHC (n=10) HF (n=16) 
Age 
mean 
(range) 
68.5 (52-84) 72 74 (62-85) 66.4 (38-91) 
Gender 
M:F 
M (5): F (4) F (1) M (2): F (8) M (7): F (9) 
Smoking 
history 
 
Not recorded 
 
Ex - 6 
Current - 1 
Never – 2 
Ex - 4 
Current - 6 
Never - 6 
Social 
history 
Live alone - 6 
With spouse - 
1 
With family - 1 
Care home - 1 
With spouse - 1 
 
Live alone - 3  
With spouse - 3  
With family - 2 
Care home - 2 
Live alone - 3 
With spouse - 
6 
With family - 5 
Care home - 2 
Capacity 
n (%) 
11 (100%) 1 (100%) 8 (80%) 15 (94%) 
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The mean age of all recruited patients was 69.3 (38-91) yrs old. New radiological consolidation 
or infective infiltration was defined according to the radiology report (chest radiograph or CT 
scan). 20 patients had radiological changes consistent with pneumonia, 12 in HF arm and 8 in 
SHC. On admission the median CURB-65 scores in HF arm were 1 (0-4) and 1 SHC (0-2). The 
average time from admission to recruitment was 6.6 days (range 1 - 23) days. Of those who 
had sputum sent for MC&S by their usual hospital care team, 3 patients had sputum positive 
for Pseudomonas aeruginosa, of which 1 was also positive for Haemophilus influenza. No 
patients had positive blood cultures or urinary pneumococcal antigen (Binax, Alere Medical). 
An outpatient visit was planned at 2 weeks after recruitment for 2 patients in the HF arm to 
enable a more urgent outpatient review of their medical condition(s). 
Primary outcome 
There was no difference between allocated group and time to recovery (Table 26). 
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Table 27: RECRI Data by Time to Recovery per Question 
 Cumulative number resolved at specified time points in each arm 
 Group Never a 
problem / 
already 
resolved 
1 day 7 days 14 
days 
21 
days 
28 - 42 
days 
Unresolved Chronic No 
data 
Q1 HF 
(n=16) 
3 
(19%) 
5 
(31%) 
9 
(56%) 
10 
(62%) 
10 
(62%) 
11 
(69%) 
1 
(6%) 
2 
(13%) 
2 
(13%) 
SHC 
(n=10) 
3 
(30%) 
3 
(30%) 
6 
(60%) 
6 
(60%) 
6 
(60%) 
6 
(60%) 
0 
(0%) 
2 
(20%) 
2 
(20%) 
Q2 HF 
(n=16) 
1 
(6%) 
2 
(13%) 
8 
(50%) 
9 
(56%) 
9 
(56%) 
9 
(56%) 
3 
(19%) 
2 
(13%) 
2 
(13%) 
SHC 
(n=10) 
4 
(40%) 
7 
(70%) 
7 
(70%) 
7 
(70%) 
8 
(80%) 
8 
(80%) 
0 
(0%) 
0 
(0%) 
2 
(20%) 
Q3 HF 
(n=16) 
2 
(13%) 
2 
(13%) 
5 
(31%) 
7 
(44%) 
8 
(50%) 
11 
(69%) 
2 
(13%) 
1 
(6%) 
2 
(13%) 
SHC 
(n=10) 
1 
(10%) 
1 
(10%) 
2 
(20%) 
2 
(20%) 
3 
(30%) 
4 
(40%) 
1 
(10%) 
3 
(30%) 
2 
(20%) 
Q4 HF 
(n=16) 
2 
(13%) 
3 
(19%) 
3 
(19%) 
7 
(44%) 
8 
(50%) 
8 
(50%) 
4 
(25%) 
2 
(13%) 
2 
(13%) 
SHC 
(n=10) 
0 
(0%) 
0 
(0%) 
1 
(10%) 
1 
(10%) 
1 
(10%) 
4 
(40%) 
3 
(30%) 
1 
(10%) 
2 
(20%) 
 
Q1. When (if at all) did your sleep return to normal? Q2. When (if at all) did your diet/appetite return to normal? Q3. When (if at all) did 
your (pre-defined) exercise capacity return to normal? 4. When (if at all) did your capacity to work or socialise (delete as appropriate) return 
to normal? 
No formal statistical analysis was performed to compare the two study arms here. 
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Secondary outcomes 
Satisfaction 
Patient and carer, next of kin (NOK) or consultee care satisfaction scores (Appendix D) were 
good in both arms. Patients without capacity or too unwell at 2 weeks were unable to 
complete this questionnaire. The carer/NOK/consultee satisfaction score in the ESDS group 
was significantly higher than that in the SHC group (-4.91; 95% CI: -7.12, -2.69; p = 0.0004). 
There was no statistical significant difference in the patient satisfaction scores (-1.47 CI: -4.49, 
1.55; p = 0.3587). 
Functionality 
19 patients completed both SF-12 questionnaires (day 0 and 6 weeks). [3 did not complete 
the questionnaire as they did not have capacity, 3 died and 1 was withdrawn]. At day 0 HF 
group mean score was 2.57 versus SHC 2.54 and at 6 weeks 2.62 versus 2.60 respectively. An 
overall mean increase of 0.06 points/subject was seen in the SHC group, and 0.05 
point/subject in the HF group between day 0 and 6 weeks. NB: using the SF-36 (a similar 
questionnaire with 36 questions) a 20-point change in the scale is believed to represent a 
clinically meaningful change; using SF-12 at least a 6-point change is deemed necessary for 
clinical significance.  
Symptom improvement 
19 subjects completed both questionnaires (13 HF, 6 SHC) [3 were not completed due to lack 
of capacity, 3 died and 1 was withdrawn]. There was no improvement in the mean CAP-SYM 
scores at 6 weeks in either group from either baseline (day -30) or recruitment (day 0) [Table 
27]. 
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Table 28: CAP-Sym Scores at Baseline, Recruitment and Outpatient Appointment 
According to Group 
 HF SHC 
Baseline [day -30] mean (range) 1.1 (0.0 – 4.2) 1.0 (0 – 2.2) 
Recruitment [day 0] mean (range) 1.2 (0.2 – 2.9) 1.2 (0.6 – 2.3) 
Outpatients [6 weeks] mean (range) 0.9 (0.0 – 2.4) 0.9 (0.2 – 2.1) 
Code: 0 = no symptoms, 1 not at all, 2 a little, 3 moderate, 4 quite a bit, 5 extremely.  
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Table 29: Data on Inflammatory Makers, Symptom Duration, Pneumococcal Vaccination, 
Statin Use, Co-Morbidity, CURB-65, Readmission, Mortality and Length of Stay in the Two 
Study Arms 
 HF SHC 
CRP on day of discharge: mean (S.D)* 74.1 
(89.6) 
58.4 
(82.0) 
WCC on day of discharge: mean (S.D)* 10.7 (4.0) 11.5 (5.3) 
Duration of symptoms prior to recruitment 
(days): mean (S.D)* 
16 (23.9) 12 (7.6) 
PPV-23 vaccine received – recollection: n 
(%)^ 
4 (25) 5 (50) 
Current HMG CoA reductase inhibitor use 
(statin) use: n (%)^ 
4 (25) 5 (50) 
Co-morbidities ≥2: n (%)^ 15 (94) 9 (90) 
Mortality at 6 weeks: n (%)^ 0 (0) 2 (20) 
Dementia: n (%)^ 1 (6) 2 (20) 
Readmissions at 6 weeks: n (%)^ 2 (13) 1 (10) 
CURB-65: median (IQR)β 1 (0.5-3) 1 (1-3) 
LOS in hospital prior to recruitment - days: 
median (IQR)β 
5.0 (1.5-8) 5.0 (3-
12.8) 
Total length of HF care – days: median (IQR) 3 (2-5) N/A 
Total length of hospital stay (Hospital +/- HF) 
- days: median (IQR)β 
5.5 (2.3-
8.0) # 
7.5 (4.0-
21.0) 
Combined LOS (Hospital +/- HF) - days: 
median (IQR)β 
7 (5.3-
13.5) 
7.5 (4-21) 
Satisfaction (mode) -    Patient and Carer  Strongly 
agree 
Agree 
Functionality (SF-12) – mean 2.57 2.54 
NB: If a CRP was recorded as <5 it was classed as 0 for statistical analysis. Mean CRP and WCC was from the day of discharge or closest 
measurement to day of discharge. If a participant is readmitted to the hospital from HF they were classed as discharged from HF care. 
# Participant withdrawn from the HF arm but remained in this analysis as intention to treat. *Unpaired T test. ^Fischer’s Exact. βMann-
whitney U. All p-values >0.05 and therefore not significant. 
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Health Economics 
ESDS identified two important inputs that were fundamental to the execution of the 
intervention in an existing standard NHS system. Staff time was the major cost of intervention. 
During the study, 725 screenings and reviews enabled 26 patients to be recruited, 16 patients 
of whom were randomised to ESDS. The costs of doctor and nurse were 1,680 GBP and 1,102 
GBP respectively, which resulted in total costs of 2,782 GBP. Distribution of this total amount 
to 26 enrolled patients corresponded to 107.0 GBP per patient as the cost of intervention. 
Since 16 patients were recruited to ESDS we found a total cost of 10716 or 1,712 GBP for 
patients in the HOME FIRST arm.  
We showed that 5 days (length of stay) in hospital can be saved for each patient. Applying the 
daily hospitalisation tariff of 120 GBP for 5 saved days for each patient, we estimated that 
HOME FIRST could save a total of 600 GBP per patient and 9,604 GBP for all 16 patients. 
If we compare these foregone or saved costs (9,604 GBP) with the costs of intervention or in 
other words, investment on HOME FIRST (1,195 GBP), we observed that 4.6 GBP can be saved 
from each GBP invested.  If we apply minimum (113 GBP) and maximum (179 GBP) expected 
values of cost per day for SHC (DoH Tariffs for pneumonia/LRTI 2015-2016), the cost saved 
from each invested GBP ranges between 4.3 and 7.4 GBP. 
If we applied this intervention only at weekends, the salary cost of doctor and nurse increases 
by 1/3 each therefore invested GBP would result in 3.2 GBP saving (ranges between 3.0 GBP 
and 5.3 GBP).  
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Table 30: Hospital Bed Days and Cost Savings (GBP) due to HOME FIRST 
 
Component                                                                               Amount                                                                                 
Intervention costs of 16 patients (GBP) 1,712 
  
Cost (GBP) saved by intervention   
Median number of LOS saved (days) 5 
Cost per day for SHC in general (GBP)# 120 
Total saved costs per patient (GBP) 600 
Total costs saved for 16 patients (GBP) 9,604 
Cost saving from each GBP investment 4.6 
#(214) 
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6.4 DISCUSSION 
 
We have shown that using defined ESDS package with defined criteria we can reduce the 
length of hospital stay (LOHS) in patients with pneumonia and LRTI. We noted a reduction in 
LOHS (bed days) by 5 days as well as a reduction in the total length of care of 2 days. The 
scheme is safe; there was no increase in readmission or mortality rates or decrease in 
recovery rate, functionality or symptom resolution at 6 weeks, and satisfaction was high. The 
ESDS package was successfully implemented in 15 participants. The scheme in its current form 
however is difficult to recruit to and large numbers of patients were screened and repeatedly 
reviewed in order to recruit a small number of patients into the study (26/351 = 7% screening: 
recruitment). Interestingly the results show that the scheme functioned not necessarily 
always as an ‘early in the admission’ discharge scheme that was managing patients with acute 
LRTI (reflected in the average time from admission to recruitment 6.6 days, despite initial 
patient screening occurring within 72hrs) but often simply as an ‘earlier discharge scheme’ 
suggesting that many patients had in fact recovered from the initial LRTI/CAP but required 
further convalescence due to multiple co-morbidities and were slower to improve clinically 
and functionally. 
With regards to functionality the lack of any clinically meaningful change between the 2 
groups at 6 weeks may suggest either a strong impact of chronic disease/co-morbidities on 
recovery or a slow return to baseline function (i.e. > 6weeks). The persistently raised CAPSYM 
scores throughout may be related to chronic disease or to the length of illness prior to 
eventual hospitalisation and a recovery period of > 6 weeks. The low mean scores throughout 
reflect the fact that we did not capture the ‘peak’ of symptoms which is likely to have been 
on the day of admission rather than the day of recruitment. 
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Satisfaction scores indicated that both patients and NOK/carers/consultees show a 
preference for ESDS care; this preference was most notably seen in the carer/NOK/consultee 
group. Anecdotally patients who were keen to get home and were randomised to ESDS were 
extremely impressed with the study and very supportive of further work.  
As with any complex intervention a number of operational and logistical issues were noted. 
As a pilot study it is important to note that we were able to reduce clinical staff workload by 
assisting with patient discharge, this in turn encouraged staff to engage with the research and 
highlight potential recruits to the study team. A ward discharge always means a new 
admission often with a new acutely ill patient; this creates a lot of work for ward staff but 
significantly improves patient flow through the acute hospital. We noted that single patient 
home visit journeys were costly in terms of staff time; linking these journeys as part of ESDS 
to other patient home visits as part of an ESDS community ‘round’ would improve efficiency 
but would be complicated in terms of co-ordination and logistics. Extensive liaison with the 
medical team/consultant was often required to allow recruitment. We found that the study 
needed to be Doctor-led, rather than senior respiratory nurse-led because we often needed 
to question (‘over-rule’) a senior clinician’s decision to keep a patient in hospital in order to 
recruit to the study. 
We found difficulties in getting hold of NOK/carer/consultee in a timely fashion when a 
potential suitable patient who did not have capacity to consent was identified; this often 
delayed or even prevented recruitment (exact numbers were not recorded). Common 
reasons for this delay were because the consultee was a distant relative, lived a distance away 
from the hospital, was working or elderly/had reduced mobility or due to incorrect contact 
details. In terms of consultees declining to complete a consultee declaration form, this only 
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happened once. This again showed that this early supported discharge scheme was generally 
well accepted by both patients and consultees/NOKs. In future studies, we would accept 
patients with all CURB-65 scores since the initial severity score does not affect whether 
someone is suitable for discharge or not. 
Similarities and differences 
Like previous HAH studies for CAP and LRTI we have shown recruitment may be difficult (215); 
we recruited 7.4% of screened patients which is comparable to other similar studies at 12% 
(84/985) (209), 11% (50/540) (118) and 7% in our feasibility study. Like our study a NZ study 
in patients with CAP showed improved patient satisfaction (p<0.001) and no difference in 
symptom score or function at 6 weeks but they increased total days of care (118). Other 
studies have, like ours shown reduced bed days and cost reductions (121, 209). 
Comparing results from this pilot to our previous feasibility study, the mean age of recruited 
patients (69.3 versus 64.6 yrs old in feasibility), fewer patients were excluded due to complex 
MDT issues (physiotherapy, social or OT needs) (10% versus 20%), due to IECOPD (8% versus 
11%), and fewer patients/NOK/carer/consultees declined (17% versus 23%).  
Strengths and weaknesses 
One of the main strengths of this novel study is the large effort made to screen patients with 
potential LRTI. There were no patient withdrawals, one participant in the HF group was 
‘withdrawn’ as they were awaiting discharge to a mental health community bed, but after 
recruitment this bed was cancelled and discharge was delayed for 7 days whilst he awaited a 
new bed. Anecdotally hospital discharges were often accelerated by HF screening even if they 
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were not recruited as the study team often highlighted certain issues and found solutions 
which enabled the patient to go home earlier. 
This was a small pilot study in a single city and therefore no powered outcome data are 
available. As mentioned in HOME FIRST feasibility study the criterion of requiring at least one 
more night of hospitalisation to be recruited is a subjective one, however the overall aim of 
the study was to reduce hospital bed days within a ‘real-life’ UK hospital setting. Continued 
hospitalisation may be due to a variety of reasons and no specific guidelines on hospital 
discharge for patients with LRTI existed when this study was performed. The higher 
prevalence of frailty and comorbidities in the elderly in particular means that improvement 
in the LRTI itself is often not the factor on which the timing of discharge is dependent (26). 
NICE guidance from 2014 suggests that the ‘benefits of on-site clinical expertise, observations 
and timely intervention must be balanced against the risk of hospital acquired infection and 
premature hospital discharge (relapse/readmission) as well as the patients quality of life and 
social circumstances’ (26).  For safe hospital discharge: 1) do not routinely discharge patients 
with CAP if in the past 24 hours they have had ≥2 of the following findings: temperature > 
37.5°C, respiratory rate ≥ 24 bpm, heart rate > 100 bpm, SBP ≤ 90 mmHg, O2 saturations < 
90% on air, abnormal mental status, inability to eat without assistance (26). With many of our 
elderly patients with chronic respiratory disease and dementia this would make routine 
hospital discharge not possible. 
We also only collected data for pneumonia symptom severity, functionality and time to 
recovery at 6 weeks; since it is well known that recovery from pneumonia can take weeks or 
months, we could expect that no significant improvement in these areas would be noted as 
early as 6 weeks. With regards to implementing an educational package for Doctors, we found 
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it hard to access senior Doctors in order to educate and effect change in their practice to 
adopt a new approach to patient discharge; our only teaching time was at the hospital ‘grand 
round’.  
HOME FIRST demonstrated clear savings in treatment costs (costs saved) because of reduced 
bed days, indicating that it is economically viable. The major intervention components (time 
costs of doctor and nurse) that had remarkable cost implication for HOME FIRST were 
captured. Our analysis showed that one invested GBP on HOME FIRST can save 4.6 GBP. 
The health tariff used in these calculations of £120/day is at the lower end of other DoH/NICE 
health tariffs (varying from £113-£179 depending on whether the patient has an LRTI or 
bronchopneumonia with and without major complications [DZ23A and DZ22C]). The average 
quoted bed cost/day however is commonly ~ £220 (2015/16 tariff) but is not specific for 
respiratory infection.  
Since we did not record patient specific variables (such as time allocated to each patient) 
there was no scope to calculating error. Strengths and limitations of our costings and 
approaches that could improve outcomes (internal and external validation) and totally change 
our conclusions (robustness) have been considered. Strengths include that time data were 
collected by each staff member daily. Limitations include that the data were not completed 
for the entire duration of the study and therefore data have been extrapolated and we also 
did not record precise data of time spent with each patient. To validate our conclusions, we 
have calculated the added cost of weekend screening to ensure a cost benefit still exists. The 
robustness of our data may be completely altered if this were a consultant rather than 
registrar led scheme. Precise figures have not been calculated. It is well known that HAH 
schemes that reduce hospital LOS do not often equate to actual savings but in fact improve 
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patient flow and productivity. A more detailed health economic assessment where all cost 
components of the intervention have been captured so that a more rigorous analysis 
calculating not only the average costs, but also the marginal costs and the impact of major 
cost drivers can be estimated, allowing a sensitivity analysis. 
There were various constraints related to the research project and staff resource during study 
recruitment. For safety, we were unable to recruit any further patients if we had 2 patients 
actively in the ESDS arm, this meant the time spent screening that week prior to this event 
was mostly redundant. 57 (26%) of potentially eligible patients were missed at repeat review 
this was due to self-discharge or discharge on days on non-recruitment due to staffing levels 
(mostly on Friday/Saturday/Sunday or bank holidays). The main reasons for patients being 
deemed unsuitable were requiring IV fluids, antibiotics or oxygen therapy. Since many 
patients’ IV antibiotics are three times per day we were unable to recruit these patients. See 
Chapter 8 for further discussion. 
In Chapter 7, we change our focus away from better therapeutics for direct clinical care and 
towards prevention in the form of pneumonia vaccines.  This chapter describes a study 
involving the inoculation (and carriage) of live pneumococcus in healthy volunteers’ noses to 
assess vaccine efficacy in order to develop a future pneumococcal vaccine testing model. 
6.5 ACKNOWLEDGEMENTS 
In this chapter I would like to specifically acknowledge the work of Sr Carole Hancock, in 
screening and recruiting patients, performing home visits and follow-up out-patient 
appointments and data collation. Also many thanks to the DMSC - Dr Rebecca Bancroft, 
Consultant Geriatrician (RLBUHT), Arthur Kang’ombe, Statistician (LSTM), Dr John Blakey, CSL 
Respiratory Medicine (UHA/LSTM) and Prof Sasha Shepperd, Professor of Health Services 
HOME FIRST Pilot 
 
191 
 
1
9
1
 
Research (University of Oxford), Dr Jahangir Khan (LSTM) and Professor Louis Niessen (LSTM) 
for their assistance with the health economic analysis, to our independent telephone 
questionnaire assessor, Debbie Jenkins and to Fiona Claxton and Rebecca Huang, Inspire 
Liverpool medical students, who assisted with putting the documents together into a manual 
of procedures (MOP). 
PCV EHPC 
 
192 
 
1
9
2
 
CHAPTER 7: Vaccine Development - First Human Challenge Testing of 
a Pneumococcal Vaccine - Double Blind Randomised Controlled Trial 
(PCV EHPC). 
 
 
 
 
 
 
7.1 INTRODUCTION 
 
Pneumococcal disease is a major global health threat for which new vaccines are urgently 
needed, particularly serotype-independent vaccines that will protect vulnerable children and 
adults against pneumococcal pneumonia. Pneumococcal disease is the most common cause 
of preventable death in children and a major cause of death among adults world-wide (216). 
Major impact on disease prevention requires interruption of colonisation (217). 
Pneumococcal conjugate vaccine (PCV) has been effective in the prevention of both 
pneumococcal colonisation (218, 219) and disease (220) in young children, with indirect herd 
protection in unvaccinated adults due to reduced community colonisation rates. However, 
the lack of a serotype independent vaccine and the level of protection afforded against 
mucosal diseases such as pneumonia and otitis media remain problematic in the current 
pneumococcal vaccination strategy. 
There is therefore a clear need for new vaccines with several in development [Table 2] (221).  
However, there is a bottleneck in non-PCV related vaccine development as clinical trials with 
tens of thousands of participants are required to compare a new vaccine with the current 
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gold standard vaccine (PCV) using an outcome of disease reduction. Testing of new vaccines 
is costly in both time and money. A pathway for licensure of PCV related products now exists 
based on non-inferiority of immunogenicity bypassing the need for phase III trials (222). This 
is based on serotype-specific IgG antibody concentration (by ELISA) and functional antibody 
titres (by OPA). 
 
A reduction in experimental colonisation acquisition rates after vaccination would provide 
proof-of-concept for both individual protection and an indication of potential reduction in 
transmission - essential for herd protection. These results would generate confidence for 
pursuing large and expensive clinical trials with pneumonia, otitis media or invasive 
pneumococcal disease as end-points (175). Studies of pneumococcal vaccine efficacy against 
pneumococcal colonisation have been proposed as an effective method to select between 
vaccine candidates and lend support to Phase 3 trial choice (175).  
 
We have developed experimental human pneumococcal carriage (EHPC) to allow 
measurement of vaccine protection against induced carriage in healthy adults (177, 178, 193). 
We first have demonstrated that nasal pneumococcal carriage could be safe and reproducibly 
achieved in carefully screened healthy adult volunteers. A dose of 80,000CFU/0.1ml/naris of 
inoculum (serotype 6B pneumococcus) achieved a target carriage rate of 40-60% in 
reproducibility testing at a density typical of natural colonisation and duration of 1 - 3 weeks 
(177, 178). We estimated that carriage rates of 50% or greater would allow the EHPC model 
to have high sensitivity for vaccine efficacy testing with small study numbers.  
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This chapter describes how we used this model in a double-blind placebo randomised control 
trial (RCT) to assess whether a current licensed pneumococcal vaccine (13-valent PCV, 
Prevenar-13), has a direct impact on pneumococcal colonisation rates, density and duration 
and therefore whether the EHPC model can be used as a surrogate for vaccine effectiveness. 
Pneumococcal conjugate vaccine (PCV) has been effective in the prevention of both 
pneumococcal colonisation and disease in young children, with indirect herd protection in 
unvaccinated adults due to reduced community colonisation rates. No previous studies have 
demonstrated the direct protective effect of PCV on pneumococcal carriage.   
 
In terms of global impact, PCV is currently considered to be an outstanding vaccine success; 
it sets the standard for future pneumococcal vaccines and is therefore the ideal ‘gold 
standard’ for EHPC testing. Here we use this EHPC model to assess whether 13-valent 
Pneumococcal Conjugate Vaccine (PCV-13, Prevenar-13) has a direct impact on experimental 
pneumococcal colonisation rates, density and duration. 
7.2 METHODS 
7.2.1 Ethical Principles 
 
This section considers the main risks and benefits associated with this CTIMP study, namely 
related to vaccination and bacterial inoculation: 
Vaccination 
All staff were experienced in vaccination administration and fully competent in anaphylaxis 
management. Full resuscitation equipment and an anaphylaxis trolley was immediately 
available. The participants remained at the clinic for 20 - 30 mins after vaccination to monitor 
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for any immediate side effects. Those who received Prevenar-13 (pneumococcal conjugate 
vaccine [PCV] - 13) received a licensed vaccine outside of the EMA marketing authorisation 
(licensed for <6yrs old and >50 years old only). Those who received Avaxim (Hepatitis A 
vaccine) received a licensed vaccine within the marketing authorisation. Both vaccines are 
generally very safe and well tolerated. Although the benefit to the participant was limited 
they were however given the opportunity if they wished to, at the end of the study complete 
the course of vaccinations (if in the Avaxim arm) or have the complete course of vaccinations 
(if in the PCV arm). Also see vaccination PIL (Appendix C). 
Bacterial Inoculation 
Inoculation of S. pneumoniae was performed by highly trained staff according to Liverpool 
School of Tropical Medicine (LSTM) SOP (Appendix B) with close post-inoculation supervision 
(24hr on call access to medical professional involved in the study) and follow-up. Specific 
inclusion and exclusion criteria were set to further protect the participant. Experienced and 
trained research staff performed venepuncture and NW. Also see inoculation PIL (Appendix 
B). 
7.2.3 Trial Design and Participants 
 
For full details see the study protocol in Appendix A. We aimed to recruit 100 non-smoking, 
healthy participants aged 18-50 years old to this double blind randomised controlled trial 
performed at the Royal Liverpool and Broadgreen University Teaching Hospital, Liverpool, UK. 
Participants were screened as below and then randomised to receive either PCV-13 
(Prevenar-13 containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F - Pfizer) 
or Hepatitis A (Avaxim - Sanofi Pasteur MSD) vaccination (control group). Natural 
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nasopharyngeal pneumococcal colonisation at the time of recruitment/screening was not an 
exclusion criteria. Serotypes included in the vaccine are termed vaccine types (VTs); those not 
included are termed non-vaccine types (NVTs). The study was approved by NHS Research and 
Ethics Committee (REC) [12/NW/0873 Liverpool]. Trial registration: EudraCT: 2012-005141-
20 and ISRCTN: 45340436. 
7.2.4 Recruitment and Selection  
 
Advertisements were placed on physical notice boards in public areas, the internet of 
Universities and Colleges within Liverpool and the surrounding area and RLBUHT and UHA 
and in the local press inviting healthy volunteers to participate. Students from Liverpool 
Universities were sent a generic advertisement email inviting them to participate in the 
research. Public open days and engagement events were also used. Interested persons were 
asked to contact the research team for further information and an initial appointment was 
made if they wished to consider participating. The RLBUHT database (consent4consent) was 
also be used to approach those who had previously been involved in research at the RLBUHT. 
Prior to attending the CRU potential participants received a patient information leaflet (PIL) 
[Appendix C]. Potential participants then attended the CRU for an informal chat and if they 
wished to proceed in the study and were eligible they signed a written consent form. 
7.2.5 Exclusion Criteria and Details 
 
We excluded participants: 
• Who had previously received PPV or PCV or a complete course of hepatitis A 
vaccination 
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• With a previous significant adverse reaction to any vaccination 
• With close contact to ‘at risk’ individuals (children, immunosuppressed adults, elderly, 
chronic ill health) – to minimise risk of pneumococcal transmission 
• Who were current smokers or had significant smoking histories (>10 pack years) – to 
minimise risk of pneumococcal infection 
• With asthma (on regular medication) or any other respiratory disease 
• Pregnant or breast feeding mothers and women of child-bearing potential who are 
deemed not to have sufficient, effective birth control in place 
• On medication that may affect the immune system in any way – to minimise risk of 
pneumococcal infection 
• Allergic to penicillin/amoxicillin 
• Involved in another clinical trial unless observational or non-interventional phase 
• Previously involved in an experimental pneumococcal colonisation study 
• With a current acute severe febrile illness – to minimise risk of pneumococcal infectio 
• With abnormal clinical observations at screening visit (systolic blood pressure <90 or 
>160 mmHg, pulse rate <40 or >100 beats per minute, oxygen saturations <96% on air) 
• With an active medical condition requiring regular hospital appointments – to 
minimise risk of pneumococcal transmission and infection 
• With a pre-inoculation white cell count of <4.0 (109/L) AND a neutrophil count of <1.5 
(109/L) – to minimise risk of pneumococcal infection 
To minimise any effect on inoculation, we excluded participants who had taken any antibiotic 
therapy <2 weeks prior to inoculation. 
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7.2.6 Randomisation, Blinding, Vaccination and Unblinding 
 
Randomisation was computer-generated and occurred in blocks of ten. An independent 
statistician from the tropical Clinical Trials Unit (tCTU) at the Liverpool School of Tropical 
Medicine (LSTM) produced the randomisation schedule and the sealed envelopes containing 
the study group allocations. 
Research (clinical and laboratory) staff and participants were blinded to the vaccination 
allocation. An unblinded vaccination team was employed to vaccinate study participants.  
Vaccines were prepared out of sight of the study participants.  At the end of the study, the 
participants were unblinded to the vaccine that they received.  
7.2.7 Nasopharyngeal Inoculation 
 
Standard operating protocols (SOP) for the preparation of the 6B inoculum stock, the 
determination of inoculum dose, the inoculation and nasal sampling method, nasal wash 
(NW) processing, the detection of pneumococcal carriage by culture and measurement of 
carriage density can be found in Appendix B respectively. 
We used our published protocol with full safety cover (178). Briefly a well-characterised 
penicillin-sensitive 6B serotype pneumococcus (BHN 418, sequence type 138) was grown to 
mid-log phase in Vegitone broth (Oxoid) and stored in 1ml aliquots containing 20% glycerol 
at -80°C.  Confirmation of serotype was performed using latex agglutination (Statens Serum 
Institute, Copenhagen) and bacterial purity was confirmed by an independent reference 
laboratory (Public Health England, Colindale, UK). 
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The prepared inoculum was taken to the clinical area where the participant was seated in a 
semi-recumbent position. 100μl of inoculum containing the desired dose (80,000 CFU [colony 
forming units]/100µl), was instilled into each nostril in a circular motion (178). Following 
inoculation the participant remained in this position for 10 -15mins. The strain was chosen as 
its genome is fully sequenced and there are negligible rates of natural colonisation with 6B in 
Liverpool. The 6B serotype has been used previously by our group and others (176, 177), and 
we have performed studies (using serotype 23F and 6B) to establish dose, safety and achieve 
stable colonisation rates (177). See Appendix B SOPs. 
7.2.8 Nasal Washing and Detection of Pneumococcal Colonisation 
 
Nasal wash (NW) samples were collected pre-vaccine, post-vaccine/pre-inoculation and post-
inoculation (day 2, 7, 14, 21). If participants were not colonised at day 2 and 7, they were 
excluded from NW at day 14. Samples were collected and processed for pneumococcal 
detection as previously described (178, 192). Briefly, 5ml of 0.9% saline was instilled into each 
naris, this was repeated twice (10ml total per nares). If less than 10mls was returned, up to 
40mls normal saline was used as necessary. All CFU density data were calculated as CFU/ml 
of NW returned. In less than 3% (n=15) of NW, >20mls of 0.9% saline was required to obtain 
the required ≥10mls of NW return. 
NW samples were transferred immediately to the lab and processed (Appendix B). 
Participants in whom experimental pneumococci were detected in NW samples at any visit 
post inoculation were defined as experimentally colonised. All experimentally colonised 
participants who did not have 2 consecutive culture-negative nasal washes received 
amoxicillin 500mg T.D.S for 3 days at the end of the study in order to ensure 6B colonisation 
clearance. 
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7.2.9 Participant Monitoring and Safety 
At the pre-vaccination visit a clinical examination, history and pregnancy test (where 
appropriate) were performed. Participants remained at the clinic for 20-30 minutes after 
vaccination to monitor for any immediate side effects. Full resuscitation equipment and an 
anaphylaxis trolley were immediately available. Four weeks after vaccination, participants 
were inoculated with pneumococcus. Prevenar-13 is a safe vaccine with a very low risk of 
adverse events (223, 224). It is currently licensed for use in children and in the UK as part of 
the childhood immunisation programme (effective from 4 September 2006). In adults over 50 
years of age vaccinated in US clinical trials the most commonly reported side effects to 
Prevenar-13 vaccination included: injection site pain/swelling/tenderness, fatigue, headache, 
muscle pain, limitation of arms movement, decreased appetite, chills and rash. Avaxim was 
chosen as a suitable control due to its safety profile, preparation (aluminium-containing 
vaccine), (assumed) lack of effect on nasal colonisation/immunity and health benefit for those 
involved in the study if the participant were to travel to hepatitis A endemic areas in the 
future. It is licensed for use in susceptible adults >16 years old. In clinical trials, adverse 
reactions were usually mild and confined to the first few days after vaccination with 
spontaneous recovery. Adverse reactions to Avaxim vaccination include (1) Asthenia, mild 
injection site pain [very common] (2) Headache, nausea, vomiting, decreased appetite, 
diarrhoea, abdominal pain, myalgia/arthralgia, mild fever [common] (3) Injection site 
erythema [uncommon] (4) nodule [rare]. 
Study screening to minimise the risk of pneumococcal infection to participants or contacts 
included (1) careful study team selection, experienced in human challenge studies (2) careful 
study design (3) serotype selection (6B) and dosing (4) participant selection and exclusion 
criteria (5) participant education and rigorous safety procedures including a 24 hour 
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emergency telephone contact with researchers (including close individual daily monitoring 
for 7 days post-inoculation via text contact to a specified member of the research team before 
1200hrs noon) and access to hospital facilities with prompt treatment if required, a post-
inoculation advice sheet (PIL), a digital thermometer and a course of amoxicillin tablets (3 day 
course of 500mg TDS) in case of emergency. The amoxicillin was only to be taken under three 
circumstances; in the event that they were unwell and were instructed to take them by the 
research team, if they were unwell and unable to contact the research team or if they were 
still colonised with pneumococcus at the end of the study. Home monitoring included a clear 
flow chart of the necessary intervention should any symptoms develop (Appendix C). If a 
participant did not make contact by the specified time; a member of the research team 
contacted them. If no contact was made then a prior defined ‘secondary contact’ was 
telephoned. 
Data on adverse events were collected and categorised as follows: headache, sore throat, 
nasal congestion/ running/ sneezing, myalgia, lethargy, earache/ muffling/ popping, pyrexia, 
neck stiffness, hospital admission and other (including shivering, wheezy, cough, abdominal 
cramps, photophobia, sinus pain and generally unwell). As per sponsor guidance, any serious 
adverse events (SAEs) were recorded and reported to the DMSC and sponsor within 24hrs. A 
Data Monitoring and Safety Committee (DMSC) monitored the study throughout and advised 
the PI and study team.  
7.2.10 Endpoints 
 
The primary endpoint was pneumococcal colonisation at any time-point (day 2, 7, 14 or 21). 
The secondary endpoints were (1) Pneumococcal colonisation at individual time points [day 
2, 7, 14 or 21] (2) Pneumococcal density at individual time points and the area under the 
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density curve, and (3) Pneumococcal colonisation duration, defined as the duration from 
inoculation to the last confirmed positive NW sample. All endpoints were defined by culture 
of NW. 
7.2.11 Statistical Methods, Analysis and Power Calculation 
 
Using data from our dose-ranging and reproducibility studies and data from previous EHPC 
studies, we estimated that 60% of the control group would be colonised with pneumococci 
following inoculation and 30% of the PCV group. A 50% reduction of carriage in PCV group 
was estimated in accordance with modelling studies (225). This allowed a power of 81% when 
recruiting 50 volunteers to each arm (Table 30). 
Analysis was based on the intention-to-treat (ITT) principle. Participants not completing the 
inoculation limb of the study were removed leading to a modified ITT population. All statistical 
analyses were performed using SAS 9.2 and Stata 13. Full details are in Appendix A (Statistical 
Analysis Plan). 
7.2.12 Study Schedule 
 
A flowchart describing the study schedule in detail with clear timelines is contained in 
Appendix A. 
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Table 31: Power Calculation with Participant Numbers per Study Arm 
 
 N Carriers Carriers Carriers Carriers Carriers Carriers 
PCV 50 5 5 10 10 15 15 
Control 50 30 25 30 25 30 25 
Power (%)  99 99 98 85 81 45 
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7.3 RESULTS 
7.3.1 Screening and Recruitment 
 
429 volunteers were screened and 100 participants were recruited between September 2013 
and April 2014. Reasons for non-recruitment included close contact with children aged < 5 
years old or ‘at risk’ individuals such as the elderly or those on immunosuppressive 
medications, asthma (on regular medication), current smoker, >10 pack year smoking history 
and penicillin/amoxicillin allergy. 99 participants were vaccinated (n=49 PCV, n=50 control – 
ITT population), 1 participant was removed after recruitment but before randomisation (they 
had previously received a Hepatitis A vaccination which was not declared on their GPQ) and 
3 participants were removed pre-inoculation (n=96 - modified ITT population) [Figure 14]. In 
less than 3% (n=15) of NW >20mls of normal saline was required to obtain the required 
≥10mls of NW return. 
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Figure 14: Consort Flow Diagram 
(Reasons for exclusion: Close contact with ‘at risk’ individuals (children n = 16, patients n = 41), did not attend appointment n = 18, cannot 
commit time to the study n = 13, current smokers or >10 pack years n = 11, lived in a Hepatitis A endemic area n = 11, previously involved 
in an experimental pneumococcal colonisation study n= 9, asthma n=8, allergic to penicillin/amoxicillin n= 7 and other n = 33). 
PCV EHPC 
 
206 
 
2
0
6
 
7.3.2 Pneumococcal Colonisation Acquisition 
 
Pneumococcal colonisation, with the inoculated 6B serotype, at any time was found in 5/48 
(10.4%) participants in the PCV group compared to 23/48 (47.9%) in the control group. The 
risk ratio of pneumococcal colonisation following PCV compared to control vaccine was 0.22 
(CI 0.09 to 0.52, p=0.0007). The corresponding odds ratio was 0.13 (95CI 0.04 to 0.3, 
p=0.0002). The percentage of colonised participants fell from 8.3% to 4.3% in the PCV group 
and from 43.8% to 33.3% in the control group between day 2 and day 21, respectively [Table 
31]. Amongst the 5 participants colonised in the PCV group, 2 participants were still colonised 
at day 21. There were no significant differences between the groups with regards to age, 
gender, time from vaccination to inoculation or dose of inoculum received [Table 32]. 
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Table 32: 6B Pneumococcal Colonisation Status Assessed According to Vaccination Group 
at Each and Any Time Point 
 
 No. colonised/total no. (%)   
Day PCV group (n=48) Control group(n=48) Odds Ratio [95%CI] p value 
Day 2 4/48 (8.3) 21/48 (43.8) 0.12[0.04-0.38] 0.0003 
Day 7 4/48 (8.3) 21/48 (43.8) 0.12[0.04-0.38] 0.0003 
Day 14 1/48 (2.1) 19/48 (39.6) 0.05[0.01-0.27]* 0.0004* 
Day 21 2/46 (4.3) 15/45 (33.3) 
Any day 5/48 (10.4) 23/48 (47.9) 0.13[0.04-0.37] 0.0002 
PCV=Pneumococcal Conjugate Vaccine. *Day 14 and Day 21 were combined to generate a stable estimate. (Note modified ITT analysis [n=96] 
was used since participants excluded post vaccination but pre-inoculation cannot develop experimental 6B colonisation). 
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Table 33: Baseline Demographics of Participants 
  
 
Characteristics PCV (n=49) Control (n=50) 
Age (year) 24.1 ± 6.1 23.2 ± 6.9 
Male 20 (40.8) 19 (38.0) 
Time from vaccination to inoculation (days) 35.0 ± 3.9* 34.1 ± 2.2* 
Dose inoculated (CFU/100µl) 83203 ± 8026* 82602 ± 8098* 
Data are number (%) or mean (SD). PCV=Pneumococcal Conjugate Vaccine. *n=48 in each group. (Data as per Intention to Treat analysis – 
ITT, n=99). 
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7.3.3 Pneumococcal Colonisation Density and Intensity 
 
PCV reduced colonisation density (Figure 15). The density of 6B pneumococci recovered from 
the nasopharynx of participants in the PCV group was on average three logs lower than the 
density recovered from the control group, with statistically significant differences seen up to 
7 days post inoculation (Table 33 and Figure 16).  There was an overall significant reduction 
in colonisation intensity as measured by the AUC (ratio 0.02, 95%CI 0.00 to 0.51, p=0.017). 
We did not observe a statistical difference in duration of established colonisation between 
the groups (p=0.1328). 
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Figure 15: 6B Pneumococcal Colonisation Intensity (Density [CFU/ml NW] in Relation to 
Duration of Colonisation [Days]) Post Inoculation at Each Time Point According to 
Vaccination Group of All Those Colonised 
6B pneumococcal colonisation intensity (density [CFU/ml of NW returned] in relation to duration of colonisation [days]) post inoculation at 
each time point according to vaccination group. (Values shown are the mean CFU per millilitre ± standard errors of the mean [Full data 
plotted in Figure 16]). 
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Figure 16: 6B Pneumococcal Colonisation Density (CFU/ml) Post Inoculation at Each Time 
Point According to Vaccination Group of All Those Colonised 
Values shown are the mean CFU per millilitre ± standard errors of the mean. 
PCV EHPC 
 
212 
 
2
1
2
 
Table 34: 6B Colonisation Density According to Vaccination Group at Each Time Point 
 Density (CFU/ml) geometric mean ± SD   
Day PCV (no. colonised at 
each time point) 
Control (no. colonised 
at each time point) 
 Ratio [95% CI] p value 
     
Day 2 99 ± 53 (4) 33694 ± 120812 (21) 0.17 [0.04-0.65] 0.0099 
Day 7 19 ± 31 (4) 50517 ± 169172 (21) 0.02 [0.00-0.14] <0.0001 
Day 14 26* (1) 3476 ± 6962 (19) 1.94 [0.09-43.90]# 0.6767# 
Day 21 3085 ± 4247 (2) 5623 ± 11855 (15) 
PCV=Pneumococcal Conjugate Vaccine. *Only 1 observation and SD is unavailable. # Day 14 and Day 21 were combined to generate a stable 
estimate. Density is only reported in participants who are colonised with 6B. (Note modified ITT analysis [n=96] was used since participants 
excluded post vaccination but pre-inoculation cannot develop experimental 6B colonisation). 
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7.3.4 Natural Pneumococcal Colonisation 
 
In total 6 participants were naturally colonised, 4 in the PCV and 2 in the control group. In the 
PCV group, 2 participants were colonised with VT (both serotype 3) and 2 with NVT. In the 
control group both were NVT (serotype 33 and 8). One participant in the control group was 
co-colonised with both the inoculated serotype 6B and a naturally acquired serotype 8 (Table 
34). 
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Table 35: Natural Pneumococcal Colonisation According to Vaccination Group 
 
Vaccine 
group 
Experimentally 
Colonised 
Pre-
inoculation 
serotype  
Day 2  
serotype  
Day 7  
serotype  
Day 14  
serotype 
Day 21  
serotype 
PCV No 23 23 ND 23 23 
PCV No 3 3 3 3 3 
PCV No NVT NVT NVT NVT NVT 
PCV No 3 3 3 3 3 
Control No 33 33 ND ND ND 
Control Yes 8 ND 6, 8 6, 8 6 
NVT - non-vaccine type, serotypes identified by Statens Serum latex kit; ND: not detected 
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7.3.5 Symptoms 
7.3.5.1 Post Vaccination 
 
Of those receiving Prevenar-13, 12 (24%) had local symptoms [sore arm (n=12), injection site 
swelling (n=2)]. Of those receiving Avaxim, 9 (19%) had local symptoms [sore arm (n=5), 
injection site pain/redness/swelling (n=4), localised numbness (n=1), neck stiffness (n=1)]. For 
both vaccines no systemic symptoms were reported and there were no episodes of 
anaphylaxis.  
7.3.5.2 Post Inoculation 
 
14 (48%) colonised and 25 (37%) non-colonised participants reported symptoms. 13 colonised 
(3 PCV, 10 control) and 23 non-colonised (14 PCV, 9 control) reported minor symptoms at least 
once up to day 21 post inoculation. Minor symptoms included: headache, sore throat, nasal 
congestion/ running/ sneezing, myalgia, lethargy, earache/ muffling/ popping, pyrexia, 
wheeze, mild photophobia, cough, abdominal and sinus pain. One participant (PCV group and 
6B colonised) was admitted to hospital overnight 72hrs post-inoculation complaining of 
pyrexia, lethargy and sore throat. This participant was diagnosed with tonsillitis and a non-
toxigenic Corynebacterium diptheriae was cultured from throat swabs. Amoxicillin 500mgs 
TDS was prescribed for 10 days and they made a full and uneventful recovery. The participant 
was included in the ITT analysis although, as expected, the antibiotic therapy terminated 6B 
colonisation. 
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7.4 DISCUSSION 
 
In this study we have demonstrated that 6B pneumococcal colonisation acquisition was 
reduced by 78% in Prevenar-13 (PCV) vaccinated adults compared to controls. When 6B 
colonisation did occur post PCV vaccination, this was at a significantly lower density than in 
control participants. Further, we demonstrated for the first time that EHPC can be used as an 
innovative approach to test vaccine efficacy in healthy adults using both pneumococcal 
colonisation acquisition rates and density as important and relevant endpoints.   
Human challenge studies in vaccination are not unusual; they have been critical to the 
development of a wide number of candidate approaches to malaria vaccination (226) and are 
in development for other infectious diseases (227). We conducted this study as a registered 
Double Blind Randomised Controlled Trial (DBRCT) to demonstrate proof of principle for EHPC 
in pneumococcal vaccine testing. The study has a number of strengths in that it is small, quick, 
safe, economical and precise. The study took 9 months to complete, required only 100 
participants, had no SAEs related to pneumococcal inoculation and a budget of ~£500K with 
the precision of the culture determined colonisation end-point giving the study a definitive 
answer. Our observations of a reduction in colonisation acquisition rate and density are the 
same as shown in RCTs conducted in children (164, 228).  Using disease as an endpoint, the 
CAPiTA (Community-Acquired Pneumonia Immunization Trial in Adults) study involved over 
85,000 participants from 58 hospitals in the Netherlands over 5 years from 2008, in order to 
evaluate the efficacy of Prevenar-13 in adults ≥65 years (167, 169, 229).  EHPC studies could 
be used to select vaccine candidates. Using colonisation as a surrogate endpoint, the cost and 
time taken from vaccine discovery to product registration and market [often over a 10 year 
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process with current cost estimates of US$200 - 500 million per vaccine (230)] could be 
substantially reduced. 
The main weakness of the study is that colonisation in healthy adults is not a clinical disease 
endpoint; nevertheless, it is a critical determinant of transmission not simply a surrogate of 
protection.  Another limitation is that this model is not suitable for use in children. Only a 
single serotype (6B) was used; our planned future work will also use other serotypes. 
Prevention of colonisation in children and adults results in herd protection through reduced 
exposure, therefore this effect is directly relevant to predicting herd protection and hence 
informing vaccine strategy. The small number of participants with natural colonisation (n=6, 
6%) in our study is typical of that expected for UK adults (219), but does not allow conclusions 
about the effect of PCV-13 vaccination on natural colonisation or its interaction with 6B. We 
note that whilst it is theoretically possible to have both natural and 6B experimental 
colonisation, this was only seen in one participant. A short interval between vaccination and 
pneumococcal challenge was chosen is order to assess the effect on colonisation during the 
period of optimal immune response to vaccination. Future studies with longer intervals are 
planned to investigate whether protection wanes with time and will investigate the role of 
viral co-colonisation. We have previously found no correlation between baseline serum anti-
capsular or anti-protein antibody levels and protection from colonisation (177). It may have 
been useful to include ‘zero’ points on Figure 16, since this figure may visually underplay the 
significant difference in colonisation density seen between the PCV and control groups. 
Epidemiological data have shown a reduction in nasopharyngeal colonisation after PCV in 
children and adults (219, 231) both by direct protection of vaccinated individuals and by 
reduction in exposure of unvaccinated individuals through herd protection. The protective 
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effectiveness of PCV-13 against VT colonisation in children was ~ 74% (231), we have 
replicated these findings in adults demonstrating a 78% reduction against VT (6B 
experimental) colonisation in adults. We have also shown a 10% PCV-13 failure rate. The large 
effect demonstrated here may either be due to our protocol design (in which we chose to 
inoculate participants at optimal immunity post PCV-13 vaccination at 4 weeks), or it may be 
that PCV-13 is particularly effective against type 6B [as has been shown in colonisation studies 
in children when compared to other VTs, post PCV-7 and -13, such as serotype 19F and 3 (231, 
232)]. 6B colonisation rates in children declined from 20% (233) to 0-2% after the introduction 
of PCV-7 (218, 232, 234, 235) in Europe. Our findings replicate the known impact of PCV on 
colonisation (impact on density and acquisition but no impact on duration) from both RCT 
and epidemiological studies (164, 228). 
This study provides data to confirm that PCV-13 not only leads to a significant reduction in 
pneumococcal colonisation acquisition rates, but also reduces the density of colonisation 
thereby offering further protection by reduced transmission. We suggest that this novel 
Experimental Human Pneumococcal Colonisation (EHPC) model can be used as a platform for 
future pneumococcal vaccine testing, using small sample sizes and shorter time scales than 
community studies in order to reduce time and cost to market. We recommend that 
colonisation acquisition rate, density and duration are all measured in these studies (177, 
178). 
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CHAPTER 8: Discussion and Future Studies 
 
 
 
 
 
 
 
8.1 General Summary and Discussion of Findings 
 
In this thesis, we have described studies that focus on the diagnostics, therapeutics and 
prevention of pneumonia and LRTI, key priorities in the UK today. 
With regards to diagnostics (Chapter 3) we conclude that neither prevalence nor density of 
nasal pneumococcal colonisation (assessed by culture or qPCR) can be used as a method of 
microbiological diagnosis in hospitalised adults with LRTI in the UK. Nationally GP antibiotic 
prescribing for LRTI is very high. Nasal sampling is not a useful diagnostic technique in 
hospitalised patients, since such patients have usually received at least two doses of 
antibiotics from their GP prior to nasal wash. We do not recommend nasal sampling in 
patients admitted to hospital with LRTI in the UK.  
With regards to therapeutics and home-based care, we have shown that ESDS (Chapter 4, 5 
and 6) is difficult but not impossible to implement and recruit to and that there is demand for 
such a service.  A large recruitment effort is needed. Using defined criteria for recruitment 
and a defined interventional package treatment of patients with LRTI and pneumonia outside 
of an acute hospital environment is safe, effective, popular with many patients and their 
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carers and by reducing length of hospital stay may be cost-saving. In the feasibility study the 
total hospital length of hospital stay was reduced by 4.9 days in the early supported discharge 
scheme (ESDS) arm. Patients and carers reported higher satisfaction with care in the ESDS and 
there were fewer readmissions and hospital-acquired infections. The feasibility study 
informed the pilot study, therefore we included patients with lack of capacity in the latter in 
order that the ESDS could benefit more patients.  In the pilot study, at 6 weeks there was no 
increase in readmission or mortality rates or decrease in recovery rate, functionality or 
symptom resolution in the ESDS group and satisfaction was high. We noted a reduction in 
LOHS (bed days) by 5 days as well as a reduction in the total length of care of 2 days. Virtual 
visits (via telephone), rather than home visits seemed adequate after the first 48hrs from 
discharge. 
With regards to prevention and vaccine development (Chapter 7), using our Experimental 
Human Pneumococcal Carriage (EHPC) model we confirmed that the current pneumococcal 
vaccine (PCV) reduces rates of pneumococcal acquisition and carriage density in healthy 
adults. The EHPC model is a safe and efficient method to determine the protective efficacy of 
new vaccines on pneumococcal colonisation; PCV provides a ‘gold standard’ against which to 
test these novel vaccines. Our robust EHPC model can now be used to test novel candidate 
vaccines using a smaller sample size and shorter timescales than clinical community studies 
in order to reduce cost and time to market. 
Overall, reflecting on the decision made to include LRTI rather than just CAP in order to make 
the results in these studies more generalisable was useful for the HAH studies (Chapter 5 and 
6) but not useful for the LRTI NW study (Chapter 3). The heterogenicity of this group made it 
potentially more difficult to achieve meaningful microbiological results in terms of 
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pneumococcal colonisation for the LRTI NW study but recruiting patients with pneumonia 
alone would have made recruitment even more challenging. When pneumococcus is the 
pathogenic organism it may more commonly cause pneumonic consolidation (if a timely CXR 
is performed) rather than a ‘simple’ LRTI without consolidation like H. influenza or respiratory 
viruses; this means that our chance of finding high pneumococcal density or indeed 
pneumococcal presence in nasal wash in such patients would have been significantly reduced 
affecting our results. 
8.2 The Future 
 
With regards to Chapter 3, since we found that prior antibiotic treatment meant that nasal 
sampling in these hospitalised patients was not useful; a future community based study of 
nasal sampling as a diagnostic technique in antibiotic naïve patients with LRTI/pneumonia 
prior to antibiotic therapy may be useful. Sample size calculations suggest that for an 80% 
power to detect a difference of 10% in qPCR (52% detection in LRTI patients versus 42% in 
controls) would require at least 200 patients in each arm. Patients with a clinical diagnosis of 
CAP (according to NICE definitions) would be included, and we would consider excluding 
patients with HAP, COPD and bronchiectasis in whom different pathogens are more common. 
Collaboration with interested local GP surgeries and screening during the winter season 
would be key. 
With regards to chapters 4, 5 and 6, better integration between primary, secondary and social 
care is key to the success of such a complex interventional model, HOME FIRST. Social support 
is a key reason for delayed discharges so without the support of physiotherapists, OTs and an 
instant access care team we will always struggle to discharge such patients, especially with 
our ever-ageing population with increasingly complex and multiple co-morbidities. A 
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significant number of patients who have complex social/mental health needs or co-
morbidities will however still require inpatient care. The novelty of these studies was a great 
strength and in developing flowcharts and a manual of procedures for this complex 
intervention we have paved the way for further future studies. The recruitment was difficult. 
Another strength was the inclusion of patients without full capacity, this made the REC 
application process more complicated but we were determined to include such patients as 
we felt they could benefit significantly from such an intervention. 
The potential patient-related (reduced risk of HAI, care in own home, improved sleep, 
increased recovery rate, improved patient and carer satisfaction, reduced risk of delirium and 
later post-hospital discharge institutionalisation) and health-service benefits (reduced risk of 
HAI, improved self-management, reduced hospital LOS and therefore cost) are critical in 
assessing service impact. Strategies to increase the proportion of low-risk patients with CAP 
treated in the community have been developed and have been reported as safe, effective and 
acceptable to patients (107) but there is an urgent need for more evidence regarding ESDS to 
facilitate the discharge of patients with more complicated needs.  
Our pilot study suggests a number of potential improvements to study recruitment 
procedures would maximise the use of ESDS: 
(1) Hospital logistics - Recruitment to future pneumonia and LRTI studies will improve if 
hospitals more proactively engage with research. Since screening is resource intensive; a 
proactive scheme where ward medical/nursing staff contacted the research team or 
screening together with the existing hospital community COPD team would be more efficient. 
Working with hospital management to improve hospital systems to reduce time spent 
screening ineligible patients may help but the new shift to hospital computer systems rather 
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than paper notes will help the screening process as this can then be performed remotely daily 
or twice daily by a trained non-clinical administrator in order to provide lists of potentially 
suitable patients. Further remote review would also be easier and faster. Increasing 
recruitment hours up to 12 hours-per-day, 7-days-per-week and more cohesive working 
between the clinical team, home IV antibiotic team and current community respiratory teams 
is required for this intervention to work more effectively and efficiently. Improved 
collaboration with microbiology in order to produce a trust policy for out-patient IV antibiotic 
therapy for LRTI and pneumonia to enable B.D. IV antibiotic dosing is important. Fast-access 
to occupational therapy within the hospital, community physiotherapy and social services 
may also aid recruitment by increasing the number of patients with complex MDT needs 
recruited. However, all of this would increase cost and therefore affect health economic 
projections. 
(2) Medical conditions - Collaboration with palliative care and community elderly care 
physicians in order to improve advanced care planning (which will also likely improve 
admission avoidance) will allow patients to be discharged with a ‘trial of antibiotic therapy’ 
for a set duration where appropriate with a clear management plan in place in case of further 
deterioration. Terminal care may be more appropriately delivered at home in such patients 
(212). 
Future developments to the HOME FIRST ESDS model may include accepting patients in whom 
clear decisions have been made (or encouraging such decisions to be made) that no escalation 
in care is appropriate if after 48hrs no improvement is seen; terminal care may be more 
appropriately delivered at home (212). It may also be useful to accept patients on more than 
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twice per day IV antibiotics and to develop closer links with ‘early response teams’ in order to 
facilitate fast and effective discharge of more complex patients.  
HAH presents an opportunity to improve health policy, healthcare delivery and services; and 
to reduce admission rates and HAIs, all areas of major strategic importance internationally. 
Hospital at Home (HAH) care is a complex clinical model (236) that may work best as part of 
a portfolio of models for patients with respiratory infection (237). ESDS is likely to more 
effective in areas with a lack of ‘cottage hospital’ or intermediate care beds for convalescence. 
Large numbers are needed to effectively assess safety and effectiveness. We propose that 
there is a clear need and demand for an ESDS but that better integration within well-
established CCG-funded chronic obstructive pulmonary disease (COPD) schemes to form a 
‘Respiratory ESDS’ is required and that a large multi-site RCT with multiple relevant patient-
related end-points is required (238). CAPSYM, RECRI, ASF-12 have not been shown to be 
useful endpoints in either HOME FIRST study. Health-economic analysis, satisfaction, 
mortality and readmission rates are however useful and important end points. 
With regards to Chapter 7, this was a well-run novel carriage study, recruitment at times was 
still challenging however; we learned a great deal about the ethics process for carriage study 
work, the best ways to recruit students to such studies and about registering and running 
CTIMP studies. We have since used this EHPC model to test a novel vaccine in a Phase 2 DBRCT 
placebo trial. We tested GEN-004 a sub-unit vaccine developed by Genocea Biosciences to 
determine whether GEN-004 protects against pneumococcal carriage (aiming to become a 
licenced vaccine against pneumococcal otitis media). We are currently using the EHPC model 
to investigate whether the nasal live attenuated influenza vaccine (LAIV) has any impact on 
pneumococcal carriage. The clinical relevance being that increased pneumococcal carriage 
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rate and density may lead to increased transmission and burden of disease in susceptible 
individuals. Further pneumococcal vaccine studies are under discussion. We are also planning 
to inoculate subjects with asthma and the elderly; and also planning a co-infection model with 
multiple pneumococcal serotypes competing in the same niche. 
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Appendices 
Appendix A 
 
Contains all study protocols (including study flowcharts and statistical analysis plans): 
 
• LRTI and Nasal Wash Study Protocol  
• HOME FIRST Feasibility Study Protocol 
• HOME FIRST Pilot Study Protocol 
• PCV EHPC Study Protocol 
• PCV EHPC Study Flowchart 
• PCV EHPC Statistical Analysis Plan 
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PROTOCOL for LRTI and NASAL WASH Study - a Study of Pneumococcal Carriage in 
Hospitalised Patients with Lower Respiratory Tract Infections. 
BACKGROUND 
Pneumococcal carriage 
Pneumococcal disease is preceded by colonisation of the nasopharynx of uninfected adults and children.  
Pneumococcal carriage rates are known to be around 1-10% in the adult population in developed countries (70, 
71) Factors including age, immune status, antibiotic use, household composition and contact with children all 
affect carriage rates. Lowest rates are seen in those adults without preschool children in the family (2-9%) and 
highest in those with preschool children (18%). Rates of up to 35-54% are seen in preschool age children (70, 
71). 
 
There are no data on pneumococcal carriage in hospitalised patients with respiratory infection in the UK. 
Pneumococcal carriage in pneumococcal vaccine naive hospitalised elderly (72) in Australia was extremely low, 
(1 of 315) on nasopharyngeal swab (NPS). Of this cohort only 10 patients had respiratory infection at the time 
of the nasal swab. 
 A South African study of predominantly HIV positive patients with community-acquired pneumonia (CAP) 
identified pneumococcus in 27% of CAP patients using composite diagnostic methods (blood and sputum 
culture, Gram stain and urine Binax testing). Patients with CAP were more frequently colonised than controls 
(44.9% v 11.7% using classical culture and 62.8 v 19.8% using lytA real time Polymerase Chain Reaction [rtPCR]). 
HIV-infected patients with CAP with positive composite diagnostic tests for pneumococcus had higher density 
on NPS than those without pneumococcus identified; density was also higher in those with pneumococcal CAP 
than asymptomatic controls. The higher the density the more likely the HIV-infected patient with CAP was to be 
pneumococcal positive on composite testing. Quantitative rtPCR could possibly be used as a new method with 
which to diagnose pneumococcal pneumonia in adults.(45) rtPCR may improve detection and quantification of 
nasal pneumococcus in patients with LRTI. 
In Chinese children, more frequent pneumococcal colonisation was detected in those with pneumonia than 
without.(78) Vietnamese children with pneumonia had higher density colonisation than those with bronchitis or 
healthy children.(79) 
With rising burden of organisms in the nasopharynx at a critical colonisation density, it is believed that the risk 
of micro-aspiration and therefore pneumonia increases.(81, 82) 
Knowledge of pneumococcal carriage in a population of hospitalised patients with respiratory infection will 
increase understanding about potential new diagnostics (nasal wash, NPS) for these patients and more targeted 
antibiotic therapy.(45) Since reduced colonisation is seen as a potential surrogate marker of pneumococcal 
vaccine efficacy, research in this area, will further knowledge as to whether this can be used as a surrogate in a 
UK population.  
It is possible that the UK population could show either the high carriage seen in South Africa and Vietnam or 
more likely the low carriage rates seen in Australia. The key question here is - Are carriage rates higher in 
hospitalised UK patients with lower respiratory tract infection (LRTI) compared to hospitalised age matched 
patients without LRTI? 
Improved treatment for lower respiratory tract infection (LRTI) 
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Better microbiological diagnostics would lead to more targeted, accurate antibiotic therapy and would reduce 
the prescription of unnecessary antibiotics. Earlier accurate treatment may reduce the risk of developing more 
severe disease that results in both hospital admission and a more prolonged hospital stay.  
 
Improved understanding of the role of pneumococcal carriage and host immunity 
Pneumococcal carriage is an immunising event.(84-86) We have shown for the first time in adults that carriage 
induces protective immunity against pneumococcal re-challenge.(87, 88) It is possible that in elderly adults a 
failure to establish occasional pneumococcal carriage (due to defective mucosal T cell function) leads to a loss 
of the immunising function of carriage and hence increased susceptibility to disease. The key question here is – 
Do LRTI patients and age matched controls have altered T cell function concurrently? 
In mice, carriage correlates with increased T regulatory cell responses in the nasopharynx.  Following exposure 
to low doses of pneumococci there are two scenarios for responses in the nasopharynx (i) an inflammatory 
response that clears the infection (ii) a T regulatory cell driven response that supports long-term stable carriage.   
If T reg numbers increase in the nasopharynx carriage occurs (increased levels may contribute to the persistence 
of that carriage event)(239), if they do not increase pneumococcal clearance occurs. (240) 
STUDY DESIGN OVERVIEW 
• Overall research aim 
 
To analyse pneumococcal carriage rates in patients hospitalised with LRTI. 
• Primary endpoint 
 
Rate of pneumococcal carriage in patients hospitalised with LRTI and age matched controls. 
• Secondary endpoints 
 
1) Density of pneumococcal carriage in patients hospitalised with LRTI and age matched controls 
2) Alterations of T cell function (Th1, Th17, T regs) in LRTI patients and age matched controls (versus 
younger adults as part of our existing ‘P4’ study). 
Study design 
 
Patients hospitalised with LRTI at the Royal Liverpool and Broadgreen Teaching Hospitals (RLBUHT) between 
November 2012 and April 2014 will be approached within 72 hours of admission.  
Patients recruited into the study will consist of those hospitalised with LRTI and a control group of age matched 
patients (within +/- 10 years) hospitalised for reasons other than respiratory infection.  
SUBJECTS AND TIMELINES 
Between November 2012 and April 2014 we will aim to recruit 100 patients with LRTI and 100 controls to the 
study. 
METHOD DETAILS 
• Recruitment and Selection 
The study team will be in regular communication with bed managers, nursing and medical co-ordinators in A&E, 
the acute medical admissions unit (AMAU) and the respiratory wards at RLBUHT Monday to Friday. Via regular 
education and information dissemination events and through daily interaction with the study team, the key staff 
will be aware of the research study and its aims, objectives and potential participants. A list of potential patients 
will be generated on a daily basis in combination with these personnel, and discussed twice per day at pre-
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defined times (by phone or bleep) to alert the study team of a potential recruit. Controls will be selected in a 
similar way with regular communication with bed managers, nursing and medical co-ordinators in A&E and 
AMAU at RLBUHT Monday to Friday. 
Relevant parts of a potentially suitable patient’s medical notes, blood, microbiology and radiology results will be 
reviewed by a study team member to assess suitability. If a patient is considered potentially suitable the clinical 
team will approach the patients and discuss whether they are happy to meet a member of the study team. If the 
patient agrees, the clinical team member will introduce the study team member to the patient. The study team 
member will then assess the patient’s capacity, clinical condition and appropriateness of their current 
environment for initial study discussion. The study will be explained to the patient and a patient information 
sheet provided. A limited clinical examination will be performed by the study doctor before recruitment and 
consent. Following this, any questions will be answered. Consent may either be obtained at this point, the 
patient may decline participation all together or after an agreed length of time, to allow patients to discuss with 
their advocates and for their reflection, consent will be re-visited and further opportunity for questions given 
(N.B. participating patients must be recruited within 72 hours of presentation to hospital). Only patients able to 
give fully informed consent will be recruited. Consent will be taken by a fully trained study team member. 
Inclusion criteria for LRTI patients 
• Non-pneumonic LRTI (no radiological consolidation but the presence of clinical signs) or community 
acquired pneumonia (radiological consolidation) 
• Able to give fully informed consent (mental capacity assessed using trust guidelines) 
• Age>18yrs old 
• Fluent English speaker 
Exclusion criteria for LRTI patients 
• Infective exacerbation of COPD or bronchiectasis without consolidation 
• Oxygen saturations <86% on air 
• Tuberculosis suspected 
• Neutropenia 
Inclusion criteria for controls 
 
• Able to give fully informed consent (mental capacity assessed using trust guidelines) 
• Age>18yrs old 
• +/- 10 years of recruited LRTI patient 
• Fluent English speaker 
Exclusion criteria for controls 
• Signs/symptoms of respiratory infection 
• Oxygen saturations <86% on air 
• Neutropenia 
Screening, Investigations and Follow-up 
Screening - Baseline clinical data which includes age, gender, history of presenting complaint, past medical 
history, social history, drug and vaccination history and allergies will be recorded. Data will also be collected with 
regards to contact with babies and children (aged≤10yrs). 
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Clinical examination – will be performed and recorded by the study doctor.  
Investigations and follow-up – Participants will be seen by the study team at two time points; on recruitment 
(day 0) and at 6 weeks following hospital discharge in the respiratory infection out-patient clinic.  Additional 
samples will be collected for investigational laboratory work. Blood and nasal wash (or nasal pharyngeal swab 
[NPS]) samples will collected by a fully trained team member at both time points. A urine sample will be collected 
at day 0 only. A chest X-ray will be performed if clinically necessary at the respiratory infection out-patient visit. 
SAMPLING AND LABORATORY TECHNIQUES 
Nasal wash or nasopharyngeal swab - Nasal wash was chosen by 91% of volunteers as being more comfortable 
and was more likely to detect pathogens using microbiological culture than NPS.(192) However some patient 
find the co-ordination needed for this technique too difficult resulting in low volume yield +/- anterior nasal 
wash only, in such patients a NPS will be taken instead. The nasal wash will be performed using a modified 
Naclerio method.(189) This is a well validated technique to collect nasal specimens with which we now have 2 
years experience. Briefly, 20ml of saline is instilled and held for a few seconds in the naris before being expelled 
in to a sterile Galli dish. In the event of nasal wash loss (defined as cough/sneeze/swallow) the procedure may 
then be repeated to obtain an adequate specimen. 
Blood – Up to 30mls of venous blood will be taken by an appropriately trained team member. 
 
Urine – up to 20mls of mid-stream urine will be collected.  
Determination of colonisation - colonisation will be defined based on the culture (+/-PCR) result of nasal 
wash/NPS taken at day 0 and 6 weeks. Nasal washes and NPS will be plated on culture media and incubated 
overnight at 37°C in 5% CO2. Colonies will be confirmed as S. pneumoniae using classical techniques including 
(i) typical draughtsman-like colony morphology (ii) the presence of α-haemolysis (iii) optochin sensitivity (iv) 
solubility in bile salts and (v) Gram-positive diplococci. Isolates will be typed using a latex agglutination kit 
(Statens Serum Institute) Density will be determined using a modified version of Miles and Misra dilutions. 
Isolates will be frozen at -80ºC for storage and reference laboratory confirmation. Results from the cultured 
nasal wash will also be confirmed using PCR based (LytA) methods of bacterial detection. 
Humoral immunity – serum will be stored for immunoglobulin assay laboratory work to compliment T cell work 
as below. 
 
Cellular immunity (Th1, Th17, Tregs) – central and effector memory T cells – Flow cytometry will be used to 
identify T cell populations in peripheral blood and nasal wash samples.  Foxp3 will be used to identify T regulatory 
cells and RORgt as a marker of Th17.  In addition, intracellular cytokine staining and ELISA analysis of nasal wash 
samples will be used to assess patterns of immune responses in patient samples.  These assays will be performed 
to test the hypothesis that LRTI in elderly patients are the result of a failure of tolerance. For this reason we will 
test for IL-10 and TGFb levels as markers of regulatory responses, and IFNg and TNFa as markers of a more 
proinflammatory response.(241) If cytokine levels prove difficult to detect in peripheral blood and nasal wash 
samples we may isolate CD4 T cells from the samples and measure cytokine responses to stimulation with 
pneumococcal antigens.  
 
SAFETY NOTES 
All samples (nasal wash/NPS, blood, urine) will be taken by experienced members of the study team. 
 
ANALYSIS PLAN  
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A research statistician, Dr Brian Faragher from LSTM, has been involved in statistical discussions. Using published 
data showing a carriage rate of 10% in developed countries in healthy adults, 11.7% in healthy South African 
adults (including HIV positive), 1% in hospitalised elderly Australian patients and 45% in South African patients 
with CAP; to detect a difference between 1 and 11.7% with an 80% power we require n=107 in each group. To 
detect a difference between controls of 11% and patients of 45% we require n=55 in each group (power 97.8%) 
or n=40 (power 91.3%). Since we will also use carriage density as well as simply culture positive for carriage yes 
or no; 100 patients in each group will be sufficient. We will need n=30 in each group to investigate T reg, Th1 
and Th17 function. 
FUTURE PLAN AND IMPLICATIONS OF THE WORK 
Success in this project will result in novel information with regards to the use of pneumococcal carriage in adults 
as a method of fast microbiological diagnosis in patients with LRTI and also the feasibility of the use of carriage 
in adults as a surrogate marker of protection from pneumococcal vaccination. 
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PROTOCOL for HOME FIRST: a feasibility study for early supported discharge in patients with 
lower respiratory tract infections. 
BACKGROUND 
The clinical and economic burden of lower respiratory tract infection (LRTI) and pneumonia 
is high(5) 
The annual incidence of LRTIs in Europe in 2002 was 25.8 million, greater than diabetes and cancer.(2) 
Pneumonia and LRTI are important health problems that are very costly to the NHS. There were over 260,000 
admissions in England with pneumonia, influenza and LRTI combined in 2009, more admissions than ischaemic 
heart disease; and with 2.3 million bed days annually, more bed days than for stroke/cerebrovascular disease.(3) 
Community-acquired pneumonia (CAP) is a major cause of hospital admissions worldwide.(5) In Europe, 
pneumonia costs over €10 billion annually with inpatient care accounting for € 5.7 billion, outpatient care €0.5 
billion and drugs €0.2 billion.(5) In the USA, 90% of CAP expenditure relates to the cost of in-patient care.(6) In 
the UK, direct CAP healthcare costs in 1992-3 were £441 million annually.(95) Seventy percent of UK pneumonia 
admissions are CURB-65 score 0-2; the median patient age is 76yrs old with two-thirds over 65yrs old.(90) In the 
UK, CAP is therefore mostly affects the older population,(5) with an annual  incidence of up to 22.4 per 1000 in 
those over 85 years old(8) in whom admission to hospital may in fact be more detrimental than care in their 
own residence.(13) Over the next decade the incidence of CAP will increase further as the population ages; as 
will the associated co-morbidities.(14) 
With support, many LRTI/CAP patients could be managed at home 
Strategies to increase the proportion of low-risk patients with CAP treated in the community have been 
developed and have been reported as safe, effective and acceptable to patients; with no significant differences 
in patient satisfaction, mortality or hospital re-admission rates noted. 
The Pneumonia Severity Index (PSI), CURB-65 and CRB-65 are pneumonia severity scoring systems that use initial 
admission data to predict mortality; they are used to aid clinical decision-making about ‘best place of care’ for 
the individual. Although hospital length of stay (LOS) for CAP has reduced over recent years mainly due to 
increased use of these severity scores, in community settings CRB-65 may over-predict 30-day mortality, 
potentially leading to more hospital admissions.(91) PSI was developed and validated to identify patients with a 
low mortality risk who could be safely managed out of hospital but it may potentially underestimate illness 
severity, especially in young patients without co-morbidities who have abnormal vital signs; whilst 
overestimating the mortality risk in older patients (as it is heavily age-weighted) with minimal acute disease 
process but a high frequency of stable co-morbidities.(92) CURB-65 on the other hand may be ideal for 
identifying patients with a high mortality risk because of acute vital sign derangement who may otherwise be 
overlooked but can underestimate disease severity in older patients with subtle vital sign abnormalities and 
decompensated co-morbid illness. CURB-65 appears to have a higher sensitivity for predicting mortality(93) 
whilst PSI overestimates risk in older patients.(13) Another approach in the elderly is SOAR(94) which omits urea 
and confusion – often common in the elderly. PSI and CURB-65 show a progressive decline in the predictive 
power for 30-day mortality with increasing patient age.(93) Age in fact has little impact on mortality after 
correcting for disease severity variables using PSI, indeed removing age from PSI and CURB-65 does not alter the 
tools’ predictive value. One solution to this issue may be much higher age cut-off values. 
Pneumonia severity scores are useful to guide the ‘best place of care’ but clinical improvement/stability and 
response to treatment are vital to assess the ‘best time for hospital discharge’. BTS guidelines for the discharge 
of patients with CAP state that patients are ‘usually not discharged if more than one of the following is present 
– temp>37.8, HR>100, RR>24, Systolic BP<90, sats<90, inability for oral (po) intake, altered mental state’. (95) 
Appendices 
 
252 
 
2
5
2
 
Sats ≤90% have good specificity but low sensitivity for adverse outcomes in CAP. As a parameter it is more useful 
in patients with asthma and those aged<50 years old at predicting adverse outcomes but less reliable in nursing 
home residents and patients with COPD; often the most difficult patients to assess out of hospital. Assessment 
of oxygen sats can therefore be used as an adjunct to decision-making but does not replace CRB-65 use in the 
community.(242) 
Despite the fact that most low-risk patients (according to severity scores) could be managed as out-patients, 
factors other than disease severity often prompt hospital admission such to inability to take oral antibiotics, co-
morbid illnesses, homelessness, substance abuse or inability to cope at home alone.(105),(112),(106),(90) (205) 
So a significant proportion of patients with CAP are low-risk but account for a significant proportion of bed days 
and costs; hospital LOS is a significant cost in caring for these patients(213). Low socioeconomic status is known 
to independently prolong hospital LOS. 
Physicians tend to over-estimate the likelihood of death from pneumonia(201) and there is large variability in 
rates of hospitalisation across nearby geographical regions, suggesting that criteria for hospital admission may 
be uncertain, physician-dependent and dependent also on socio-economic status and social support.(106, 110, 
111) The risk of adverse outcomes (death, readmission rates, delayed return to work/usual activity) does not 
vary between hospitals when comparing LOS.(106) 
A recent expert review suggested the need to further investigate ‘which elderly patients with CAP truly benefit 
from hospitalisation’ and stated that supported home care - Hospital at Home (HAH) - showed enormous 
potential for improving the care of elderly and disabled patients, and should be further evaluated in terms of 
efficacy and cost-effectiveness.(117) We feel that with careful selection criteria and 24hr help numbers, many 
patients can be safely discharged and supported at home. Despite the fact that much of the evidence presented 
is for CAP (a strict definition), we feel that including a more heterogeneous group of patients in our study is 
important, safe and allows more patients to benefit from our study. 
Hospital at Home (HAH) schemes are effective in other conditions 
HAH is defined as a service where active treatment is provided by healthcare professionals in the patient's home 
for a condition that otherwise would require acute hospital in-patient care, for a limited time period.(97) With 
increasing bed pressures on acute hospital trusts, HAH schemes and other innovations that reduce the demand 
for beds have become increasingly popular.(96) It has been suggested that ‘the widespread development of HAH 
services may be a cheaper substitute to in-patient care even within health care systems that have well developed 
primary care services’.(97) HAH schemes may provide a cost effective alternative to acute care.(104) HAH 
schemes can be admission avoidance (avoiding hospital admission altogether) or early discharge (discharging 
patients from hospital earlier than standard care and thereby reducing length of stay [LOS]). HAH schemes exist 
for COPD, stroke, heart failure and post-operative patients. The potential economic benefits to a healthcare 
system are clear.(97) Patient-related and economic outcomes are both critical in assessing the efficacy of such 
services. Many HAH schemes specifically for patients with acute exacerbations of chronic obstructive pulmonary 
disease (COPD) have shown potential economic as well as patient and carer benefits e.g. the Liverpool ACTRITE 
scheme - invented and pioneered by Dr Lisa Davies (a key collaborator on this study) at University Hospital 
Aintree in Liverpool in the late 1990's. Therefore Liverpool has significant local expertise in this type of scheme. 
Home-care for patients with acute exacerbations of COPD is popular in many countries. Several studies have 
shown non-inferiority to standard hospital care and potential economic benefit as well as patient and carer 
benefits.(243-250)  
Reduced mortality - A recent meta-analysis on ‘admission avoidance HAH’ schemes showed that those allocated 
to HAH had a significantly reduced risk of death at 6 months.(104) 
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Increased satisfaction - A HAH scheme containing a mixed cohort of patients including those with respiratory 
illness (32% CAP, COPD 28%)(96) reported increased patient satisfaction with HAH.(96, 104) Carer satisfaction 
has been noted to be higher in the HAH group.(119) Evidence suggests that patient satisfaction is innately related 
to the quality of communication and personal care received.(119) 
Readmissions - Evidence suggests that admission avoidance HAH services reduce hospital admission rates(96) 
however some subsequent studies suggest that re-admission rates may increase.(104) 
 
Functional status – The CAP severity score may predict functional decline.(13) HAH may not alter quality of life 
(QOL), function, or cognitive abilities (e.g. mental alertness) more than in-hospital care.(104) HAH may be 
especially beneficial in older patients (>70 yrs old) who more commonly experience adverse effects such as 
delirium in hospital.(96),(114),(115) It has been reported that frail elderly patients with dementia cared for with 
HAH were less likely to be institutionalised at longer term follow-up. 
 
Health-economics - HAH services may be less expensive than in-hospital care(104); inter-healthcare cost 
comparisons can however be difficult. Evidence of cost savings is varied, some schemes are more expensive(97), 
some showing cost reduction(96, 97) others cost neutral/inconclusive.(104),(97),(118) The cost-effectiveness of 
COPD HAH schemes has been noted.(251),(245) Differences in the way that a service is structured, organised 
and delivered will clearly affect cost (e.g. 24hr care v. once daily visits v. telephone support). 
 
HAH is in-line with the NIHR/MRC, NHS and government strategy 
The concept of HAH is clearly consistent with current strategic NHS policies and the stated objectives and 
strategies of national research organisations (NIHR/MRC strategy for public health infection research). QIPP 
(Quality, Innovation, Prevention(s) and Productivity) is a strategy that seeks to improve clinical outcomes and 
experience for patients and to maximise resource use. QIPP aims to reduce unscheduled hospital admissions by 
20%, reduce hospital LOS by 25% and maximise the number of patients controlling their own disease through 
systematic knowledge transfer and care planning.(101) The NHS Outcomes Framework (2011/12) states that it 
is of paramount importance that we provide safe and effective treatment and care (measured by clinical and 
patient-reported outcomes).(102) This scheme has good fit with the reforms in the current White Paper that 
state we should ‘aim to provide the NHS with greater incentives to increase efficiency and quality’ and state that 
‘patient choice will reward the most efficient, high quality services; reducing expenditure on less efficient 
care’.(103) 
Our study is a prime example of worthy research since it is stated that the ‘NHS will support creative approaches 
to service provision, which will improve choice, personalisation, efficiency and effectiveness e.g.: reducing 
avoidable admissions to acute hospitals through making the best use of social care resource; identify New service 
solutions to avoid unnecessary attendance to the Emergency Department (ED) and hospital admissions and 
deliver new and innovative services in community settings/homes.(206) A HAH scheme for patients with LRTI is 
an example of clinical innovators developing skills and extending roles to 
enable patients to be managed at home’. As ‘champions of clinical quality will use new methodologies to 
embrace continuous improvement and drive up standards by seeking and using patient, carer and family 
feedback to improve service provision’.(206) Emergency departments should be encouraged to develop 
strategies to manage more patients with CAP within the community.(108) 
The HOME FIRST (Home Followed-up with Infection Respiratory Support Team) feasibility study is a proactive, 
innovative and creative scheme which will enable patients with LRTI to be provided with high-quality safe, 
effective, efficient patient-centred care, tailored to their needs in their own home; therefore improving the 
overall experience of the service-user, improving patient outcomes and reducing hospital LOS.  This is an 
opportunity to improve health policy, healthcare delivery and services and to simultaneously reduce admission 
rates, an area of major strategic importance to the NHS.  
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The experience of HAH for CAP is limited 
Although there is evidence that earlier discharge of CAP patients is safe and effective there is little evidence for 
early supported discharge schemes.(108)  A non-randomised study of a scheme (specifically for CAP patients) 
from Barcelona showed that the majority of patients have low risk scores (288/327 = 88%) CURB-65 0-1; and 
only 35 patients CURB-65 2 and 4 patients CURB-65 3-5. This also illustrates that selected patients with higher 
severity scores can be safely cared for at home.(120) In another study, patient satisfaction improved by 40% 
(p<0.001) in those CAP patients allocated to HAH.(118) A relatively small decrease in hospital LOS may have a 
substantial economic impact: in the USA, it is estimated that a ½ day reduction in hospital LOS for CAP (due to a 
change from moxifloxacin to levofloxacin) would generate a potential cost saving of approximately $8500 million 
annually.(6) A significant cost reduction associated with HAH specifically for CAP patients was noted.  
There are potential benefits of LRTI/CAP HAH for both patients and the health service 
Patient-related outcomes 
• Reducing risk of nosocomial infection (hospital-acquired pneumonia, MRSA and C. difficile).(115) 
• Able to be cared for in their own home 
• Improved sleep  
• Faster recovery 
• Increased satisfaction (patients and carers) 
• Reduced risk of delirium 
• Reduced chance of later post hospital discharge institutionalisation. 
 
Health service benefits  
• Reduced hospital LOS - economic benefit 
• Reduced risk of nosocomial infection – economic benefit 
• Improved public health awareness of LRTI/CAP and public education 
• Improved self-management of condition 
 
The hazards of HAH can be anticipated and prevented 
The risks to individuals are limited by the study design: 
• Strict patient selection - Highly trained respiratory clinical staff (respiratory physicians - consultants and 
senior SpRs and senior specialist nurses with community experience) will carefully select the correct patients 
(using strict inclusion/exclusion criteria and using their extensive clinical experience in caring for such 
patients) 
• Competent and experienced specialist staff  
• Thorough patient education – specific patient- individualised self-management plan 
• Rigorous safety procedures for patients - daily patient monitoring at home, lifeline (pendant alarm) 
supplied 
• Rigorous safety procedures for staff – pendant alarms, planned route with set ‘call-in’ times 
• Regular home visits - daily reviews will occur to ensure that any clinical deterioration is effectively assessed 
and managed and patients are re-admitted to hospital if deemed necessary by either the study team or the 
patient. A coordinated MDT will be key to the HOME FIRST care approach to patient care 
• No delay in recognition of clinical deterioration – the patient will be given a detailed patient information 
leaflet with red-flag symptoms, a 24hr emergency telephone contact number. During 08.30 – 19.00 
telephone access (with additional home visits as necessary) to a specialist respiratory study nurse and 
doctor will minimise any risks of delayed recognition of clinical deterioration. The patient’s condition is 
monitored closely at home. Portable observation machines will be used by HOME FIRST to monitor blood 
pressure (BP), heart rate (HR), oxygen saturations (sats) and temperature during home visits 
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• IV antibiotic provision - patients still requiring IV antibiotics will not be included in our study since we 
consider that they are not yet stable and therefore unsuitable for HOME FIRST 
 
There are immediate operational questions 
• Should HOME FIRST aim to just implement supported earlier discharge or admission avoidance as well? 
• What proportion of all hospitalised patients with LRTI/CAP/HAP etc would be suitable for HOME FIRST? 
• What proportion of all hospitalised patients with LRTI/CAP/HAP etc consent to the HOME FIRST feasibility 
study? 
• Could the full RCT begin to accept patients who would be palliated after 48hrs if no clinical improvement - 
what extra MDT services may this require? 
• Could the full RCT accept patients directly from the community to avoid hospital admission altogether? 
• Are any other staff needed to efficiently run HOME FIRST home care? Is a full-time occupational therapist, 
social worker or physiotherapy needed? 
• What frequency of visits are necessary and for how long?  
• What is the maximum numbers of patients that can be safely looked after by HOME FIRST at any one time? 
 
There are (i) clinical and (ii) laboratory scientific questions that can be answered in order to 
guide future treatment algorithms 
• (i) Can a biomarker of recovery be developed that can help to predict whether a patient is likely to be at one 
end of the recovery spectrum or the other? This may allow us to determine a more tailored strategy for an 
individual in terms of antibiotic prescription (or not) and duration, and the best ‘place of care’ e.g. own 
home with GP support as needed, ‘HAH’ (supported discharge – early discharge [e.g. HOME FIRST] or 
admission avoidance), ward bed, HDU or ICU; as well as to develop therapies to aid rehabilitation and 
improve recovery rate. 
• (ii) The correlates of disease, recovery and immunity are poorly understood in CAP. This cohort of patients 
will be studied as part of a larger project (including patients from our other pneumonia studies) investigating 
the immunological reasons behind the spectrum of pneumococcal pneumonia disease severity and 
recovery. The full RCT study will recruit volunteers inoculated with pneumococcus (carriers and non-carriers 
from the experimental human pneumococcal carriage [EHPC] study), patients with mild and moderate 
pneumonia (HOME FIRST and PASS cohort) and ICU patients with severe pneumonia. In the future we aim 
to be able to develop effective future vaccines for pneumococcal pneumonia and to be able to predict the 
course of an individual’s pneumococcal pneumonia early on in the disease process. 
STUDY DESIGN OVERVIEW 
• Principal research outcome and overall aim 
 
Our overall aim is to provide a scheme to discharge patients with LRTI safely and effectively back to their 
own home i.e. proof of concept. Our study question(s): (i) Is a study in which patients are randomised to 
early supported discharge or standard hospital care acceptable to patients? (ii) Can selected patients with 
respiratory infection benefit from care at home? 
N.B. HOME FIRST does NOT support patients at home that could have been discharged anyway without 
support. 
If this study shows the feasibility of HOME FIRST, the second stage is a full multi-centre NIHR funded RCT 
with 100 patients in each limb. If the RCT shows positive overall effects we will ‘roll-out’ a fully operational 
HOME FIRST scheme across the northwest and ultimately nationally +/- internationally. 
 
• Specific objectives 
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A feasibility study, and in the future a full RCT: 
• To show equivalence of critical outcomes during  an acute illness episode 
• Qualitative assessment to show increased patient and carer satisfaction compared to hospital care 
• Economic assessment to show financial advantage to care in the community 
• Follow-up cohort to ensure re-admission rates are equivalent and to monitor longer term health 
outcomes (up to 1 year). 
• To use our patient and public involvement (PPI) group in order to constantly develop and improve the 
service. 
 
• Primary endpoint 
 
This feasibility study will assess the patient uptake to participate in a study in which volunteers are 
randomised to early supported discharge with HOME FIRST or standard hospital care. 
Uptake/acceptability in this study is defined as - the proportion of patients that are both eligible and suitable 
(fit all inclusion/exclusion criteria) who are prepared to ‘ACCEPT’, and give their consent to, be involved in a 
research study in which they are randomised to either standard hospital care or HOME FIRST compared to 
the proportion that are eligible and suitable and do not give their consent. Objectively we are therefore 
studying the percentage uptake of the HOME FIRST scheme. 
• Secondary endpoints 
 
1. Clinical (safety, mortality, satisfaction, readmissions, functional status, quality of life) 
 
a. Safety and mortality 
 
We will assess the safety i.e. ensure there is no increase in mortality in the HOME FIRST limb.  
b. Patient and carer satisfaction 
 
HOME FIRST should have at least equivalence with standard hospital care. 
A validated questionnaire will be conducted over the telephone at 2 weeks by an independent 
assessor 
c. Re-admission rates, total days of care (HOME FIRST and hospital combined v. Standard care 
in hospital)/total bed days 
 
(i) Total number of days of HOME FIRST care and hospital bed days combined v. standard care in 
hospital (ii) Total in-hospital bed days for both limbs (iii) Readmission rates for both limbs 
 
d. Functional status (physical and mental) and quality of life (QOL) 
 
Validated questionnaires will be completed to assess recovery post respiratory infection. 
i. A SF-12 (physical and mental function) at day 0, day 2, day 7 and at 1 and 6 mths. 
ii. A CAP-SYM (disease recovery rate) will be completed at day 0 (for day minus 30 as 
well), day 2, day 7 and 1 and 6 mths. [Day 0 score = A, Day -30 score = B, A - B = C, 
Day 28 score = D. The calculation of recovery at one month is Recovery (%) = 100 
(D/C x100)].  
 
2. Health service (health-economic, operational) 
a. Health-economic 
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A formal planned health economic analysis (by an NIHR Research Design Service [RDS] recommended 
health-economist) will measure costs and resource utilisation, using costs that are sensitive to the 
different resources used during each care episode, to assess the cost-effectiveness of HOME FIRST. 
b. Operational  
 
This study should answer several operational questions (see operational guidelines section). 
 
3. Laboratory (microbiology and host response) 
 
Specific hypotheses and research questions related to the patient group are: 
 
a. Microbiology 
 
Hypothesis - We hypothesise that prolonged hospital admission leads to alterations in the naso-
pharyngeal and lower respiratory tract flora (colonising microbes), which in turn results in an 
increased risk of hospital-acquired pneumonia.   
Question - Are patients allocated to HOME FIRST at a lower risk of nosocomial pneumonia due to 
less alteration in naso-pharyngeal and lower respiratory tract flora than those randomised to 
standard care (i.e. prolonged hospitalisation)? 
 
Method -  
 
(i) Carriage – we will perform nasal washings at days 0, 2 and 7 in all patients recruited to the 
study, in order to assess the relationship between place of care and naso-pharyngeal flora.  
(ii)  Lung Human Microbiome Project (LHMP) – IN THE FULL RCT ONLY - we will compare the lower 
airway microbiome (microbes) in patients in each limb of the HOME FIRST study to assess the 
relationship between place of care and lower airway flora. The lower airways will be sampled using 
broncho-alveolar lavage (BAL) and protected specimen brushings (PSB) at bronchoscopy. 
Objective - To better understand the alterations in naso-pharyngeal and lower respiratory tract 
flora that occur with short-term (early discharge – HOME FIRST) and prolonged hospitalisation 
(standard care). 
 
b. Biomarker of recovery 
 
Hypothesis - A biomarker of recovery can identify patients, specifically with confirmed 
pneumococcal pneumonia (blood/urine PCR positive, blood or sputum-culture positive) and a 
clearly defined phenotype (mild, moderate, severe disease), at risk of slower recovery: 
Question - What differences in anti-inflammatory immunological response to pneumococcal 
pneumonia are associated with the spectrum of disease recovery? 
 
 (i) Monitor cfu/ml and copy numbers of pneumococcus in blood by PCR techniques and urine 
antigen testing in disease and recovery 
(ii) Blood transcriptomics in disease and recovery 
(iii) Investigate the acquired humoral and cellular anti-inflammatory phase in serum and nasal wash 
during recovery.  
Objective – in this study, we will test the logistical possibilities of taking and processing these 
samples, in the full RCT we will develop a biomarker of recovery from pneumococcal CAP. 
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Study design 
 
This is a feasibility study of patients admitted to the Royal Liverpool and Broadgreen (RLBUHT), and Aintree 
University (UHA) Teaching Hospitals with symptoms of LRTI from November 2011 – March 2012. This is not a 
full randomised-controlled study but patients will be randomised in order to assess patient’s acceptability to the 
randomisation process within the HOME FIRST scheme. This feasibility study will lead onto a full RCT in the near 
future, ideally encompassing both early discharge and admission avoidance approaches.  
Research to investigate the views of (a) recruited patients (b) the carers of recruited patients to such a scheme 
will be investigated. A broad semi-quantitative analysis of patient acceptability to HOME FIRST is vital.  
PPI is very important; we are currently actively recruiting members of the public to become involved. Since LRTI 
is an acute disease, so is different to chronic disease PPI groups, this will be a ‘rolling’ cohort of patients. The PPI 
group will be demographically and ethnically representative of the population that presents with LRTI. ‘Breathe-
easy’ patient groups are also being consulted. 
Our feasibility study has been developed so far with input from nurses and doctors involved with ‘COPD early 
facilitated discharge schemes’ and respiratory physicians from various hospitals, including New Zealand. 
It is important that the HOME FIRST study recruits from the most representative group of patients so that the 
results have the widest possible applicability. However this must be balanced against non-maleficence and 
safety, therefore inclusion and exclusion criteria apply. 
SUBJECTS AND TIMELINES 
From November 2011 we will aim to recruit 10 patients to each limb of the study. Patients randomised to HOME 
FIRST will be followed up for at least 48hrs after discharge, at least twice per day by our study respiratory nurse(s) 
for the first 48hrs and at least once in total by the study doctor. 
METHOD DETAILS 
• Recruitment and Selection 
The study team will be in regular communication with bed managers, nursing and medical co-ordinators in A&E, 
the medical admissions unit and the respiratory wards at RLBUHT and UHA. Via regular education and 
information dissemination events and through daily interaction with the study team, the key staff will be aware 
of the research study and its aims, objectives and potential participants. A list of potential patients will be 
generated on a daily basis in combination with these personnel, and discussed twice per day at pre-defined 
times (by phone or bleep) to alert the study team of a potential recruit.  
Relevant parts of a potentially suitable patient’s medical notes, blood, microbiology and radiology results will be 
reviewed by a study team member to assess suitability. After this review if the patient is still considered suitable 
the study team member will then introduce themselves and consider the patient’s capacity, clinical stability and 
appropriateness of their current environment for initial study discussion. The study will be explained to the 
patient and a patient information sheet will be reviewed. At the end of the process, questions will be answered, 
consent may either be obtained at that point, the patient may decline participation all together or after an 
agreed length of time - 'overnight' (giving opportunity for patients to discuss with their advocates and for patient 
reflection) consent will be re-visited and further opportunity for questions given. Only patients able to give fully 
informed consent will be able to participate in the feasibility study. Consent will be taken by a fully trained study 
team member. 
Although not all patients screened will be suitable or eligible, all screened patients will have a patient identity 
code generated and sticker and case report form (CRF) completed and placed in the clinical case notes, this is so 
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that the usual medical team are aware of the outcome of the assessment and so the study team can record the 
number of patients screened and reasons for exclusion. A full clinical examination will be performed by the study 
doctor before recruitment and randomisation. 
• Patient Eligibility 
Patients with any of the following conditions: 
• Pneumonia - community-acquired (CAP) or hospital-acquired (HAP) - pneumonia definition - a series of 
clinical symptoms with radiological consolidation 
N.B. All pneumonia CURB-65 scores will be considered but patients with CURB-65 ≥3 MUST have had at least 
24hrs of in-patient observation before recruitment into the study. 
• Acute tracheo-bronchitis & acute bronchitis 
• Non-pneumonic lower respiratory tract infection 
• Influenza with respiratory manifestations 
• Infective exacerbation of bronchiectasis 
• Lung abscess 
• Pneumonia with concomitant COPD (if this service is not provided elsewhere) 
 
• Patient Suitability 
Inclusion criteria must be answered ‘YES’ and exclusion criteria ‘NO’ for the patient to be suitable. Certain 
exclusion criteria relate specifically to either those with or those without chronic respiratory conditions. (# All 
cases to be discussed with study Dr) 
 
Inclusion criteria 
• Simple pleural effusions only (#if no diagnostic pleural tap performed please discuss) 
• Can manage ADLs with current support (immediate OT/physio/social assessment/care can be arranged 
prior to discharge (if needed) and continued at home) 
• Able to give fully informed consent 
• Has a phone 
• Age>18yrs old 
• EWS ≤2 AND SBP>90 (all observations must be stable for 12-24hrs) AND mild confusion only (defined 
as an 10-point AMTS ≥7) 
• All observations must be stable for 12-24hrs 
• Improving inflammatory markers (WCC/CRP)  
• Stable or improving U&Es 
 
Exclusion criteria 
• Acute exacerbations of COPD – infective & non-infective (other services already provided) 
• Patients with CURB-65 >3 admitted<24hrs ago 
• Patients unable to manage at home even with maximal support from HOME FIRST (this may include some 
patients IV drug users, with ETOH excess or mental health problems) 
• Serious co-morbidities requiring hospital treatment (eg: CKD, CCF) or deemed unstable (significant AKD) 
• Suspected MI/raised TnI/T consistent with NSTEMI (Or acute ECG changes) within 5 days of discharge  
• Empyema or complicated parapneumonic effusion 
• SBP<90mmHg 
• Neutropenia 
• No fixed abode 
• Tuberculosis suspected 
• Well enough for discharge without HOME FIRST homecare support 
• Sats <92% on air - for patients without chronic respiratory illness 
• Sats <88% on air [except asthma sats must be >92%] - for patients with chronic respiratory illness. #All 
such cases MUST be discussed as oxygen assessment may be needed. 
 
• Screening, Assessment and Follow-up 
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Screening  
• Clinical examination – Baseline clinical data which includes age, gender, history of presenting 
complaint, past medical history, a complete social history, drug history and allergies, will be performed 
and recorded by the study doctor. 
• Inclusion/exclusion criteria - We feel that using careful selection criteria and 24hr help telephone 
number such patients can be safely discharged and supported at home. If a patient is selected for 
inclusion (based on their eligibility and suitability) and consents to the study; they are then randomised 
using a computer generated random allocation number, and their allocation is obtained by telephone 
from an independent randomisation co-ordinator. 
 
Assessment and follow-up 
a. Investigations - Extra samples will be collected for investigational laboratory work (i) Bloods - day 
0 (day of recruitment and randomisation), day 2 (48hrs post) and day 7 (in patient's own home if 
necessary). All venepuncture will be performed by a fully trained member of the study team to 
minimise patient discomfort. Blood will also be taken at 1 and 6 mth clinic visits (ii) Nasal wash - 
day 0, 2 and 7. A fully trained member of the study team will perform this in order to minimise 
patient discomfort (iii) Urine sampling – day 0 and day 7. 
 
b. Qualitative questionnaires 
i. SF-12 (physical and mental function) [performed 5 times in total] - at recruitment (day 0), day 2, 
day 7 and at 1 and 6 mth out-patient appointments. 
ii. CAP-SYM [performed 6 times in total] - at recruitment day 0 (twice including to complete day minus 
30) day 2, day 7 and at 1 and 6 mth out-patient appointments. 
iii. Patient (and carer) satisfaction - conducted over the telephone at 2 wks by an independent 
assessor. 
c. Initial follow-up post discharge 
Patients randomised to HOME FIRST care - Initially up to twice daily respiratory specialist nurse visits 
will occur for 48hrs, after this time period the frequency and duration of visits will depend on clinical 
need. See daily review diary information sheet. The study nurse will establish the need for the 
involvement of other MDT team members. Venepuncture will be performed daily AT MOST in the 
HOME FIRST limb: as for those patients in-hospital frequency of venepuncture depends on clinical 
assessment of need. The patient will have venepuncture and nasal washes performed at 48hrs and 7 
days post-recruitment. 
Patients randomised to standard hospital care - all management and discharge decisions will be made 
by the patient's usual hospital team; if any significant or concerning clinical issues are noted during 
study team's visits, the usual medical team will be alerted. The patient will be seen by a study team 
member at 48hrs and 7 days for bloods and nasal washes (in patient's own home if already discharged). 
All patients will be discussed at a weekly case-notes MDT meeting. 
 
 
 
d. Later follow-up 
• All study patients will be followed-up on discharge in the ‘Respiratory Infection’ out-patient clinic at 1 month 
to ensure progress (clinical and functional) and again at 6 months to monitor longer-term outcomes. All 
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patients will also receive a telephone call from an independent person to ask for feedback about their 
involvement in the study and the care received at 2 wks post randomisation.  
 
• IN THE FULL RCT patients will be offered a bronchoscopy (BAL +/- PSB) - to assess patient ‘acceptability’ to 
this technique, in the feasibility study the procedure including risks and benefits, will be discussed with all 
patients at the 1 mth clinic visit and the patient will be asked whether they would have given their consent 
to bronchoscopy (at 5-7wks) had it been offered to them. 
 
• Operational Guidelines 
Patients discharged from hospital will remain the responsibility of the study Dr (chief investigator) during the 
time that they are supported by HOME FIRST. The patient's GP and hospital consultant (as of discharge day) will 
be informed of any specific interventions and outcomes using a specific HOME FIRST discharge summary. 
Patients recruited to the study that are randomised to standard in-hospital care will remain under the care of 
their current consultant. Patients can be readmitted to the hospital as determined by the study team via bed 
managers; completion of a treatment failure or complication development proforma on the CRF will occur. New 
referrals will be accepted between 08.30-16.00 7 days per week. Referrals after 16.00 will be seen the following 
working day. The team are available for telephone advice from 08.30 - 19.00 7-days-per-week. Home visits will 
occur from 08.30 - 19.00 7-days-per-week. 24hr cover is available via telephone to the HOME FIRST study team. 
In the event of an emergency an ambulance will be called. If the patient needs non-emergency medical attention 
at home between 19.00 - 08.30, a district nurse or out-of-hours GP will be contacted by the study team.  
The patient’s condition is monitored closely at home. Portable observation machines will be used by HOME 
FIRST to monitor blood pressure (BP), heart rate (HR), oxygen sats and temperature during home visits.  In order 
to provide consistent, high-quality care; the clinical assessment and evaluation will be carried out using the 
HOME FIRST CRF. The CRF will remain in the clinical notes, except when patients are visited in their own home 
when only the CRF will be removed from hospital premises (this contains no patient identifiable information). 
In the full RCT we hope to administer home IV antibiotics to patients with pneumonia and other conditions such 
as bronchiectasis. For safety we feel that patient’s still needing IV antibiotics for pneumonia are not yet stable 
or suitable for supported discharge during the feasibility study.  
HOME FIRST will provide coordinated MDT care, provision of 24 hr emergency telephone cover, access to fully 
trained respiratory study nurse(s) and study doctor(s). The HOME FIRST MDT consists of: 
• Study doctors (trained respiratory physicians - consultants and senior SpRs) 
• Highly trained respiratory specialist nursing staff 
• Close links with a physiotherapist (mobility and respiratory) 
• Home help provision (temporary assistance with ADLs by carers) which may include OT or social worker 
involvement (HOME FIRST has fast access to meals-on-wheels and ‘lifeline’ devices) 
• Close links with palliative care, dietetics, SALT, smoking cessation and community matrons, pharmacy (for 
rapid dispensing of TTOs). 
 
 
ETHICAL ISSUES 
The main risks associated with this study are those of deterioration at home (those in the HOME FIRST limb). 
The main ethical principles under which these risks are considered are those of autonomy and non-maleficence. 
• Autonomy - The volunteers will be given sufficient information that is written or spoken in a non-jargon 
way to allow them to understand the objectives behind the research, the risks of any procedures and the 
possible benefits.  They then need to be given time to consider the information before consenting to any 
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involvement.  At no stage should the volunteer feel pressured or persuaded into participating in the 
research. Once the volunteer has consented to the study, consent can be withdrawn at any time. 
• Beneficence – improved patient related and health-economic outcomes with HOME FIRST. 
• Non-maleficence - As researchers we have the responsibility to minimise the risk of harm to the volunteers. 
This involves the researchers having sufficient knowledge, having reviewed current evidence in the 
literature about the proposed interventions and making themselves aware of potential risks.  Highly trained 
respiratory clinical staff will be used to ensure that any clinical deterioration is effectively assessed and 
managed and that patients are re-admitted to hospital if deemed necessary by either the study team or the 
patient. 
• Justice - This must be balanced with non-maleficence. The research is open to all individuals with LRTI (not 
currently provided with a similar early discharge scheme service) but important exclusion criteria are in 
place, primarily to protect individuals from undue risk. 
 
SAFETY NOTES 
Patient safety - All patients will also receive a verbal and written self management plan for their specific 
condition, a list of symptoms to prompt contact with team and a 24hr contact number. In the CRF a proforma 
will be completed if any treatment failure or complications requiring hospital re-admission occur. Adverse events 
will be reported using the correct documentation within the CRF. The study will be stopped if there is any 
mortality in the HOME FIRST limb whilst patients are at home. Any adverse events will result in a SUSAR form 
being completed and the ethics committee (REC) and sponsor(s) will be informed immediately.  
 
The risks to individuals are limited by the study design: 
• Strict patient selection and inclusion/exclusion criteria 
• Fully competent and experienced respiratory staff 
• Thorough patient education – specific patient- individualised self-management plan 
• Rigorous safety procedures for patients - daily patient monitoring at home (+/- patient operated home 
telemedicine observations machine) 
 
Staff safety – there are specific important safety issues around attending a patient’s own home. This is a carefully 
considered and high priority area. Staff will carry personal alarm devices at all times - if this is activated - a GPS 
tracking service at a local private security firm will locate the team member and they will immediately attend. 
They will alert the police as necessary. Team members will have up-to-date conflict resolution training. All team 
members will print off a daily diary which states all home visits (planned home visit route) detailing times and 
addresses and contact numbers, if team members do not arrive/telephone at set time points, team members 
will contact them and if uncontactable the private security firm/police will be called as necessary. Occasionally 
two team members will attend together if felt necessary. If there are considered to be any threats to the health 
and safety of the attending member of the study team (either by the patient, the carers, family members, 
neighbours or the external community) – patients in the HOME FIRST limb will be readmitted to hospital (if 
necessary) and HOME FIRST attendance will be stopped.  
 
 
ANALYSIS PLAN  
A research statistician, Dr Brian Faragher from LSTM, has been involved in statistical discussions. The statistical 
power of this feasibility study is limited by small sample size; therefore statistical significance of clinical 
outcomes is neither expected nor required. The analysis will be descriptive (summary statistics) only, with no 
formal between-group comparisons made. 
With regards to the primary outcome of uptake - the percentage of eligible and suitable patients who 
consented to the study versus those who did not consent will be analysed. 
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With regards to secondary endpoints – clinical outcomes such as safety and mortality (7 day, 1 and 6 mths) and 
rate of readmission will be analysed comparing the HOME FIRST limb with standard hospital care. Validated 
questionnaires (SF-12, CAP-SYM, and patient and carer satisfaction) will be quantitatively analysed to assess 
functional status/quality of life/satisfaction. A formal health-economic analysis will measure costs and resource 
utilisation, using costs that are sensitive to the different resources used during each patient care episode. In 
conjunction with the NIHR Research Design Service (RDS) team, analysis methodology has been developed, 
including the involvement of a health-economist.  
FUTURE PLAN AND IMPLICATIONS OF THE WORK 
Success in this project will result in an application for a NIHR Programme Grant for Applied Research (PGfAR) to 
fund a full RCT with 100 patients per limb. Dependent on its success the aim is ultimately to ‘roll-out’ a fully 
operational HOME FIRST scheme nationally +/- internationally. 
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PROTOCOL for HOME FIRST Pilot: a study of early supported discharge in patients with 
lower respiratory tract infections. 
 
BACKGROUND 
The clinical and economic burden of lower respiratory tract infection (LRTI) is high(5) and 
with support many more could be managed at home. 
The annual incidence of LRTIs in Europe in 2002 was 25.8 million, which is greater than both diabetes and 
cancer.(2) Pneumonia and LRTI are important health problems that are very costly to the NHS. In England in 
2009 there were more admissions for pneumonia, influenza and LRTI combined than ischaemic heart disease 
and more bed days than for cerebrovascular disease.(3) Community-acquired pneumonia (CAP) is a major cause 
of hospital admissions worldwide.(5) In the USA, 90% of CAP expenditure relates to the cost of in-patient care.(6) 
Seventy percent of UK pneumonia admissions are with mild or moderate pneumonia (CURB-65 score 0-2). 
Hospital length of stay (LOS) is a significant cost in caring for these patients.(213) In the UK, CAP mostly affects 
the older population,(5) in whom admission to hospital may in fact be more detrimental than care in their own 
residence.(13) Over the next decade the incidence of CAP will increase further as the population ages, as will 
the associated co-morbidities.(14) 
Strategies to increase the proportion of low-risk patients with CAP treated in the community have been 
developed and have been reported as safe, effective and acceptable to patients; with no significant differences 
in patient satisfaction, mortality or hospital re-admission rates noted.(107) 
Despite the fact that most low-risk patients (according to severity scores) could be managed as out-patients, 
factors other than disease severity often prompt hospital admission such to inability to take oral antibiotics, co-
morbid illnesses, homelessness, substance abuse or inability to cope at home alone.(105),(112),(106),(90) (205) 
Thus a significant proportion of patients with CAP are low-risk but account for a substantial proportion of bed 
days and costs. 
Physicians tend to over-estimate the likelihood of death from pneumonia(201) and there is large variability in 
rates of hospitalisation across nearby geographical regions, suggesting that criteria for hospital admission may 
be uncertain, physician-dependent and dependent also on socio-economic status and social support.(106, 110, 
111) The risk of adverse outcomes (death, readmission rates, delayed return to work/usual activity) does not 
vary between hospitals when comparing LOS.(106) 
A recent expert review suggested the need to further investigate ‘which elderly patients with CAP truly benefit 
from hospitalisation’ and stated that supported home care - Hospital at Home (HAH) - showed enormous 
potential for improving the care of elderly and disabled patients, and should be further evaluated in terms of 
efficacy and cost-effectiveness.(117)  
Our recent HOME FIRST feasibility study showed that although large numbers of potentially eligible patients 
needed to be screened in order to recruit patients to the early supported discharge scheme, satisfaction was 
excellent, outcomes were at least as good and the length of hospital stay was reduced. Notably in this feasibility 
study, 20% of those screened were not eligible due to an abbreviated mini-mental test score of <7, due to 
dementia, learning disability or delirium. In fact these patients are one of the key groups most likely to benefit 
from such an intervention as noted below – this pilot study will therefore include patients unable to give 
informed consent. 
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Hospital at Home (HAH) schemes are effective in other conditions and potential benefits for 
those with LRTI is clear 
HAH is defined as a service where active treatment is provided by healthcare professionals in the patient's home 
for a condition that otherwise would require acute hospital in-patient care, for a limited time period.(97) With 
increasing bed pressures on acute hospital trusts, HAH schemes and other innovations that reduce the demand 
for beds have become increasingly popular.(96) HAH schemes may provide a cost effective alternative to acute 
care.(104) HAH schemes can be admission avoidance (avoiding hospital admission altogether) or early discharge 
(discharging patients from hospital earlier than standard care and thereby reducing LOS). HAH schemes exist for 
COPD (243-250), stroke, heart failure and post-operative patients. The potential economic benefits to a 
healthcare system are clear.(97) HAH schemes have shown reduced mortality at 6 months,(104) increased 
patient satisfaction,(96, 104) and carer satisfaction,(119) and potentially reduced readmissions. HAH may be 
especially beneficial in older patients (>70 yrs old) who more commonly experience adverse effects such as 
delirium in hospital.(96),(114),(115) It has been reported that frail elderly patients with dementia cared for with 
HAH were less likely to be institutionalised at longer term follow-up. 
Health-economics - HAH services may be less expensive than in-hospital care(104); inter-healthcare cost 
comparisons can however be difficult. Evidence of cost savings is varied, some schemes are more expensive(97), 
some showing cost reduction(96, 97) others cost neutral/inconclusive.(104),(97),(118) The cost-effectiveness of 
COPD HAH schemes has been noted.(251),(245) Differences in the way that a service is structured, organised 
and delivered clearly affect cost. 
 
Potential benefits for patients with LRTI include: 
Patient-related outcomes 
• Reducing risk of hospital-acquired infection (hospital-acquired pneumonia, MRSA and C. 
difficile).(115) 
• Able to be cared for in their own home 
• Improved sleep  
• Faster recovery 
• Increased satisfaction (patients and carers) 
• Reduced risk of delirium 
• Reduced chance of later post hospital discharge institutionalisation. 
 
Health service benefits  
• Reduced hospital LOS 
• Reduced risk of hospital-acquired infection 
• Improved public health awareness of LRTI/CAP and public education 
• Improved self-management of condition 
 
HAH is in-line with the NIHR/MRC, NHS and government strategy 
The concept of HAH is clearly consistent with current strategic NHS policies and the stated objectives and 
strategies of national research organisations (NIHR/MRC strategy for public health infection research). QIPP 
(Quality, Innovation, Prevention(s) and Productivity) is a strategy that seeks to improve clinical outcomes and 
experience for patients and to maximise resource use. QIPP aims to reduce unscheduled hospital admissions by 
20%, reduce hospital LOS by 25% and maximise the number of patients controlling their own disease through 
systematic knowledge transfer and care planning.(101) Emergency departments should be encouraged to 
develop strategies to manage more patients with CAP within the community.(108) 
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The early supported discharge scheme called HOME FIRST (Home Followed-up with Infection Respiratory 
Support Team) will enable patients with LRTI to be provided with high-quality safe, effective, efficient patient-
centred care, tailored to their needs in their own home; therefore aiming to improve the overall experience of 
the service-user, improve patient outcomes and reduce hospital LOS whilst simultaneously reducing admission 
rates, an area of major strategic importance to the NHS.  
The experience of HAH for pneumonia is limited 
Although there is evidence that earlier discharge of CAP patients is safe and effective there is little evidence for 
early supported discharge schemes.(108) In an admission avoidance study for patients with CAP, patient 
satisfaction improved by 40% (p<0.001) in those allocated to HAH.(118) Our HOME FIRST feasibility study shows 
that there is a demand for this service but further research is needed. 
STUDY DESIGN OVERVIEW 
• Overall research aim 
 
Our overall aim is to reduce the length of hospital stay. Length of stay is the key indicator of success in this 
study. We will record the date at which patients in both arms are suitable for discharge by HOME FIRST, 
however only the HOME FIRST group will be discharged on that day. We will record reasons for the delayed 
discharge in those randomised to SHC, these will include social, OT and physiotherapy, clinical deterioration, 
lack of senior review, awaiting investigations that could be performed as an out-patient  and ‘unclear’ to 
the study team. 
• Primary endpoint 
 
Our primary endpoint is time to recovery. This is assessed by our simple ‘RECRTI’ (functional RECovery from 
Respiratory Tract Infection) questionnaire (non-validated) which is completed at 6 weeks 
 
Patients (or consultees) will be asked at recruitment to define their/the patient’s best exercise capacity in the 
last 3 months e.g chair to bed with 1, unlimited exercise tolerance etc 
 
At the 6 week out-patient appointment they will be asked 4 simple questions: (marked on a likert-type scale in 
days and weeks): 
 
1. When (if at all) did your sleep return to normal?  
2. When (if at all) did your diet/appetite return to normal? 
3. When (if at all) did your (pre-defined) exercise capacity return to normal? 
4. When (if at all) did your capacity to work or socialise (delete as appropriate) return to normal? 
 
Secondary endpoints 
 
4. Clinical (safety, mortality, satisfaction, length of stay, readmission, functional status, quality of life) 
 
A. Safety and mortality 
We will assess the safety i.e. ensure there is no delayed recovery, no pneumonia (or non-pneumonia) 
complications or increase in mortality in the HOME FIRST limb. 
B. Patient and carer/consultee satisfaction 
HOME FIRST should have at least equivalence with standard hospital care. 
A validated questionnaire will be conducted via telephone at 2 weeks by an independent assessor 
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C. Length of hospital stay and total length of stay (including hospital and home care) 
D. Re-admission rates 
Within 6 weeks of recruitment. Reasons for re-admission will be noted in the case report form. 
E. Functional status (physical and mental) and quality of life (QOL) 
Validated questionnaires will be completed to assess recovery post respiratory infection. 
• A SF-12 (physical and mental function) at day 0 and 6 weeks 
• A CAP-SYM (disease recovery rate) will be completed at day 0 (for day minus 30 as well) 
and 6 weeks. [Day 0 score = A, Day -30 score = B, A - B = C, Day 28 score = D. The calculation 
of recovery at one month is Recovery (%) = 100 (D/C x100)].  
1. Health-economic 
A formal planned health economic analysis (by Professor Louis Niessen a health-economist at LSTM) will 
measure costs and resource utilisation (using self-reported staff and independently  validated time data 
collection), using costs that are sensitive to the different resources used during each care episode, to assess 
the cost-effectiveness of HOME FIRST. 
N.B. HOME FIRST does NOT support patients at home that could have been discharged anyway without support. 
If this study shows the success of the HOME FIRST pilot, the second stage is a full multi-centre NIHR funded RCT 
with 100 patients in each limb. If the RCT shows positive overall effects we will ‘roll-out’ a fully operational HOME 
FIRST scheme across the northwest and ultimately nationally +/- internationally. 
Study design 
 
A randomised interventional clinical care pathway study of early supported discharge (termed ‘HOME FIRST’) 
versus standard hospital care for patients hospitalised with LRTI. 
 
HOME FIRST will provide coordinated MDT care, provision of 24hr emergency telephone cover, access to fully 
trained respiratory study nurse(s) and study doctor(s). The HOME FIRST MDT consists of: 
• Study doctors (trained respiratory physicians - consultants and senior SpRs) 
• Highly trained respiratory specialist nursing staff 
• Close links with a physiotherapist (mobility and respiratory) 
• Home help provision (temporary assistance with ADLs by carers) which may include occupational therapy or 
social worker involvement (HOME FIRST has fast access to meals-on-wheels) 
• Close links with pharmacy for rapid dispensing of discharge medication. 
 
Patients hospitalised with LRTI at the Royal Liverpool and Broadgreen (RLBUHT) Teaching Hospitals between 
October 2012 and December 2014 will be approached.  
Patients (or the next of kin if the patient is unable to give informed consent) will be offered participation in the 
study if they fit the strict inclusion/exclusion criteria. They will be then be randomised to receive HOME FIRST or 
standard hospital care (SHC).  
SUBJECTS AND TIMELINES 
Between October 2012 and December 2014 we will aim to recruit 25 patients to each arm of the study. 
METHOD DETAILS 
• Recruitment and Selection 
The study team will be in regular communication with bed managers, nursing and medical co-ordinators in A&E, 
the medical admissions unit and the respiratory wards at RLBUHT. Via regular education and information 
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dissemination events and through daily interaction with the study team, the key staff will be aware of the 
research study and its aims, objectives and potential participants. A list of potential patients will be generated 
on a daily basis in combination with these personnel, and discussed twice per day at pre-defined times (by phone 
or bleep) to alert the study team of a potential recruit.  
Relevant parts of a potentially suitable patient’s medical notes, blood, microbiology and radiology results will be 
reviewed by a study team member to assess suitability. After this review if the patient is still considered suitable 
the study team member will then introduce themselves and consider the patient’s capacity, clinical condition 
and appropriateness of their current environment for initial study discussion. 
If the patient is deemed to have capacity to consent to study participation by the study team then the study will 
be explained to the patient and the patient information sheet will be reviewed. At the end of the process, 
questions will be answered, consent may either be obtained at that point, the patient may decline participation 
all together or after an agreed length of time - 'overnight' (giving opportunity for patients to discuss with their 
advocates and for patient reflection) consent will be re-visited and further opportunity for questions given. 
If the patient is deemed NOT to have capacity to consent to the study then their next of kin will be approached 
and the relative information leaflet will be discussed and at the end of the process an assent form will be signed 
if the next of kin is happy for the patient’s participation. 
If a patient regains capacity during the study they may choose to (a) continue (b) withdraw – allowing data 
gathered so far to be retained (c) withdraw completely – all data collected up to that point will be destroyed. 
Consent, assent and later retrospective consent (as needed) will be taken by a fully trained study team member. 
A full clinical examination will be performed by the study doctor before recruitment. 
• Patient Eligibility 
 
Patients with any of the following conditions: 
• Pneumonia - community-acquired (CAP) or hospital-acquired (HAP) - pneumonia definition - a series of 
clinical symptoms with radiological consolidation  
N.B. All pneumonia CURB-65 scores will be considered but patients with CURB-65 ≥3 MUST have had 
at least 24hrs of in-patient observation before recruitment into part B of the study. 
• Pneumonia with concomitant COPD or bronchiectasis 
• Non-pneumonic lower respiratory tract infection without COPD or bronchiectasis 
 
• Patient Suitability 
 
Appropriate patient selection for the study is paramount. Using strict selection criteria in combination with 
robust patient safety provisions, including 24-hour telephone support, we suggest that some patients can be 
safely discharged and supported at home. Inclusion in the scheme is ultimately at the discretion of the 
experienced study team. 
 
Inclusion criteria for those without chronic respiratory disease 
• Patients with CAP or HAP with or without concomitant COPD or bronchiectasis 
• Patients with lower respiratory tract infection without COPD or bronchiectasis 
• Age>18yrs old 
• All observations must be stable for 12-24hrs 
• EWS ≤2 AND SBP>90 (all observations must be stable for 12-24hrs)  
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• Has a telephone 
• Can manage activities of daily living with current available support (If needed, immediate occupational 
therapy/physiotherapy/social assessment and care can be arranged prior to discharge and continued 
at home) 
• Improving/stable inflammatory markers 
• Improving/stable U&Es 
• Fluent English speaker 
• Oxygen saturations ≥94% on air(252) 
 
Inclusion criteria for those with chronic respiratory disease 
• Patients with CAP or HAP with or without concomitant COPD or bronchiectasis 
• Patients with lower respiratory tract infection without COPD or bronchiectasis 
• Age>18yrs old 
• All observations must be stable for 12-24hrs 
• SBP>90 (stable for 12-24hrs)  
• Has a telephone 
• Can manage activities of daily living with current available support (If needed, immediate occupational 
therapy/physiotherapy/social assessment and care can be arranged prior to discharge and continued 
at home) 
• Improving/stable inflammatory markers 
• Improving/stable U&Es 
• Oxygen saturations ≥88% on air or oxygen (if long term oxygen therapy [LTOT] is to be provided) 
(excluding asthma for which oxygen saturations must be ≥94% on air). Oxygen assessment may be 
needed.(252) 
• Fluent English speaker 
 
Exclusion criteria 
• Acute exacerbations of COPD  
• Acute exacerbations of bronchiectasis without consolidation not requiring prolonged requiring intravenous 
antibiotics 
• Patients with CURB-65 >3 admitted <24 hours ago 
• Patients unable to manage at home even with maximal support from HOME FIRST (This may include 
intravenous drug users, patients with history of excess alcohol consumption or mental health problems) 
• Empyema or untapped pleural effusion (If no diagnostic pleural tap performed - discuss with study doctor) 
• Suspected/proven pulmonary infarct 
• Serious co-morbidities requiring hospital treatment (e.g. CKD, CCF) or deemed unstable (significant AKD) 
• Suspected MI/raised TnI/T consistent with NSTEMI (Or acute ECG changes) within 5 days of discharge  
• SBP<90mmHg 
• Neutropenia 
• No fixed abode 
• Tuberculosis suspected 
• Well enough for discharge without HOME FIRST support 
 
• Screening, Questionnaires and Follow-up 
 
1. Screening  
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Baseline clinical data which includes age, gender, history of presenting complaint, past medical history, a 
complete social history, drug and vaccination history and allergies, will be performed and recorded by the 
study doctor.  
2. Randomisation 
 
If a patient is selected for inclusion and consents to participation they are allocated at random to HOME 
FIRST or SHC. Randomisation is via computer generated random number and patient allocation is obtained 
by using numbered sealed envelopes. 
 
3. Questionnaires 
 
No research investigations will occur except for questionnaires. Clinical bloods and other investigations will 
be taken/requested as necessary. 
SF-12 (physical and mental function) [performed twice in total] - at recruitment (day 0) and 6 weeks 
CAP-SYM [performed 3 times in total] - at recruitment day 0 (twice including day minus 30) and 6 weeks 
Patient (and carer/consultee) satisfaction - conducted over the telephone at 2 wks by an independent 
assessor. 
4. Initial follow-up post discharge 
 
Patients randomised to HOME FIRST care will initially receive up to twice daily respiratory specialist nurse 
visits for the first 48 hours. After this time period, the frequency and duration of visits will depend on clinical 
need. (See daily review diary information sheet.) The study nurse will establish the need for the involvement 
of other MDT team members. Laboratory tests will performed as clinically indicated at the discretion of the 
study team. Venepuncture will be performed by fully trained research staff for clinical purposes as needed 
in the HOME FIRST limb: as for those patients in the SHC limb frequency of venepuncture depends on clinical 
assessment of need by their regular medical team.  
 
Patients randomised to standard hospital care (SHC) - All management and discharge decisions will be made 
by the patient's usual hospital team. Clinical tests will be performed at the discretion of the medical team. 
If any significant or concerning clinical issues are noted during study team's visits, the usual medical team 
will be alerted. 
 
All patients will be discussed at a weekly case-note MDT meeting. 
 
5. Later follow-up 
 
All patients will be followed-up on discharge in the ‘Respiratory Infection’ out-patient clinic (in the patient’s 
own home if necessary) at 6 weeks, with a repeat chest X-ray if needed.  
 
 
Operational Guidelines 
Patients discharged from hospital will remain the responsibility of the Chief Investigator during the time that 
they are supported by HOME FIRST. The patient's GP and hospital consultant (as of discharge day) will be 
informed of any specific interventions and outcomes by discharge letter. Patients recruited to the study that are 
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randomised to SHC will remain under the care of their current consultant. Patients can be readmitted to the 
hospital as determined by the study team via the bed managers. For all readmissions a ‘treatment failure or 
complication development’ proforma on the CRF will be completed. Home visits will occur from 08.00 - 17.00 
up to 5-days-per-week. Telephone visits are available 7 days per week. 24hr cover is available via telephone to 
the HOME FIRST study team, this will be provided by a rotered team of respiratory study research doctors. In 
the event of an emergency an ambulance will be called. If the patient needs non-emergency medical attention 
at home between 17.00 - 08.00, a district nurse or out-of-hours GP will be contacted by the study team.  
The patient’s condition is monitored closely at home. Portable observation machines will be used by HOME 
FIRST to monitor blood pressure (BP), heart rate (HR), oxygen saturations (sats) and temperature during home 
visits.  In order to provide consistent, high-quality care, the clinical assessment and evaluation will be carried out 
using the CRF. The CRF, which contains no patient identifiable information, will be removed from hospital 
premises for home visits. 
HOME FIRST will provide coordinated MDT care, provision of 24 hr emergency telephone cover, access to fully 
trained respiratory study nurse(s) and study doctor(s). The HOME FIRST MDT consists of: 
• Study doctors (trained respiratory physicians - consultants and senior SpRs) 
• Highly trained respiratory specialist nursing staff 
• Close links with a physiotherapist (mobility and respiratory) 
• Home help provision (temporary assistance with ADLs by carers) which may include occupational therapy or 
social worker involvement (HOME FIRST has fast access to meals-on-wheels) 
• Close links with pharmacy for rapid dispensing of discharge medication (TTOs). 
 
SAFETY NOTES 
The risks to individuals are limited by the study design: 
• Strict patient selection - Highly trained respiratory clinical staff (respiratory physicians - consultants and 
senior SpRs and senior specialist nurses with community experience) will carefully select suitable patients 
using strict inclusion/exclusion criteria and discretion based on extensive relevant clinical experience. 
• Competent and experienced specialist staff  
• Thorough patient education – Specific patient-individualised self-management plan. 
• Regular home visits - Daily reviews will occur to ensure that any clinical deterioration is effectively assessed 
and managed and patients are re-admitted to hospital if deemed necessary by either the study team. A 
coordinated MDT will be key to the HOME FIRST care approach to patient care 
• No delay in recognition of clinical deterioration – The patient/carer will be given a detailed patient 
information leaflet with red-flag symptoms, a 24hr emergency telephone contact number. During 08.00 – 
17.00 telephone access (with additional home visits as necessary) to a specialist respiratory study nurse and 
doctor will minimise any risks of delayed recognition of clinical deterioration. The patient’s condition is 
monitored closely at home. Portable observation machines will be used during home visits. 
• Rigorous safety procedures for patients/carers - All patients/carers will also receive a verbal and written 
self management plan for their specific condition, a list of symptoms to prompt contact with team and a 
24hr contact number (study on-call team). In the CRF a proforma will be completed if any treatment failure 
or complications requiring hospital re-admission occur. Adverse events will be reported using the correct 
documentation within the CRF. The study will be stopped if there is any mortality in the HOME FIRST limb 
whilst patients are at home. Any adverse events will result in a SAE form being completed and the ethics 
committee (REC) and sponsor(s) will be informed immediately. The risks to individuals are limited by the 
study design. 
• Rigorous staff safety procedures – there are specific important safety issues around attending a patient’s 
own home. This is a carefully considered and high priority area. Staff will carry personal alarm devices at all 
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times. If this is activated, a GPS tracking service at a local private security firm will locate the team member 
and they will immediately attend. They will alert the police as necessary. Team members will have up-to-
date conflict resolution training. All team members will print off a daily diary which states all planned home 
visits and details times, addresses and contact numbers. If team members do not arrive/telephone at set 
time points, team members will contact them and if un-contactable the private security firm/police will be 
called as necessary. Occasionally two team members will attend together if felt necessary. If there are 
considered to be any threats to the health and safety of the attending member of the study team (either by 
the patient, the carers, family members, neighbours or the external community), patients in the HOME 
FIRST limb will be readmitted to hospital (if necessary) and HOME FIRST attendance will be stopped. 
• A Data monitoring committee (DMC) has been formed following an SAE in January 2014. The DMC consists 
Dr Rebecca Bancroft, Consultant Physician RLBUHT, Arthur Ricky Kang’ombe, Lecturer/Biostatistician, 
Liverpool School of Tropical Medicine and Sasha Shepperd, Professor of Health Services Research, Oxford 
University. A terms of reference document is available. The DMC will provide the independent review of 
safety data for this study. To carry out this function, the DMC will (1) Review emerging safety data from the 
study.  Data will be presented to the committee by spreadsheet weekly during the duration of the study.  
Responses are copied to all by email. This system has proved effective in our other research projects (such 
as experimental carriage models), (2) review, evaluate and make recommendations to the Investigators and 
the Trust as to whether to modify, suspend, terminate or extend the study, (3) be notified of any SUSAR 
without delay. DMC will also review SAEs/AEs on a regular basis and in particular review the causality 
assessments of all adverse events with regards to the patient selection criteria. Meetings will be held by 
email circulation. At a minimum there will be one meeting prior to recruitment of 30 patients and one when 
recruitment is completed or a decision is made that sufficient patient numbers have been screened. Other 
meetings may take place at the discretion of the members. Other external panel members may also be 
invited to attend meetings to discuss specific topics. 
 
ANALYSIS PLAN  
A research statistician, Dr Brian Faragher from LSTM, has been involved in statistical discussions.  
With regards to the primary outcome of time to recovery, this is a non-inferiority trial. With regards to secondary 
endpoints, safety and mortality, patient and carer/consultee satisfaction, re-admission rates, functional status 
(physical and mental) and quality of life (QOL) and costs will be analysed. Clinical outcomes such as safety and 
mortality and rate of readmission (at 6 weeks) will be analysed comparing the HOME FIRST limb with standard 
hospital care. Validated questionnaires (SF-12, CAP-SYM, and patient and carer/consultee satisfaction) will be 
quantitatively analysed to assess functional status/quality of life/satisfaction. A formal health-economic analysis 
is planned to measure costs and resource utilisation (Professor Louis Niessen), using costs that are sensitive to 
the different resources used during each patient care episode. In conjunction with the NIHR Research Design 
Service (RDS) team, analysis methodology has been developed, including the involvement of a health-
economist. 
FUTURE PLAN AND IMPLICATIONS OF THE WORK 
Success in this project will result in an early supported discharge scheme model for patients with LRTI leading to 
a reduction in hospital LOS, without an increase in re-admission rates or mortality and at least comparable 
patient satisfaction scores. 
Success will result in an application for a NIHR Programme Grant for Applied Research (PGfAR) to fund a full 
multi-centre RCT with 100 patients per limb. Dependent on its success the aim is ultimately to ‘roll-out’ a fully 
operational HOME FIRST scheme nationally. 
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Full title: Pneumococcal Conjugate Vaccine-13 (Prevenar-13) and Experimental Human Pneumococcal 
Carriage Study (EHPC) Protocol 
Short title: PCV/EHPC 
EudraCT no. 2012-005141-20 
 
Background 
Pneumococcal disease is a major global health threat for which new vaccines are urgently needed, particularly 
those that will protect vulnerable children and adults against pneumonia. Testing of new vaccines is costly in 
both time and money. Experimental Human Pneumococcal Carriage (EHPC) is safe and reproducible but has not 
yet been tested as a means of measuring vaccine protection. We will use current licensed vaccines to measure 
protection against EHPC. 
 
Current vaccines 
Pneumococcal polysaccharide vaccination (PPV) provides protection against invasive pneumococcal disease 
(IPD) but is less protective against pneumonia in adults(126) and is ineffective in young children. Pneumococcal 
conjugate vaccine (PCV) show good serotype-specific immunity against invasive disease (83-94%) in children and 
herd immunity effects in adults, by reducing carriage.(141) Prevenar-13 is currently licensed for use in children 
aged 6 weeks to 6 years. It is also licensed as a single dose vaccination for adults aged>50 yrs old. 
 
PCV and carriage  
Several studies have described that PCV is immunogenic in children(145) and elderly(146) as well as in HIV-
infected subjects.(147) PCV induces systemic B and T cell responses and therefore IPD caused by vaccine types 
has declined in children following vaccination in the UK.(152) Epidemiological data have also suggested a 
reduction in nasopharyngeal carriage by vaccine types after PCV in both children and adults,(164, 165) both by 
direct protection of vaccinated individuals and by the reduction in exposure of unvaccinated individuals to 
vaccine types through herd protection. Modelling studies of anticapsular immunity have shown that the 
protection conferred by the serotype-specific immunity elicited during life by natural exposure to pneumococci 
is estimated as >50%, frequently allowing repeated colonisations with the same serotype.(225) There are no 
studies, however, demonstrating the direct protective effect of PCV and its serotype-specific induced immunity 
on pneumococcal carriage.  
Important current questions  
This study will address important current questions with regards to the impact of Prevenar-13 on pneumococcal 
carriage in adult human subjects. Examination of individuals pre and post Prevenar-13 vaccination, and 
comparison of the immune response of colonised versus non-colonised subjects and the vaccinated and 
unvaccinated subjects will provide new information on the innate, cellular and humoral immune responses to 
PCV vaccination and pneumococcal colonisation. In the future this model will be used in testing the effect of 
new candidate vaccines.  
 
Study design overview 
In our previous dose-ranging and reproducibility EHPC studies, we have demonstrated that nasal pneumococcal 
carriage could be reproducibly achieved in healthy adult volunteers. In this double-blind placebo randomised 
control trial (RCT) study we will use the EHPC model to carry out vaccine effect testing. The dose-response curve 
predicted a 30-60% endpoint allowing the combined testing for benefit and harm for our future vaccine studies. 
Following thorough screening to minimise individual risk of pneumococcal disease and transmission to 
vulnerable contacts; healthy volunteers will be randomised to receive either Prevenar-13 or hepatitis A (Avaxim) 
vaccination. 5-12 weeks after vaccination (to which both the volunteer and study team are blinded) the 
volunteers will be inoculated with 0.1ml serotype 6B pneumococci per nostril at 80,000 cfu/nostril. They will 
then be followed for up to 3 weeks to determine the presence and duration of pneumococcal carriage, and the 
nature of the local and systemic immune responses induced. 
 
Appendices 
 
294 
 
2
9
4
 
The primary endpoint is PCV-induced protection against pneumococcal carriage. Classical culture methods (and 
PCR techniques) will be used to detect the presence, density and duration of pneumococcal carriage in nasal 
wash post inoculation. 
The secondary endpoints are: 
(a) Innate, humoral and cellular responses (detailed below) to pneumococcal colonisation will be assessed by 
immunological assays performed oncollected samples. In a subgroup of volunteers, bronchoalveolar lavage 
(BAL) will be collected  after vaccination and experimental challenge. These data will allow us to define the host 
variables that predict colonisation and protection due to PCV  
 
(b) PCV-induced alterations in nasal microbiota when possible 
 
c) The effect of natural pneumococcal colonisation at the time of vaccination on PCV immunogenicity and 
subsequent post-vaccination colonisation duration and density.  
 
Aims 
The main study aim is to determine whether PCV is protective against pneumococcal carriage in healthy adult 
volunteers, in a safe and controlled manner. 
 
The secondary aims are to examine the local and systemic innate, humoral and cellular immune responses to 
PCV +/- pneumococcal nasal carriage. 
 
Implications 
The major applications of this study are assessing whether: (a) PCV administered to adults reduces colonisation 
and therefore may improve herd immunity (b) there is a correlation between immunogenicity of the specific 
serotype and protection against carriage (c) natural colonisation at time of vaccination is affected by PCV (d) 
natural colonisation affects the immunogenicity of PCV (e) the EHPC model can be used as a surrogate for vaccine 
effectiveness (f) synchronous sampling of upper, lower respiratory tract and systemic compartments to 
determine correlates of PCV-induced protection. 
 
Subjects and timelines 
We will recruit healthy non-smoking volunteers and randomise them to receive either PCV or hepatitis A vaccine. 
We will then inoculate them with a well-characterised penicillin-sensitive pneumococcus (6B) and observe the 
volunteers for the development of pneumococcal carriage. We plan to inoculate up to 100 subjects (sample size 
calculations and justifications are detailed below). To allow for a drop-out rate of 20% prior to inoculation, up 
to 120 subjects will be initially recruited.  
 
Outline timetable for volunteers:  
 
• Week 0 Initial appointment to discuss potential study involvement, consent obtained. 
• Week 1-2 Pre-vaccine samples - nasal wash, urine and blood collection. Clinical examination and 
history. Pregnancy test. 
Randomised to either Prevenar-13 or Avaxim vaccine arm and first dose of Prevenar-13 or Avaxim 
administered, pregnancy test prior to vaccination. 
Day 1 post vaccination blood sample 
Day 2 post vaccination blood sample 
• Week 5-15 (10 week variation allows for staggering to inoculate a safe number of participants per 
week). Post-vaccine samples - nasal wash, urine, throat swab and blood collection 
• Week 6-16 Pneumococcal inoculation - 0.1ml serotype 6B pneumococci administered to each nostril at 
80,000 cfu/nostril.  
Day 1 post inoculation blood sample 
Day 2  post inoculation nasal wash, throat swab and blood samples 
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Daily telephone contact with researcher (by telephone) for 7 days following inoculation.  
 
• Week 7-17 Nasal wash and throat swab (7 days post inoculation) 
• Week 8-18 Nasal wash and throat swab (14 days post inoculation). Only attended by participants that 
developed carriage at at least one time point post inoculation 
• Week 9-19 Nasal wash, blood and urine (21 days post inoculation, final sample) 
• Week 9-19 UNBLINDING OCCURS AT THIS POINT 
• Week 9-onwards A subgroup of volunteers may be offered an optional bronchoscopy and BAL 
[performed post carriage] (consent obtained as per separate consent form attached). 
All experimental carriers who have not had 2 consecutive negative nasal washes will receive amoxicillin 
500mg tds for 3 days. 
• Week 9-onwards Research bronchoscopy and BAL +/- blood sample (if > 2 weeks since study 
completed). Optional and in a subgroup only. Post-bronchoscopy follow-up occurs within 5 days. 
• Week 9-onwards Volunteers are offered the full course of vaccine(s) that they did not receive at 
randomisation (if in Prevenar-13 group) or offered to complete the vaccination course (if in the Avaxim 
group). 
We will endeavour to take all samples at the above times however to allow maximum flexibility for our 
volunteers (allowing for illness, bereavements, exams and travel issues) we will allow +/- 7 days for 
sampling visits as appropriate. 
Method details 
1. Recruitment and selection  
 
Advertisements will be placed on physical notice boards in public areas, the internet of Universities and Colleges 
within Liverpool and the surrounding area and RLBUHT and University Hospital Aintree and in the local press 
inviting healthy volunteers to participate. Students from Liverpool Universities will be sent a generic 
advertisement email inviting them to participate in the research. Public open days and engagement events will 
be used to advertise the research. Interested persons are asked to contact the research team for further 
information and an initial appointment will be made should they wish to consider participating. The RLBUHT 
database (consent4consent) may also be used to approach those who have previously been involved in research 
at the RLBUHT. In order to prevent of ‘over-volunteering’ we will be using the TOPS database. We will enter into 
the database the volunteer’s National Insurance number (if a UK citizen) or passport number and country of 
origin (if not a UK citizen) and the date of the last dose of study medicine. We may call other units to check 
volunteer details. Details may be kept for up to 3 years.  
Inclusion criteria:  
• Adults aged 18-50 yrs - ages chosen to minimise the risk of pneumococcal infection  
• Fluent spoken English - to ensure a comprehensive understanding of the research project and their 
proposed involvement  
 
Exclusion criteria: 
• Previously received PPV (23-valent pneumococcal polysaccharide vaccine [pneumovax]) or any 
conjugate vaccine (PCV) - at any age – full vaccine history obtained from General Practitioner as 
necessary 
 
• Previously received a complete course of hepatitis A vaccination 
 
• Previous significant adverse reaction to any vaccination/immunisation 
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• Close contact with at risk individuals (children, immunosuppressed adults, elderly, chronic ill health) – 
to minimise risk of pneumococcal transmission  
• Current smoker or significant smoking history (>10 pack yrs) – to minimise risk of pneumococcal 
infection and optional bronchoscopy  
• Current diagnosis of asthma (on regular medication) or respiratory disease – to minimise risk of 
pneumococcal infection and optional bronchoscopy 
• Pregnancy – to minimise risk of pneumococcal infection and no safety data exists for either vaccine in 
pregnancy 
• Breast-feeding mothers - no safety data exists for either vaccine in pregnancy 
• Women of child-bearing potential (WOCBP) who are deemed not to have sufficient, effective birth 
control in place for 1 month prior to vaccination and 1 month after the final vaccination 
• On medication that may affect the immune system in any way e.g. steroids, steroid nasal spray 
• Allergic to penicillin/amoxicillin  
• Involved in another clinical trial unless observational or in follow-up (non-interventional) phase 
• Previously been involved in a clinical trial involving experimental human pneumococcal carriage 
• Unable to give fully informed consent  
• Current acute severe febrile illness. 
It is anticipated that 10-15% of screened participants will have natural pneumococcal colonisation at the time of 
recruitment as demonstrated by the initial nasal wash. These individuals will be permitted to continue in the 
study and follow an unaltered study protocol.  
 
Vaccination history will be confirmed by the GP. The research team will complete sections of a GP questionnaire, 
this should be checked and signed by the GP before the patient is commenced in the study. 
 
 
2. Screening and preliminary assessment  
Clinical examination - the initial clinic visit will include a focused clinical history and targeted clinical examination 
involving auscultation of the lung fields and heart sounds. Should a previously unrecognised abnormality be 
identified this will be explained to the individual and appropriate investigations and follow-up will then be 
arranged by the study doctor. Further participation will be determined at the discretion of the study doctor 
dependent on the nature of the abnormality detected.  
3. Clinical specimens and collection procedures 
Nasal wash - will be performed using a modified Naclerio method.(189) This is a well-used and validated 
technique to collect nasal cytology specimens with which we now have 2 years experience. Briefly, 5ml of saline 
is instilled and held for a few seconds in the nares before being expelled in to a sterile Galli pot; this is usually 
repeated up to 20ml in total. In the event of nasal wash loss (defined as cough/sneeze/swallow) the procedure 
may then be repeated to obtain an adequate specimen.  
 
Venous blood – will be taken by an appropriately trained team member. Up to 40ml of blood will be collected 
at 3 time points (pre-vaccine, post vaccine and final samples post challenge). An EDTA sample will be taken at 
both the pre-vaccination and the pre-inoculation/post-vaccination visits. 
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Extra blood samples - will be taken by an appropriately trained team member. Up to 10mls blood will be taken 
at pre vaccination (within the 40mls) and day 1 and day 2 post vaccination and day 1 and day 2 post inoculation 
+/- on the day of the bronchoscopy (if > 2 weeks since study completed) only. 
Urine – up to 20mls of mid-stream urine is collected at 3 time points (pre-vaccine, post vaccine and final samples 
post challenge). 
Oropharyngeal swab - In brief, the individuals tongue will be depressed using a tongue depressor exposing the 
palatopharyngeal arch. A sample will be obtained by making 5 small circular motions of the right 
palatopharyngeal in contact with the mucosa whilst avoiding the patients tongue. The oropharyngeal swab will 
be transferred into growth media, frozen and later analysed for the presence of respiratory pathogens using 
microbiological culture and molecular techniques. Recent data suggests increased identification of bacteria 
using oro-pharyngeal swabs in comparison to traditional sampling methods. Therefore we aim to compare 
results obtained from nasal wash samples using traditional culture and molecular techniques, such as qPCR, with 
the results from oro-pharyngeal swabs. 
3. Randomisation and blinding. 
Randomisation will be computer-generated and occur in blocks of 10. An independent co-ordinator will produce 
sealed envelopes containing the study group allocations. The research team will be blinded to the vaccination 
group as the vaccination will be administered by unblinded staff from the RLBUHT and the Liverpool School of 
Tropical Medicine (LSTM) Well Travelled Clinic [WTC]) in the RLBUHT clinical research facility (CRF). After the 
final 21 day post inoculation samples have been taken, un-blinding will occur to allow the study team to offer 
volunteers the alternative vaccine, these will be administered at the LSTM WTC and arranged by the volunteer 
directly with the WTC.  
4. The vaccine(s) 
The vaccines will be purchased by the RLBUHT clinical trials pharmaceutical team. The vaccines will be stored at 
the appropriate temperature as per manufacturer’s instructions and stored and administered as per at CRF 
policy. Prevenar-13 will be purchased from Pfizer Pharmaceuticals and administered in a single dose via 
intramuscular injection (0.5mL supplied in a prefilled syringe). The hepatitis A vaccine (Avaxim) will be 
administered as a single dose (0.5mL supplied in a prefilled syringe) by intramuscular injection. The vaccines will 
be administered by an experienced, trained health care professionals from the RLBUHT or the WTC. As per CRF 
policy, the participant will be observed for 20-30 minutes following vaccination to ensure that they do not 
experience a reaction to the vaccine. If any adverse reaction occurs the volunteer will be transferred to the 
RLBUHT emergency department and the study team informed. Immediate un-blinding will occur in the event of 
an adverse event requiring medical attention for which knowledge of the vaccine given will effect treatment and 
ongoing immediate care. 
Avaxim has been chosen as a suitable control due to its safety profile, preparation (aluminium-containing 
vaccine), lack of effect on nasal colonisation/immunity and health benefit for those involved in the study if the 
volunteer travels to endemic areas in the future. It is licensed for use in susceptible adults >16 years old. Initial 
protection is achieved with one single dose of vaccine. In order to provide long-term protection, a second dose 
(booster) should be given preferably between 6 - 12 months after but may be administered up to 36 months 
after the first dose. The vaccine may also be used to provide the second dose (booster) in subjects who received 
another inactivated hepatitis A vaccine (monovalent or with purified Vi polysaccharide typhoid) 6 - 36 months 
previously. 
 
The hepatitis A immunisation course is 2 vaccinations in total. After un-blinding, volunteers in the hepatitis A 
arm will be offered 1 further hepatitis A vaccination, via the WTC, to complete their course (cost paid for by 
study) depending on their prior vaccination status. Those in the PCV arm will be offered a full course (2) of 
hepatitis A vaccinations through the WTC, depending on their prior vaccination status. All these appointments 
are arranged directly between the volunteer and the WTC after completion of the study. 
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The RLBUHT clinical trials pharmaceutical team will be responsible for ‘over-labelling’ both vaccines with a trial 
specific label which is annex compliant. 
5. Preparation of 6B bacterial stock for inoculation 
Preparation of bacteria for carriage studies - mid-log broth culture of pneumococcus (type 6B) will be frozen at 
-80°C in aliquots of glycerol-enriched media. Frozen aliquots will be thawed and checked for cfu/ml, E-test 
penicillin susceptibility and purity. These checks will first be carried out in our laboratory and then identification 
and characterisation will be confirmed in a reference laboratory. On experimental days, aliquots will be thawed, 
washed twice, and re-suspended at an appropriate density for each inoculation dose.  
Inoculation - using a P200 micropipette 0.1ml broth containing the desired dose (80,000cfu/nostril) of 6B 
pneumococcus will be instilled in each nostril. The participant will be seated in a semi-recumbent position. After 
inoculation, the participant will remain in this position for up to 15mins. Following the inoculation visit the 
participant will be given a post-inoculation advice sheet (including emergency contact details), thermometer 
and a course of amoxicillin. 
Determination of colonisation - colonisation will be defined by the result of nasal washes taken post inoculation. 
Nasal washes will be plated on culture media and incubated overnight at 37°C in 5% CO2. Colonies will be 
confirmed as S. pneumoniae using classical techniques including (i) typical draughtsman-like colony morphology 
(ii) the presence of α-haemolysis (iii) optochin sensitivity (iv) solubility in bile salts and (v) Gram-positive 
diplococci. Typing will be done using a latex agglutination kit to confirm pneumococcal serotypes. Isolates will 
be frozen at -80ºC for storage and in any case of uncertainty will be confirmed by a reference laboratory. Results 
from the cultured nasal wash will also be confirmed using moleculat methods of bacterial detection. 
Monitoring of colonisation - monitoring of colonisation will occur by 48 hour post-inoculation and then weekly 
nasal washes. Home monitoring will include a clear flow chart of the necessary intervention should any 
symptoms develop (see patient inoculation information sheet). A three day course of amoxicillin and a digital 
thermometer are issued. Participants will be required to make text message contact with a specified member of 
the research team before 1200hrs (noon) every day for 7 days post inoculation. Should they not make contact 
by the specified time; a member of the research team will contact the volunteer. If no contact is made then a 
prior defined ‘secondary contact’ will be telephoned. During the post inoculation period volunteers will have 
access to a 24/7 on-call telephone service until the end of the study. 
6. Termination of carriage 
 
All study participants who were experimental carriers, and who have not had 2 consecutive negative nasal 
washes, will receive amoxicillin 500mg tds for 3 days orally.  
7. Immunological response measurements 
 
Immunological assays to determine susceptibility to colonisation and immunological response to carriage will 
be carried out on collected samples.   
 
Bacterial carriage and microbiota evaluation  
 
Molecular techniques will be employed to determine the carriage density (primers including lytA) of 
pneumococcus and other nasopharyngeal and lower airway microbiota. Modern techniques include 16S rRNA 
sequencing, deep sequencing with 454 technology, transcriptomic profiling, and microarray. None of these 
methods are clinically validated and so we will use conventional techniques to determine the primary endpoint. 
We will also characterise the dynamics of co-colonisation, particularly of S. pneumoniae with staphylococci and 
Haemophilus spp. 
 
 
Collaborations 
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Samples collected during this study including PBMCs, whole blood, bacterial cell pellets, nasal wash supernatant 
will be sent to our collaborators (Nationally and Internationally) once Material Transfer Agreements compliant 
with HTA regulation have been established. These collaborators have expertise that are complementary to our 
laboratory team and meet the aims of this project. 
 
 
End of the study 
 
Last visit of the last subject (LVLS) 
 
Provision of additional care after the trial has ended 
 
No specific provision is necessary in the study 
 
8. Risks and Benefits 
 
Risks 
 
The main risks associated with this study are those of vaccination, experimental bacterial inoculation and 
research bronchoscopy. The main ethical principles under which these risks are considered are those of 
autonomy and non-maleficence. 
 
 
Autonomy 
 
The volunteers will be given sufficient information that is written and spoken in a non-jargon way to allow them 
to understand the research objectives, the risks of any procedures and the possible benefits. They then need to 
be given time to consider the information before consenting to any involvement. At no stage should the 
volunteer feel pressured or persuaded into participating in the research. 
 
We have addressed this by specifying that potential volunteers will be passively recruited after volunteer 
initiated enquiry, rather than the researcher contacting the individual to prevent any possible influence or 
coercion on the part of the research team. Volunteers have the right to withdraw their consent and therefore 
withdraw from the study at any time without giving reason. 
 
Non-maleficence 
 
As researchers we have the responsibility to minimise the risk of harm to the volunteers. This involves the 
researchers having sufficient knowledge, having reviewed current evidence in the literature about the proposed 
interventions and making themselves aware of potential risks. For bronchoscopy this will be done by following 
recommended guidelines (BTS 2001). Bronchoscopy will be performed in the correct environment by highly 
trained and competent staff. 
 
Trained staff will administer the vaccination. Staff are experienced in vaccination administration and fully 
competent in anaphylaxis management. Full resuscitation equipment and an anaphylaxis trolley are immediately 
available. The volunteers will remain at the clinic for 20 - 30 mins after vaccination to monitor for any immediate 
side effects. 
 
Inoculation of S. pneumoniae will be as per previous studies and will be performed by highly trained staff with 
close supervision (24hr on call access to medical professional involved in the research study) and follow-up. 
 
Specific inclusion and exclusion criteria are set to further protect the volunteer. In our previous dose-ranging 
and reproducibility EHPC studies, we demonstrated that nasal pneumococcal carriage could be reproducibly 
achieved in healthy adult volunteers.  
 
Those who receive the Prevenar-13 are receiving a licensed vaccine outside of the EMA marketing authorisation 
(licensed for <6yrs old and >50 years old only). Prevenar-13 when administered to children/babies aged <6yrs 
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old and adults aged 50-95yrs old was associated with minor adverse reactions/side effects only, as detailed later. 
It is generally very safe and well tolerated. 
 
Those who receive Avaxim are receiving a licensed vaccine within the marketing authorisation. The safety of this 
vaccine has been assessed in many clinical trials. It is generally very safe and well tolerated, adverse 
reactions/side effects are detailed below. 
 
Experienced and trained research staff will perform venepuncture and nasal washes. 
 
Beneficence 
 
Although the benefit to the volunteer is limited they are however given the opportunity if they wish, to at the 
end of the study to complete the course of vaccinations in the arm they were randomly assigned and to have 
the (course) of vaccination(s) in the other arm of the study. They will also be examined and assessed by a clinical 
research doctor who may identify unsuspected illness. The patient will also have an opportunity to discuss other 
illnesses with a trained general medical doctor as they wish. 
 
There is no current data available as to any benefit to those aged 18 – 50 of receiving Prevenar-13.  
 
Justice 
 
This must be balanced with non-maleficence. The research is open to all individuals but important exclusion 
criteria are in place, primarily to protect individuals from undue risk. This study offers the potential for both local 
(UK) and global impact in the prevention of pneumococcal disease. This value has been underscored by 
substantial funding from the Gates Foundation as part of the global effort to prevent pneumonia by vaccination. 
 
Benefits 
 
Participants will learn about clinical research from their experience and there is a possibility of detecting 
unsuspected medical problems during clinical examination, which will be further investigated as needed. 
 
Additional health benefits for those involved in the study are that the volunteer has the ability to receive both 
the Prevenar-13 and Avaxim vaccination as part of the study free of charge. The latter offers 20 years of 
protection against hep A if they complete the course offered as part of this study. 
 
Remuneration will be offered for travel, time and inconvenience the fees will reflect remuneration and not 
financial coercion. The payment compensates individuals for time, inconvenience, discomfort and the risk of 
participation but does not entice individuals to take part in the study for financial gain.  The sums offered in this 
study have been developed over the course of many years for bronchoscopy and over the last 2 years for EHPC. 
 
9. Safety considerations  
 
Pneumococcus is responsible for infections including otitis media (OM), sinusitis, pneumonia, bacteraemia and 
meningitis. The milder forms of infection (OM, sinusitis) are many times more common than the serious invasive 
forms of disease. While the risk to individuals of developing any infection is very low (10% adults experience 
colonisation at any time, and the incidence of invasive disease is 20/100,000 patient years), the study is designed 
to ensure any risk is minimal by appropriate: 
 
• a study team experienced in EHPC 
• study design  
• careful serotype selection and dosing  
• volunteer selection and exclusion criteria  
• volunteer education and availability of antibiotics  
• rigorous safety procedures including daily monitoring  
• 24 hour emergency telephone contact with researchers (including close individual daily monitoring) 
and access to hospital facilities and prompt treatment if required.  
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We have experience with inoculating and following over 200 healthy volunteers using several serotypes, and a 
range of doses. No episodes of pneumococcal infection or SUSARs have occurred in any of our volunteers. 
 
Prevenar-13 is a safe vaccine with a very low risk of adverse events.(223, 224) It is currently licensed for use in 
children and in the UK as part of the Childhood Immunisation programme (effective from 4 September 2006). In 
adults over 50 years of age vaccinated in US clinical trials the most commonly reported side effects to Prevenar-
13 vaccination included: injection site pain/swelling/tenderness, fatigue, headache, muscle pain, limitation of 
arms movement, decreased appetite, chills and rash.  
Avaxim is a safe vaccine for use in travellers visiting hepatitis A endemic areas. In clinical trials, adverse reactions 
were usually mild and confined to the first few days after vaccination with spontaneous recovery. The adverse 
reactions observed with Avaxim include:  
• Very common: asthenia, mild injection site pain 
• Common reaction: headache, nausea, vomiting, decreased appetite, diarrhoea, abdominal pain, 
myalgia/arthralgia, mild fever 
• Uncommon: injection site erythema  
• Rare: injection site nodule 
Reactions were less frequently reported after the booster dose than after the first dose. Avaxim was well 
tolerated in both sero-negative and positive subjects 
 
Trained staff from the LSTM WTC or RLBUHT will administer the vaccination at the clinical research facility (CRF). 
LSTM WTC, RLBUHT and CRF staff are experienced in vaccination administration and fully competent in 
anaphylaxis management. Full resuscitation equipment and an anaphylaxis trolley are immediately available. 
The volunteers will remain at the clinic for 20-30 minutes after vaccination to monitor for any immediate side 
effects. 
 
The Data Monitoring and Safety Committee (DMSC) is charged with monitoring the study and advising the PI 
and study team. 
 
It consists of:  
(1) Professor Robert C Read, Chair of Infectious Diseases, University of Sheffield (Chair) – supervises Neisseria 
human inoculation studies and is an expert on mucosal defence against infection  
(2) Professor David Lalloo, LSTM – an experienced clinical trialist with substantial experience of DMSC work  
(3) Dr Brian Faragher, Senior Lecturer in Statistics, LSTM – is experienced in clinical trials and DMSC work. 
 
The DMSC will receive a weekly update on all recruitment (by email) and will meet by formally biannually and in 
the event of any serious unexpected serious adverse reactions (SUSARs). When the DMSC formally meet they 
will review the SmPCs (on medicines.org.uk) for both Avaxim and Prevenar-13 for updates and any serious 
adverse events (SAE’s) from the study so far, updating the protocol as necessary. 
 
Bronchoscopy and BAL  
We have experience of over 1000 of these procedures and have published both an audit of volunteer 
experience(253) and a visualised version of this technique.(254) A full risk assessment is carried out and a 
separate hospital consent form is completed. Complication rates are very low (mild symptoms in less than 25% 
subjects) and no serious adverse events.(255) 
 
10. Contraception/lactation and women of child-bearing potential (WOCBP) 
 
The effects of the Prevenar-13 and Avaxim on the unborn child are not known. Women who are pregnant or 
breast-feeding may not participate. Sexually active women must therefore be using an effective form of birth 
control approved by the study team for 1 month prior to and after the final vaccination. Contraception methods 
can include – hormonal contraceptives (oral, injection, trans-dermal patch, implants, cervical ring), barrier 
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methods (diaphragm with spermicide or a condom), an intra-uterine device, male sterilisation (for monogamous 
individuals only) and true abstinence. Women must have a negative pregnancy test at enrolment and on the day 
of vaccination and must confirm that they do not intend to become pregnant during the study. Those who think 
they may be pregnant are urged to notify the study doctor immediately. 
 
11. Adverse events  
 
Adverse drug reaction (ADR): any untoward and unintended response in a subject to an investigational 
medicinal product (IMP) which is related to any dose administered to that subject. 
Unexpected adverse reaction: an adverse reaction the nature and severity of which is not consistent with the 
information about the IMP in the summary of product characteristics (SmPC). 
Serious adverse event (SAE) or serious unexpected serious adverse reaction (SUSAR): an adverse event, 
adverse reaction or unexpected adverse reaction, respectively, that: (a) results in death (b) is life-threatening (c) 
requires hospitalisation or prolongation of existing hospitalisation (d) results in persistent or significant disability 
or incapacity (e) consists of a congenital anomaly or birth defect. 
Any SAEs will be recorded and reported to the DMSC and sponsor (within 24hrs). Hypersensitivity reactions 
including facial oedema, dyspnoea and bronchospasm are rare SAEs to Prevenar-13. The reaction may result in 
brief hospitalisation (<48 hours) - no further vaccinations are necessary to remain a participant in the study.  
In the event of any SUSAR the trial will be stopped temporarily for investigation and any further work referred 
back to the REC and MHRA for further consideration, through the sponsor (within 7 days). 
12. Analysis plan and sample size 
 
The primary endpoint of this study is PCV-induced protection against pneumococcal colonisation determined by 
the presence, density and duration of pneumococcus in nasal wash collected from vaccinated volunteers 
following experimental pneumococcal inoculation. Using data from our dose-ranging and reproducibility studies 
and data from previous PCV studies, we estimate that 60% of the control (hepatitis A vaccine) group will be 
colonised with pneumococci following inoculation and 30% of the PCV group. A 50% reduction of carriage in PCV 
group was estimated in accordance with modelling studies.(225) This allows a power of 81% when recruiting 50 
volunteers to each arm. 
 
 n Pneumococcal 
carriers 
Pneumococcal 
carriers 
Pneumococcal 
carriers 
Pneumococcal 
carriers 
Pneumococcal 
carriers 
Pneumococcal 
carriers 
PCV 50 5 5 10 10 15 15 
Control 50 30 25 30 25 30 25 
Power 
(%) 
 99 99 98 85 81 45 
 
Important secondary endpoints including the immune responses, in particular humoral and cellular responses, 
will also be assessed. Immunological parameters will be compared between pre-vaccination and pre-inoculation 
values in paired analyses using parametric or non-parametric tests as appropriate. In the case of BAL data, we 
will only have one sample and therefore we will compare vaccinated colonised (natural and experimental) and 
non-colonised subjects and by non-paired comparison between groups from our previous experimental carriage 
studies samples. 
 
Hypotheses regarding bacterial co-colonisation will be tested using molecular techniques. These methods are 
inherently semi-quantitative and so evaluation will be by comparison of proportions in samples at different time. 
We will be advised by the statistician Brian Faragher who is also member of our DMSC. 
 
13. Future plan and implications of the work  
 
Success in this project will result in: 
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a) A robust EHPC and vaccine testing protocol that can be used in novel vaccine evaluation 
b) New information regarding mucosal responses to Prevenar-13 and bacterial colonisation after vaccination in 
adults with direct application to mucosal vaccine development 
c) A greater understanding of the effect of Prevenar-13 on the nasal microbiota 
d) A greater understanding of the effect of natural carriage on the immunogenesis of Prevenar-13. 
 
Future work will be planned to build on both of these anticipated outcomes by engaging with vaccine 
manufacturing companies and mucosal adjuvant programmes.  
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PCV EHPC Study Schedule Flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Wk 6-16 
Wk 1-2 
Experimental carrier at any time point? 
Except for subjects with 2 negative NW 
Take amoxicillin 500mg TDS for 3/7 
Daily text/ 
phone 
contact with 
research 
team for 7/7 
Study complete 
2 day nasal wash, blood throat swab 
7 day nasal wash and throat swab 
14 day nasal wash and throat swab (subgroup only) 
Wk 5-15 
Wk 9 -19 
Wk 8-18 
Wk 9 
onwards 
21 day (FINAL) blood, nasal wash and urine 
UNBLINDING 
All volunteers offered the complete course of hepatitis A vaccines 
Wk 7-17 
Wk 9-19 
YES NO  
Discussion with participant and consent to study 
Pre-vaccine samples - blood, nasal wash, urine 
and clinical examination. Pregnancy test 
Prevenar-13 received 
Randomised to receive vaccine A or vaccine B. 
Pregnancy test 
 
Avaxim received 
Inoculate with 0.1ml pneumococcus each nostril 
Post-vaccine samples – nasal wash, throat swab, blood and urine 
Wk 0 
1 day blood 
1 day blood 
2 day blood 
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Pneumococcal Conjugate Vaccine-13 Reduces Experimental Human Pneumococcal 
Carriage Rates: A Randomised Double-blind Control Trial – STATISTICAL ANALYSIS PLAN 
Authors: A M Collins, A D Wright, J F Gritzfeld, E Mitsi, C Hancock, D Shaw, S H Pennington, 
D Wang, B Morton, D M Ferreira, S B Gordon – to be confirmed.  
EudraCT: 2012-005141-20  
ISRCTN: 45340436  
REC ref: 12/NW/0873  
 
Introduction  
New vaccines are urgently needed to protect the vulnerable from pneumonia. The 23-valent 
pneumococcal polysaccharide vaccine (PPV - pneumovax) provides protection against 
invasive pneumococcal disease (IPD) but is less protective against pneumonia in adults [1] and 
is ineffective in young children. The pneumococcal conjugate vaccine (PCV) shows good 
serotype-specific immunity against invasive pneumococcal disease [IPD] (83-94%). (95) The 
23-valent pneumococcal polysaccharide vaccine (PPV - pneumovax) provides protection 
against IPD but is less protective against pneumonia in adults [1]. Several studies have 
described that PCV is immunogenic in children [3] and elderly [4] as well as in HIV-infected 
subjects.[5] Epidemiological data have suggested a reduction in nasopharyngeal carriage by 
vaccine types after PCV in both children and adults,[6, 7] both by direct protection of 
vaccinated individuals and by the reduction in exposure of unvaccinated individuals to vaccine 
types (VT) through herd protection. There have been no studies, however, demonstrating the 
direct protective effect of PCV and its serotype-specific induced immunity on pneumococcal 
carriage.  
We have developed a model of Experimental Human Pneumococcal Carriage (EHPC) in 
healthy adults and reported that experimental carriage is safe and reproducible. [8] Here we 
use this model to assess whether 13-valent Pneumococcal Conjugate Vaccine (PCV-13) has a 
direct impact of pneumococcal carriage.  
Methods  
Ethical approvals were obtained from the National Health Service Research and Ethics 
Committee (REC 12/NW/0873) and the study was sponsored by the Royal Liverpool and 
Broadgreen University Hospital Trust and the Liverpool School of Tropical Medicine. The study 
was approved by MHRA registered with EudraCT: 2012-005141-20 and ISRCTN: 45340436. 
CONSORT methodology was followed. [9]  
Trial design and participants  
100 non-smoking, healthy volunteers aged between 18-50 years old, were recruited and 
commenced the study (see CONSORT diagram). Subjects were screened to minimise 
individual risk of developing pneumococcal disease and transmission to vulnerable contacts; 
and then randomised 1:1 to receive either 13-valent Pneumococcal Conjugate Vaccine 
(Prevenar-13) or Hepatitis A (Avaxim) vaccination (control group).  
To minimise the risk of transmission, pneumococcal infection and vaccination, we excluded 
subjects; 
 
(1) That had previously received PPV or PCV or a complete course of hepatitis A vaccination  
(2) With a previous significant adverse reaction to any vaccination  
(3) With close contact to ‘at risk’ individuals (children, immunosuppressed adults, elderly, 
chronic ill health)  
(4) Who were current smokers or had significant smoking histories (>10 pack years)  
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(5) With asthma (on regular medication) or any other respiratory disease  
(6) Pregnant or breast feeding mothers and women of child-bearing potential who are 
deemed not to have sufficient, effective birth control in place  
(7) On medication that may affect the immune system in any way  
(8) Allergic to penicillin/amoxicillin  
(9) Involved in another clinical trial unless observational or non-interventional phase  
(10) Previously involved in an experimental pneumococcal carriage study  
(11) With a current acute severe febrile illness.  
 
We also excluded all subjects taking any antibiotic therapy <2 weeks prior to inoculation, with 
abnormal clinical observations at the screening visit (systolic blood pressure <90, >160 mmHg, 
pulse rate <40, >100 beats per minute, oxygen saturations <96% on air), with an active 
medical condition requiring regular hospital appointments or with a white cell count pre-
inoculation of <4.0 (109/L) AND a neutrophil count (109/L).  
 
Screened subjects that were found to have natural pneumococcal colonisation at the time of 
recruitment as demonstrated by the initial nasal wash continued in the study and followed 
an unaltered study protocol.  
 
Randomisation, blinding, vaccination and unblinding  
 
A double blind randomised study design was performed. Randomisation was computer-
generated and occurred in blocks of ten by envelopes. An independent co-ordinator from the 
tropical Clinical Trials Unit (tCTU) produced sealed envelopes containing the study group 
allocations. Research (clinical and laboratory) staff and subjects were blinded to vaccination 
allocation. An unblinded vaccination team was employed to vaccinate study subjects. The 
vaccines were drawn up out of sight of the study volunteers. At the end of the study (usually 
day 21 post-inoculation) the subjects were unblinded to the vaccine they received by a 
research nurse not involved in the conduct of the study.  
Hepatitis A vaccine (Avaxim) was chosen as a suitable control predominately due to its safety 
profile, preparation (aluminium-containing vaccine), lack of effect on nasal 
colonisation/immunity and health benefit for those involved in the study.  
 
Subject monitoring and safety   
 
Pneumococcus is responsible for infections including otitis media, sinusitis, pneumonia, 
bacteraemia and meningitis. While the risk to individuals of developing any infection is very 
low, the study was designed to ensure any risk is minimal by appropriate:  
• a study team experienced in EHPC  
• study design  
• careful serotype selection and dosing  
• volunteer selection and exclusion criteria  
• volunteer education and availability of antibiotics  
• rigorous safety procedures including daily monitoring  
• 24 hour emergency telephone contact with researchers (including close individual 
daily monitoring for 7 days post-inoculation via text contact) and access to hospital 
facilities and prompt treatment if required.  
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Subjects remained at the clinic for 20-30 minutes after vaccination to monitor for any 
immediate side effects. Full resuscitation equipment and an anaphylaxis trolley were 
immediately available. A Data Monitoring and Safety Committee (DMSC) monitored the study 
throughout.  
 
Data on adverse events was collected. Specific codes were used for: headache (1), sore throat 
(2), nasal congestion/running (3), myalgia (4), lethargy (5), earache/muffling/popping (6), 
pyrexia (7), neck stiffness (8), hospital admission (9), other [including shivering, wheezy, 
cough, abdominal cramps] (10). Serious adverse events (SAE) or serious unexpected serious 
adverse reactions (SUSAR) were defined as: an adverse event or unexpected adverse reaction 
that: (a) results in death (b) is life-threatening (c) requires hospitalisation or prolongation of 
existing hospitalisation (d) results in persistent or significant disability or incapacity. SAEs 
were recorded and reported to the DMSC and sponsor within 24hrs.  
 
Sample collection  
 
Samples were taken pre-vaccine, post-vaccine/pre-inoculation and post-inoculation (day 2, 7, 
14, 21). Samples included nasal wash, urine, throat swab, saliva and blood collection. At the 
pre-vaccination visit a clinical examination, clinical history and a pregnancy test were 
performed. 5 – 12 weeks post-vaccination the subjects were inoculated with 6B 
pneumococcus and then followed up for a further 3 weeks for detection of pneumococcal 
carriage. The day 14 visit was only attended by subjects that were carriage positive (either 
experimental or natural) at one time point post-inoculation (at day 2 or 7).  
 
Inoculation  
 
Bacterial stocks preparation was carried out as previously described [10]. Briefly a clinical 
isolate of S. pneumoniae serotype 6B (sequence type 138) was grown to mid-log phase in 
Vegitone broth (Oxoid) and stored in 1ml aliquots containing 20% glycerol at -80°C. 
Confirmation of serotype was performed using latex agglutination (Statens Serum Institute, 
Copenhagen) and bacterial purity was confirmed by an independent reference laboratory 
(Health Protection Agency, Colindale, UK).  
On each day of inoculation an aliquot was thawed, centrifuged and the bacterial pellet was 
washed before being re-suspended and diluted in 0.9% sterile saline to reach the desired 
concentration of  
 
bacteria. For inoculation the stock was then taken to the clinical area of inoculation and using 
a P200 micropipette 100μl inoculum containing the desired dose (80,000 cfu/100μl/nostril), 
well-characterised penicillin-sensitive 6B serotype pneumococcus (BHN 418) was instilled in 
each nostril whilst the subject was then seated in a semi-recumbent position. [11] Serial 
dilutions of the original inocula were plated onto blood agar for dose confirmation.  
 
After inoculation, the participant remained in this position for up to 15mins. A post-
inoculation advice sheet (including emergency contact details), thermometer and a course of 
amoxicillin was given to all subjects. Monitoring of colonisation occurred by 48 hour post-
inoculation and then weekly nasal washes. During the post inoculation period subjects had 
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access to a 24/7 on-call telephone service and were required to make text contact daily for 7 
days with the research team. Secondary point of contact (emergency) telephone details were 
also taken from all subjects.  
 
Diagnosis of carriage: colonisation and detection  
 
Nasal wash (NW) samples were collected pre- and post- inoculation and processed as 
previously described. [11] [12] Briefly, 5ml of 0.9% saline was instilled into each naris with the 
subject seated and leaning back supported at 45° to the horizontal. At instillation, the subjects 
were asked to hold their breath whilst pushing their tongue up and backwards against the 
roof of the mouth. Saline was held in the nasopharynx for up to 5 seconds and then expelled 
by gently tipping the head forward and exhaling rapidly through their nose into a sterile foil 
bowl. Usually this was repeated up to 20ml in total (10ml total per nares), if less than 10mls 
was returned, up to 40mls normal saline was used as necessary. Notably all CFU density is 
calculated by taking into account the total volume of saline returned.  
 
NW samples were spun at 3350g for 10 minutes and the supernatant stored at -80°C. The 
pellet was re-suspended in 100μl of skim milk tryptone glucose glycerol (STGG) medium. 20μl 
was plated onto Columbia Horse Blood Agar (Oxoid) with gentamicin (Sigma) and the 
remainder diluted to 1 ml with STGG and plated (50μl) on blood and chocolate agar for 
determination of co-colonising flora. Remaining STGG samples were stored at -80 °C for 
confirmation if needed. Plates were inspected after 24 hours incubation at 37 °C, 5% CO2 and 
alpha haemolytic, draughtsman-like colonies were sub-cultured to determine pneumococcal 
phenotype. Optochin sensitivity, bile solubility and latex agglutination testing were 
performed to confirm pneumococcal phenotype. 6B serotype was confirmed using latex 
agglutination kit (Statens Serum Institute, Copenhagen). Subjects in whom 6B pneumococci 
were detected in NW samples from any visits post inoculation were defined as experimental 
carriers. Isolates were frozen at -80°C for storage and reference laboratory confirmation. 
Results from the cultured NW were also confirmed using PCR based (LytA) methods of 
bacterial detection and to determine the carriage density.  
 
Saliva samples were collected using salivettes retained for 2 minutes between the gum and 
buccal mucosa as per the manufacturer’s instructions. Oro-pharyngeal swab was obtained by 
making 5 small circular motions of the palatopharyngeal arch in contact with the mucosa 
whilst avoiding the patients tongue.  
 
All experimental carriers who did not had 2 consecutive culture-negative nasal washes 
received amoxicillin 500mg tds for 3 days at the end of the study. 
 
Sample size and endpoints  
 
The primary endpoint is PCV-induced protection against pneumococcal colonisation 
determined by the presence of pneumococcus in NW collected from vaccinated subjects 
following experimental pneumococcal inoculation at any post treatment time point up to and 
including day 21, detected using classical microbiological methods. 
 
Secondary endpoints:  
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• The presence of pneumococcus in NW collected from vaccinated subjects following 
experimental pneumococcal inoculation at day 2, 7, 14 and 21 detected using classical 
microbiological methods  
• the presence of pneumococcus in NW collected from vaccinated subjects following 
experimental pneumococcal inoculation at any post treatment time point up to and 
including day 21 detected using qPCR method  
• the presence of pneumococcus in NW collected from vaccinated subjects following 
experimental pneumococcal inoculation at day 2, 7, 14 and 21 detected using qPCR 
method  
• the density of pneumococcal colonisation in NW collected from vaccinated subjects 
following experimental pneumococcal inoculation at day 2, 7, 14 and 21  
• the duration of pneumococcal colonisation in NW collected from vaccinated subjects 
following experimental pneumococcal inoculation at the end of study  
 
Using data from our dose-ranging and reproducibility studies and data from previous PCV 
studies, we estimated that 40 - 60% of the control (hepatitis A vaccine) group will be colonised 
with pneumococci following inoculation and 30% of the PCV group. A 50% reduction of 
carriage in PCV group was estimated in accordance with modelling studies. [13] This allowed 
a power of 81% when recruiting 50 volunteers to each arm.  
 
Statistical methods and analysis  
 
Two populations will be considered in the analysis as follows:  
 
Intent-to-Treat population  
 
Intent to treat (ITT) will be defined at the moment the randomisation is performed. For the 
primary outcome analysis in this trial, subjects will be followed with their ITT arm. In analyses 
referring to a specific number of days, the randomisation day will be considered day 0. A 
randomised subject who does not have follow-up date due to loss to follow-up will not be 
included in the ITT population, leading to a modified ITT population.  
 
Per-protocol population  
 
Per-protocol (PP) population is based on the treatment group actually assigned to the subject. 
The PP population will exclude subjects who are known to have received no interventions. 
Protocol violators include those whose were recruited not vaccinated and also those who 
were vaccinated but withdrew before inoculation. Natural carriers may also be removed from 
the population prior to data analysis for the primary outcome.  
 
Primary endpoint analysis   
 
Primary outcomes will be summarised by number (%) of events and analysed using a 
generalized linear model that includes treatment as a single predictor (A=PCV group, B= 
control group), which will generate risk ratio and odds ratio together with their 95%CIs of 
having a pneumococcus between PCV and control group. The primary endpoint analysis will 
be based on ITT population. The main conclusions in the clinical report will be based on the 
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ITT analysis of the primary outcome. An additional analysis of the primary outcome will also 
be presented using the PP.  
 
Secondary outcome analysis  
 
The binary secondary endpoints will be summarised using number (%) of events at each time 
point and analysed using a generalised estimating equation (GEE) model, in which treatment 
(A=PCV group, B= control group), time (day=2, 7, 14 and 21), interaction between treatment 
and time as fixed effects and subject as random effect. Exchangeable covariance structure 
will be used. The odds ratio together with their 95%CIs at each time point will be derived.  
 
The continuous secondary endpoints will be summarised using number, mean, standard 
deviation, median, minimum and maximum at each time point and analysed using a 
generalised estimating equation (GEE) model, in which treatment (A=PCV group, B= control 
group), time (day=2, 7, 14 and 21), interaction between treatment and time as fixed effects 
and subject as random effect. Exchangeable covariance structure will be used. The mean 
difference together with their 95%CIs at each time point will be derived.  
 
The duration of pneumococcal colonisation in NW collected from vaccinated subjects 
following experimental pneumococcal inoculation at the end of study will be determined by 
the presence of pneumococcus in the most recent visit. This data will take only 5 possible 
values (0, 2, 7, 14 and 21). Empirical studies show that the density and duration of 
pneumococcal colonisation tended to have a fraction of zero values and did not follow the 
normal distribution. We will therefore perform a quantile regression analysis on these two 
outcomes with treatment as only covariate. In case of density analysis, quantile regression 
analysis will be performed at day 2, 7, 14 and 21 separately. The treatment effect will be 
derived from the quantile regression model.  
 
Summary descriptive statistics will be used to describe natural carriers (VT and NVT) at 
different time points (pre-vaccination), post vaccination/pre-inoculation and post inoculation 
and also density (CFU/ml). Adverse events will also be described by number (%) of patients 
with at least one adverse events by treatment group for the following adverse events – 1 
headache, 2 sore throat, 3 nasal congestion/running, 4 myalgia, 5 lethargy, 6 
earache/muffling/popping, 7 pyrexia, 8 neck stiffness, 9 hospital admission, 10 other 
(including shivering, wheezy, cough, abdominal cramps), according the vaccine group, time 
(≤2, 2-7, 7-21 days) and carriage status.  
 
Subgroup analysis  
 
Subgroup analysis will be performed for primary endpoint by the vaccination status (vaccine 
type [VT] and non-vaccine type [NVT]). The treatment effect in each of subgroup of the above 
selected variables will be estimated within the framework of generalised linear model, which 
will include treatment, vaccination status, and interaction between treatment and 
vaccination status. Treatment effect within each subgroup of vaccination status will be 
estimated and presented together with the p-value for the interaction test.   
 
Baseline data  
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Demographics and baseline characteristics will be summarised appropriately by treatment 
groups. In general for the continuous demographic variables results for each treatment group 
will be summarised using number of observations, mean, standard deviation, and minimum 
and maximum values, and for categorical (nominal) variables, the number and percentage of 
subjects will be used. Baseline data will include, total number of recruits, mean age (+/- SD 
and range), gender, inoculum dose (CFU/ml), number of natural carriers and VT or NVT) and 
time from vaccination to inoculation in both groups.  
 
All statistical analyses will be performed using SAS 9.2 and Stata 13.  
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Appendix B 
 
Contains all Standard Operating Procedures (SOPs): 
• Nasal Wash Collection Protocol 
• Experimental Human S. pneumoniae Inoculation Protocol 
• Nasal Wash Processing and Pneumococcal Carriage Detection Protocol 
• DNA Extraction and qPCR Protocol  
 
Appendices 
 
313 
 
3
1
3
 
Nasal Wash Collection 
Protocol 
Version 3 (09/01/2015) 
 
Objective 
Nasal Wash Collection/Sampling for EHPC PCV, HF feasibility and LRTI NW protocols. 
Reagents and Materials Required 
Saline 20ml 
Foil bowl 
Gloves 
Apron 
Tissues 
20ml syringe 
Centrifuge tube 
 
Protocol 
• Nasal washes (NW) are performed at an initial screening visit, as well as 48 hr, 7, and 14 
days post- inoculation 
 
• The volunteer is seated comfortably with their head is tilted back 30° from the vertical 
 
• Ask the volunteer to take a deep breath in and hold their breath whilst pushing their tongue 
up and backwards against the roof of the mouth 
 
• Whilst in this position, the volunteer is asked to signal that they are ready 
 
• A syringe filled with 20 ml saline is inserted into the anterior nasal space and 5 ml of saline 
is expelled. The volunteer then leans forward immediately and expels the fluid by exhaling 
rapidly through their nose into a foil bowl 
 
• Repeat this procedure 3 more times so that each naris has been washed twice and the full 
20 ml has been used 
 
• Pool all samples together in a centrifuge tube and send to the laboratory at room 
temperature for processing. 
 
References 
 
Naclerio, R.M., et al. Mediator release after nasal airway challenge with allergen. Am. Rev. Respir. 
Dis. 128, 597-602 (1983). 
Risks/Dangers 
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• S. pneumoniae is an opportunistic pathogen, care should be taken to prevent aerosols and 
subsequent inhalation of bacteria. 
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Experimental Human S. 
pneumoniae Inoculation 
Protocol 
Version 1A (22/12/2011) 
 
Objective 
As part of the EHPC protocol, volunteers will be inoculated with 6B 
pneumococcus. 
Reagents and Materials Required 
Blood plates – Oxoid PB0122A 
6B stock vial from -80 freezer 
Sterile 0.9% NaCl – hospital grade 
Microcentrifuge  
Microcentrifuge tubes  
Pipettes – sterile, EHPC designated, in fume hood 
96 well plate – U bottom  
All work performed in fume hood 
Protocol 
30mins prior to inoculation appointment 
• Using 6B stock from -80°C freezer, thaw tube and spin in microcentrifuge full 
speed(13000rpm) for 3mins. 
• Take blood plates out of fridge and put in incubator to warm  
• Prepare 96-well plate for M&M, adding 180ul saline to each well 
• Prepare dilution tubes according to desired dose 
• Take 6B tube and remove vegitone broth supernatant 
• Add 1ml of saline and resuspend pellet by pipetting up and down 
• Centrifuge again at full speed for 3mins 
• Remove supernatant and resuspend pellet in 1ml saline 
• Prepare dilution tube for inoculation 
• Plate out dilutions to determine inoculum dose both PRE and POST 
inoculation* 
 
6B Inoculation 
80,000 CFU/100ul dose 
• Using 1ml tube ONLY, take 68ul out and add to 1250ul saline, mix vigorously 
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Plating changes: 
* Plate dilutions on individual blood plates – tilt plate at slight angle sideways, 
drop 10ul on left and let it run down length of plate, repeat twice underneath 
so there are 3 lines of bacteria. Count colonies the next day and divide by 3 as 
in M&M SOP 
*Post plating done IMMEDIATELY upon return to LSTM. Try to limit time between 
pre and post to 30mins 
Risks/Dangers 
• S. pneumoniae is an opportunistic pathogen, care should be taken to prevent 
aerosols and subsequent inhalation of bacteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendices 
 
317 
 
3
1
7
 
 
 
Nasal Wash Processing   
and Pneumococcal 
Carriage Detection 
Protocol 
Version 2A (09/01/2012) 
Objective 
Process NW for PCV EHPC, HF feasibility and NW LRTI protocol and detect 
presence of pneumococcus. 
Reagents and Materials Required 
Blood plates – Oxoid PB0122A  
Chocolate plates - Oxoid 
STGG medium 
O’Brien, K.L. & Nohynek H. Report from a WHO working group: standard 
method for detecting upper respiratory carriage of Streptococcus 
pneumoniae. Pediatr Infect Dis J 2003, 22: e1-11. 
 
Oxoid tryptone-soya broth (CM 129) 3.0ml; glucose 0.5g; Oxoid skim milk 
powder (CM L31) 2.0g; glycerol 10.0ml; double distilled water 100.00ml. 
Dispense in 1ml amounts into bijoux’s and autoclave at 15lb for no more than 
10 min. Store tubes at 4-6°C. Resuspend the pellet at the bottom of the tube 
before use by vortexing for 10 to 15 s. 
 
Saline 
For Miles and Misra dilutions – see M&M SOP  
Pipettes 
96 well plate – for dilutions 
Eppendorf tubes 
Cryotubes * if freezing for extraction 
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Centrifuge 
  
Protocol 
• Centrifuge the samples for 10 min at 3,345 x g 
• Remove the supernatant and store as 1 ml aliquots in labelled Eppendorf 
tubes at -80 °C 
• Add 100 μl of STGG medium9 to the pellet and mix thoroughly. Ensure 
that the total volume in the tube at this point is determined. This dilution 
will be used in calculating the CFU of a carriage positive NW 
• Plate a 20 μl drop of the STGG containing the re-suspended pellet onto 
a blood agar plate containing gentamicin and streak the entire plate. If 
the NW is post-inoculation, remove 10 μl from the STGG containing the 
re-suspended pellet and use for bacterial quantification by M&M 
method 
• Add another 800 μl of STGG to the NW tube and mix thoroughly 
• Plate 25 μl onto a blood agar plate and 25 μl onto a chocolate agar 
plate, streaking the entire plate 
• Divide the remaining amount bacteria suspended in STGG medium into 
2 cryovials and store at -80 °C 
• Incubate the plates at 37 °C overnight in 5% CO2 
• Examine the plates the next day for pneumococcus. Pneumococci are 
identified on plates by colony morphology. Alpha haemolytic colonies 
with draughtsman morphology are sub-cultured onto blood agar with an 
optochin disc and incubated overnight. Presumptive pneumococcal 
colonies that are optochinsensitive are Gram stained to confirm Gram 
positive diplococci and serotyped using the Statens Serum Institut 
Pneumotest-Latex kit. 
 
STORAGE 
• Add 800ul STGG to the NW tube, pipette up and down 
• Divide remaining amount into cryovials (400ul approx into each) for -80°C 
for later DNA extraction and PCR. 
•  
Risks/Dangers 
• S. pneumoniae is an opportunistic pathogen, care should be taken to prevent 
aerosols and subsequent inhalation of bacteria. 
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DNA Extraction and qPCR 
Protocol 
Version 1 (22/12/2013) 
Objective 
As part of the LRTI NW protocol qPCR was carried out to assess for pneumococcal carriage. 
Reagents and Materials Required 
QIAamp DNA mini kit 
 
Lysozyme Sigma-L-6876 
 
Mutanolysin Sigma-M9901 
 
TE buffer (10mM Tris-HCl, 1 mM EDTA, pH 8.0) 
 
Primers and probe (Carvalho Mda G et al. Evaluation and improvement of real-time PCR 
assays Targeting LytA, Ply, and PsaA genes for detection of pneumococcal DNA. J Clin 
Microbiol. 2007 Aug;45(8):2460-6. Epub 2007 May 30.) 
 
10uM working stock – want 200nm final 
10uM (V1) = 0.2uM (25ul rxn) 
V1 = 0.5ul/rxn 
 
DNA free water (Millipore, H20MB0106) 
 
Plates – Agilent 401334 
 
Strip caps – Agilent 401425 
 
Taq – Invitrogen 11785-200 
 
Pipettes 
 
ALL WORK PERFORMED IN FUME HOOD 
Protocol 
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• DNA is extracted from 200 µl of the NW bacterial pellet stored in STGG using the QIAamp 
DNA mini kit and the Centers for Disease Control protocol 
• The pellet is then resuspended in 200 µl TE buffer containing 0.04 g/ml lysozyme and 75 U/ml 
mutanolysin (Sigma) and incubated at 37°C for 1 hr. Vortex the sample 
• Add 20 µl of proteinase K and 200 µl of Buffer AL to the sample and then incubate at 56°C 
for 30 min 
• Centrifuge briefly and add 260 µl of ethanol. Then follow the manufacturer’s instructions for 
all further steps. 
• DNA is eluted in 100 µl of QIAGEN elution buffer and stored at -20°C 
• Colonisation density is determined by targeting the pneumococcal autolysin lytA gene 
• Include a no-template control, a negative extraction control (parallel extraction of TE 
buffer) and a S. pneumoniae (BHN418) positive control in each run. 
• Amplify DNA with the Mx3005P system (Stratagene) and the data should be analysed using 
the instrument software 
• A sample is considered positive if both duplicates had a cycle threshold (CT) value below 
a mean 35. Values of >8000 copies/ml should be considered clinically relevant. Our (lower) 
limit of detection (LLD) is 40 copies. 
 
Reading/References 
1. Albrich WC, Madhi SA, Adrian PV, van Niekerk N, Mareletsi T, Cutland C, Wong M, 
Khoosal M, Karstaedt A, Zhao P et al: Use of a rapid test of pneumococcal colonization 
density to diagnose pneumococcal pneumonia. Clinical infectious diseases : an official 
publication of the Infectious Diseases Society of America 2012, 54(5):601-609. 
2. CDC: http://www.cdc.gov/ncidod/biotech/files/pcr-body-fluid-DNA-extract-
strep.pdf. Accessed August 2013. 
3. Carvalho Mda G, Tondella ML, McCaustland K, Weidlich L, McGee L, Mayer LW, 
Steigerwalt A, Whaley M, Facklam RR, Fields B et al: Evaluation and improvement of 
real-time PCR assays targeting lytA, ply, and psaA genes for detection of 
pneumococcal DNA. J Clin Microbiol 2007, 45(8):2460-2466 
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Appendix C 
Contains emergency patient information leaflets (PILs): 
• HOME FIRST Feasibility PIL 
• HOME FIRST Pilot PIL 
• PCV EHPC Vaccination PIL 
• PCV EHPC Inoculation PIL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendices 
 
 
 
3
2
2 
Appendices 
 
 
 
3
2
3 
Appendices 
 
 
 
3
2
4  
Appendices 
 
 
 
3
2
5  
Appendices 
 
 
 
3
2
6 
 
Appendices 
 
 
 
3
2
7  
Appendices 
 
 
 
3
2
8 
 
Appendices 
 
 
 
3
2
9  
Appendices 
 
330 
 
Appendix D  
 
Contains outcome measures from the HOME FIRST studies: 
• Telephone Satisfaction Questionnaire (Patient) 
• Telephone Satisfaction Questionnaire (NOK, carer, consultee) 
• CAPSYM Questionnaire 
• SF-12 Questionnaire 
• RECRI Questions 
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HOME FIRST Telephone Patient Satisfaction Questionnaire 
Q1 I have been treated with 
kindness and respect by staff 
Strongly 
agree  
Agree  Disagree  Strongly 
disagree  
Q2 The staff attended well to my 
personal needs 
Strongly 
agree  
Agree  Disagree  Strongly 
disagree  
Q3 I was able to talk to the staff 
about any problems that I might 
have had 
Strongly 
agree  
Agree  Disagree  Strongly 
disagree  
Q4 I received all the information I 
wanted about the cause and 
nature of my illness 
Strongly 
agree  
Agree  Disagree  Strongly 
disagree  
Q5 The doctors and nurses have 
done everything they can to 
make me well again 
Strongly 
agree  
Agree  Disagree  Strongly 
disagree  
Q6 I am happy with the amount of 
recovery I have made 
Strongly 
agree  
Agree  Disagree  Strongly 
disagree  
 
(adapted from Wilson et al, B.J. Gen Pract 2002) 
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HOME FIRST Telephone Carer / Next of Kin / Consultee Satisfaction Questionnaire 
 
 
(Adapted from Wilson et al, B.J. Gen Pract 2002) 
They have been treated with 
kindness and respect by staff 
Strongly 
agree 
Agree Disagree Strongly 
disagree 
The staff attended well to 
their personal needs 
Strongly 
agree 
Agree Disagree Strongly 
disagree 
I was able to talk to the staff 
about any problems/ 
questions that I might have 
had 
Strongly 
agree 
Agree Disagree Strongly 
disagree 
I received all the information 
I wanted about the cause and 
nature of their illness 
Strongly 
agree 
Agree Disagree Strongly 
disagree 
The doctors and nurses have 
done everything they can to 
make them well again 
Strongly 
agree 
Agree Disagree Strongly 
disagree 
I am happy with the amount 
of recovery they have made 
Strongly 
agree 
Agree Disagree Strongly 
disagree 
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HOME FIRST CAPSYM Questionnaire
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HOME FIRST SF-12® Patient Questionnaire   
 
Examination date (circle):  
Day 0        Day 2           Day 7          1 mth clinic appt                    6mth clinic appt 
  
This information will help your doctors keep track of how you feel and how well you can do 
your usual activities. Answer every question by placing a check mark on the line in front of 
the appropriate answer. If you are unsure about how to answer a question, please give the 
best answer you can and make a written comment beside your answer. 
 
1. In general, would you say your health is: 
_____ Excellent (1) 
_____ Very good (2) 
_____ Good (3) 
_____ Fair (4) 
_____ Poor (5) 
 
The following two questions are about activities you might do during a typical day. Does 
YOUR HEALTH NOW LIMIT YOU in these activities? If so, how much? 
 
2. MODERATE ACTIVITIES, such as moving a table, pushing a vacuum cleaner, bowling, or 
playing 
golf: 
_____ Yes, limited a lot (1) 
_____ Yes, limited a little (2) 
_____ No, not Limited at all (3) 
 
3. Climbing SEVERAL flights of stairs: 
_____ Yes, limited a lot (1) 
_____ Yes, limited a little (2) 
_____ No, not limited at all (3) 
 
During the PAST 4 WEEKS have you had any of the following problems with your work or 
other regular 
activities AS A RESULT OF YOUR PHYSICAL HEALTH? 
 
4. ACCOMPLISHED LESS than you would like: 
_____ Yes (1) 
_____ No (2) 
 
5. Were limited in the KIND of work or other activities: 
_____ Yes (1) 
_____ No (2) 
 
During the PAST 4 WEEKS, were you limited in the kind of work you do or other regular 
activities AS A RESULT OF ANY EMOTIONAL PROBLEMS (such as feeling depressed or 
anxious)? 
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6. ACCOMPLISHED LESS than you would like: 
_____ Yes (1) 
_____ No (2) 
 
7. Didn’t do work or other activities as CAREFULLY as usual: 
_____ Yes (1) 
_____ No (2) 
 
8. During the PAST 4 WEEKS, how much did PAIN interfere with your normal work (including 
both work outside the home and housework)? 
_____ Not at all (1) 
_____ A little bit (2) 
_____ Moderately (3) 
_____ Quite a bit (4) 
_____ Extremely (5) 
 
The next three questions are about how you feel and how things have been DURING THE 
PAST 4 WEEKS. For each question, please give the one answer that comes closest to the way 
you have been feeling. How much of the time during the PAST 4 WEEKS – 
 
9. Have you felt calm and peaceful? 
_____ All of the time (1) 
_____ Most of the time (2) 
_____ A good bit of the time (3) 
_____ Some of the time (4) 
_____ A little of the time (5) 
_____ None of the time (6) 
 
10. Did you have a lot of energy? 
_____ All of the time (1) 
_____ Most of the time (2) 
_____ A good bit of the time (3) 
_____ Some of the time (4) 
_____ A little of the time (5) 
_____ None of the time (6) 
 
11. Have you felt downhearted and blue? 
_____ All of the time (1) 
_____ Most of the time (2) 
_____ A good bit of the time (3) 
_____ Some of the time (4) 
_____ A little of the time (5) 
_____ None of the time (6) 
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12. During the PAST 4 WEEKS, how much of the time has your PHYSICAL HEALTH OR 
EMOTIONAL PROBLEMS interfered with your social activities (like visiting with friends, 
relatives, etc.)? 
_____ All of the time (1) 
_____ Most of the time (2) 
_____ A good bit of the time (3) 
_____ Some of the time (4) 
_____ A little of the time (5) 
_____ None of the time (6) 
 
SF-12® Health Survey © 1994, 2002 by Medical Outcomes Trust 
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Functional RECovery from Respiratory tract Infection Questionnaire (RECRI). 
 
 
1. When (if at all) did your sleep return to normal?  
 
I       I                      I                         I                       I                        I                       I                          I 
1 day           1 week           2 weeks        3 weeks          4 weeks            5 weeks           6 weeks 
 
 
 
2. When (if at all) did your diet/appetite return to normal? 
 
I       I                      I                         I                       I                        I                       I                          I 
2 day           1 week           2 weeks        3 weeks          4 weeks            5 weeks           6 weeks 
 
 
3. When (if at all) did your (pre-defined on day of recruitment) exercise capacity return to 
normal?  
 
I       I                      I                         I                       I                        I                       I                          I 
1 day     1 week           2 weeks        3 weeks          4 weeks            5 weeks           6 weeks 
 
 
4. When (if at all) did your capacity to work/socialise (delete as appropriate) return to 
normal? 
I       I                      I                         I                       I                        I                       I                          I 
1 day           1 week           2 weeks        3 weeks          4 weeks            5 weeks           6 weeks 
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Appendix E contains miscellaneous HOME FIRST documents: 
• HOME FIRST Pilot Staff Roles and Responsibilities 
• HOME FIRST DMSC Terms of Reference  
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HF Staff Roles and Responsibilities.  
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Recruiting  X x Both nurse and doctor recruited, it was anticipated that this would 
most commonly be the Doctor’s role as they may be better placed 
to discuss the patient’s potential discharge with fellow medical 
colleagues. The recruitment log was completed by the nurse. 
Clinical exam (both); blood tests (both); TTO’s (Doctor) discharge 
letter (Doctor), ambulance/liaising with family or NH (both), 
checking bloods (both) and discharge checklists (ward staff). 
Ward / department 
teaching 
X x Disseminated information about the study during planned teaching 
sessions (wards), at consultants meeting on A&E, and ad hoc whilst 
screening. 
Advertising 
 
 x Arranged with hospital communications team for ethically 
approved posters to be placed in hospital; communication – paper 
and intranet. Posters were laminated and placed in clinical and 
patient areas in the hospital. 
Screening  X x Nurse checked inpatient status on IPM (or similar) [especially on 
Mondays] before planning ward based re- reviews. Those 
discharged / missed were updated on the screening log. The ward 
location of patient was confirmed (if previously in AMAU / A&E). 
Doctor screened all relevant hospital areas and delegated screening 
wards to nurse. 
Screening log X x • Completed paper screening logs on a daily basis for 
screened patients 
• Patient location changes were updated  
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• Nurse confirmed the location of each patient previously on 
AMAU & A&E prior to repeat review 
• Notes made on A4 paper, then transcribed onto the 
screening log 
• Nurse uploaded data onto electronic screening log 
(usually) on a weekly basis 
OSIRIS or similar 
 
 x Database of all those recruited, visits and when they completed the 
study. Monitored by RD&I. 
Demographics 
database 
 x Completed spreadsheets for: 
• Demographics with a summary of each patient / learning 
outcome, clinical results, LOS etc 
• CAPSYM: -30, day 0 & 6 weeks 
• SF12: day 0 & 6 weeks 
• RECRI: 6 weeks 
• Patient satisfaction questionnaire 
• Carer/NOK/relative satisfaction questionnaire 
Electronic site file   x Maintained by nurse. An electronic replica of the physical site file 
was available and was password protected, on the shared drive. 
Home visits  
  
x x Wherever possible they occurred before midday – in order that if a 
patient was unwell, results from clinical blood samples were back 
before 4pm. Green bag and CRF were taken to the property, and 
completed. The following documents were followed, completed 
and referenced as needed: 
• Escalation & readmission flow chart 
• Telephone contact chart (in and out of hours)  
• Review criteria and flowchart for discharge 
During a home visit clinical examination was performed and the 
study team checked for any issues – they spent time talking to care 
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giver / family - particularly for care home patients when required. 
Routine planned bloods such as INR or as required bloods 
depending on clinical picture were to be taken. Catheters inserted 
or removed as needed. The study team ensured equipment had 
been delivered / ensures supplied / meal on wheels food delivered. 
It was not the team’s responsibility to liaise with landlords or deal 
with other non-clinical issues. All home visits were discussed with a 
study Doctor the same day, either face to face, via text / telephone 
or email. A management plan was then agreed.   
Paper site file 
 
 x Maintained by nurse.  Doctor emailed relevant documents as 
needed or when received.   
BP equipment 
 
 x Arranged for equipment to be calibrated regularly and added 
certificates to electronic and site file. Spare batteries were kept in 
green bag. 
Green bag 
 
 x Used contents checklist to ensure maintained in date stock. Nurse 
arranged regular calibration of equipment with supplier. 
CRF / recruitment 
packs  
 x Made up recruitment packs. Nurse ensured blood results and 
investigations section on CRF and all questionnaires (day – 30; day 
0, 6 weeks) and databases were completed. 
Ordering case notes   x Ordered case notes via IPM (or similar system) clinic appointments 
and stored in locked office.   
Arranging 
remuneration 
payments 
 
 x Bank details were collected during recruitment. Information was 
stored on a secure database, and any paperwork was shredded. 
Nurse gave bank payment forms to finance department at LSTM. 
Occasionally cash payments were made if absolutely necessary. 
Updating database 
for OPD dates 
 x A database recorded all of the above information. This allowed the 
team to see at a glance where each patient was up to in the study.  
GP letters posted  x 
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Ward thank you gifts  x x Study team gave final thank you to ward staff after recruitment had 
closed. 
Annual progress 
report   
 x This was completed using an RD&I template. After being signed by 
PI, it was emailed to REC/ RD&I / LCRN/ PI. Stored in site file and 
electronically. 
End of study 
declaration form 
 x Completed at the end of the study. 
Final report  x x Completed within 12 months of the end of the study. 
SAE reporting  x x Completed necessary documentation and submitted it to RD&I 
(sponsor). The study was put on holding pending 
investigation/review as needed. 
Delegation log 
 
 x Nurse ensured delegation log was up to date. Nurse ensured 
research team’s CVs and GCP all up to date and in paper and 
electronic site file. 
Chest XR 
 
x x Ordered repeat CXR and any other investigations at 6/52 OPD as 
needed. Nurse documented radiology reports on demographic 
database 
DMSC 
 
x  Updated DMSC on a weekly basis by email – highlighted any 
relevant issues. 
Time data  x x Doctor and nurse recorded all time spent on screening and home 
visits and travel time to enable a health economic assessment, this 
was cross checked by an independent assessor. 
Telephone numbers 
to switch 
 
x x List of all relevant telephone numbers and names was made and 
given to switch. On call flowchart was used as required. Forwarding 
the on call mobile was usually the simplest and safest solution. 
LOS 
 
 x Calculated using online tool 
http://www.timeanddate.com/date/duration.html. 
Data was stored on demographic database. 
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Patient summaries  x x Brief summary of anything interesting or unusual about each case 
was completed i.e. future learning points. 
Reliance device  x x Nurse received a monthly report from Reliance. Used by all staff at 
all home visits 
Taxis 
 
 x Booked via local taxi company by nurse if needed. The process at 
RLBUHT was as follows: 
• Nurse confirmed taxi required 
• Phoned taxi to get quote 
• Phoned / emailed LSTM to raise purchase invoice 
• Phoned taxi and gave purchase invoice number, then 
proceeded with booking. 
Booking OPDs and 
home visits on 
calendar  
 x Referred patient for OPD and booked slot. If patient was unable to 
attend the 6 week OPD a home visit was arranged. All OPDs and 
home visits were booked on at least 2 staff calendars with patient’s 
initials / address/ post code/ phone number included for safety 
purposes. I.e. if no contact with doctor or nurse at set time, the 
police were informed where the nurse/doctor was last known to be. 
Independent 
telephone 
questionnaire 
 
 x Performed by an administration clerk after training from nurse. 
Training included: reminding volunteer about the study they took 
part in when they were in hospital, telling volunteer that they were 
an independent assessor; explaining the questionnaire; negotiating 
more convenient times to complete it if volunteer / carer was too 
busy 
Notes were made by nurse on reverse of questionnaire to assist 
caller i.e. if volunteer was in HF or SHC arm, date interview due / 
volunteer details / carer details / telephone numbers 
Results were uploaded onto a database by nurse 
Contacts list  x x Maintained by nurse with a list of useful and important contacts.  
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Data Monitoring and Safety Committee Terms of Reference 
 
 
HOME FIRST PILOT STUDY 
 
Short title: HOME FIRST PILOT STUDY 
 
REC Ref: 12/NW/0731 
 
Chief Investigator:  Stephen Gordon 
                      Chair in Respiratory Medicine 
         3rd Floor CTID Building 
         Liverpool School of Tropical Medicine 
         Pembroke Place 
         Liverpool 
         L3 5QA 
        (0151) 705 3169 
         
Sponsors:  Royal Liverpool and Broadgreen University Hospital NHS Trust and Liverpool 
School of Tropical Medicine 
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1.  Introduction 
The HOME FIRST (early supported discharge scheme for patients with lower respiratory tract 
infection) originally began in winter 2011-2012 with the feasibility study.  Results of this 
feasibility study have been published (BMC Pulmonary Medicine 2014) and presented in 
appropriate international meetings (BTS winter meeting 2012).  The pilot study began 
recruiting in October 2014. In total 15 patients have been recruited and 187 patients have 
been screened. There have been 2 readmissions from the HOME FIRST arm. The North-West 
REC has approved this study.  
2. Remit & Responsibilities 
The DMC will provide the independent review of safety data for this study. To carry out this 
function, the DMC will: 
a) Review emerging safety data from the study.  Data will be presented to the committee 
by spreadsheet weekly during the duration of the study.  Responses are copied to all 
by email. This system has proved effective in our other research projects (such as 
experimental carriage models) 
b) Review, evaluate and make recommendations to the Investigators and the Trust as to 
whether to modify, suspend, terminate or extend the study. 
c) Be notified of any SUSAR without delay. DMC will also review SAEs/AEs on a regular 
basis and in particular review the causality assessments of all adverse events with 
regards to the patient selection criteria.  
 
3. Membership 
The DMC will comprise three members who will include one clinician and one statistician.  
Also in attendance will be the Chief Investigator and Lead Research Nurse,  a member of the 
Trust’s RD & I Department will also be invited to attend. Only the three members of the DMC 
will be involved in decision making, which may be carried out in closed sessions as needed. 
4. Attendance & Frequency of Meetings 
Meetings will be held by email circulation. At a minimum there will be one meeting prior to 
recruitment of 30 patients and one when recruitment is completed or a decision is made that 
sufficient patient numbers have been screened. Other meetings may take place at the 
discretion of the members. Other external panel members may also be invited to attend 
meetings to discuss specific topics. 
5. Quorum 
All three members of the DMC will constitute a Quorum. A Chair plus one member may be 
quorate providing the third member confirms by email that he/she agrees to all decisions 
recorded in the minutes of the meeting. 
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6. Reporting Arrangements 
a. Prior to each meeting a report will be prepared by the Chief Investigator and 
Research Nurse/Doctor. 
b. Individual patient data will be available if required. 
c. Minutes shall be formally recorded and submitted to the RLUH RD & I 
Department.   
Agreement to be a Member of the DMC 
I have read the Data Monitoring Committee Charter for the above study, and I am willing to 
abide by this charter and serve as a member of the DMC. I declare my interests below, and 
agree to provide details of any future conflicts of interests, should they arise.  
1. Name:  Rebecca Bancroft 
Title: Consultant Physician RLBUHT 
Signed:      Date:  
I declare the following interests 
2. Name:  Arthur Ricky Kang’ombe 
Title: Lecturer/Biostatistician, Liverpool School of Tropical Medicine 
Signed:     Date:  
I declare the following interests 
3. Name:  Sasha Shepperd 
Title: Professor of Health Services Research, Oxford University 
Signed:      Date:  
I declare the following interests 
4. Name:  Stephen Gordon 
Title: Chief Investigator  
Signed:      Date:  
I declare the following interests 
 
